Selected Publications

2016
  1. Ahmad R, Postnov A, Bormans G, Versijpt J, Vandenbulcke M, Van Laere K: Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer’s disease. European journal of nuclear medicine and molecular imaging 2016, 43:2219-2227.
  2. Airan RD, Foss CA, Ellens NP, Wang Y, Mease RC, Farahani K, Pomper MG: MR-Guided Delivery of Hydrophilic Molecular Imaging Agents Across the Blood-Brain Barrier Through Focused Ultrasound. Molecular Imaging and Biology 2016:1-7.
  3. Akkus F, Treyer V, Johayem A, Ametamey SM, Mancilla BG, Sovago J, Buck A, Hasler G: Association of long-term nicotine abstinence with normal metabotropic glutamate receptor-5 binding. Biological psychiatry 2016, 79:474-480.
  4. Arakawa R, Tateno A, Kim W, Sakayori T, Ogawa K, Okubo Y: Time-course of serotonin transporter occupancy by single dose of three SSRIs in human brain: A positron emission tomography study with [11 C] DASB. Psychiatry Research: Neuroimaging 2016, 251:1-6.
  5. Aranda-Lara L, Ferro-Flores G, de María Ramírez F, Ocampo-García B, Santos-Cuevas C, Díaz-Nieto L, Isaac-Olivé K: Improved radiopharmaceutical based on 99mTc-Bombesin–folate for breast tumour imaging. Nuclear medicine communications 2016, 37:377-386.
  6. Aung W, Tsuji AB, Sudo H, Sugyo A, Furukawa T, Ukai Y, Kurosawa Y, Saga T: Immunotargeting of Integrin α6β4 for Single-Photon Emission Computed Tomography and Near-Infrared Fluorescence Imaging in a Pancreatic Cancer Model. Molecular Imaging 2016, 15:1536012115624917.
  7. Babiloni C, Del Percio C, Caroli A, Salvatore E, Nicolai E, Marzano N, Lizio R, Cavedo E, Landau S, Chen K: Cortical sources of resting state EEG rhythms are related to brain hypometabolism in subjects with Alzheimer’s disease: an EEG-PET study. Neurobiology of Aging 2016, 48:122-134.
  8. Bak-Fredslund KP, Munk OL, Keiding S, Sørensen M: 2-[18 F] fluoro-2-deoxy-D-galactose PET/CT of hepatocellular carcinoma is not improved by co-administration of galactose. Nuclear Medicine and Biology 2016.
  9. Ballarini T, Iaccarino L, Magnani G, Ayakta N, Miller BL, Jagust WJ, Gorno‐Tempini ML, Rabinovici GD, Perani D: Neuropsychiatric subsyndromes and brain metabolic network dysfunctions in early onset Alzheimer’s disease. Human Brain Mapping 2016, 37:4234-4247.
  10. Bang J-I, Jung IS, Song YS, Park HS, Moon BS, Lee BC, Kim SE: PET imaging of dopamine transporters with [18 F] FE-PE2I: Effects of anti-Parkinsonian drugs. Nuclear Medicine and Biology 2016, 43:158–164.
  11. Barret O, Alagille D, Sanabria S, Comley RA, Weimer RM, Borroni E, Mintun M, Seneca N, Papin C, Morley T: Kinetic Modeling of the Tau PET Tracer 18F-AV-1451 in Human Healthy Volunteers and Alzheimer’s Disease Subjects. Journal of Nuclear Medicine 2016:jnumed. 116.182881.
  12. Barron AM, Tokunaga M, Zhang M-R, Ji B, Suhara T, Higuchi M: Assessment of neuroinflammation in a mouse model of obesity and β-amyloidosis using PET. Journal of Neuroinflammation 2016, 13:221.
  13. Bascuas T, Moreno M, Mónaco A, Reyes L, Paolino A, Oliver P, Kramer MG, Engler H, Pacheco JP, Grille S: A novel non-Hodgkin lymphoma murine model closer to the standard clinical scenario. Journal of Translational Medicine 2016, 14:323.
  14. Bascuñana P, Javela J, Delgado M, de la Rosa RF, Shiha AA, García-García L, Pozo MÁ: [18F] FDG PET Neuroimaging Predicts Pentylenetetrazole (PTZ) Kindling Outcome in Rats. Molecular Imaging and Biology 2016:1-8.
  15. Bauer M, Karch R, Tournier N, Cisternino S, Wadsak W, Hacker M, Marhofer P, Zeitlinger M, Langer O: Assessment of P-glycoprotein Transport Activity at the Human Blood‐Retinal Barrier with (R)‐11C-verapamil PET. Journal of Nuclear Medicine 2016:jnumed. 116.182147.
  16. Benito AB, Aiertza MK, Marradi M, Gil-Iceta L, Shekhter Zahavi T, Szczupak B, Jiménez-González M, Reese T, Scanziani E, Passoni L: Functional Single-Chain Polymer Nanoparticles: Targeting and Imaging Pancreatic Tumors in Vivo. Biomacromolecules 2016, 17:3213-3221.
  17. Berti V, Sciagrà R, Neglia D, Pietilä M, Scholte AJ, Nekolla S, Rouzet F, Pupi A, Knuuti J: Segmental quantitative myocardial perfusion with PET for the detection of significant coronary artery disease in patients with stable angina. European journal of nuclear medicine and molecular imaging 2016:1-8.
  18. Boileau I, McCluskey T, Tong J, Furukawa Y, Houle S, Kish SJ: Rapid Recovery of Vesicular Dopamine Levels in Methamphetamine Users in Early Abstinence. Neuropsychopharmacology 2016, 41:1179-1187.
  19. Boileau I, Payer D, Rusjan PM, Houle S, Tong J, McCluskey T, Wilson AA, Kish SJ: Heightened dopaminergic response to amphetamine at the D3 dopamine receptor in methamphetamine users. Neuropsychopharmacology 2016, 41:2994-3002.
  20. Bolcaen J, Lybaert K, Moerman L, Descamps B, Deblaere K, Boterberg T, Kalala J-P, Van den Broecke C, De Vos F, Vanhove C: Kinetic modeling and graphical analysis of 18F-fluoromethylcholine (FCho), 18F-fluoroethyltyrosine (FET) and 18F-fluorodeoxyglucose (FDG) PET for the fiscrimination between high-grade glioma and radiation necrosis in rats. PloS one 2016, 11:e0161845.
  21. Brackhan M, Bascunana P, Postema JM, Ross TL, Bengel FM, Bankstahl M, Bankstahl JP: Serial quantitative TSPO-targeted PET reveals peak microglial activation up to two weeks after an epileptogenic brain insult. Journal of Nuclear Medicine 2016:jnumed. 116.172494.
  22. Branger P, Arenaza-Urquijo EM, Tomadesso C, Mézenge F, André C, De Flores R, Mutlu J, de La Sayette V, Eustache F, Chételat G: Relationships between sleep quality and brain volume, metabolism, and amyloid deposition in late adulthood. Neurobiology of aging 2016, 41:107-114.
  23. Brendel M, Jaworska A, Probst F, Overhoff F, Korzhova V, Lindner S, Carlsen J, Bartenstein P, Harada R, Kudo Y: Small-Animal PET Imaging of Tau Pathology with 18F-THK5117 in 2 Transgenic Mouse Models. Journal of Nuclear Medicine 2016, 57:792-798.
  24. Brendel M, Reinisch V, Kalinowski E, Levin J, Delker A, Därr S, Pogarell O, Förster S, Bartenstein P, Rominger A: Hypometabolism in Brain of Cognitively Normal Patients with Depressive Symptoms is Accompanied by Atrophy-Related Partial Volume Effects. Current Alzheimer Research 2016, 13:475-486.
  25. Bresch A, Rullmann M, Luthardt J, Arelin K, Becker GA, Patt M, Lobsien D, Baldofski S, Drabe M, Zeisig V: In-vivo serotonin transporter availability and somatization in healthy subjects. Personality and Individual Differences 2016, 94:354-359.
  26. Bresch A, Rullmann M, Luthardt J, Becker G, Reissig G, Patt M, Ding YS, Hilbert A, Sabri O, Hesse S: Emotional eating and in vivo norepinephrine transporter availability in obesity: A [11C] MRB PET pilot study. International Journal of Eating Disorders 2016.
  27. Buhour MS, Doidy F, Laisney M, Pitel AL, de La Sayette V, Viader F, Eustache F, Desgranges B: Pathophysiology of the behavioral variant of frontotemporal lobar degeneration: A study combining MRI and FDG-PET. Brain Imaging and Behavior 2016:1–13.
  28. Butler T, Li Y, Tsui W, Friedman D, Maoz A, Wang X, Harvey P, Tanzi E, Morim S, Kang Y: Transient and chronic seizure‐induced inflammation in human focal epilepsy. Epilepsia 2016, 57.
  29. Capistrano R, Vangestel C, Wouters A, Dockx Y, Pauwels P, Stroobants S, Apers S, Lardon F, Pieters L, Staelens S: Efficacy Screening of Gloriosa Superba Extracts in a Murine Pancreatic Cancer Model Using 18F-FDG PET/CT for Monitoring Treatment Response. Cancer Biotherapy and Radiopharmaceuticals 2016, 31:99-109.
  30. Caravaggio F, Chung JK, Gerretsen P, Fervaha G, Nakajima S, Plitman E, Iwata Y, Wilson A, Graff-Guerrero A: Exploring the relationship between social attachment and dopamine D2/3 receptor availability in the brains of healthy humans using [11C]-(+)-PHNO. Social neuroscience 2016:1-11.
  31. Caravaggio F, Fervaha G, Chung JK, Gerretsen P, Nakajima S, Plitman E, Iwata Y, Wilson A, Graff-Guerrero A: Exploring personality traits related to dopamine D 2/3 receptor availability in striatal subregions of humans. European Neuropsychopharmacology 2016, 26:644-652.
  32. Castagnoli H, Ferrantini C, Coppini R, Passeri A, Baldini K, Berti V, Cecchi F, Olivotto I, Sciagrà R: Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal. European journal of nuclear medicine and molecular imaging 2016, 43:2413-2422.
  33. Ceccon G, Lohmann P, Stoffels G, Judov N, Filss CP, Rapp M, Bauer E, Hamisch C, Ruge MI, Kocher M: Dynamic O-(2-18F-fluoroethyl)-L-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy. Neuro-Oncology 2016:now149.
  34. Chakraborty S, Balogh L, Das T, Polyák A, Andócs G, Máthé D, Király R, Thuróczy J, R Chaudhari P, A Jánoki G et al: Evaluation of; 177Lu-EDTMP in Dogs with Spontaneous Tumor Involving Bone: Pharmacokinetics, Dosimetry and Therapeutic Efficacy. Current radiopharmaceuticals 2016, 9:64–70.
  35. Chan S-C, Chang K-P, Fang Y-HD, Tsang N-M, Ng S-H, Hsu C-L, Liao C-T, Yen T-C: Tumor heterogeneity measured on F‐18 fluorodeoxyglucose positron emission tomography/computed tomography combined with plasma Epstein‐Barr Virus load predicts prognosis in patients with primary nasopharyngeal carcinoma. The Laryngoscope 2016.
  36. Chapman S: Tetramodal Imaging using MRI/Pet or MRI/SPECT modalities: A simplified cross-platform and co-registration technique. Journal of Nuclear Medicine 2016, 57:1289-1289.
  37. Chekol R, Gheysens O, Ahamed M, Cleynhens J, Pokreisz P, Vanhoof G, Janssens S, Verbruggen A, Bormans GM: Carbon-11 and Fluorine-18 Radiolabeled Pyridopyrazinone Derivatives for PET Imaging of Phosphodiesterase-5 (PDE5). Journal of Medicinal Chemistry 2016.
  38. Chen Q, Meng X, McQuade P, Rubins D, Lin S-A, Zeng Z, Haley H, Miller P, González Trotter D, Low PS: Synthesis and Preclinical Evaluation of Folate-NOTA-Al18F for PET Imaging of Folate-Receptor-Positive Tumors. Molecular pharmaceutics 2016, 13:1520-1527.
  39. Chen X, Zhou Y, Wang R, Cao H, Reid S, Gao R, Han D, Initiative AsDN: Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer’s Disease Progression. PloS one 2016, 11:e0154406.
  40. Cheng N-M, Fang Y-HD, Tsan D-L, Hsu C-H, Yen T-C: Respiration-averaged CT for attenuation correction of PET images–impact on PET texture features in non-small cell lung cancer patients. PloS one 2016, 11:e0150509.
  41. Chiotellis A, Müller Herde A, Rössler SL, Brekalo A, Gedeonova E, Mu L, Keller C, Schibli R, Krämer SD, Ametamey SM: Synthesis, Radiolabelling and Biological Evaluation of 5-Hydroxy-2 [18F] Fluoroalkyl-Tryptophan Analogues as Potential PET Radiotracers for Tumor Imaging. Journal of medicinal chemistry 2016.
  42. Chiotis K, Saint-Aubert L, Savitcheva I, Jelic V, Andersen P, Eriksson J, Lubberink M, Almkvist O, Wall A, Antoni G: Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm. European journal of nuclear medicine and molecular imaging 2016:1-14.
  43. Cho S-G, Park KS, Kim J, Kang S-R, Song H-C, Kim JH, Cho JY, Hong YJ, Jabin Z, Park HJ: Coronary flow reserve and relative flow reserve measured by N-13 ammonia PET for characterization of coronary artery disease. Annals of nuclear medicine 2016:1-9.
  44. Choi JY, Lyoo CH, Kim JS, Kim KM, Lee M, Ryu YH: Biodistribution and Radiation Dosimetry of [18F] Mefway in Humans. Molecular Imaging and Biology 2016:1-4.
  45. Choi JY, Song JS, Lee M, Cho W-K, Chung J, Lyoo CH, Kim CH, Park J, Lee KC, Kim KM: P-Glycoprotein, not BCRP, Limits the Brain Uptake of [18F] Mefway in Rodent Brain. Molecular Imaging and Biology 2016, 18:267-273.
  46. Choi JY, Yang J, Noworolski SM, Behr S, Chang AJ, Simko JP, Nguyen HG, Carroll PR, Kurhanewicz J, Seo Y: 18F Fluorocholine Dynamic Time-of-Flight PET/MR Imaging in Patients with Newly Diagnosed Intermediate-to High-Risk Prostate Cancer: Initial Clinical-Pathologic Comparisons. Radiology 2016:160220.
  47. Choi WH, Um YH, Jung WS, Kim SH: Automated quantification of amyloid positron emission tomography: a comparison of PMOD and MIMneuro. Annals of Nuclear Medicine 2016, 30:682-689.
  48. Christensen AN, Rydhög JS, Søndergaard RV, Andresen TL, Holm S, af Rosenschöld PM, Conradsen K, Jølck RI: Injectable silver nanosensors: in vivo dosimetry for external beam radiotherapy using positron emission tomography. Nanoscale 2016, 8:11002-11011.
  49. Cleeren F, Lecina J, Koole M, Verbruggen A, Bormans G: RESTRAINED COMPLEXING AGENTS FOR AL 18 F-LABELLING OF HEAT-SENSITIVE BIOMOLECULES. 18 F-labelling of biomolecules for PET 2016:45.
  50. Clemmensen AE, Ghotbi AA, Bodholdt RP, Hag AMF, Hasbak P, Ripa RS, Kjaer A: Perfusion imaging using rubidium-82 (82Rb) PET in rats with myocardial infarction: First small animal cardiac 82Rb-PET. Journal of Nuclear Cardiology 2016:1-3.
  51. Cochran BJ, Ryder WJ, Parmar A, Tang S, Reilhac A, Arthur A, Charil A, Hamze H, Barter PJ, Kritharides L: In vivo PET imaging with [18F] FDG to explain improved glucose uptake in an apolipoprotein AI treated mouse model of diabetes. Diabetologia 2016:1-8.
  52. Collantes M, Serrano-Mendioroz I, Benito M, Molinet-Dronda F, Delgado M, Vinaixa M, Sampedro A, de Salamanca RE, Prieto E, Pozo MA: Glucose metabolism during fasting is altered in experimental porphobilinogen deaminase deficiency. Human molecular genetics 2016:ddw013.
  53. Collste K, Forsberg A, Varrone A, Amini N, Aeinehband S, Yakushev I, Halldin C, Farde L, Cervenka S: Test–retest reproducibility of [11C] PBR28 binding to TSPO in healthy control subjects. European journal of nuclear medicine and molecular imaging 2016, 43:173–183.
  54. Coughlin JM, Wang Y, Ambinder EB, Ward RE, Minn I, Vranesic M, Kim PK, Ford CN, Higgs C, Hayes LN: In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [ 11C] DPA-713 PET and analysis of CSF and plasma. Translational psychiatry 2016, 6:e777.
  55. Courchesne-Loyer A, Croteau E, Castellano C-A, St-Pierre V, Hennebelle M, Cunnane SC: Inverse relationship between brain glucose and ketone metabolism in adults during short-term moderate dietary ketosis: A dual tracer quantitative positron emission tomography study. J Cereb Blood Flow Metab doi 2016, 10.
  56. Cressier D, Dhilly M, Pham TTC, Fillesoye F, Gourand F, Maïza A, Martins AF, Morfin J-F, Geraldes CF, Tóth É: Gallium-68 Complexes Conjugated to Pittsburgh Compound B: Radiolabeling and Biological Evaluation. Molecular Imaging and Biology 2016, 18:334-343.
  57. da Cunha-Bang S, Hjordt LV, Perfalk E, Beliveau V, Bock C, Lehel S, Thomsen C, Sestoft D, Svarer C, Knudsen GM: Serotonin 1B Receptor Binding Is Associated With Trait Anger and Level of Psychopathy in Violent Offenders. Biological psychiatry 2016.
  58. da Silva ES, Gómez‐Vallejo V, Baz Z, Llop J, López‐Gallego F: Efficient Enzymatic Preparation of 13N‐Labelled Amino Acids: Towards Multipurpose Synthetic Systems. Chemistry-A European Journal 2016, 22:13619-13626.
  59. Daerr S, Brendel M, Zach C, Mille E, Schilling D, Zacherl MJ, Bürger K, Danek A, Pogarell O, Schildan A: Evaluation of early-phase [18 F]-florbetaben PET acquisition in clinical routine cases. NeuroImage: Clinical 2016.
  60. Dang LC, Samanez-Larkin GR, Castrellon JJ, Perkins SF, Cowan RL, Zald DH: Associations between dopamine D2 receptor availability and BMI depend on age. NeuroImage 2016.
  61. De Bruycker S, Vangestel C, Van den Wyngaert T, Wouters A, Pauwels P, Staelens S, Stroobants S: Baseline [18F] FMISO μPET as a Predictive Biomarker for Response to HIF-1α Inhibition Combined with 5-FU Chemotherapy in a Human Colorectal Cancer Xenograft Model. Molecular Imaging and Biology 2016:1–11.
  62. Deleye S, Waldron A-M, Richardson JC, Schmidt M, Langlois X, Stroobants S, Staelens S: The Effects of Physiological and Methodological Determinants on 18F-FDG Mouse Brain Imaging Exemplified in a Double Transgenic Alzheimer Model. Molecular imaging 2016, 15:1536012115624919.
  63. Denis-Bacelar AM, Cronin SE, Da Pieve C, Paul RL, Eccles SA, Spinks TJ, Box C, Hall A, Sosabowski JK, Kramer-Marek G: Pre-clinical quantitative imaging and mouse-specific dosimetry for 111In-labelled radiotracers. EJNMMI research 2016, 6:85.
  64. Devriese J, Beels L, Maes A, Van de Wiele C, Pottel H: Evaluation of CT-based SUV normalization. Physics in Medicine and Biology 2016, 61:6369.
  65. Doi H, Sato K, Shindou H, Sumi K, Koyama H, Hosoya T, Watanabe Y, Ishii S, Tsukada H, Nakanishi K: Blood–brain barrier permeability of ginkgolide: Comparison of the behavior of PET probes 7α-[18 F] fluoro-and 10-O-p-[11 C] methylbenzyl ginkgolide B in monkey and rat brains. Bioorganic & Medicinal Chemistry 2016, 24:5148-5157.
  66. Domercq M, Szczupak B, Gejo J, Gómez-Vallejo V, Padro D, Gona KB, Dollé F, Higuchi M, Matute C, Llop J: PET Imaging with [18F] FSPG Evidences the Role of System xc-on Brain Inflammation Following Cerebral Ischemia in Rats. Theranostics 2016, 6:1753.
  67. Dunet V, Klein R, Allenbach G, Renaud J, Prior JO: Myocardial blood flow quantification by Rb-82 cardiac PET/CT: A detailed reproducibility study between two semi-automatic analysis programs. Journal of Nuclear Cardiology 2016, 23:499-510.
  68. Eberl S, Katsifis A, Peyronneau MA, Wen L, Henderson D, Loc’h C, Greguric I, Verschuer J, Pham T, Lam P: Preclinical in vivo and in vitro comparison of the translocator protein PET ligands [18F] PBR102 and [18F] PBR111. European Journal of Nuclear Medicine and Molecular Imaging 2016:1-12.
  69. Elvas F, Boddaert J, Vangestel C, Pak K, Gray B, Kumar-Singh S, Staelens S, Stroobants S: 99mTc-Duramycin SPECT imaging of early tumor response to targeted therapy: a comparison with 18F-FDG PET. Journal of Nuclear Medicine 2016:jnumed. 116.182014.
  70. Elvas F, Vangestel C, Pak K, Vermeulen P, Gray B, Stroobants S, Staelens S, Wyffels L: Early Prediction of Tumor Response to Treatment: Preclinical Validation of 99mTc-Duramycin. Journal of Nuclear Medicine 2016, 57:805-811.
  71. Eriksson O, Selvaraju R, Eich T, Willny M, Brismar TB, Carlbom L, Ahlström H, Tufvesson G, Lundgren T, Korsgren O: Positron Emission Tomography to assess the outcome of intraportal islet transplantation. Diabetes 2016:db160222.
  72. Fan D, Liu S, Jiang S, Li Z, Mo X, Ruan H, Zou GM, Fan C: The use of SHP‐2 gene transduced bone marrow mesenchymal stem cells to promote osteogenic differentiation and bone defect repair in rat. Journal of Biomedical Materials Research Part A 2016.
  73. Fang XT, Eriksson J, Antoni G, Yngve U, Cato L, Lannfelt L, Sehlin D, Syvänen S: Brain mGluR5 in mice with amyloid beta pathology studied with in vivo [11 C] ABP688 PET imaging and ex vivo immunoblotting. Neuropharmacology 2017, 113:293-300.
  74. Feiock C, Yagi M, Maidman A, Rendahl A, Hui S, Seelig D: Central Nervous System Injury–A Newly Observed Bystander Effect of Radiation. PloS one 2016, 11:e0163233.
  75. Feng L, Jensen P, Thomsen G, Dyssegaard A, Svarer C, Knudsen LV, Møller K, Thomsen C, Mikkelsen JD, Guilloteau D: The variability of translocator protein signal in brain and blood of genotyped healthy humans using in vivo 123I-CLINDE SPECT imaging–a test-retest study. Journal of Nuclear Medicine 2016:jnumed. 116.183202.
  76. Feng L, Svarer C, Madsen K, Ziebell M, Dyssegaard A, Ettrup A, Hansen HD, Lehel S, Yndgaard S, Paulson OB: Design of Infusion Schemes for Neuroreceptor Imaging: Application to [11C] Flumazenil-PET Steady-State Study. BioMed research international 2016, 2016.
  77. Fernandez AM, Hernandez-Garzón E, Perez-Domper P, Perez-Alvarez A, Mederos S, Matsui T, Santi A, Trueba-Saiz A, García-Guerra L, Pose-Utrilla J: Insulin Regulates Astrocytic Glucose Handling Through Cooperation With Insulin-Like Growth Factor I. Diabetes 2016:db160861.
  78. Fervaha G, Caravaggio F, Mamo DC, Mulsant BH, Pollock BG, Nakajima S, Gerretsen P, Rajji TK, Mar W, Iwata Y: Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study. Psychopharmacology 2016, 233:3803-3813.
  79. Freeby MJ, Kringas P, Goland RS, Leibel RL, Maffei A, Divgi C, Ichise M, Harris PE: Cross-sectional and Test-Retest Characterization of PET with [18F] FP-(+)-DTBZ for β Cell Mass Estimates in Diabetes. Molecular Imaging and Biology 2016, 18:292-301.
  80. Frings L, S Spehl T, Hüll M, T Meyer P: Left Anterior Temporal Glucose Metabolism and not Amyloid-beta Load Predicts Naming Impairment in Alzheimer’s Disease. Current Alzheimer Research 2016, 13:678-681.
  81. Fujita M, Richards EM, Niciu MJ, Ionescu DF, Zoghbi SS, Hong J, Telu S, Hines CS, Pike VW, Zarate CA: cAMP signaling in brain is decreased in unmedicated depressed patients and increased by treatment with a selective serotonin reuptake inhibitor. Molecular Psychiatry 2016.
  82. Gabler AS, Kühnel C, Winkens T, Freesmeyer M: Assessment of minimum activity of 124Iodine in pre-therapeutic uptake measurement prior to radioiodine therapy of benign thyroid diseases. Journal of Nuclear Medicine 2016:jnumed. 115.171066.
  83. Gabler AS, Kühnel C, Winkens T, Freesmeyer M: Assessment of Minimum 124I Activity Required in Uptake Measurements Before Radioiodine Therapy for Benign Thyroid Diseases. Journal of Nuclear Medicine 2016, 57:1201-1206.
  84. Gao R, Zhang G, Chen X, Yang A, Smith G, Wong DF, Zhou Y: CSF Biomarkers and Its Associations with 18 F-AV133 Cerebral VMAT2 Binding in Parkinson’s Disease—A Preliminary Report. PloS one 2016, 11:e0164762.
  85. García-Casares N, García-Arnés JA, Rioja J, Ariza MJ, Gutiérrez A, Alfaro F, Nabrozidis A, González-Alegre P, González-Santos P: Alzheimer’s like brain changes correlate with low adiponectin plasma levels in type 2 diabetic patients. Journal of diabetes and its complications 2016, 30:281-286.
  86. García-García L, Shiha AA, Bascuñana P, de Cristóbal J, de la Rosa RF, Delgado M, Pozo MA: Serotonin depletion does not modify the short-term brain hypometabolism and hippocampal neurodegeneration induced by the lithium–pilocarpine model of status epilepticus in rats. Cellular and molecular neurobiology 2016, 36:513-519.
  87. Garg PK, Lokitz SJ, Nazih R, Garg S: Biodistribution and Radiation Dosimetry of C-11 Nicotine from Whole Body PET Imaging in Humans. Journal of Nuclear Medicine 2016:jnumed. 116.180059.
  88. Garousi J, Andersson KG, Mitran B, Pichl M-L, St\a ahl S, Orlova A, Löfblom J, Tolmachev V: PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR: 2377 affibody molecules. International Journal of Oncology.
  89. Gijs M, Becker G, Plenevaux A, Bahri MA, Aerts A, Impens N, Baatout S, Luxen A: Biodistribution of Novel 68Ga-Radiolabelled HER2 Aptamers in Mice. Journal of Nuclear Medicine and Radiation Therapy 2016, 7.
  90. Gnesin S, Canetti L, Adib S, Cherbuin N, Monteiro MS, Bize P, Denys A, Prior JO, Baechler S, Boubaker A: Partition Model–Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison. Journal of Nuclear Medicine 2016, 57:1672-1678.
  91. Gnesin S, Leite Ferreira P, Malterre J, Laub P, Prior JO, Verdun FR: Phantom Validation of Tc-99m Absolute Quantification in a SPECT/CT Commercial Device. Computational and Mathematical Methods in Medicine 2016, 2016.
  92. Gómez-Vallejo V, Ugarte A, García-Barroso C, Cuadrado-Tejedor M, Szczupak B, Dopeso-Reyes IG, Lanciego JL, García-Osta A, Llop J, Oyarzabal J et al: Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels. Journal of neurochemistry 2016, 136:403–415.
  93. Gonneaud J, Arenaza-Urquijo EM, Fouquet M, Perrotin A, Fradin S, de La Sayette V, Eustache F, Chételat G: Relative effect of APOE ε4 on neuroimaging biomarker changes across the lifespan. Neurology 2016, 87:1696-1703.
  94. Gorbenko I, Kałużyński K, Mikołajczyk K: Template design for craniometric landmarks identification. In: Advanced Mechatronics Solutions. edn.: Springer; 2016: 461-466.
  95. Gräni C, Benz DC, Possner M, Clerc OF, Mikulicic F, Vontobel J, Stehli J, Fuchs TA, Pazhenkottil AP, Gaemperli O: Fused cardiac hybrid imaging with coronary computed tomography angiography and positron emission tomography in patients with complex coronary artery anomalies. Congenital Heart Disease 2016.
  96. Grimmer T, Wutz C, Alexopoulos P, Drzezga A, Förster S, Förstl H, Goldhardt O, Ortner M, Sorg C, Kurz A: Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment. Journal of Nuclear Medicine 2016, 57:204-207.
  97. Grkovski M, Schwartz J, Gönen M, Schöder H, Lee NY, Carlin SD, Zanzonico PB, Humm JL, Nehmeh SA: Feasibility of 18F-fluoromisonidazole kinetic modeling in head and neck cancer using shortened acquisition times. Journal of Nuclear Medicine 2016, 57:334-341.
  98. Grkovski M, Schwartz J, Rimner A, Schöder H, Carlin SD, Zanzonico PB, Humm JL, Nehmeh SA: Reproducibility of 18 F-fluoromisonidazole intratumour distribution in non-small cell lung cancer. EJNMMI research 2016, 6:79.
  99. Groman SM, Smith NJ, Petrullli JR, Massi B, Chen L, Ropchan J, Huang Y, Lee D, Morris ED, Taylor JR: Dopamine D3 Receptor Availability Is Associated with Inflexible Decision Making. The Journal of Neuroscience 2016, 36:6732-6741.
  100. Guo T, Brendel M, Grimmer T, Rominger A, Yakushev I: Predicting regional pattern of longitudinal beta-amyloid accumulation by baseline positron emission tomography. Journal of Nuclear Medicine 2016:jnumed. 116.176115.
  101. Hahn A, Schain M, Erlandsson M, Sjölin P, James GM, Strandberg OT, Hägerström D, Lanzenberger R, Jögi J, Olsson TG: Modeling strategies for quantification of in vivo 18F-AV1451 binding in patients with tau pathology. Journal of Nuclear Medicine 2016:jnumed. 116.174508.
  102. Haider A, Herde AM, Slavik R, Weber M, Mugnaini C, Ligresti A, Schibli R, Mu L, Ametamey SM: Synthesis and Biological Evaluation of Thiophene-Based Cannabinoid Receptor Type 2 Radiotracers for PET Imaging. Frontiers in Neuroscience 2016, 10.
  103. Hamelin L, Lagarde J, Dorothée G, Leroy C, Labit M, Comley RA, de Souza LC, Corne H, Dauphinot L, Bertoux M: Early and protective microglial activation in Alzheimer’s disease: a prospective study using 18F-DPA-714 PET imaging. Brain 2016, 139:1252-1264.
  104. Hanssen MJ, van der Lans AA, Brans B, Hoeks J, Jardon KM, Schaart G, Mottaghy FM, Schrauwen P, van Marken Lichtenbelt WD: Short-term cold acclimation recruits brown adipose tissue in obese humans. Diabetes 2016, 65:1179-1189.
  105. Harada N, Kimura H, Onoe S, Watanabe H, Matsuoka D, Arimitsu K, Ono M, Saji H: Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer. Journal of Nuclear Medicine 2016, 57:1978-1984.
  106. Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, Tago T, Hiraoka K, Watanuki S, Shidahara M: 18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease. Journal of Nuclear Medicine 2016, 57:208-214.
  107. Haylock A-K, Spiegelberg D, Mortensen AC, Selvaraju RK, Nilvebrant J, Eriksson O, Tolmachev V, Nestor MV: Evaluation of a novel type of imaging probe based on a recombinant bivalent mini-antibody construct for detection of CD44v6-expressing squamous cell carcinoma. International journal of oncology 2016, 48:461–470.
  108. Hendrikx G, Vries MH, Bauwens M, De Saint-Hubert M, Wagenaar A, Guillaume J, Boonen L, Post MJ, Mottaghy FM: Comparison of LDPI to SPECT perfusion imaging using 99mTc-sestamibi and 99mTc-pyrophosphate in a murine ischemic hind limb model of neovascularization. EJNMMI research 2016, 6:1-10.
  109. Hernandez‐Garzón E, Fernandez AM, Perez‐Alvarez A, Genis L, Bascuñana P, Fernandez de la Rosa R, Delgado M, Angel Pozo M, Moreno E, McCormick PJ: The insulin‐like growth factor I receptor regulates glucose transport by astrocytes. Glia 2016, 64:1962-1971.
  110. Hickey RD, Mao SA, Glorioso J, Elgilani F, Amiot B, Chen H, Rinaldo P, Marler R, Jiang H, DeGrado TR: Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1. Science Translational Medicine 2016, 8:349ra399-349ra399.
  111. Hjorth S, Karlsson C, Jucaite A, Varnäs K, Hamrén UW, Johnström P, Gulyás B, Donohue SR, Pike VW, Halldin C et al: A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates. Neuropharmacology 2016, 101:519–530.
  112. Hjuler KF, Gormsen L, Vendelbo MH, Egeberg A, Nielsen J, Iversen L: Increased global arterial and subcutaneous adipose tissue inflammation in patients with moderate‐to‐severe psoriasis. British Journal of Dermatology 2016.
  113. Ho K-C, Fang Y-HD, Chung H-W, Yen T-C, Ho T-Y, Chou H-H, Hong J-H, Huang Y-T, Wang C-C, Lai C-H: A preliminary investigation into textural features of intratumoral metabolic heterogeneity in 18F-FDG PET for overall survival prognosis in patients with bulky cervical cancer treated with definitive concurrent chemoradiotherapy. American journal of nuclear medicine and molecular imaging 2016, 6:166.
  114. Horsager J, Bak-Fredslund K, Larsen LP, Villadsen GE, Bogsrud TV, Sørensen M: Optimal 2-[18. EJNMMI research 2016, 6:1-7.
  115. Hou M, Acton PD: Understanding the tampon density and density gradient through computed tomography imaging. Textile Research Journal 2016, 86:573-579.
  116. Hovhannisyan N, Dhilly M, Guillouet S, Leporrier M, Barré L: Comparative Analysis between [18F] Fludarabine-PET and [18F] FDG-PET in a Murine Model of Inflammation. Molecular pharmaceutics 2016.
  117. Huang C-C, Pan W-Y, Tseng MT, Lin K-J, Yang Y-P, Tsai H-W, Hwang S-M, Chang Y, Wei H-J, Sung H-W: Enhancement of cell adhesion, retention, and survival of HUVEC/cbMSC aggregates that are transplanted in ischemic tissues by concurrent delivery of an antioxidant for therapeutic angiogenesis. Biomaterials 2016, 74:53–63.
  118. Huang Y-C, Li R-Y, Chen J-Y, Chen J-K: Biphasic release of gentamicin from chitosan/fucoidan nanoparticles for pulmonary delivery. Carbohydrate Polymers 2016, 138:114–122.
  119. Huang Y-E, Huang Y-J, Ko M, Hsu C-C, Chen C-F: Dual-time-point 18F-FDG PET/CT in the diagnosis of solitary pulmonary lesions in a region with endemic granulomatous diseases. Annals of nuclear medicine 2016, 30:652-658.
  120. Huang Y-S, Liu F-Y, Lin C-Y, Hsiao T, Guilleminault C: Brain imaging and cognition in young narcoleptics. Sleep Medicine 2016.
  121. Huang Z-R, Tsai C-L, Huang Y-Y, Shiue C-Y, Tzen K-Y, Yen R-F, Hsin L-W: A Novel Potential Positron Emission Tomography Imaging Agent for Vesicular Monoamine Transporter Type 2. PloS one 2016, 11:e0161295.
  122. Ikawa M, Lohith TG, Shrestha S, Telu S, Zoghbi SS, Castellano S, Taliani S, Da Settimo F, Fujita M, Pike VW: 11C-ER176, a radioligand for 18-kDa translocator protein (TSPO), has adequate sensitivity to robustly image all three affinity genotypes in human brain. Journal of Nuclear Medicine 2016:jnumed. 116.178996.
  123. Ishibashi K, Miura Y, Ishikawa K, Zhang M-R, Toyohara J, Ishiwata K, Ishii K: Relationship between type 1 metabotropic glutamate receptors and cerebellar ataxia. Journal of neurology 2016, 263:2179-2187.
  124. Ishibashi K, Wagatsuma K, Ishiwata K, Ishii K: Alteration of the regional cerebral glucose metabolism in healthy subjects by glucose loading. Human brain mapping 2016.
  125. Ishiki A, Harada R, Okamura N, Tomita N, Rowe CC, Villemagne VL, Yanai K, Kudo Y, Arai H, Furumoto S: Tau imaging with [18F] THK‐5351 in progressive supranuclear palsy. European Journal of Neurology 2016.
  126. Jarcho JM, Feier NA, Labus JS, Naliboff B, Smith SR, Hong J-Y, Colloca L, Tillisch K, Mandelkern MA, Mayer EA et al: Placebo analgesia: Self-report measures and preliminary evidence of cortical dopamine release associated with placebo response. NeuroImage: Clinical 2016, 10:107–114.
  127. Jensen JB, Sundelin EI, Jakobsen S, Gormsen LC, Munk OL, Frøkiær J, Jessen N: [11C]-Labeled Metformin Distribution in the Liver and Small Intestine Using Dynamic Positron Emission Tomography in Mice Demonstrates Tissue-Specific Transporter Dependency. Diabetes 2016, 65:1724-1730.
  128. Ji B, Kaneko H, Minamimoto T, Inoue H, Takeuchi H, Kumata K, Zhang M-R, Aoki I, Seki C, Ono M: Multimodal Imaging for DREADD-Expressing Neurons in Living Brain and Their Application to Implantation of iPSC-Derived Neural Progenitors. Journal of Neuroscience 2016, 36:11544-11558.
  129. Jochimsen TH, Zeisig V, Schulz J, Werner P, Patt M, Patt J, Dreyer AY, Boltze J, Barthel H, Sabri O: Fully automated calculation of image-derived input function in simultaneous PET/MRI in a sheep model. EJNMMI physics 2016, 3:1.
  130. Jørgensen LM, Weikop P, Villadsen J, Visnapuu T, Ettrup A, Hansen HD, Baandrup AO, Andersen FL, Bjarkam CR, Thomsen C et al: Cerebral 5-HT release correlates with [11C] Cimbi36 PET measures of 5-HT2A receptor occupancy in the pig brain. Journal of Cerebral Blood Flow & Metabolism 2016:0271678X16629483.
  131. Kaller S, Rullmann M, Luthardt J, Girbardt J, Meyer P, Werner P, Hesse S, Fritz T, Sabri O: Measurements of dopamine D1-type receptors using simultaneous PET-MRI scanner: Study on test-retest reliability. Journal of Nuclear Medicine 2016, 57:1795-1795.
  132. Kanazawa M, Ohba H, Harada N, Kakiuchi T, Muramatsu S-i, Tsukada H: Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys. Journal of Nuclear Medicine 2016, 57:303-308.
  133. Kanegawa N, Collste K, Forsberg A, Schain M, Arakawa R, Jucaite A, Lekander M, Höglund CO, Kosek E, Lampa J et al: In vivo evidence of a functional association between immune cells in blood and brain in healthy human subjects. Brain, behavior, and immunity 2016.
  134. Karjalainen T, Tuominen L, Manninen S, Kalliokoski KK, Nuutila P, Jääskeläinen IP, Hari R, Sams M, Nummenmaa L: Behavioural-Activation-System Sensitivity is Associated with Cerebral μ-opioid Receptor Availability. Social cognitive and affective neuroscience 2016:nsw044.
  135. Karmani L, Levêque P, Bouzin C, Bol A, Dieu M, Walrand S, Vander Borght T, Feron O, Grégoire V, Bonifazi D: Biodistribution of 125 I-labeled anti-endoglin antibody using SPECT/CT imaging: Impact of in vivo deiodination on tumor accumulation in mice. Nuclear medicine and biology 2016, 43:415-423.
  136. Kasanova Z, Ceccarini J, van Amelsvoort T, Frank M, Booij J, Heinzel A, Rong Y, Winz O, Mottaghy F, Myin-Germeys I: Striatal dopaminergic modulation of reward processing in healthy individuals at a genetic risk for psychosis. ENVIRONMENTAL REACTIVITY FOR BETTER OR WORSE 2016:23.
  137. Kasanova Z, Hernaus D, Vaessen T, Van Amelsvoort T, Winz O, Heinzel A, Pruessner J, Mottaghy FM, Collip D, Myin-Germeys I: Early-Life Stress Affects Stress-Related Prefrontal Dopamine Activity in Healthy Adults, but Not in Individuals with Psychotic Disorder. PloS one 2016, 11:e0150746.
  138. Kaschwich M, Lützen U, Zhao Y, Tjiong A, Marx M, Haenisch S, Wiedow O, Preuss S, Culman J, Zuhayra M: Biodistribution and pharmacokinetics of the 99m Tc labeled human elastase inhibitor, elafin, in rats. Drug Metabolism and Pharmacokinetics 2016.
  139. Katiyar P, Divine MR, Kohlhofer U, Quintanilla-Martinez L, Schölkopf B, Pichler BJ, Disselhorst JA: Spectral Clustering predicts tumor tissue heterogeneity using dynamic 18F-FDG PET: a complement to the standard compartmental modeling approach. Journal of Nuclear Medicine 2016:jnumed-116.
  140. Kawaguchi H, Shimada H, Kodaka F, Suzuki M, Shinotoh H, Hirano S, Kershaw J, Inoue Y, Nakamura M, Sasai T: Principal Component Analysis of Multimodal Neuromelanin MRI and Dopamine Transporter PET Data Provides a Specific Metric for the Nigral Dopaminergic Neuronal Density. PloS one 2016, 11:e0151191.
  141. Kikuchi A, Okamura N, Hasegawa T, Harada R, Watanuki S, Funaki Y, Hiraoka K, Baba T, Sugeno N, Oshima R: In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET. Neurology 2016, 87:2309-2316.
  142. Kim BS, Pak K, Yi K-I, Kim IJ, Roh H-J, Cho K-S: Prognostic value of tumoral heterogeneity and volumetric parameters as measured by F18-FDG PET/CT in sinonasal cancer. European Archives of Oto-Rhino-Laryngology 2016:1-7.
  143. Kim D-H, Jung J-h, Son SH, Kim C-Y, Jeong SY, Lee S-W, Lee J, Ahn B-C: Quantification of Intratumoral Metabolic Macroheterogeneity on 18F-FDG PET/CT and Its Prognostic Significance in Pathologic N0 Squamous Cell Lung Carcinoma. Clinical nuclear medicine 2016, 41:e70–e75.
  144. Kim H-S, Lee B-i, Kim JH, Bom H-S, Kim D-Y, Min J-J: Comparison of Reconstruction Methods in a Small Animal Cardiac PET Study Using a 18 F-Labeled Myocardial Agent,[18 F] FPTP. Iranian Journal of Radiology 2016.
  145. Kim J-H, Kim J-H, Son Y-D, Joo Y-H, Lee S-Y, Kim H-K, Woo M-K: Altered interregional correlations between serotonin transporter availability and cerebral glucose metabolism in schizophrenia: A high-resolution PET study using [11 C] DASB and [18 F] FDG. Schizophrenia Research 2016.
  146. Kim Y, Lee H-Y, Yoon H-J, Kim BS: Utility of 18 F-fluorodeoxy glucose and 18 F-sodium fluoride positron emission tomography/computed tomography in the diagnosis of medication-related osteonecrosis of the jaw: A preclinical study in a rat model. Journal of Cranio-Maxillofacial Surgery 2016.
  147. Kimura Y, Maeda J, Yamada M, Takahata K, Yokokawa K, Ikoma Y, Seki C, Ito H, Higuchi M, Suhara T: Measurement of psychological state changes at low dopamine transporter occupancy following a clinical dose of mazindol. Psychopharmacology 2016:1–6.
  148. Kimura Y, Seki C, Ikoma Y, Ichise M, Kawamura K, Takahata K, Moriguchi S, Nagashima T, Ishii T, Kitamura S: [11C] TASP457, a novel PET ligand for histamine H3 receptors in human brain. European journal of nuclear medicine and molecular imaging 2016:1-11.
  149. Knudsen GM, Jensen PS, Erritzoe D, Baaré WF, Ettrup A, Fisher PM, Gillings N, Hansen HD, Hansen LK, Hasselbalch SG et al: The Center for Integrated Molecular Brain Imaging (Cimbi) database. NeuroImage 2016, 124:1213–1219.
  150. Köfalvi A, Lemos C, Martín-Moreno AM, Pinheiro BS, García-García L, Pozo MA, Valério-Fernandes Â, Beleza RO, Agostinho P, Rodrigues RJ: Stimulation of brain glucose uptake by cannabinoid CB 2 receptors and its therapeutic potential in Alzheimer’s disease. Neuropharmacology 2016.
  151. Kong X, Luo S, Wu JR, Wu S, De Cecco CN, Schoepf UJ, Spandorfer AJ, Wang CY, Tian Y, Chen HJ: 18F-DPA-714 PET Imaging for Detecting Neuroinflammation in Rats with Chronic Hepatic Encephalopathy. Theranostics 2016, 6:1220.
  152. Kong Y, Guan Y, Hua F, Zhang Z, Lu X, Zhu T, Zhao B, Zhu J, Li C, Chen J: Optimization and Biodistribution of [11C]-TKF, An Analog of Tau Protein Imaging Agent [18F]-THK523. Molecules 2016, 21:1019.
  153. Kotsougiani D, Hundepool CA, Bulstra LF, Friedrich PF, Shin AY, Bishop AT: Recipient‐derived angiogenesis with short term immunosuppression increases bone remodeling in bone vascularized composite allotransplantation: A pilot study in a swine tibial defect model. Journal of Orthopaedic Research 2016.
  154. Kreisl WC, Lyoo CH, Liow J-S, Snow J, Page E, Jenko KJ, Morse CL, Zoghbi SS, Pike VW, Turner RS: Distinct patterns of increased translocator protein in posterior cortical atrophy and amnestic Alzheimer’s disease. Neurobiology of Aging 2016.
  155. Kreisl WC, Lyoo CH, Liow J-S, Wei M, Snow J, Page E, Jenko KJ, Morse CL, Zoghbi SS, Pike VW: 11 C-PBR28 binding to translocator protein increases with progression of Alzheimer’s disease. Neurobiology of Aging 2016, 44:53-61.
  156. Kristian A, Holtedahl JE, Torheim T, Futsaether C, Hernes E, Engebraaten O, Mælandsmo GM, Malinen E: Dynamic 2-Deoxy-2-[18F] Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts. Molecular Imaging and Biology 2016:1-9.
  157. Krohn T, Birmes A, Winz OH, Drude NI, Mottaghy FM, Behrendt FF, Verburg FA: The reconstruction algorithm used for [68Ga] PSMA-HBED-CC PET/CT reconstruction significantly influences the number of detected lymph node metastases and coeliac ganglia. European Journal of Nuclear Medicine and Molecular Imaging 2016:1-8.
  158. Kurland BF, Peterson LM, Lee JH, Schubert EK, Currin ER, Link JM, Krohn KA, Mankoff DA, Linden HM: Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer. Clinical Cancer Research 2016.
  159. Kwee SA, Sato MM, Kuang Y, Franke A, Custer L, Miyazaki K, Wong LL: [18F] Fluorocholine PET/CT Imaging of Liver Cancer: Radiopathologic Correlation with Tissue Phospholipid Profiling. Molecular Imaging and Biology 2016:1-10.
  160. Le Foll B, Payer D, Di Ciano P, Guranda M, Nakajima S, Tong J, Mansouri E, Wilson AA, Houle S, Meyer JH: Occupancy of Dopamine D3 and D2 Receptors by Buspirone: A [ 11C]-(+)-PHNO PET Study in Humans. Neuropsychopharmacology 2016, 41:529-537.
  161. Ledermann K, Jenewein J, Sprott H, Hasler G, Schnyder U, Warnock G, Johayem A, Kollias S, Buck A, Martin-Soelch C: Relation of dopamine receptor 2 binding to pain perception in female fibromyalgia patients with and without depression–A [11 C] raclopride PET-study. European Neuropsychopharmacology 2016, 26:320-330.
  162. Lee J-H, Ryu YH, Lyoo CH, Choi S-H, Kim J-J, Choi JY: Optimal timing of [18 F] Mefway PET for imaging the serotonin 1A receptor in healthy male subjects. Applied Radiation and Isotopes 2016, 107:127–132.
  163. Lee SB, Ahn SB, Lee S-W, Jeong SY, Ghilsuk Y, Ahn B-C, Kim E-M, Jeong H-J, Lee J, Lim D-K: Radionuclide-embedded gold nanoparticles for enhanced dendritic cell-based cancer immunotherapy, sensitive and quantitative tracking of dendritic cells with PET and Cerenkov luminescence. NPG Asia Materials 2016, 8:e281.
  164. Lee SB, Yoon G, Lee SW, Jeong SY, Ahn BC, Lim DK, Lee J, Jeon YH: Combined Positron Emission Tomography and Cerenkov Luminescence Imaging of Sentinel Lymph Nodes Using PEGylated Radionuclide‐Embedded Gold Nanoparticles. Small 2016, 12:4894-4901.
  165. Lerner RP, Bimpisidis Z, Agorastos S, Scherrer S, Dewey SL, Cenci MA, Eidelberg D: Dissociation of metabolic and hemodynamic levodopa responses in the 6-hydroxydopamine rat model. Neurobiology of Disease 2016, 96:31-37.
  166. Leurquin-Sterk G, Van den Stock J, Crunelle CL, de Laat B, Weerasekera A, Himmelreich U, Bormans G, Van Laere K: Positive Association Between Limbic Metabotropic Glutamate Receptor 5 Availability and Novelty-Seeking Temperament in Humans: a 18F-FPEB PET study. Journal of Nuclear Medicine 2016:jnumed-116.
  167. Leurquin‐Sterk G, Postnov A, De Laat B, Casteels C, Celen S, Crunelle CL, Bormans G, Koole M, Van Laere K: Kinetic modeling and long‐term test‐retest reproducibility of the mGluR5 PET tracer 18F‐FPEB in human brain. Synapse 2016.
  168. Leyton CE, Cassidy B, Villemagne VL, Jones G, Kwok JB, Rowe CC, Ballard KJ, Piguet O, Hodges JR: Divergent Network Patterns of Amyloid-β Deposition in Logopenic and Amnestic Alzheimer’s Disease Presentations. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 2016, 1:24–31.
  169. Li CT, Juan CH, Su TP, Liou YJ, Chen MH: Transcranial Magnetic Stimulation-Derived Motor Parameters and Regional Glucose Metabolism of Motor Cortex. J Neurol Neurophysiol 2016, 7:386.
  170. Li C-T, Chen M-H, Lin W-C, Hong C-J, Yang B-H, Liu R-S, Tu P-C, Su T-P: The effects of low‐dose ketamine on the prefrontal cortex and amygdala in treatment‐resistant depression: A randomized controlled study. Human brain mapping 2016, 37:1080-1090.
  171. Li K-C, Lo S-C, Sung L-Y, Liao Y-H, Chang Y-H, Hu Y-C: Improved calvarial bone repair by hASCs engineered with Cre/loxP‐based baculovirus conferring prolonged BMP‐2 and MiR‐148b co‐expression. Journal of Tissue Engineering and Regenerative Medicine 2016.
  172. Liga R, Vontobel J, Rovai D, Marinelli M, Caselli C, Pietila M, Teresinska A, Aguadé-Bruix S, Pizzi MN, Todiere G: Multicentre multi-device hybrid imaging study of coronary artery disease: results from the EValuation of INtegrated Cardiac Imaging for the Detection and Characterization of Ischaemic Heart Disease (EVINCI) hybrid imaging population. Eur Heart J Cardiovasc Imaging 2016:jew038.
  173. Lin C-Y, Cheng Y-S, Liao T-Y, Lin C, Chen Z-t, Twu W-I, Chang C-W, Tan DT-W, Liu R-S, Tu P-h: Intranasal Administration of a Polyethylenimine-Conjugated Scavenger Peptide Reduces Amyloid-β Accumulation in a Mouse Model of Alzheimer’s Disease. Journal of Alzheimer’s Disease 2016:1-15.
  174. Lindbo S, Garousi J, \AAstrand M, Honarvar H, Orlova A, Hober S, Tolmachev V: Influence of histidine-containing tags on the biodistribution of ADAPT scaffold proteins. Bioconjugate chemistry 2016.
  175. Liu M, Fang W, Liu S: Novel 99mTc (III) Complexes [99mTcCl (CDO)(CDOH) 2B–R](CDOH2= Cyclohexanedione Dioxime) Useful as Radiotracers for Heart Imaging. Bioconjugate Chemistry 2016, 27:2770-2779.
  176. Liu M, Zheng Y, Avcibasi U, Liu S: Novel 99m Tc (III)-azide complexes [99m Tc (N 3)(CDO)(CDOH) 2 BR](CDOH 2= cyclohexanedione dioxime) as potential radiotracers for heart imaging. Nuclear Medicine and Biology 2016.
  177. Liu N-W, Ke C-C, Zhao Y, Chen Y-A, Chan K-C, Tan DT-W, Lee J-S, Chen Y-Y, Hsu T-W, Hsieh Y-J: Evolutional Characterization of Photochemically Induced Stroke in Rats: a Multimodality Imaging and Molecular Biological Study. Translational Stroke Research 2016:1-13.
  178. Lohmann P, Stoffels G, Ceccon G, Rapp M, Sabel M, Filss CP, Kamp MA, Stegmayr C, Neumaier B, Shah NJ: Radiation injury vs. recurrent brain metastasis: combining textural feature radiomics analysis and standard parameters may increase 18F-FET PET accuracy without dynamic scans. European Radiology 2016:1-12.
  179. Lohmann P, Willuweit A, Neffe AT, Geisler S, Gebauer TP, Beer S, Coenen HH, Fischer H, Hermanns-Sachweh B, Lendlein A: Bone regeneration induced by a 3D architectured hydrogel in a rat critical-size calvarial defect. Biomaterials 2017, 113:158-169.
  180. Longo DL, Michelotti F, Consolino L, Bardini P, Digilio G, Xiao G, Sun PZ, Aime S: In Vitro and In Vivo Assessment of Nonionic Iodinated Radiographic Molecules as Chemical Exchange Saturation Transfer Magnetic Resonance Imaging Tumor Perfusion Agents. Investigative radiology 2016, 51:155-162.
  181. Lou HC, Rosenstand A, Brooks DJ, Bender D, Jakobsen S, Blicher JU, Hansen KV, Møller A: Exogenous dopamine reduces GABA receptor availability in the human brain. Brain and behavior 2016.
  182. Ma K-H, Liu T-T, Weng S-J, Chen C-FF, Huang Y-S, Chueh S-H, Liao M-H, Chang K-W, Sung C-C, Hsu T-H: Effects of dextromethorphan on MDMA-induced serotonergic aberration in the brains of non-human primates using [123I]-ADAM/SPECT. Scientific Reports 2016, 6:38695.
  183. Martín A, Vázquez-Villoldo N, Gómez-Vallejo V, Padro D, Soria FN, Szczupak B, Plaza-García S, Arrieta A, Reese T, Llop J: In vivo imaging of system xc-as a novel approach to monitor multiple sclerosis. European journal of nuclear medicine and molecular imaging 2016, 43:1124-1138.
  184. Martínez-Vélez N, Xipell E, Vera B, de la Rocha AA, Zalacain M, Marrodán L, Gonzalez-Huarriz M, Toledo G, Cascallo M, Alemany R: The oncolytic adenovirus VCN-01 as therapeutic approach against pediatric osteosarcoma. Clinical Cancer Research 2016, 22:2217-2225.
  185. Matsuo Y, Ogawa T, Yamamoto M, Shibamoto A, Sáenz JRV, Yokoyama M, Kanda Y, Toyohara J, Sasaki K: Evaluation of peri-implant bone metabolism under immediate loading using high-resolution Na18F-PET. Clinical Oral Investigations 2016:1-9.
  186. Matsuoka K, Yasuno F, Shinkai T, Miyasaka T, Takahashi M, Kiuchi K, Kosaka J, Inoue M, Kichikawa K, Hasegawa M: Test-retest reproducibility of extrastriatal binding with 123 I-FP-CIT SPECT in healthy male subjects. Psychiatry Research: Neuroimaging 2016, 258:10-15.
  187. Matsuura Y, Ueda M, Higaki Y, Watanabe K, Habara S, Kamino S, Saji H, Enomoto S: Noninvasive evaluation of nicotinic acetylcholine receptor availability in mouse brain using single-photon emission computed tomography with [123 I] 5IA. Nuclear medicine and biology 2016, 43:372-378.
  188. Mazère J, Lamare F, Fernandez P, Allard M, Mayo W: 123I-iodobenzovesamicol SPECT Imaging of Cholinergic Systems in Dementia with Lewy Bodies. Journal of Nuclear Medicine 2016:jnumed. 116.176180.
  189. McGuire SM, Bhatia SK, Sun W, Jacobson GM, Menda Y, Ponto LLB, Smith BJ, Gross BA, Bayouth JE, Sunderland J: Using FLT PET to quantify and reduce hematologic toxicity due to chemoradiation therapy for pelvic cancer patients. International Journal of Radiation Oncology* Biology* Physics 2016.
  190. Meckel M, Kubíček V, Hermann P, Miederer M, Rösch F: A DOTA based bisphosphonate with an albumin binding moiety for delayed body clearance for bone targeting. Nuclear Medicine and Biology 2016, 43:670-678.
  191. Médoc M, Dhilly M, Matesic L, Toutain J, Krause-Heuer AM, Delamare J, Fraser BH, Touzani O, Barré L, Greguric I et al: In Vivo Evaluation of Radiofluorinated Caspase-3/7 Inhibitors as Radiotracers for Apoptosis Imaging and Comparison with [18F] ML-10 in a Stroke Model in the Rat. Molecular Imaging and Biology 2016, 18:117–126.
  192. Meletta R, Herde AM, Dennler P, Fischer E, Schibli R, Krämer SD: Preclinical imaging of the co-stimulatory molecules CD80 and CD86 with indium-111-labeled belatacept in atherosclerosis. EJNMMI research 2016, 6:1.
  193. Mitran B, Varasteh Z, Selvaraju RK, Lindeberg G, Sörensen J, Larhed M, Tolmachev V, Rosenström U, Orlova A: Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26. International journal of oncology 2016, 48:2124-2134.
  194. Mitsui K, Morimoto N, Niwa T, Yamaura Y, Ohba H, Tsukada H, Katsumata S: Quantification of ONO-2952 occupancy of translocator protein 18kDa in conscious monkey brain using positron emission tomography. Journal of Pharmacology and Experimental Therapeutics 2016:jpet. 116.238568.
  195. Momosaki S, Ito M, Yamato H, Iimori H, Sumiyoshi H, Morimoto K, Imamoto N, Watabe T, Shimosegawa E, Hatazawa J: Longitudinal imaging of the availability of dopamine transporter and D2 receptor in rat striatum following mild ischemia. Journal of Cerebral Blood Flow & Metabolism 2016:0271678X16635183.
  196. Moraga A, Gómez-Vallejo V, Cuartero MI, Szczupak B, San Sebastián E, Markuerkiaga I, Pradillo JM, Higuchi M, Llop J, Moro MÁ et al: Imaging the role of toll-like receptor 4 on cell proliferation and inflammation after cerebral ischemia by positron emission tomography. Journal of Cerebral Blood Flow & Metabolism 2016:0271678X15627657.
  197. Moriguchi S, Kimura Y, Ichise M, Arakawa R, Takano H, Seki C, Ikoma Y, Takahata K, Nagashima T, Yamada M: PET quantification of the norepinephrine transporter in human brain with (S, S)-18F-FMeNER-D2. Journal of Nuclear Medicine 2016:jnumed-116.
  198. Mu L, Müller Herde A, Rüefli PM, Sladojevich F, Milicevic Sephton S, Krämer SD, Thompson AJ, Schibli R, Ametamey SM, Lochner M: Synthesis and Pharmacological Evaluation of [11C] granisetron and [18F] fluoropalonosetron as PET Probes for 5-HT3 Receptor Imaging. ACS chemical neuroscience 2016, 7:1552-1564.
  199. Mukherjee J, Majji D, Kaur J, Constantinescu CC, Narayanan TK, Shi B, Nour MT, Pan M-L: PET radiotracer development for imaging high‐affinity state of dopamine D2 and D3 receptors: Binding studies of fluorine‐18 labeled aminotetralins in rodents. Synapse 2016.
  200. Nag S, Fazio P, Lehmann L, Kettschau G, Heinrich T, Thiele A, Svedberg M, Amini N, Leesch S, Catafau AM: In Vivo and In Vitro Characterization of a Novel MAO-B Inhibitor Radioligand, 18F-Labeled Deuterated Fluorodeprenyl. Journal of Nuclear Medicine 2016, 57:315-320.
  201. Nagai Y, Kikuchi E, Lerchner W, Inoue K-i, Ji B, Eldridge MA, Kaneko H, Kimura Y, Oh-Nishi A, Hori Y: PET imaging-guided chemogenetic silencing reveals a critical role of primate rostromedial caudate in reward evaluation. Nature Communications 2016, 7:13605.
  202. Neveu M-A, De Preter G, Marchand V, Bol A, Brender JR, Saito K, Kishimoto S, Porporato PE, Sonveaux P, Grégoire V: Multimodality Imaging Identifies Distinct Metabolic Profiles In Vitro and In Vivo. Neoplasia 2016, 18:742-752.
  203. Neyt S, Vliegen M, Verreet B, De Lombaerde S, Braeckman K, Vanhove C, Huisman MT, Dumolyn C, Kersemans K, Hulpia F: Synthesis, in vitro and in vivo small-animal SPECT evaluation of novel technetium labeled bile acid analogues to study (altered) hepatic transporter function. Nuclear Medicine and Biology 2016, 43:642-649.
  204. Ng S-H, Liao C-T, Lin C-Y, Chan S-C, Lin Y-C, Yen T-C, Chang JT-C, Ko S-F, Fan K-H, Wang H-M: Dynamic contrast-enhanced MRI, diffusion-weighted MRI and 18F-FDG PET/CT for the prediction of survival in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation. European radiology 2016:1-11.
  205. Nikolaus S, Beu M, Angelica De Souza Silva M, Huston JP, Hautzel H, Antke C, Müller HW: DAT versus D2 receptor binding in the rat striatum: l‐DOPA‐induced motor activity is better predicted by reuptake than release of dopamine. Synapse 2016.
  206. Nishino A, Tajima Y, Takuwa H, Masamoto K, Taniguchi J, Wakizaka H, Kokuryo D, Urushihata T, Aoki I, Kanno I: Long-term effects of cerebral hypoperfusion on neural density and function using misery perfusion animal model. Scientific reports 2016, 6.
  207. Nitzsche B, Barthel H, Lobsien D, Boltze J, Zeisig V, Dreyer AY: Focal Cerebral Ischemia by Permanent Middle Cerebral Artery Occlusion in Sheep: Surgical Technique, Clinical Imaging, and Histopathological Results. Experimental Neurosurgery in Animal Models 2016:195-225.
  208. Nkoulou R, Fuchs TA, Pazhenkottil AP, Kuest SM, Ghadri JR, Stehli J, Fiechter M, Herzog BA, Gaemperli O, Buechel RR: Absolute Myocardial Blood Flow and Flow Reserve Assessed by Gated SPECT with Cadmium–Zinc–Telluride Detectors Using 99mTc-Tetrofosmin: Head-to-Head Comparison with 13N-Ammonia PET. Journal of Nuclear Medicine 2016, 57:1887-1892.
  209. Novy J, Allenbach G, Bien CG, Guedj E, Prior JO, Rossetti AO: FDG-PET hyperactivity pattern in anti-NMDAr encephalitis. Journal of Neuroimmunology 2016.
  210. Nugent S, Castellano CA, Bocti C, Dionne I, Fulop T, Cunnane SC: Relationship of metabolic and endocrine parameters to brain glucose metabolism in older adults: do cognitively-normal older adults have a particular metabolic phenotype? Biogerontology 2016, 17:241–255.
  211. Nummenmaa L, Tuominen L, Dunbar R, Hirvonen J, Manninen S, Arponen E, Machin A, Hari R, Jääskeläinen IP, Sams M: Social Touch Modulates Endogenous μ-opioid System Activity in Humans. NeuroImage 2016.
  212. Ohba H, Kanazawa M, Kakiuchi T, Tsukada H: Effects of acetaminophen on mitochondrial complex I activity in the rat liver and kidney: a PET study with 18F-BCPP-BF. EJNMMI research 2016, 6:82.
  213. Okita K, Ghahremani DG, Payer DE, Robertson CL, Dean AC, Mandelkern MA, London ED: Emotion dysregulation and amygdala dopamine D2-type receptor availability in methamphetamine users. Drug and alcohol dependence 2016, 161:163-170.
  214. Okita K, Ghahremani DG, Payer DE, Robertson CL, Mandelkern MA, London ED: Relationship of Alexithymia Ratings to Dopamine D2-type Receptors in Anterior Cingulate and Insula of Healthy Control Subjects but Not Methamphetamine-Dependent Individuals. International Journal of Neuropsychopharmacology 2016, 19:pyv129.
  215. Okita K, Mandelkern MA, London ED: Cigarette Use and Striatal Dopamine D2/3 Receptors: Possible Role in the Link between Smoking and Nicotine Dependence. International Journal of Neuropsychopharmacology 2016, 19:pyw074.
  216. Okita K, Petersen N, Robertson CL, Dean AC, Mandelkern MA, London ED: Sex differences in midbrain dopamine D2-type receptor availability and association with nicotine dependence. Neuropsychopharmacology 2016, 41:2913-2919.
  217. Olberg DE, Bauer N, Andressen KW, Hjørnevik T, Cumming P, Levy FO, Klaveness J, Haraldsen I, Sutcliffe JL: Brain penetrant small molecule 18 F-GnRH receptor (GnRH-R) antagonists: Synthesis and preliminary positron emission tomography imaging in rats. Nuclear medicine and biology 2016, 43:478-489.
  218. Ory D, Celen S, Gijsbers R, Van Den Haute C, Postnov A, Koole M, Vandeputte C, Andrés J-I, De Angelis M, Langlois X: Preclinical evaluation of a P2X7 receptor selective radiotracer: PET studies in a rat model with local overexpression of the human P2X7 receptor and in non-human primates. Journal of Nuclear Medicine 2016:jnumed. 115.169995.
  219. Ory D, Postnov A, Koole M, Celen S, de Laat B, Verbruggen A, Van Laere K, Bormans G, Casteels C: Quantification of TSPO overexpression in a rat model of local neuroinflammation induced by intracerebral injection of LPS by the use of [18F] DPA-714 PET. European journal of nuclear medicine and molecular imaging 2016, 43:163–172.
  220. Overhoff F, Brendel M, Jaworska A, Korzhova V, Delker A, Probst F, Focke C, Gildehaus F-J, Carlsen J, Baumann K: Automated spatial brain normalization and hindbrain white matter reference tissue give improved [18F]-florbetaben PET quantitation in Alzheimer’s model mice. Frontiers in neuroscience 2016, 10.
  221. Özbay PS, Warnock G, Rossi C, Kuhn F, Akin B, Pruessmann KP, Nanz D: Probing neuronal activation by functional quantitative susceptibility mapping under a visual paradigm: A group level comparison with BOLD fMRI and PET. NeuroImage 2016.
  222. Pajak MZ, Volgyes D, Pimlott SL, Salvador CC, Asensi AS, McKeown C, Waldeck J, Anderson KI: NEMA NU4-2008 Performance Evaluation of Albira: A Two-Ring Small-Animal PET System Using Continuous LYSO Crystals. Open Medicine Journal 2016, 3.
  223. Pak K, Lee SH, Lee JG, Seok JW, Kim IJ: Comparison of Visceral Fat Measures with Cardiometabolic Risk Factors in Healthy Adults. PloS one 2016, 11:e0153031.
  224. Pan M-L, Mukherjee MT, Patel HH, Patel B, Constantinescu CC, Mirbolooki MR, Liang C, Mukherjee J: Evaluation of [11C] TAZA for amyloid β plaque imaging in postmortem human Alzheimer’s disease brain region and whole body distribution in rodent PET/CT. Synapse 2016.
  225. Parente A, Feltes PK, García DV, Sijbesma JW, Jeckel CMM, Dierckx RA, de Vries EF, Doorduin J: Pharmacokinetic Analysis of 11C-PBR28 in the Rat Model of Herpes Encephalitis: Comparison with (R)-11C-PK11195. Journal of Nuclear Medicine 2016, 57:785-791.
  226. Parthoens J, Verhaeghe J, Servaes S, Miranda A, Stroobants S, Staelens S: Performance Characterization of an Actively Cooled Repetitive Transcranial Magnetic Stimulation Coil for the Rat. Neuromodulation: Technology at the Neural Interface 2016.
  227. Pedersen L, Jensen JB, Wogensen L, Munk OL, Jessen N, Frøki\a er J, Jakobsen S: Renal PET-imaging with 11 C-metformin in a transgenic mouse model for chronic kidney disease. EJNMMI research 2016, 6:54.
  228. Peng K-T, Hsieh M-Y, Lin CT, Chen C-F, Lee MS, Huang Y-Y, Chang P-J: Treatment of critically sized femoral defects with recombinant BMP-2 delivered by a modified mPEG-PLGA biodegradable thermosensitive hydrogel. BMC Musculoskeletal Disorders 2016, 17:286.
  229. Perrone M, Moon BS, Park HS, Laquintana V, Jung JH, Cutrignelli A, Lopedota A, Franco M, Kim SE, Lee BC: A novel PET imaging probe for the detection and monitoring of translocator protein 18 kDa expression in pathological disorders. Scientific reports 2016, 6.
  230. Petrik M, Zhai C, Novy Z, Urbanek L, Haas H, Decristoforo C: In vitro and in vivo comparison of selected Ga-68 and Zr-89 labelled siderophores. Molecular Imaging and Biology 2016, 18:344-352.
  231. Pfeifer P, Tüscher O, Buchholz HG, Gründer G, Vernaleken I, Paulzen M, Zimmermann US, Maus S, Lieb K, Eggermann T: Acute effect of intravenously applied alcohol in the human striatal and extrastriatal D2/D3 dopamine system. Addiction Biology 2016.
  232. Pflugrad H, Meyer G-J, Dirks M, Raab P, Tryc AB, Goldbecker A, Worthmann H, Wilke F, Boellaard R, Yaqub M et al: Cerebral microglia activation in hepatitis C virus infection correlates to cognitive dysfunction. Journal of Viral Hepatitis 2016.
  233. Pluhacek T, Petrik M, Luptakova D, Benada O, Palyzova A, Lemr K, Havlicek V: Aspergillus infection monitored by multimodal imaging in a rat model. Proteomics 2016.
  234. Porrino LJ, Miller MD, Smith HR, Nader SH, Nader MA: Neural Correlates of Exposure to Cocaine Cues in Rhesus Monkeys: Modulation by the Dopamine Transporter. Biological psychiatry 2016.
  235. Portnoy E, Polyak B, Inbar D, Kenan G, Rai A, Wehrli SL, Roberts TP, Bishara A, Mann A, Shmuel M: Tracking inflammation in the epileptic rat brain by bi-functional fluorescent and magnetic nanoparticles. Nanomedicine: Nanotechnology, Biology and Medicine 2016, 12:1335-1345.
  236. Pottier G, Marie S, Goutal S, Auvity S, Peyronneau M-A, Stute S, Boisgard R, Dollé F, Buvat I, Caillé F: Imaging the impact of the P-glycoprotein (ABCB1) function on the brain kinetics of metoclopramide. Journal of Nuclear Medicine 2016, 57:309-314.
  237. Pravenec M, Mlejnek P, Zidek V, Landa V, Simakova M, Silhavy J, Strnad H, Eigner S, Eigner-Henke K, Skop V: Autocrine effects of transgenic resistin reduce palmitate and glucose oxidation in brown adipose tissue in spontaneously hypertensive rat. Physiological genomics 2016:physiolgenomics. 00122.02015.
  238. Pretze M, Pallavi P, Roscher M, Klotz S, Caballero J, Binzen U, Greffrath W, Treede R-D, Harmsen MC, Hafner M: Radiofluorinated N-Octanoyl Dopamine ([18F] F-NOD) as tool to study tissue distribution and elimination of NOD in vitro and in vivo. Journal of Medicinal Chemistry 2016.
  239. Rahmim A, Salimpour Y, Jain S, Blinder SA, Klyuzhin IS, Smith GS, Mari Z, Sossi V: Application of texture analysis to DAT SPECT imaging: relationship to clinical assessments. NeuroImage: Clinical 2016.
  240. Ramage LE, Akyol M, Fletcher AM, Forsythe J, Nixon M, Carter RN, van Beek EJ, Morton NM, Walker BR, Stimson RH: Glucocorticoids Acutely Increase Brown Adipose Tissue Activity in Humans, Revealing Species-Specific Differences in UCP-1 Regulation. Cell Metabolism 2016, 24:130-141.
  241. Rapic S, Vangestel C, Verhaeghe J, Thomae D, Pauwels P, Van den Wyngaert T, Staelens S, Stroobants S: Evaluation of [18F] fluorothymidine as a biomarker for early therapy response in a mouse model of colorectal cancer. Molecular Imaging and Biology 2016:1-11.
  242. Reid WC, Casas R, Papadakis GZ, Muthusamy S, Lee DE, Ibrahim WG, Nair A, Koziol D, Maric D, Hammoud DA: Neurobehavioral Abnormalities in the HIV-1 Transgenic Rat Do Not Correspond to Neuronal Hypometabolism on 18 F-FDG-PET. PloS one 2016, 11:e0152265.
  243. Rodríguez-Cueto C, Hernández-Gálvez M, Hillard CJ, Maciel P, García-García L, Valdeolivas S, Pozo MA, Ramos JA, Gómez-Ruiz M, Fernández-Ruiz J: Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3. Neuroscience 2016, 339:191-209.
  244. Rodriguez-Vieitez E, Carter SF, Chiotis K, Saint-Aubert L, Leuzy A, Schöll M, Almkvist O, Wall A, Långström B, Nordberg A: Comparison of Early-Phase 11C-Deuterium-L-Deprenyl and 11C-PiB PET for Assessing Brain Perfusion in Alzheimer’s Disease. Journal of Nuclear Medicine 2016:jnumed. 115.168732.
  245. Roelcke U, Wyss MT, Nowosielski M, Rudà R, Roth P, Hofer S, Galldiks N, Crippa F, Weller M, Soffietti R: Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. Neuro-oncology 2016, 18:744-751.
  246. Roffman JL, Tanner AS, Eryilmaz H, Rodriguez-Thompson A, Silverstein NJ, Ho NF, Nitenson AZ, Chonde DB, Greve DN, Abi-Dargham A: Dopamine D1 signaling organizes network dynamics underlying working memory. Science Advances 2016, 2:e1501672.
  247. Rotstein BH, Placzek MS, Krishnan HS, Pekošak A, Collier TL, Wang C, Liang SH, Burstein ES, Hooker JM, Vasdev N: Preclinical PET neuroimaging of [11C] bexarotene. Molecular imaging 2016, 15.
  248. Rullmann M, Dukart J, Hoffmann K-T, Luthardt J, Tiepolt S, Patt M, Gertz H-J, Schroeter ML, Seibyl J, Schulz-Schaeffer WJ: Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans. Journal of Nuclear Medicine 2016, 57:198-203.
  249. Sachpekidis C, Kopka K, Eder M, Hadaschik BA, Freitag MT, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A: 68Ga-PSMA-11 Dynamic PET/CT imaging in primary prostate cancer. Clinical Nuclear Medicine 2016, 41:e473-e479.
  250. Saint-Aubert L, Almkvist O, Chiotis K, Almeida R, Wall A, Nordberg A: Regional tau deposition measured by [18 F] THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer’s disease. Alzheimer’s Research & Therapy 2016, 8:38.
  251. Santoro GC, Shukla S, Patel K, Kaczmarzyk J, Agorastos S, Choi YY, Veith C, Carrion J, Silverman R, Mullin D et al: A Novel Strategy for Attenuating Opioid Withdrawal in Neonates. J Addict Res Ther 2016, 7:2.
  252. Sasaki T, Kobayashi K, Kita S, Kojima K, Hirano H, Shen L, Takenaka F, Kumon H, Matsuura E: In vivo distribution of single chain variable fragment (scFv) against atherothrombotic oxidized LDL/β 2-glycoprotein I complexes into atherosclerotic plaques of WHHL rabbits: Implication for clinical PET imaging. Autoimmunity Reviews 2016.
  253. Savolainen H, Meerlo P, Elsinga PH, Windhorst AD, Dierckx RA, Colabufo NA, van Waarde A, Luurtsema G: P-glycoprotein Function in the Rodent Brain Displays a Daily Rhythm, a Quantitative In Vivo PET Study. The AAPS Journal 2016, 18:1524-1531.
  254. Savolainen H, Windhorst AD, Elsinga PH, Cantore M, Colabufo NA, Willemsen AT, Luurtsema G: Evaluation of [18 F] MC225 as a PET radiotracer for measuring P-glycoprotein function at the blood-brain barrier in rats; kinetics, metabolism, and selectivity. J Cereb Blood Flow Metab 2016.
  255. Schabel C, Gatidis S, Bongers M, Hüttig F, Bier G, Kupferschlaeger J, Bamberg F, la Fougère C, Nikolaou K, Pfannenberg C: Improving CT-Based PET Attenuation Correction in the Vicinity of Metal Implants by an Iterative Metal Artifact Reduction Algorithm of CT Data and Its Comparison to Dual-Energy–Based Strategies: A Phantom Study. Investigative Radiology 2017, 52:61-65.
  256. Schankin CJ, Maniyar FH, Seo Y, Kori S, Eller M, Chou DE, Blecha J, Murphy ST, Hawkins RA, Sprenger T: Ictal lack of binding to brain parenchyma suggests integrity of the blood–brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine. Brain 2016:aww096.
  257. Schipke CG, Koglin N, Bullich S, Joachim LK, Haas B, Seibyl J, Barthel H, Sabri O, Peters O: Correlation of florbetaben PET imaging and the amyloid peptide Aß42 in cerebrospinal fluid. Psychiatry Research: Neuroimaging 2016.
  258. Schmitt CC, Aranias T, Viel T, Chateau D, Le Gall M, Waligora-Dupriet A-J, Melchior C, Rouxel O, Kapel N, Gourcerol G: Intestinal invalidation of the glucose transporter GLUT2 delays tissue distribution of glucose and reveals an unexpected role in gut homeostasis. Molecular Metabolism 2016.
  259. Schmitt S, Delamare J, Tirel O, Fillesoye F, Dhilly M, Perrio C: N-[18 F]-FluoropropylJDTic for κ-opioid receptor PET imaging: Radiosynthesis, pre-clinical evaluation, and metabolic investigation in comparison with parent JDTic. Nuclear Medicine and Biology 2017, 44:50-61.
  260. Schweifer A, Maier F, Ehrlichmann W, Lamparter D, Kneilling M, Pichler BJ, Hammerschmidt F, Reischl G: [18 F] Fluoro-azomycin-2´-deoxy-β-d-ribofuranoside—A new imaging agent for tumor hypoxia in comparison with [18 F] FAZA. Nuclear Medicine and Biology 2016, 43:759-769.
  261. Seith F, Gatidis S, Schmidt H, Bezrukov I, la Fougère C, Nikolaou K, Pfannenberg C, Schwenzer N: Comparison of Positron Emission Tomography Quantification Using Magnetic Resonance–and Computed Tomography–Based Attenuation Correction in Physiological Tissues and Lesions: A Whole-Body Positron Emission Tomography/Magnetic Resonance Study in 66 Patients. Investigative radiology 2016, 51:66–71.
  262. Sekine T, Buck A, Delso G, ter Voert EE, Huellner M, Veit-Haibach P, Warnock G: Evaluation of atlas-based attenuation correction for integrated PET/MR in human brain: application of a head atlas and comparison to true CT-based attenuation correction. Journal of Nuclear Medicine 2016, 57:215-220.
  263. Sekine T, Burgos N, Warnock G, Huellner MW, Buck A, ter Voert EE, Cardoso MJ, Hutton BF, Ourselin S, Veit-Haibach P et al: Multi atlas-based attenuation correction for brain FDG-PET imaging using a TOF-PET/MR scanner–comparison with clinical single atlas-and CT-based attenuation correction. Journal of Nuclear Medicine 2016:jnumed–115.
  264. Sekine T, ter Voert EE, Warnock G, Buck A, Huellner M, Veit-Haibach P, Delso G: Clinical Evaluation of Zero-Echo-Time Attenuation Correction for Brain 18F-FDG PET/MRI: Comparison with Atlas Attenuation Correction. Journal of Nuclear Medicine 2016, 57:1927–1932.
  265. Servaes S, Glorie D, Verhaeghe J, Stroobants S, Staelens S: [18F]-FDG PET neuroimaging in rats with quinpirole-induced checking behavior as a model for obsessive compulsive disorder. Psychiatry Research: Neuroimaging 2016, 257:31-38.
  266. Shah D, Deleye S, Verhoye M, Staelens S, Van der Linden A: Resting-state functional MRI and [18F]-FDG PET demonstrate differences in neuronal activity between commonly used mouse strains. NeuroImage 2016, 125:571–577.
  267. Shcherbinin S, Schwarz AJ, Joshi AD, Navitsky M, Flitter M, Shankle WR, Devous MD, Mintun MA: Kinetics of the tau PET tracer 18F-AV-1451 (T807) in subjects with normal cognitive function, mild cognitive impairment and Alzheimer’s disease. Journal of Nuclear Medicine 2016:jnumed–115.
  268. Shi K, Bayer C, Astner ST, Gaertner FC, Vaupel P, Schwaiger M, Huang S-C, Ziegler SI: Quantitative Analysis of [18F] FMISO PET for Tumor Hypoxia: Correlation of Modeling Results with Immunohistochemistry. Molecular Imaging and Biology 2016:1-10.
  269. Shingaki T, Katayama Y, Nakaoka T, Irie S, Onoe K, Okauchi T, Hayashinaka E, Yamaguchi M, Tanki N, Ose T et al: Visualization of drug translocation in the nasal cavity and pharmacokinetic analysis on nasal drug absorption using positron emission tomography in the rat. European Journal of Pharmaceutics and Biopharmaceutics 2016, 99:45–53.
  270. Shingaki T, Katayama Y, Nakaoka T, Takashima T, Onoe K, Okauchi T, Hayashinaka E, Wada Y, Cui Y, Watanabe Y: Exploration of Antiemetics for Osteoporosis Therapy-Induced Nausea and Vomiting Using PET Molecular Imaging Analysis to Gastrointestinal Pharmacokinetics. Pharmaceutical research 2016, 33:1235-1248.
  271. Shukuri M, Mawatari A, Ohno M, Suzuki M, Doi H, Watanabe Y, Onoe H: Detection of cyclooxygenase-1 in activated microglia during amyloid plaque progression: PET studies in Alzheimer’s disease model mice. Journal of Nuclear Medicine 2016, 57:291-296.
  272. Sijbesma JW, Zhou X, García DV, Houwertjes MC, Doorduin J, Kwizera C, Maas B, Meerlo P, Dierckx RA, Slart RH: Novel Approach to Repeated Arterial Blood Sampling in Small Animal PET: Application in a Test-Retest Study with the Adenosine A1 Receptor Ligand [11C] MPDX. Molecular Imaging and Biology 2016:1-9.
  273. Silva-Rodríguez J, García-Varela L, López-Arias E, Domínguez-Prado I, Cortés J, Pardo-Montero J, Fernández-Ferreiro A, Ruibal Á, Sobrino T, Aguiar P: Impact of benzodiazepines on brain FDG-PET quantification after single-dose and chronic administration in rats. Nuclear Medicine and Biology 2016, 43:827-834.
  274. Slavik R, Müller Herde A, Haider A, Krämer SD, Weber M, Schibli R, Ametamey SM, Mu L: Discovery of a fluorinated 4‐oxo‐quinoline derivative as a potential positron emission tomography radiotracer for imaging cannabinoid receptor type 2. Journal of Neurochemistry 2016, 138:874-886.
  275. Smith CT, Dang LC, Cowan RL, Kessler RM, Zald DH: Variability in paralimbic dopamine signaling correlates with subjective responses to d-amphetamine. Neuropharmacology 2016, 108:394-402.
  276. Smith R, Schain M, Nilsson C, Strandberg O, Olsson T, Hägerström D, Jögi J, Borroni E, Schöll M, Honer M: Increased basal ganglia binding of 18F‐AV‐1451 in patients with progressive supranuclear palsy. Movement Disorders 2016.
  277. Sneddon D, Niemans R, Bauwens M, Yaromina A, van Kuijk SJ, Lieuwes NG, Biemans R, Pooters I, Pellegrini PA, Lengkeek NA: Synthesis and in Vivo Biological Evaluation of 68Ga-Labeled Carbonic Anhydrase IX Targeting Small Molecules for Positron Emission Tomography. Journal of Medicinal Chemistry 2016, 59:6431-6443.
  278. Son HJ, Jeong YJ, Yoon HJ, Wang L, Kim HJ, Park J-H, Kang D-Y: Visual Pattern and Serial Quantitation of 18F-Sodium Fluoride PET/CT in Asymptomatic Patients After Hip and Knee Arthroplasty. Nuclear Medicine and Molecular Imaging 2016, 50:308-321.
  279. Spiegelberg D, Mortensen AC, Selvaraju RK, Eriksson O, Stenerlöw B, Nestor M: Molecular imaging of EGFR and CD44v6 for prediction and response monitoring of HSP90 inhibition in an in vivo squamous cell carcinoma model. European journal of nuclear medicine and molecular imaging 2016, 43:974-982.
  280. Sridharan S, Lepelletier F-X, Trigg W, Banister S, Reekie T, Kassiou M, Gerhard A, Hinz R, Boutin H: Comparative Evaluation of Three TSPO PET Radiotracers in a LPS-Induced Model of Mild Neuroinflammation in Rats. Molecular Imaging and Biology 2016:1-13.
  281. Stegmayr C, Schöneck M, Oliveira D, Willuweit A, Filss C, Galldiks N, Shah NJ, Coenen HH, Langen K-J: Reproducibility of O-(2-18F-fluoroethyl)-L-tyrosine uptake kinetics in brain tumors and influence of corticoid therapy: an experimental study in rat gliomas. European journal of nuclear medicine and molecular imaging 2016, 43:1115-1123.
  282. Suda M, Onoguchi M, Tomiyama T, Ishihara K, Takahashi N, Sakurai M, Matsumoto K, Kumita S-i: The reproducibility of time-of-flight PET and conventional PET for the quantification of myocardial blood flow and coronary flow reserve with 13N-ammonia. Journal of Nuclear Cardiology 2016, 23:457-472.
  283. Takaji M, Takemoto A, Yokoyama C, Watakabe A, Mizukami H, Ozawa K, Onoe H, Nakamura K, Yamamori T: Distinct roles for primate caudate dopamine D1 and D2 receptors in visual discrimination learning revealed using shRNA knockdown. Scientific Reports 2016, 6.
  284. Tamura Y, Takahashi K, Takata K, Eguchi A, Yamato M, Kume S, Nakano M, Watanabe Y, Kataoka Y: Noninvasive Evaluation of Cellular Proliferative Activity in Brain Neurogenic Regions in Rats under Depression and Treatment by Enhanced [18F] FLT-PET Imaging. Journal of Neuroscience 2016, 36:8123-8131.
  285. ter Voert EE, Delso G, de Galiza Barbosa F, Huellner M, Veit-Haibach P: The Effect of Defective PET Detectors in Clinical Simultaneous [18F] FDG Time-of-Flight PET/MR Imaging. Molecular Imaging and Biology 2016:1-10.
  286. ter Voert EE, Delso G, Porto M, Huellner M, Veit-Haibach P: Intravoxel Incoherent Motion Protocol Evaluation and Data Quality in Normal and Malignant Liver Tissue and Comparison to the Literature. Investigative Radiology 2016, 51:90–99.
  287. Terada T, Yokokura M, Yoshikawa E, Futatsubashi M, Kono S, Konishi T, Miyajima H, Hashizume T, Ouchi Y: Extrastriatal spreading of microglial activation in Parkinson’s disease: a positron emission tomography study. Annals of nuclear medicine 2016, 30:579-587.
  288. Testa A, Dall‘Angelo S, Mingarelli M, Augello A, Schweiger L, Welch A, Elmore CS, Sharma P, Zanda M: Design, Synthesis, In Vitro Characterization and Preliminary Imaging Studies on Fluorinated Bile Acid Derivatives as PET Tracers to Study Hepatic Transporters. Bioorganic & Medicinal Chemistry 2016.
  289. Thanos PK, Kim R, Delis F, Ananth M, Chachati G, Rocco MJ, Masad I, Muniz JA, Grant SC, Gold MS: Chronic Methamphetamine Effects on Brain Structure and Function in Rats. PloS one 2016, 11:e0155457.
  290. Thanos PK, Kim R, Delis F, Rocco MJ, Cho J, Volkow ND: Effects of chronic methamphetamine on psychomotor and cognitive functions and dopamine signaling in the brain. Behavioural Brain Research 2016.
  291. Thengone DJ, Voss HU, Fridman EA, Schiff ND: Local changes in network structure contribute to late communication recovery after severe brain injury. Science Translational Medicine 2016, 8:368re365-368re365.
  292. Thomas B, Molton J, Leek F, Totman J, Townsend D, Paton N: Comparison of 18F-FDG PET-CT and PET-MR imaging of pulmonary tuberculosis. Journal of Nuclear Medicine 2016, 57:546-546.
  293. Thomas BA, Cuplov V, Bousse A, Mendes A, Thielemans K, Hutton BF, Erlandsson K: PETPVC: a toolbox for performing partial volume correction techniques in positron emission tomography. Physics in Medicine and Biology 2016, 61:7975.
  294. Thongpraparn T, Ikoma Y, Shiraishi T, Yamaya T, Ito H: Effects of point spread function-based image reconstruction on neuroreceptor binding in positron emission tomography study with [11C] FLB 457. Radiological physics and technology 2016, 9:127–137.
  295. Tiepolt S, Hesse S, Patt M, Luthardt J, Schroeter ML, Hoffmann K-T, Weise D, Gertz H-J, Sabri O, Barthel H: Early [18F] florbetaben and [11C] PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer’s disease. European journal of nuclear medicine and molecular imaging 2016:1-10.
  296. Tompkins VS, Sompallae R, Rosean TR, Walsh S, Acevedo M, Kovalchuk AL, Han SS, Jing X, Holman C, Rehg JE: Transgenic mouse model of IgM+ lymphoproliferative disease mimicking Waldenström macroglobulinemia. Blood Cancer Journal 2016, 6:e488.
  297. Tóth M, Little P, Arnberg F, Häggkvist J, Mulder J, Halldin C, Gulyás B, Holmin S: Acute neuroinflammation in a clinically relevant focal cortical ischemic stroke model in rat: longitudinal positron emission tomography and immunofluorescent tracking. Brain Structure and Function 2016, 221:1279-1290.
  298. Tournier N, Goutal S, Auvity S, Traxl A, Mairinger S, Wanek T, Helal O-B, Buvat I, Soussan M, Caillé F: Strategies to inhibit ABCB1-and ABCG2-mediated efflux transport of erlotinib at the blood-brain barrier: a PET study in non-human primates. Journal of Nuclear Medicine 2016:jnumed. 116.178665.
  299. Toyohara J, Okamoto M, Aramaki H, Zaitsu Y, Shimizu I, Ishiwata K: (R)-[11 C] Emopamil as a novel tracer for imaging enhanced P-glycoprotein function. Nuclear medicine and biology 2016, 43:52–62.
  300. Tsartsalis S, Tournier BB, Huynh-Gatz T, Dumas N, Ginovart N, Moulin-Sallanon M, Millet P: 5-HT2A receptor SPECT imaging with [123 I] R91150 under P-gp inhibition with tariquidar: More is better? Nuclear medicine and biology 2016, 43:81–88.
  301. Tsukada H, Nishiyama S, Takahashi K: Imaging of Muscarinic Receptors in the Central Nervous System. Muscarinic Receptor: From Structure to Animal Models 2016:181–203.
  302. Tuszynski T, Rullmann M, Luthardt J, Butzke D, Tiepolt S, Gertz H-J, Hesse S, Seese A, Lobsien D, Sabri O et al: Evaluation of software tools for automated identification of neuroanatomical structures in quantitative β-amyloid PET imaging to diagnose Alzheimer’s disease. European journal of nuclear medicine and molecular imaging 2016:1–11.
  303. van Bergen JMG, Li X, Hua J, Schreiner SJ, Steininger SC, Quevenco FC, Wyss M, Gietl AF, Treyer V, Leh SE: Colocalization of cerebral iron with Amyloid beta in Mild Cognitive Impairment. Scientific Reports 2016, 6.
  304. van der Lans AA, Vosselman MJ, Hanssen MJ, Brans B, van Marken Lichtenbelt WD: Supraclavicular skin temperature and BAT activity in lean healthy adults. The Journal of Physiological Sciences 2016, 66:77–83.
  305. Van Laeken N, Taylor O, Polis I, Neyt S, Kersemans K, Dobbeleir A, Saunders J, Goethals I, Peremans K, De Vos F: In Vivo Evaluation of Blood Based and Reference Tissue Based PET Quantifications of [11 C] DASB in the Canine Brain. PloS one 2016, 11:e0148943.
  306. Vancraeynest D, Roelants V, Bouzin C, Hanin F-X, Walrand S, Bol V, Bol A, Pouleur A-C, Pasquet A, Gerber B: α V β 3 integrin-targeted microSPECT/CT imaging of inflamed atherosclerotic plaques in mice. EJNMMI research 2016, 6:1.
  307. Vangestel C, Thomae D, Van Soom J, Ides J, Pauwels P, Stroobants S, Van der Veken P, Magdolen V, Joossens J, Augustyns K: Preclinical evaluation of [111In] MICA‐401, an activity‐based probe for SPECT imaging of in vivo uPA activity. Contrast Media & Molecular Imaging 2016.
  308. Vanicek T, Kutzelnigg A, Philippe C, Sigurdardottir HL, James GM, Hahn A, Kranz GS, Höflich A, Kautzky A, Traub‐Weidinger T: Altered interregional molecular associations of the serotonin transporter in attention deficit/hyperactivity disorder assessed with PET. Human Brain Mapping 2016.
  309. Verbrugghen T, Monnery BD, Glassner M, Stroobants S, Hoogenboom R, Staelens S: μPET imaging of the pharmacokinetic behavior of medium and high molar mass 89 Zr-labeled poly (2-ethyl-2-oxazoline) in comparison to poly (ethylene glycol). Journal of Controlled Release 2016, 235:63-71.
  310. Wakabayashi T, Iuchi T, Tsuyuguchi N, Nishikawa R, Arakawa Y, Sasayama T, Miyake K, Nariai T, Narita Y, Hashimoto N: Diagnostic Performance and Safety of Positron Emission Tomography Using 18F-Fluciclovine in Patients with Clinically Suspected High-or Low-grade Gliomas: A Multicenter Phase IIb Trial. Asia Oceania Journal of Nuclear Medicine and Biology 2016.
  311. Waldron A-M, Verhaeghe J, Richardson JC, Schmidt M, Stroobants S, Langlois X, Staelens S: Longitudinal Characterization of [18F]-FDG and [18F]-AV45 Uptake in the Double Transgenic TASTPM Mouse Model. Journal of Alzheimer’s Disease 2016:1-12.
  312. Wang C, Placzek MS, Van de Bittner GC, Schroeder FA, Hooker JM: A Novel Radiotracer for Imaging Monoacylglycerol Lipase in the Brain Using Positron Emission Tomography. ACS chemical neuroscience 2016, 7:484-489.
  313. Wang C, Schroeder FA, Hooker JM: Development of New Positron Emission Tomography Radiotracer for BET Imaging. ACS Chemical Neuroscience 2016.
  314. Warnier C, Lemaire C, Becker G, Zaragoza G, Giacomelli F, Aerts J, Otabashi M, Bahri MA, Mercier J, Plenevaux A: Enabling Efficient Positron Emission Tomography (PET) Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) with a Robust and One-Step Radiosynthesis of a Highly Potent 18F-Labeled Ligand ([18F] UCB-H). Journal of Medicinal Chemistry 2016, 59:8955-8966.
  315. Weng Y-H, Chen C-Y, Lin K-J, Chen Y-L, Yeh T-H, Hsiao T, Chen J, Lu C-S, Wang H-L: (R1441C) LRRK2 induces the degeneration of SN dopaminergic neurons and alters the expression of genes regulating neuronal survival in a transgenic mouse model. Experimental neurology 2016, 275:104–115.
  316. Westerlund K, Honarvar H, Norrström E, Strand J, Mitran B, Orlova A, Eriksson Karlström A, Tolmachev V: Increasing the net negative charge by replacement of DOTA chelator with DOTAGA improves the biodistribution of radiolabeled second-generation synthetic Affibody molecules. Molecular pharmaceutics 2016, 13:1668-1678.
  317. Wollenweber FA, Därr S, Müller C, Duering M, Buerger K, Zietemann V, Malik R, Brendel M, Ertl-Wagner B, Bartenstein P: Prevalence of Amyloid Positron Emission Tomographic Positivity in Poststroke Mild Cognitive Impairment. Stroke 2016, 47:2645-2648.
  318. Wu B, Warnock G, Zaiss M, Lin C, Chen M, Zhou Z, Mu L, Nanz D, Tuura R, Delso G: An overview of CEST MRI for non-MR physicists. EJNMMI physics 2016, 3:19.
  319. Wu K-Y, Liu C-Y, Chen C-S, Chen C-H, Hsiao T, Hsieh C-J, Lee C-P, Yen T-C, Lin K-J: Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: 18F-florbetapir (AV-45/Amyvid) PET study. European journal of nuclear medicine and molecular imaging 2016:1–10.
  320. Wu Y-W, Yang W-S: Time course of cardiometabolic alterations in obese diabetic male db/db mice model using small-animal dynamic FDG PET. Journal of Nuclear Medicine 2016, 57:1635-1635.
  321. Yalçin H, Valenta I, Yalçin F, Corona-Villalobos C, Vasquez N, Ra J, Kucukler N, Tahari A, Pozios I, Zhou Y: Effect of Diffuse Subendocardial Hypoperfusion on Left Ventricular Cavity Size by 13 N-Ammonia Perfusion PET in Patients With Hypertrophic Cardiomyopathy. The American Journal of Cardiology 2016.
  322. Yanai S, Toyohara J, Ishiwata K, Ito H, Endo S: Long-term cilostazol administration ameliorates memory decline in senescence-accelerated mouse prone 8 (SAMP8) through a dual effect on cAMP and blood-brain barrier. Neuropharmacology 2016.
  323. Yang K-C, Stepanov V, Amini N, Martinsson S, Takano A, Nielsen J, Bundgaard C, Bang-Andersen B, Grimwood S, Halldin C: Characterization of [11C] Lu AE92686 as a PET radioligand for phosphodiesterase 10A in the nonhuman primate brain. European Journal of Nuclear Medicine and Molecular Imaging 2016:1-13.
  324. Yang Y, Wang Z-H, Jin S, Gao D, Liu N, Chen S-P, Zhang S, Liu Q, Liu E, Wang X: Opposite monosynaptic scaling of BLP-vCA1 inputs governs hopefulness-and helplessness-modulated spatial learning and memory. Nature Communications 2016, 7.
  325. Yasuno F, Kazui H, Morita N, Kajimoto K, Ihara M, Taguchi A, Yamamoto A, Matsuoka K, Kosaka J, Kudo T: High amyloid‐β deposition related to depressive symptoms in older individuals with normal cognition: a pilot study. International journal of geriatric psychiatry 2016.
  326. Yasuno F, Kazui H, Morita N, Kajimoto K, Ihara M, Taguchi A, Yamamoto A, Matsuoka K, Takahashi M, Nakagawara J: Use of T1-weighted/T2-weighted magnetic resonance ratio to elucidate changes due to amyloid β accumulation in cognitively normal subjects. NeuroImage: Clinical 2016.
  327. Yokoyama C, Mawatari A, Kawasaki A, Takeda C, Onoe K, Doi H, Newman-Tancredi A, Zimmer L, Onoe H: Marmoset serotonin 5-HT1A receptor mapping with a biased agonist PET probe 18F-F13714: comparison with an antagonist tracer 18F-MPPF in awake and anesthetized states. International Journal of Neuropsychopharmacology 2016:pyw079.
  328. Zamboglou C, Schiller F, Fechter T, Wieser G, Jilg CA, Chirindel A, Salman N, Drendel V, Werner M, Mix M: 68Ga-HBED-CC-PSMA PET/CT Versus Histopathology in Primary Localized Prostate Cancer: A Voxel-Wise Comparison. Theranostics 2016, 6:1619.
  329. Zhang JL, Morey AM, Kadrmas DJ: Application of separable parameter space techniques to multi-tracer PET compartment modeling. Physics in medicine and biology 2016, 61:1238.
  330. Zhang M, Jasim DA, Ménard-Moyon C, Nunes A, Iijima S, Bianco A, Yudasaka M, Kostarelos K: Radiolabeling, whole-body single photon emission computed tomography/computed tomography imaging, and pharmacokinetics of carbon nanohorns in mice. International Journal of Nanomedicine 2016, 11:3317.
  331. Zhao R-J, Lin S-H, Lee L-T, Lee IH, Chen PS, Chen KC, Yang YK: Probing the Serotonin Transporter Availability Among Male Cigarette Smokers: A SPECT Study With [123I] ADAM. Journal of addiction medicine 2016, 10:87-90.
  332. Zhao Z-Q, Yang Y, Fang W, Liu S: Comparison of biological properties of 99m Tc-labeled cyclic RGD Peptide trimer and dimer useful as SPECT radiotracers for tumor imaging. Nuclear Medicine and Biology 2016.
  333. Zhou X, Khanapur S, de Jong JR, Willemsen AT, Dierckx RA, Elsinga PH, de Vries EF: In vivo evaluation of [11C] preladenant positron emission tomography for quantification of adenosine A2A receptors in the rat brain. Journal of Cerebral Blood Flow & Metabolism 2016:0271678X16634714.
  334. Zhu W, Yao S, Xing H, Zhang H, Tai Y-c, Zhang Y, Liu Y, Ma Y, Wu C, Wang H: Biodistribution and Radiation Dosimetry of the Enterobacteriaceae-Specific Imaging Probe [18F] Fluorodeoxysorbitol Determined by PET/CT in Healthy Human Volunteers. Molecular Imaging and Biology 2016:1-6.
  335. Zientek F, Winter K, Müller A, Rullmann M, Luthardt J, Becker G-A, Bresch A, Patt M, Sabri O, Hilbert A: Effortful control as a dimension of temperament is negatively associated with prefrontal serotonin transporter availability in obese and non‐obese individuals. European Journal of Neuroscience 2016, 44:2460-2466.
2015
  1. Abdulghani M, Duell J, Smith M, Chen W, Bentzen SM, Asoglu R, Klein T, Bob-Manuel T, Saliaris A, See V: Global and regional myocardial innervation before and after ablation of drug-refractory ventricular tachycardia assessed with 123I-MIBG. Journal of Nuclear Medicine 2015, 56(Supplement 4):52S-58S.
  2. Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, Eisenhut M, Kübler W, Holland-Letz T, Giesel FL: The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. Journal of Nuclear Medicine 2015, 56(11):1697-1705.
  3. Airas L, Dickens AM, Elo P, Marjamäki P, Johansson J, Eskola O, Jones PA, Trigg W, Solin O, Haaparanta-Solin M: In Vivo PET Imaging Demonstrates Diminished Microglial Activation After Fingolimod Treatment in an Animal Model of Multiple Sclerosis. Journal of Nuclear Medicine 2015, 56(2):305-310.
  4. Akkus F, Treyer V, Johayem A, Ametamey SM, Gomez Mancilla B, Sovago J, Buck A, Hasler G: Association of Long Term Abstinence with Normal Metabotropic Glutamate Receptor-5 Binding. Biological Psychiatry 2015(0).
  5. Albertoni C, Leoni B, Rosi A, D’Alessio V, Carollo V, Spagnoli LG, van Echteld C, De Santis R: Radionuclide Therapy of Unresectable Tumors with AvidinOX and 90Y-biotinDOTA: Tongue Cancer Paradigm. Cancer Biotherapy and Radiopharmaceuticals 2015, 30(7):291-298.
  6. Amhaoul H, Hamaide J, Bertoglio D, Reichel SN, Verhaeghe J, Geerts E, Van Dam D, De Deyn PP, Kumar-Singh S, Katsifis A: Brain inflammation in a chronic epilepsy model: Evolving pattern of the translocator protein during epileptogenesis. Neurobiology of disease 2015.
  7. Andersen JB, Henning WS, Lindberg U, Ladefoged CN, Højgaard L, Greisen G, Law I: Positron emission tomography/magnetic resonance hybrid scanner imaging of cerebral blood flow using 15O-water positron emission tomography and arterial spin labeling magnetic resonance imaging in newborn piglets. Journal of Cerebral Blood Flow & Metabolism 2015.
  8. Anitua E, Pelacho B, Prado R, Aguirre JJ, Sánchez M, Padilla S, Aranguren XL, Abizanda G, Collantes M, Hernandez M: Infiltration of plasma rich in growth factors enhances in vivo angiogenesis and improves reperfusion and tissue remodeling after severe hind limb ischemia. Journal of Controlled Release 2015, 202:31-39.
  9. Aquaro GD, Frijia F, Positano V, Menichetti L, Santarelli MF, Lionetti V, Giovannetti G, Recchia FA, Landini L: Cardiac Metabolism in a Pig Model of Ischemia–Reperfusion by Cardiac Magnetic Resonance with Hyperpolarized 13C-Pyruvate. IJC Metabolic & Endocrine 2015, 6(0):17-23.
  10. Arsenault D, Coulombe K, Zhu A, Gong C, Kil K-E, Choi J-K, Poutiainen P, Brownell A-L: Loss of Metabotropic Glutamate Receptor 5 Function on Peripheral Benzodiazepine Receptor in Mice Prenatally Exposed to LPS. PloS one 2015, 10(11):e0142093.
  11. Bailly M, Ribeiro MJS, Vercouillie J, Hommet C, Gissot V, Camus V, Guilloteau D: 18F-FDG and 18F-Florbetapir PET in Clinical Practice: Regional Analysis in Mild Cognitive Impairment and Alzheimer Disease. Clinical nuclear medicine 2015, 40(2):e111-e116.
  12. Baldinger P, Höflich AS, Mitterhauser M, Hahn A, Rami-Mark C, Spies M, Wadsak W, Lanzenberger R, Kasper S: Effects of Silexan on the serotonin-1A receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging. International Journal of Neuropsychopharmacology 2015, 18(4):pyu063.
  13. Baldinger P, Kraus C, Rami-Mark C, Gryglewski G, Kranz GS, Haeusler D, Hahn A, Spies M, Wadsak W, Mitterhauser M et al: Interaction between 5-HTTLPR and 5-HT1B genotype status enhances cerebral 5-HT1A receptor binding. NeuroImage 2015, 111(0):505-512.
  14. Ballard ME, Dean AC, Mandelkern MA, London ED, Morton JB: Striatal Dopamine D2/D3 Receptor Availability Is Associated with Executive Function in Healthy Controls but Not Methamphetamine Users. PloS one 2015(12).
  15. Ballard ME, Mandelkern MA, Monterosso JR, Hsu E, Robertson CL, Ishibashi K, Dean AC, London ED: Low dopamine D2/D3 receptor availability is associated with steep discounting of delayed rewards in methamphetamine dependence. International Journal of Neuropsychopharmacology 2015:pyu119.
  16. Bang J-I, Jung IS, Song YS, Park HS, Moon BS, Lee BC, Kim SE: PET imaging of dopamine transporters with [18 F] FE-PE2I: Effects of anti-Parkinsonian drugs. Nuclear Medicine and Biology 2015.
  17. Barret O, Hannestad J, Vala C, Alagille D, Tavares A, Laruelle M, Jennings D, Marek K, Russell D, Seibyl J: Characterization in Humans of 18F-MNI-444, a PET Radiotracer for Brain Adenosine 2A Receptors. Journal of Nuclear Medicine 2015, 56(4):586-591.
  18. Bauer M, Karch R, Zeitlinger M, Philippe C, Römermann K, Stanek J, Maier-Salamon A, Wadsak W, Jäger W, Hacker M: Approaching complete inhibition of P-glycoprotein at the human blood–brain barrier: an (R)-[ 11C] verapamil PET study. Journal of Cerebral Blood Flow & Metabolism 2015, 35(5):743-746.
  19. Besson FL, La Joie R, Doeuvre L, Gaubert M, Mézenge F, Egret S, Landeau B, Barré L, Abbas A, Ibazizene M: Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer’s Disease. The Journal of Neuroscience 2015, 35(29):10402-10411.
  20. Bishara A, Meir M, Portnoy E, Shmuel M, Eyal S: Near infrared imaging of indocyanine green distribution in pregnant mice and effects of concomitant medications. Molecular pharmaceutics 2015.
  21. Boileau I, McCluskey T, Tong J, Furukawa Y, Houle S, Kish SJ: Rapid Recovery of Vesicular Dopamine Levels in Methamphetamine Users in Early Abstinence. Neuropsychopharmacology 2015.
  22. Bolcaen J, Descamps B, Deblaere K, Boterberg T, Pharm FDV, Kalala J-P, Van den Broecke C, Decrock E, Leybaert L, Vanhove C: 18 F-fluoromethylcholine (FCho), 18 F-fluoroethyltyrosine (FET), and 18 F-fluorodeoxyglucose (FDG) for the discrimination between high-grade glioma and radiation necrosis in rats: A PET study. Nuclear medicine and biology 2015, 42(1):38-45.
  23. Boonstra MC, Van Driel PB, Van Willigen DM, Stammes MA, Prevoo HA, Tummers QR, Mazar AP, Beekman FJ, Kuppen PJ, Van de Velde CJ: uPAR-targeted multimodal tracer for pre-and intraoperative imaging in cancer surgery. Oncotarget, 2015 2015.
  24. Boss SD, Betzel T, Müller C, Fischer CR, Haller S, Reber J, Groehn V, Schibli R, Ametamey SM: Comparative Studies of Three Pairs of α-and γ-Conjugated Folic Acid Derivatives Labeled with Fluorine-18. Bioconjugate chemistry 2015.
  25. Brendel M, Högenauer M, Delker A, Sauerbeck J, Bartenstein P, Seibyl J, Rominger A: Improved longitudinal [18F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction. NeuroImage 2015, 108(0):450-459.
  26. Brendel M, Jaworska A, Griessinger E, Rotzer C, Burgold S, Gildehaus FJ, Carlsen J, Cumming P, Baumann K, Haass C et al: Cross-sectional comparison of small animal [18F]-florbetaben amyloid-PET between transgenic AD mouse models. PLoS One 2015, 10(2):e0116678.
  27. Brendel M, Pogarell O, Xiong G, Delker A, Bartenstein P, Rominger A: Depressive symptoms accelerate cognitive decline in amyloid-positive MCI patients. European Journal of Nuclear Medicine and Molecular Imaging 2015, 42(5):716-724.
  28. Bretin F, Bahri MA, Bernard C, Warnock G, Aerts J, Mestdagh N, Buchanan T, Otoul C, Koestler F, Mievis F et al: Biodistribution and Radiation Dosimetry for the Novel SV2A Radiotracer [18F]UCB-H: First-in-Human Study. Molecular Imaging and Biology 2015:1-8.
  29. Broeders EP, Nascimento EB, Havekes B, Brans B, Roumans KH, Tailleux A, Schaart G, Kouach M, Charton J, Deprez B: The Bile Acid Chenodeoxycholic Acid Increases Human Brown Adipose Tissue Activity. Cell metabolism 2015, 22(3):418-426.
  30. Brownell A-L, Kuruppu D, Kil K-E, Jokivarsi K, Poutiainen P, Zhu A, Maxwell M: PET imaging studies show enhanced expression of mGluR5 and inflammatory response during progressive degeneration in ALS mouse model expressing SOD1-G93A gene. Journal of neuroinflammation 2015, 12(1):217.
  31. Buchholz H-G, Wenzel F, Gartenschläger M, Thiele F, Young S, Reuss S, Schreckenberger M: Construction and comparative evaluation of different activity detection methods in brain FDG-PET. Biomedical engineering online 2015, 14(1):79.
  32. Buchsbaum M, DeCastro A: Positron-Emission Tomography and Computed Tomography Measurement of Brown Fat Thermal Activation: Key Tools for Developing Novel Pharmacotherapeutics for Obesity and Diabetes. In: Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development. edn. Edited by Krentz AJ, Heinemann L, Hompesch M: Springer London; 2015: 121-137.
  33. Caravaggio F, Borlido C, Hahn M, Feng Z, Fervaha G, Gerretsen P, Nakajima S, Plitman E, Chung JK, Iwata Y: Reduced Insulin Sensitivity Is Related to Less Endogenous Dopamine at D2/3 Receptors in the Ventral Striatum of Healthy Nonobese Humans. International Journal of Neuropsychopharmacology 2015, 18(7):pyv014.
  34. Caravaggio F, Raitsin S, Gerretsen P, Nakajima S, Wilson A, Graff-Guerrero A: Ventral striatum binding of a dopamine D 2/3 receptor agonist but not antagonist predicts normal body mass index. Biological psychiatry 2015, 77(2):196-202.
  35. Carluer L, Mondou A, Buhour M-S, Laisney M, Pélerin A, Eustache F, Viader F, Desgranges B: Neural substrate of cognitive theory of mind impairment in amyotrophic lateral sclerosis. Cortex 2015, 65:19-30.
  36. Castellano C, Baillargeon J, Nugent S, Tremblay S, Fortier M, Imbeault H, Duval J, Cunnane S: Regional Brain Glucose Hypometabolism in Young Women with Polycystic Ovary Syndrome: Possible Link to Mild Insulin Resistance. PloS one 2015, 10(12):e0144116.
  37. Castillo X, Rosafio K, Wyss MT, Drandarov K, Buck A, Pellerin L, Weber B, Hirt L: A probable dual mode of action for both L-and D-lactate neuroprotection in cerebral ischemia. Journal of Cerebral Blood Flow & Metabolism 2015, 35(10):1561-1569.
  38. Ceccarini J, Kuepper R, Kemels D, Os J, Henquet C, Van Laere K: [18F] MK‐9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users. Addiction biology 2015, 20(2):357-367.
  39. Chang CC, Hsiao IT, Huang SH, Lui CC, Yen TC, Chang WN, Huang CW, Hsieh CJ, Chang YY, Lin KJ: 18F-FP-(+)-DTBZ positron emission tomography detection of monoaminergic deficient network in patients with carbon monoxide related parkinsonism. European Journal of Neurology 2015, 22(5):845-e860.
  40. Chang WH, Lee L-T, Lee IH, Chi MH, Chen KC, Chiu NT, Yao WJ, Chen PS, Yang YK: Which demographic variables are necessary to correct in neuroimaging studies of serotonin transporter availability? A SPECT study with [123I]ADAM. Psychiatry Research: Neuroimaging 2015, 231(3):320-324.
  41. Chen YJ, Rosario BL, Mowrey W, Laymon CM, Lu X, Lopez OL, Klunk WE, Lopresti BJ, Mathis CA, Price JC: Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PET. Journal of Nuclear Medicine 2015, 56(8):1199-1205.
  42. Cheng N-M, Fang Y-H, Lee L-y, Chang J-C, Tsan D-L, Ng S-H, Wang H-M, Liao C-T, Yang L-Y, Hsu C-H et al: Zone-size nonuniformity of 18F-FDG PET regional textural features predicts survival in patients with oropharyngeal cancer. European Journal of Nuclear Medicine and Molecular Imaging 2015, 42(3):419-428.
  43. Cheng X, Li Z, Liu Z, Navab N, Huang SC, Keller U, Ziegler S, Shi K: Direct Parametric Image Reconstruction in Reduced Parameter Space for Rapid Multi-Tracer PET Imaging. IEEE transactions on medical imaging 2015.
  44. Cheng Z, Wei R, Wu C, Qing H, Jiang X, Lu H, Chen S, Li X, Xu G, Ai H: Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model. Nuclear medicine communications 2015.
  45. Cho S-G, Kim JH, Cho JY, Kim HS, Kwon SY, Bom H-S: Characteristics of anginal patients with high resting myocardial blood flow measured with N-13 ammonia PET/CT. Nuclear medicine communications 2015, 36(6):619-624.
  46. Choi HS, Kim HJ, Oh J-H, Park H-G, Ra JC, Chang K-A, Suh Y-H: Therapeutic potentials of human adipose-derived stem cells on the mouse model of Parkinson’s disease. Neurobiology of Aging 2015, 36(10):2885-2892.
  47. Choi JY, Lyoo CH, Kim JS, Kim KM, Kang JH, Choi S-H, Kim J-J, Ryu YH: 18F-Mefway PET Imaging of Serotonin 1A Receptors in Humans: A Comparison with 18F-FCWAY. PloS one 2015, 10(4).
  48. Choi JY, Song JS, Lee M, Cho W-K, Chung J, Lyoo CH, Kim CH, Park J, Lee KC, Kim KM: P-Glycoprotein, not BCRP, Limits the Brain Uptake of [18F] Mefway in Rodent Brain. Molecular Imaging and Biology 2015:1-7.
  49. Cicuendez M, Lorenzo-Bosquet C, Cuberas-Borrós G, Martinez-Ricarte F, Cordero E, Martinez-Saez E, Castell-Conesa J, Sahuquillo J: Role of [11 C] methionine positron emission tomography in the diagnosis and prediction of survival in brain tumours. Clinical neurology and neurosurgery 2015, 139:328-333.
  50. Collste K, Forsberg A, Varrone A, Amini N, Aeinehband S, Yakushev I, Halldin C, Farde L, Cervenka S: Test–retest reproducibility of [11C] PBR28 binding to TSPO in healthy control subjects. European journal of nuclear medicine and molecular imaging 2015:1-11.
  51. Coughlin JM, Wang Y, Munro CA, Ma S, Yue C, Chen S, Airan R, Kim PK, Adams AV, Garcia C et al: Neuroinflammation and brain atrophy in former NFL players: An in vivo multimodal imaging pilot study. Neurobiology of Disease 2015, 74(0):58-65.
  52. Cressier D, Dhilly M, Pham TTC, Fillesoye F, Gourand F, Maïza A, Martins AF, Morfin J-F, Geraldes CF, Tóth É: Gallium-68 Complexes Conjugated to Pittsburgh Compound B: Radiolabeling and Biological Evaluation. Molecular Imaging and Biology 2015:1-10.
  53. Cui Y, Toyoda H, Sako T, Onoe K, Hayashinaka E, Wada Y, Yokoyama C, Onoe H, Kataoka Y, Watanabe Y: A voxel-based analysis of brain activity in high-order trigeminal pathway in the rat induced by cortical spreading depression. NeuroImage 2015, 108(0):17-22.
  54. de Laat B, Leurquin-Sterk G, Celen S, Bormans G, Koole M, Van Laere K, Casteels C: Preclinical evaluation and quantification of 18F-FPEB as a radioligand for PET imaging of the metabotropic glutamate receptor 5. Journal of Nuclear Medicine 2015:jnumed. 115.162636.
  55. Deau E, Robin E, Voinea R, Percina N, Satała G, Fînaru A-L, Chartier A, Tamagnan GD, Alagille D, Bojarski AJ: Rational Design, Pharmacomodulation, Synthesis of Dual 5-Hydroxytryptamine 7 (5-HT7)/5-Hydroxytryptamine 2A (5-HT2A) Receptors Antagonists and Evaluation by [18F]-PET Imaging in a Primate Brain. Journal of medicinal chemistry 2015.
  56. Di Ciano P, Guranda M, Lagzdins D, Tyndale RF, Gamaleddin I, Selby P, Boileau I, Le Foll B: Varenicline-Induced Elevation of Dopamine in Smokers: A Preliminary [ 11C]-(+)-PHNO PET Study. Neuropsychopharmacology 2015.
  57. Di Grigoli G, Monterisi C, Belloli S, Masiello V, Politi LS, Valenti S, Paolino M, Anzini M, Matarrese M, Cappelli A: Radiosynthesis and Preliminary Biological Evaluation of [18 F] VC701, a Radioligand for Translocator Protein. therapy 2015, 2:3.
  58. Dubroff J, Doot R, Falcone M, Schnoll R, Ray R, Tyndale R, Brody A, Hou C, Schmitz A, Lerman C: Decreased nicotinic receptor availability in smokers with slow rates of nicotine metabolism. Journal of Nuclear Medicine 2015:jnumed. 115.155002.
  59. Dumas N, Moulin-Sallanon M, Fender P, Tournier BB, Ginovart N, Charnay Y, Millet P: In Vivo Quantification of 5-HT2A Brain Receptors in Mdr1a KO Rats with 123I-R91150 Single-Photon Emission Computed Tomography. Molecular imaging 2015, 14:5-7.
  60. Dunet V, Klein R, Allenbach G, Renaud J, Prior JO: Myocardial blood flow quantification by Rb-82 cardiac PET/CT: A detailed reproducibility study between two semi-automatic analysis programs. J Nucl Cardiol 2015:1-12.
  61. Elvas F, Vangestel C, Rapic S, Verhaeghe J, Gray B, Pak K, Stroobants S, Staelens S: Characterization of [99mTc] Duramycin as a SPECT Imaging Agent for Early Assessment of Tumor Apoptosis. Molecular Imaging and Biology 2015:1-10.
  62. Eriksson O, Antoni G: [11 C] Carfentanil Binds Preferentially to µ-Opioid Receptor Subtype 1 Compared to Subtype 2. Molecular imaging 2015, 14.
  63. Eriksson O, Mikkola K, Espes D, Tuominen L, Virtanen K, Forsbäck S, Haaparanta-Solin M, Hietala J, Solin O, Nuutila P: The Cannabinoid Receptor-1 is an imaging biomarker of Brown Adipose Tissue. Journal of Nuclear Medicine 2015:jnumed. 115.156422.
  64. Evans E, Buonincontri G, Izquierdo D, Methner C, Hawkes RC, Ansorge RE, Krieg T, Carpenter TA, Sawiak SJ: Combining MRI with PET for partial volume correction improves image-derived input functions in mice. IEEE transactions on nuclear science 2015, 62(3 Pt 1):628-633.
  65. Fiz F, Morbelli S, Piccardo A, Bauckneht M, Ferrarazzo G, Pestarino E, Cabria M, Democrito A, Riondato M, Villavecchia G: 18F-NaF uptake by the atherosclerotic plaque at PET/CT imaging: inverse correlation between calcification density and mineral metabolic activity. Journal of Nuclear Medicine 2015:jnumed. 115.154229.
  66. Freeby MJ, Kringas P, Goland RS, Leibel RL, Maffei A, Divgi C, Ichise M, Harris PE: Cross-sectional and Test-Retest Characterization of PET with [18F] FP-(+)-DTBZ for β Cell Mass Estimates in Diabetes. Molecular Imaging and Biology 2015:1-10.
  67. Freesmeyer M, Kühnel C, Westphal J: Time efficient 124I-PET volumetry in benign thyroid disorders by automatic isocontour procedures: mathematic adjustment using manual contoured measurements in low-dose CT. Annals of Nuclear Medicine 2015, 29(1):8-14.
  68. Fresneau N, Dumas N, Tournier BB, Fossey C, Ballandonne C, Lesnard A, Millet P, Charnay Y, Cailly T, Bouillon J-P et al: Design of a serotonin 4 receptor radiotracer with decreased lipophilicity for single photon emission computed tomography. European Journal of Medicinal Chemistry 2015, 94(0):386-396.
  69. Frings L, Hellwig S, Spehl TS, Bormann T, Buchert R, Vach W, Minkova L, Heimbach B, Klöppel S, Meyer PT: Asymmetries of amyloid-β burden and neuronal dysfunction are positively correlated in Alzheimer’s disease. Brain 2015, 138(10):3089-3099.
  70. Frokjaer VG, Pinborg A, Holst KK, Overgaard A, Henningsson S, Heede M, Larsen EC, Jensen PS, Agn M, Nielsen AP: Role of Serotonin Transporter Changes in Depressive Responses to Sex-Steroid Hormone Manipulation: A Positron Emission Tomography Study. Biological psychiatry 2015.
  71. Fukuyama Y, Yuki Y, Katakai Y, Harada N, Takahashi H, Takeda S, Mejima M, Joo S, Kurokawa S, Sawada S: Nanogel-based pneumococcal surface protein A nasal vaccine induces microRNA-associated Th17 cell responses with neutralizing antibodies against Streptococcus pneumoniae in macaques. Mucosal immunology 2015.
  72. García-Casares N, García-Arnés JA, Rioja J, Ariza MJ, Gutiérrez A, Alfaro F, Nabrozidis A, González-Alegre P, González-Santos P: Alzheimer’s like brain changes correlate with low adiponectin plasma levels in type 2 diabetic patients. Journal of Diabetes and its Complications 2015.
  73. García-García L, Delgado M, Al-Sayed A, Bascuñana P, Fernández de la Rosa R, Bermejo-Bescós P, Martín-Aragón S, Pozo M: In Vivo [18F] FDG PET Imaging Reveals that p-Chloroamphetamine Neurotoxicity is Associated with Long-Term Cortical and Hippocampal Hypometabolism. Molecular Imaging and Biology 2015, 17(2):239-247.
  74. García-García L, Shiha AA, Bascuñana P, de Cristóbal J, de la Rosa RF, Delgado M, Pozo MA: Serotonin Depletion Does not Modify the Short-Term Brain Hypometabolism and Hippocampal Neurodegeneration Induced by the Lithium–Pilocarpine Model of Status Epilepticus in Rats. Cellular and molecular neurobiology 2015:1-7.
  75. Gheysens O, Postnov A, Deroose CM, Vandermeulen C, de Hoon J, Declercq R, Dennie J, Mixson L, De Lepeleire I, Van Laere K: Quantification, Variability, and Reproducibility of Basal Skeletal Muscle Glucose Uptake in Healthy Humans Using 18F-FDG PET/CT. Journal of Nuclear Medicine 2015, 56(10):1520-1526.
  76. Gietl AF, Warnock G, Riese F, Kälin AM, Saake A, Gruber E, Leh SE, Unschuld PG, Kuhn FP, Burger C: Regional cerebral blood flow estimated by early PiB uptake is reduced in mild cognitive impairment and associated with age in an amyloid-dependent manner. Neurobiology of aging 2015, 36(4):1619-1628.
  77. Grkovski M, Schwartz J, Gönen M, Schöder H, Lee NY, Carlin SD, Zanzonico PB, Humm JL, Nehmeh SA: Feasibility of 18F-fluoromisonidazole kinetic modeling in head and neck cancer using shortened acquisition times. Journal of Nuclear Medicine 2015:jnumed. 115.160168.
  78. Hae Kang J, Lee M, Hoon Ryu Y, Hyoung Lyoo C, Hoon Kim C, Chul Lee K, Hyun Choi T, Yong Choi J: [18F]FPEB and [18F]FDEGPECO comparative study of mGlu5 quantification in rodent brain. Applied Radiation and Isotopes 2015, 98(0):103-107.
  79. Han JH, Lim SY, Lee MS, Lee WW: Sodium [18F] Fluoride PET/CT in Myocardial Infarction. Molecular Imaging and Biology 2015, 17(2):214-221.
  80. Hansen AE, Petersen AL, Henriksen JR, Boerresen B, Rasmussen P, Elema DR, Rosenschoeld PM, Kristensen AT, Kjær A, Andresen TL: Positron Emission Tomography based Elucidation of the Enhanced Permeability and Retention Effect in Dogs with Cancer using Copper-64 Liposomes. ACS Nano 2015.
  81. Hanssen MJ, Broeders E, Samms RJ, Vosselman MJ, van der Lans AA, Cheng CC, Adams AC, van Marken Lichtenbelt WD, Schrauwen P: Serum FGF21 levels are associated with brown adipose tissue activity in humans. Scientific reports 2015, 5.
  82. Hanssen MW, Wierts R, Hoeks J, Gemmink A, Brans B, Mottaghy F, Schrauwen P, van Marken Lichtenbelt W: Glucose uptake in human brown adipose tissue is impaired upon fasting-induced insulin resistance. Diabetologia 2015, 58(3):586-595.
  83. Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, Hiraoka K, Watanuki S, Shidahara M, Miyake M et al: [18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease. European Journal of Nuclear Medicine and Molecular Imaging 2015:1-10.
  84. Harrison S, Tyrer A, Levitan R, Xu X, Houle S, Wilson A, Nobrega J, Rusjan P, Meyer J: Light therapy and serotonin transporter binding in the anterior cingulate and prefrontal cortex. Acta Psychiatrica Scandinavica 2015.
  85. Hatano K, Sekimata K, Yamada T, Abe J, Ito K, Ogawa M, Magata Y, Toyohara J, Ishiwata K, Biggio G: Radiosynthesis and in vivo evaluation of two imidazopyridineacetamides,[11C] CB184 and [11C] CB190, as a PET tracer for 18 kDa translocator protein: direct comparison with [11C](R)-PK11195. Annals of nuclear medicine 2015, 29(4):325-335.
  86. Heinzel A, Shali SM, Dafotakis M, Verburg FA, Mottaghy FM, Winz OH: Comparison of automatic versus manual procedures for the quantification of dopamine D2 receptor availability using I-123-IBZM-SPECT. Nuclear medicine communications 2015, 36(11):1120-1126.
  87. Hendrikx G, De Saint-Hubert M, Dijkgraaf I, Bauwens M, Douma K, Wierts R, Pooters I, Van den Akker N, Hackeng T, Post M et al: Molecular imaging of angiogenesis after myocardial infarction by 111In-DTPA-cNGR and 99mTc-sestamibi dual-isotope myocardial SPECT. EJNMMI research 2015, 5(1):1-10.
  88. Henriksen JR, Petersen AL, Hansen AE, Frankær CG, Harris P, Elema DR, Kristensen AT, Kjær A, Andresen TL: Remote Loading of 64Cu2+ into Liposomes without the Use of Ion Transport Enhancers. ACS applied materials & interfaces 2015, 7(41):22796-22806.
  89. Hernaus D, Collip D, Kasanova Z, Winz O, Heinzel A, van Amelsvoort T, Shali S, Booij J, Rong Y, Piel M: No evidence for attenuated stress-induced extrastriatal dopamine signaling in psychotic disorder. Translational psychiatry 2015, 5(4):e547.
  90. Hickey RD, Mao SA, Amiot B, Suksanpaisan L, Miller A, Nace R, Glorioso J, O’Connor MK, Peng KW, Ikeda Y: Noninvasive 3‐dimensional imaging of liver regeneration in a mouse model of hereditary tyrosinemia type 1 using the sodium iodide symporter gene. Liver Transplantation 2015, 21(4):442-453.
  91. Hiraoka K, Narita W, Kikuchi H, Baba T, Kanno S, Iizuka O, Tashiro M, Furumoto S, Okamura N, Furukawa K: Amyloid deposits and response to shunt surgery in idiopathic normal-pressure hydrocephalus. Journal of the neurological sciences 2015, 356(1):124-128.
  92. Hiraoka K, Tashiro M, Grobosch T, Maurer M, Oda K, Toyohara J, Ishii K, Ishiwata K, Yanai K: Brain histamine H1 receptor occupancy measured by PET after oral administration of levocetirizine, a non-sedating antihistamine. Expert opinion on drug safety 2015, 14(2):199-206.
  93. Hjorth S, Karlsson C, Jucaite A, Varnäs K, Hamrén UW, Johnström P, Gulyás B, Donohue SR, Pike VW, Halldin C: A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates. Neuropharmacology 2015.
  94. Holub J, Meckel M, Kubíček V, Rösch F, Hermann P: Gallium (III) complexes of NOTA‐bis (phosphonate) conjugates as PET radiotracers for bone imaging. Contrast media & molecular imaging 2015, 10(2):122-134.
  95. Holvoet B, Quattrocelli M, Belderbos S, Pollaris L, Wolfs E, Gheysens O, Gijsbers R, Vanoirbeek J, Verfaillie CM, Sampaolesi M: Sodium Iodide Symporter PET and BLI Noninvasively Reveal Mesoangioblast Survival in Dystrophic Mice. Stem cell reports 2015, 5(6):1183-1195.
  96. Hong J, Lu S, Xu R, Liow J-S, Woock AE, Jenko KJ, Gladding RL, Zoghbi SS, Innis RB, Pike VW: [carbonyl-11 C] 4-Fluoro-N-methyl-N-(4-(6-(methylamino) pyrimidin-4-yl) thiazol-2-yl) benzamide ([11 C] FIMX) is an effective radioligand for PET imaging of metabotropic glutamate receptor 1 (mGluR1) in monkey brain. Nuclear medicine and biology 2015.
  97. Hosokawa C, Ishii K, Kimura Y, Hyodo T, Sakaguchi K, Usami K, Shimamoto K, Yamazoe Y, Murakami T: Performance of 11C-PiB PET binding potential images in the equivocal static images in the detection of amyloid deposits. Journal of Nuclear Medicine 2015:jnumed. 115.156414.
  98. Hou M, Acton PD: Understanding the tampon density and density gradient through computed tomography imaging. Textile Research Journal 2015:0040517515595026.
  99. Hovhannisyan N, Guillouet S, Fillesoye F, Dhilly M, Patin D, Galateau F, Leporrier M, Barré L: Evaluation of the specificity of [18F] fludarabine PET/CT in a xenograft model of follicular lymphoma: comparison with [18F] FDG and impact of rituximab therapy. EJNMMI research 2015, 5.
  100. Huang C-C, Pan W-Y, Tseng MT, Lin K-J, Yang Y-P, Tsai H-W, Hwang S-M, Chang Y, Wei H-J, Sung H-W: Enhancement of cell adhesion, retention, and survival of HUVEC/cbMSC aggregates that are transplanted in ischemic tissues by concurrent delivery of an antioxidant for therapeutic angiogenesis. Biomaterials 2015.
  101. Huang C-C, Wei H-J, Lin K-J, Lin W-W, Wang C-W, Pan W-Y, Hwang S-M, Chang Y, Sung H-W: Multimodality noninvasive imaging for assessing therapeutic effects of exogenously transplanted cell aggregates capable of angiogenesis on acute myocardial infarction. Biomaterials 2015, 73:12-22.
  102. Huang C-Y, Liu C-H, Tsao E, Hsieh C-J, Weng Y-H, Hsiao T, Yen T-C, Lin K-J, Huang C-C: Chronic manganism: A long-term follow-up study with a new dopamine terminal biomarker of 18 F-FP-(+)-DTBZ (18 F-AV-133) brain PET scan. Journal of the neurological sciences 2015, 353(1):102-106.
  103. Huang S-y, Bolch W, Lee C, Van Brocklin H, Pampaloni M, Hawkins R, Sznewajs A, DuBois S, Matthay K, Seo Y: Patient-Specific Dosimetry Using Pretherapy [124I]m-iodobenzylguanidine ([124I]mIBG) Dynamic PET/CT Imaging Before [131I]mIBG Targeted Radionuclide Therapy for Neuroblastoma. Molecular Imaging and Biology 2015, 17(2):284-294.
  104. Hwang D-R, Hu E, Allen JR, Davis C, Treanor J, Miller S, Chen H, Shi B, Narayanan TK, Barret O: Radiosynthesis and initial characterization of a PDE10A specific PET tracer [18 F] AMG 580 in non-human primates. Nuclear medicine and biology 2015.
  105. Iguchi Y, Michiue H, Kitamatsu M, Hayashi Y, Takenaka F, Nishiki T-i, Matsui H: Tumor-specific delivery of BSH-3R for boron neutron capture therapy and positron emission tomography imaging in a mouse brain tumor model. Biomaterials 2015, 56:10-17.
  106. Ikoma Y, Sasaki T, Kimura Y, Seki C, Okubo Y, Suhara T, Ito H: Evaluation of semi-quantitative method for quantification of dopamine transporter in human PET study with 18F-FE-PE2I. Annals of nuclear medicine 2015:1-12.
  107. Irkle A, Vesey AT, Lewis DY, Skepper JN, Bird JL, Dweck MR, Joshi FR, Gallagher FA, Warburton EA, Bennett MR: Identifying active vascular microcalcification by 18F-sodium fluoride positron emission tomography. Nature communications 2015, 6.
  108. Ishibashi K, Miura Y, Ishikawa K, Ishii K, Ishiwata K: Decreased metabotropic glutamate receptor type 1 availability in a patient with spinocerebellar ataxia type 6: A 11 C-ITMM PET study. Journal of the neurological sciences 2015, 355(1):202-205.
  109. Ishiki A, Okamura N, Furukawa K, Furumoto S, Harada R, Tomita N, Hiraoka K, Watanuki S, Ishikawa Y, Tago T: Longitudinal Assessment of Tau Pathology in Patients with Alzheimer’s Disease Using [18 F] THK-5117 Positron Emission Tomography. PloS one 2015, 10(10):e0140311.
  110. Jagust WJ, Landau SM, Koeppe RA, Reiman EM, Chen K, Mathis CA, Price JC, Foster NL, Wang AY: The Alzheimer’s Disease Neuroimaging Initiative 2 PET Core: 2015. Alzheimer’s & dementia : the journal of the Alzheimer’s Association 2015, 11(7):757-771.
  111. Jahan M, Johnström P, Nag S, Takano A, Korsgren O, Johansson L, Halldin C, Eriksson O: Synthesis and biological evaluation of [11C]AZ12504948; a novel tracer for imaging of glucokinase in pancreas and liver. Nuclear Medicine and Biology 2015, 42(4):387-394.
  112. Jennings D, Seibyl J, Sabbagh M, Lai F, Hopkins W, Bullich S, Gimenez M, Reininger C, Putz B, Stephens A: Age dependence of brain β-amyloid deposition in Down syndrome An [18F] florbetaben PET study. Neurology 2015, 84(5):500-507.
  113. Jochimsen TH, Schulz J, Busse H, Werner P, Schaudinn A, Zeisig V, Kurch L, Seese A, Barthel H, Sattler B: Lean body mass correction of standardized uptake value in simultaneous whole-body positron emission tomography and magnetic resonance imaging. Physics in medicine and biology 2015, 60(12):4651.
  114. Kanazawa M, Ohba H, Harada N, Kakiuchi T, Muramatsu S-i, Tsukada H: Evaluation of 6-11C-Methyl-m-tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11-L-DOPA and 18F-FDOPA in Parkinson’s Disease Monkeys. Journal of Nuclear Medicine 2015:jnumed. 115.161802.
  115. Kanazawa M, Ohba H, Iwazaki A, Kakiuchi T, Tsukada H: Synthesis of 6-[11C]methyl-m-tyrosine ([11C]6MemTyr) for dopamine synthesis imaging in living brain using PET. Bioorganic & Medicinal Chemistry 2015, 23(4):729-734.
  116. Kang JH, Lee M, Ryu YH, Lyoo CH, Kim CH, Lee KC, Choi TH, Choi JY: [18 F] FPEB and [18 F] FDEGPECO comparative study of mGlu5 quantification in rodent brain. Applied Radiation and Isotopes 2015, 98:103-107.
  117. Karlsson HK, Tuominen L, Tuulari JJ, Hirvonen J, Parkkola R, Helin S, Salminen P, Nuutila P, Nummenmaa L: Obesity Is Associated with Decreased μ-Opioid But Unaltered Dopamine D2 Receptor Availability in the Brain. The Journal of Neuroscience 2015, 35(9):3959-3965.
  118. Kawamura K, Shimoda Y, Kumata K, Fujinaga M, Yui J, Yamasaki T, Xie L, Hatori A, Wakizaka H, Kurihara Y: In vivo evaluation of a new 18 F-labeled PET ligand,[18 F] FEBU, for the imaging of I 2-imidazoline receptors. Nuclear medicine and biology 2015, 42(4):406-412.
  119. Kikuta S, Nakamura Y, Yamamura Y, Tamura A, Homma N, Yanagawa Y, Tamura H, Kasahara J, Osanai M: Quantitative activation-induced manganese-enhanced MRI reveals severity of Parkinson’s disease in mice. Scientific reports 2015, 5.
  120. Kim CH, Lee KC, Choi TH, Choi JY: Jee Hae Kang, Minkyung Lee b, Young Hoon Ryu c, Chul Hyoung Lyoo d. Applied Radiation and Isotopes 2015, 98:103-107.
  121. Kim D-H, Jung J-h, Son SH, Kim C-Y, Jeong SY, Lee S-W, Lee J, Ahn B-C: Quantification of Intratumoral Metabolic Macroheterogeneity on 18F-FDG PET/CT and Its Prognostic Significance in Pathologic N0 Squamous Cell Lung Carcinoma. Clinical nuclear medicine 2015.
  122. Kim D-Y, Kim HS, Min J-J: Radiosynthesis and evaluation of 18F-labeled aliphatic phosphonium cations as a myocardial imaging agent for positron emission tomography. Nuclear medicine communications 2015.
  123. Kim D-Y, Kim HS, Reder S, Zheng JH, Herz M, Higuchi T, Pyo A, Bom H-S, Schwaiger M, Min J-J: Comparison of 18F-Labeled Fluoroalkylphosphonium Cations with 13N-NH3 for PET Myocardial Perfusion Imaging. Journal of Nuclear Medicine 2015, 56(10):1581-1586.
  124. Kim D-Y, Min J-J: Synthesis and Evaluation of 18F-Labeled Fluoroalkyl Triphenylphosphonium Salts as Mitochondrial Voltage Sensors in PET Myocardial Imaging. In: Mitochondrial Medicine. Volume 1265, edn. Edited by Weissig V, Edeas M: Springer New York; 2015: 59-72.
  125. Kim J-H, Son Y-D, Kim J-H, Choi E-J, Lee S-Y, Joo Y-H, Kim Y-B, Cho Z-H: Self-transcendence trait and its relationship with in vivo serotonin transporter availability in brainstem raphe nuclei: An ultra-high resolution PET-MRI study. Brain research 2015, 1629:63-71.
  126. Kim JS, Kang SH, Moon HS, Lee ES, Kim SH, Sung JK, Lee BS, Jeong HY, Chung WS: Impact of Bowel Preparation Quality on Adenoma Identification During Colonoscopy and Optimal Timing of Surveillance. Digestive diseases and sciences 2015, 60(10):3092-3099.
  127. Kim K, Son YD, Bresler Y, Cho ZH, Ra JB, Ye JC: Dynamic PET reconstruction using temporal patch-based low rank penalty for ROI-based brain kinetic analysis. Physics in medicine and biology 2015, 60(5):2019.
  128. Kimura Y, Ichise M, Ito H, Shimada H, Ikoma Y, Seki C, Takano H, Kitamura S, Shinotoh H, Kawamura K: PET Quantification of Tau Pathology in Human Brain with 11C-PBB3. Journal of Nuclear Medicine 2015, 56(9):1359-1365.
  129. Knešaurek K: Improving 18F-Fluoro-D-Glucose-Positron Emission Tomography/Computed Tomography Imaging in Alzheimer’s Disease Studies. World journal of nuclear medicine 2015, 14(3):171.
  130. Knudsen GM, Jensen PS, Erritzoe D, Baaré WF, Ettrup A, Fisher PM, Gillings N, Hansen HD, Hansen LK, Hasselbalch SG: The Center for Integrated Molecular Brain Imaging (Cimbi) database. NeuroImage 2015.
  131. Kobayashi K, Sasaki T, Takenaka F, Yakushiji H, Fujii Y, Kishi Y, Kita S, Shen L, Kumon H, Matsuura E: A Novel PET Imaging Using 64 Cu-Labeled Monoclonal Antibody against Mesothelin Commonly Expressed on Cancer Cells. Journal of immunology research 2015, 2015.
  132. Koyasu S, Tsuji Y, Harada H, Nakamoto Y, Nobashi T, Kimura H, Sano K, Koizumi K, Hamaji M, Togashi K: Evaluation of Tumor-associated Stroma and Its Relationship with Tumor Hypoxia Using Dynamic Contrast-enhanced CT and 18F Misonidazole PET in Murine Tumor Models. Radiology 2015:150416.
  133. Kranz GS, Wadsak W, Kaufmann U, Savli M, Baldinger P, Gryglewski G, Haeusler D, Spies M, Mitterhauser M, Kasper S et al: High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People. Biol Psychiatry 2015, 78(8):525-533.
  134. Kreisl WC, Bhatia R, Morse CL, Woock AE, Zoghbi SS, Shetty HU, Pike VW, Innis RB: Increased Permeability-Glycoprotein Inhibition at the Human Blood–Brain Barrier Can Be Safely Achieved by Performing PET During Peak Plasma Concentrations of Tariquidar. Journal of Nuclear Medicine 2015, 56(1):82-87.
  135. Kuang Y, Wu L, Hirata E, Miyazaki K, Sato M, Kwee SA: Volumetric Modulated Arc Therapy Planning for Primary Prostate Cancer With Selective Intraprostatic Boost Determined by 18 F-Choline PET/CT. International Journal of Radiation Oncology* Biology* Physics 2015, 91(5):1017-1025.
  136. Kuhn FP, Warnock G, Schweingruber T, Sommerauer M, Buck A, Khan N: Quantitative H 2 [15 O]-PET in Pediatric Moyamoya Disease: Evaluating Perfusion before and after Cerebral Revascularization. Journal of Stroke and Cerebrovascular Diseases 2015, 24(5):965-971.
  137. Lange C, Kurth J, Seese A, Schwarzenböck S, Steinhoff K, Umland-Seidler B, Krause BJ, Brenner W, Sabri O, Hesse S: Robust, fully automatic delineation of the head contour by stereotactical normalization for attenuation correction according to Chang in dopamine transporter scintigraphy. European radiology 2015:1-9.
  138. Lapa C, Spehl TS, Brumberg J, Isaias IU, Schlögl S, Lassmann M, Herrmann K, Meyer PT: Influence of CT-based attenuation correction on dopamine transporter SPECT with [123I] FP-CIT. American journal of nuclear medicine and molecular imaging 2015, 5(3):278-286.
  139. Lavisse S, Inoue K, Jan C, Peyronneau MA, Petit F, Goutal S, Dauguet J, Guillermier M, Dollé F, Rbah-Vidal L et al: [18F]DPA-714 PET imaging of translocator protein TSPO (18 kDa) in the normal and excitotoxically-lesioned nonhuman primate brain. European Journal of Nuclear Medicine and Molecular Imaging 2015, 42(3):478-494.
  140. Le Foll B, Payer D, Di Ciano P, Guranda M, Nakajima S, Tong J, Mansouri E, Wilson AA, Houle S, Meyer JH: Occupancy of Dopamine D3 and D2 Receptors by Buspirone: A [ 11C]-(+)-PHNO PET Study in Humans. Neuropsychopharmacology 2015.
  141. Ledermann K, Jenewein J, Sprott H, Hasler G, Schnyder U, Warnock G, Johayem A, Kollias S, Buck A, Martin-Soelch C: Relation of Dopamine Receptor 2 Binding to Pain Perception in Female Fibromyalgia Patients with and without Depression–an [11 C] raclopride PET-study. European Neuropsychopharmacology 2015.
  142. Lee DE, Yue X, Ibrahim WG, Lentz MR, Peterson KL, Jagoda EM, Kassiou M, Maric D, Reid WC, Hammoud DA: Lack of neuroinflammation in the HIV-1 transgenic rat: an [18 F]-DPA714 PET imaging study. Journal of neuroinflammation 2015, 12(1):171.
  143. Lee L-T, Tsai HC, Chi MH, Chang WH, Chen KC, Lee IH, Chen PS, Yao WJ, Chiu NT, Yang YK: Lower availability of striatal dopamine transporter in generalized anxiety disorder: a preliminary two-ligand SPECT study. International clinical psychopharmacology 2015, 30(3):175-178.
  144. Lee M, Ryu YH, Cho WG, Kang YW, Lee SJ, Jeon TJ, Lyoo CH, Kim CH, Kim DG, Lee K et al: Relationship between dopamine deficit and the expression of depressive behavior resulted from alteration of serotonin system. Synapse 2015, 69(9):453-460.
  145. Li CT, Tu PC, Hsieh JC, Lee HC, Bai YM, Tsai CF, Wang SJ, Hsu JW, Huang KL, Hong CJ: Functional dysconnection in the prefrontal–amygdala circuitry in unaffected siblings of patients with bipolar I disorder. Bipolar disorders 2015, 17(6):626-635.
  146. Li C-T, Su T-P, Wang S-J, Tu P-C, Hsieh J-C: Prefrontal glucose metabolism in medication-resistant major depression. The British Journal of Psychiatry 2015, 206(4):316-323.
  147. Li F, Jørgensen JT, Madsen J, Kjaer A: Pharmacokinetic Analysis of 64Cu-ATSM Dynamic PET in Human Xenograft Tumors in Mice. Diagnostics 2015, 5(2):96-112.
  148. Lin C-Y, Wang Y-H, Li K-C, Sung L-Y, Yeh C-L, Lin K-J, Yen T-C, Chang Y-H, Hu Y-C: Healing of massive segmental femoral bone defects in minipigs by allogenic ASCs engineered with FLPo/Frt-based baculovirus vectors. Biomaterials 2015, 50:98-106.
  149. Lin H-C, Li C-T, Tat-Wei Tan D, Cheng C-W, Chou T-K, Kong F-L, Yu T-H, Huang W-S, Su D-P, Liu R-S: Non-Linear Alteration of Serotonin Transport Availability in Posttraumatic Stress Disorder Measured with 4-[18F] ADAM Positron Emission Tomography. Current Molecular Imaging 2015, 4(1):57-64.
  150. Lin S-H, Chen KC, Lee S-Y, Chiu NT, Lee IH, Chen PS, Yeh TL, Lu R-B, Chen C-C, Liao M-H et al: The association between heroin expenditure and dopamine transporter availability—A single-photon emission computed tomography study. Psychiatry Research: Neuroimaging 2015, 231(3):292-297.
  151. Lin S-H, Lee IH, Chen KC, Chen PS, Chiu NT, Yao WJ, Yang YK: Serotonin transporter availability may moderate the association between perceiving stress and depressive tendencies—A SPECT with 5-HTTLPR genotyping study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2015, 61:24-29.
  152. Liu L, Collier AC, Link JM, Domino KB, Mankoff DA, Eary JF, Spiekerman CF, Hsiao P, Deo AK, Unadkat JD: Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: a PET Imaging Study. Drug Metabolism and Disposition 2015:dmd. 114.058685.
  153. Liu S, Cai W, Liu S, Zhang F, Fulham M, Feng D, Pujol S, Kikinis R: Multimodal neuroimaging computing: the workflows, methods, and platforms. Brain Informatics 2015, 2(3):181-195.
  154. Lohmann P, Herzog H, Rota Kops E, Stoffels G, Judov N, Filss C, Galldiks N, Tellmann L, Weiss C, Sabel M et al: Dual-time-point O-(2-[18F]fluoroethyl)-L-tyrosine PET for grading of cerebral gliomas. European radiology 2015:1-8.
  155. Lyoo CH, Ikawa M, Liow J-S, Zoghbi SS, Morse CL, Pike VW, Fujita M, Innis RB, Kreisl WC: Cerebellum Can Serve As a Pseudo-Reference Region in Alzheimer Disease to Detect Neuroinflammation Measured with PET Radioligand Binding to Translocator Protein. Journal of Nuclear Medicine 2015, 56(5):701-706.
  156. Maier FC, Keller MD, Bukala D, Bender B, Mannheim JG, Brereton IM, Galloway GJ, Pichler BJ: Quantification of β-Amyloidosis and rCBF with Dedicated PET, 7 T MR Imaging, and High-Resolution Microscopic MR Imaging at 16.4 T in APP23 Mice. Journal of Nuclear Medicine 2015, 56(10):1593-1599.
  157. Martignani C, Diemberger I, Nanni C, Biffi M, Ziacchi M, Boschi S, Corzani A, Fanti S, Sambuceti G, Boriani G: Cardiac resynchronization therapy and cardiac sympathetic function. European journal of clinical investigation 2015, 45(8):792-799.
  158. Martín A, Szczupak B, Gómez-Vallejo V, Domercq M, Cano A, Padro D, Muñoz C, Higuchi M, Matute C, Llop J: In Vivo PET Imaging of the α4β2 Nicotinic Acetylcholine Receptor As a Marker for Brain Inflammation after Cerebral Ischemia. The Journal of Neuroscience 2015, 35(15):5998-6009.
  159. Martín A, Vázquez-Villoldo N, Gómez-Vallejo V, Padro D, Soria FN, Szczupak B, Plaza-García S, Arrieta A, Reese T, Llop J: In vivo imaging of system xc-as a novel approach to monitor multiple sclerosis. European Journal of Nuclear Medicine and Molecular Imaging 2015:1-15.
  160. Martínez-Vélez N, Xipell E, Vera B, Zalacain M, Marrodan L, Gonzalez-Huarriz M, Toledo G, Cascallo M, Alemany R, Patiño-García A: The oncolytic adenovirus VCN-01 as therapeutic approach against pediatric osteosarcoma. Clinical Cancer Research 2015:clincanres. 1899.2015.
  161. Mathur A, Sharma AK, Murhekar V, Mallia MB, Pawade S, Sarma H, Chaudhari P, Sachdev S, Banerjee S: Syntheses and biological evaluation of 99m Tc-HYNIC-fatty acid complexes for myocardial imaging. RSC Advances 2015, 5(113):93374-93385.
  162. Mazère J, Mayo W, Pariscoat G, Schulz J, Allard M, Fernandez P, Lamare F: Simplified quantification method for in vivo SPECT imaging of the Vesicular Acetylcholine Transporter with 123I-IBVM. Journal of Nuclear Medicine 2015:jnumed. 114.147074.
  163. Médoc M, Dhilly M, Matesic L, Toutain J, Krause-Heuer AM, Delamare J, Fraser BH, Touzani O, Barré L, Greguric I: In Vivo Evaluation of Radiofluorinated Caspase-3/7 Inhibitors as Radiotracers for Apoptosis Imaging and Comparison with [18F] ML-10 in a Stroke Model in the Rat. Molecular Imaging and Biology 2015:1-10.
  164. Melasch J, Rullmann M, Hilbert A, Luthardt J, Becker G, Patt M, Villringer A, Arelin K, Meyer P, Lobsien D: The central nervous norepinephrine network links a diminished sense of emotional well-being to an increased body weight. International Journal of Obesity 2015.
  165. Mena-Romano P, Cheng C, Glowa C, Peschke P, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A, Karger CP: Measurement of hypoxia-related parameters in three sublines of a rat prostate carcinoma using dynamic 18F-FMISO-Pet-Ct and quantitative histology. American journal of nuclear medicine and molecular imaging 2015, 5(4):348.
  166. Milan E, Gallo L, Sartorello A, Giubbini R: Regadenoson vs Dypiridamole in the quantification of Myocardial Blood Flow. Initial Italian experience. Journal of Nuclear Medicine 2015, 56(supplement 3):1533-1533.
  167. Mirbolooki MR, Schade KN, Constantinescu CC, Pan ML, Mukherjee J: Enhancement of 18F‐fluorodeoxyglucose metabolism in rat brain frontal cortex using a β3 adrenoceptor agonist. Synapse 2015, 69(2):96-98.
  168. Mizutani A, Matsunari I, Kobayashi M, Nishi K, Fujita W, Miyazaki Y, Nekolla SG, Kawai K: Impact of injection dose, post-reconstruction filtering, and collimator choice on image quality of myocardial perfusion SPECT using cadmium-zinc telluride detectors in the rat. EJNMMI Phys 2015, 2(1):1-17.
  169. Molinet-Dronda F, Gago B, Quiroga-Varela A, Juri C, Collantes M, Delgado M, Prieto E, Ecay M, Iglesias E, Marín C et al: Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson’s disease: A longitudinal in-vivo study. Neurobiology of Disease 2015, 77(0):165-172.
  170. Mondal S, Roy D, Camacho-Pereira J, Khurana A, Chini E, Yang L, Baddour J, Stilles K, Padmabandu S, Leung S et al: HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancer. Oncotarget 2015.
  171. Moody JB, Lee BC, Corbett JR, Ficaro EP, Murthy VL: Precision and accuracy of clinical quantification of myocardial blood flow by dynamic PET: A technical perspective. J Nucl Cardiol 2015:1-17.
  172. Moody JB, Murthy VL, Lee BC, Corbett JR, Ficaro EP: Variance Estimation for Myocardial Blood Flow by Dynamic PET. IEEE transactions on medical imaging 2015, 34(11):2343-2353.
  173. Morales A, Kohno M, Robertson C, Dean A, Mandelkern M, London E: Gray-matter volume, midbrain dopamine D2/D3 receptors and drug craving in methamphetamine users. Molecular psychiatry 2015, 20(6):764-771.
  174. Morgan DA, McDaniel LN, Yin T, Khan M, Jiang J, Acevedo MR, Walsh SA, Ponto LLB, Norris AW, Lutter M: Regulation of glucose tolerance and sympathetic activity by MC4R signaling in the lateral hypothalamus. Diabetes 2015, 64(6):1976-1987.
  175. Mukherjee J, Bajwa AK, Wooten DW, Hillmer AT, Pan ML, Pandey SK, Saigal N, Christian BT: Comparative assessment of 18F‐Mefway as a serotonin 5‐HT1A receptor PET imaging agent across species: Rodents, nonhuman primates, and humans. Journal of Comparative Neurology 2015.
  176. Mukherjee J, Constantinescu CC, Hoang AT, Jerjian T, Majji D, Pan ML: Dopamine D3 receptor binding of 18F‐Fallypride: Evaluation using in vitro and in vivo PET imaging studies. Synapse 2015.
  177. Muller I: Innovation Delivered. Immunology 2015.
  178. Muylle K, Flamen P, Vugts DJ, Guiot T, Ghanem G, Meuleman N, Bourgeois P, Vanderlinden B, van Dongen GA, Everaert H: Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab. European journal of nuclear medicine and molecular imaging 2015:1-11.
  179. Muzi M, Peterson LM, O’Sullivan JN, Fink JR, Rajendran JG, McLaughlin LJ, Muzi JP, Mankoff DA, Krohn KA: 18F-Fluoromisonidazole Quantification of Hypoxia in Human Cancer Patients Using Image-Derived Blood Surrogate Tissue Reference Regions. Journal of Nuclear Medicine 2015, 56(8):1223-1228.
  180. Nag S, Fazio P, Lehmann L, Kettschau G, Heinrich T, Thiele A, Svedberg M, Amini N, Leesch S, Catafau A: In Vivo/In Vitro Characterisation of a Novel MAO-B Inhibitor Radioligand, Fluorine-18 Labeled Deuterated Fluorodeprenyl (18F-Fluorodeprenyl-D2). Journal of Nuclear Medicine 2015:jnumed. 115.161083.
  181. Nahimi A, Jakobsen S, Munk OL, Vang K, Phan JA, Rodell A, Gjedde A: Mapping α2 Adrenoceptors of the Human Brain with 11C-Yohimbine. Journal of Nuclear Medicine 2015, 56(3):392-398.
  182. Nakajima S, Caravaggio F, Boileau I, Chung JK, Plitman E, Gerretsen P, Wilson AA, Houle S, Mamo DC, Graff-Guerrero A: Lack of age-dependent decrease in dopamine D3 receptor availability: a [(11)C]-(+)-PHNO and [(11)C]-raclopride positron emission tomography study. J Cereb Blood Flow Metab 2015, 35(11):1812-1818.
  183. Nakajima S, Caravaggio F, Mamo DC, Mulsant BH, Chung JK, Plitman E, Iwata Y, Gerretsen P, Uchida H, Suzuki T: Dopamine D 2/3 receptor availability in the striatum of antipsychotic-free older patients with schizophrenia—A [11 C]-raclopride PET study. Schizophrenia research 2015, 164(1):263-267.
  184. Neveu M-A, Bol V, Bol A, Bouzin C, Grégoire V, Feron O, Jordan BF, Gallez B: The increase in tumor oxygenation under carbogen breathing induces a decrease in the uptake of [18 F]-fluoro-deoxy-glucose. Radiotherapy and Oncology 2015.
  185. Nguyen DH, Chou PY, Hsieh YH, Momeni A, Fang YHD, Patel KM, Yang CY, Cheng MH: Quantity of lymph nodes correlates with improvement in lymphatic drainage in treatment of hind limb lymphedema with lymph node flap transfer in rats. Microsurgery 2015.
  186. Nieto E, Delgado M, Sobrado M, de Ceballos ML, Alajarín R, García-García L, Kelly J, Lizasoain I, Pozo MA, Álvarez-Builla J: Preliminary research on 1-(4-bromo-2-nitroimidazol-1-yl)-3-[18 F] fluoropropan-2-ol as a novel brain hypoxia PET tracer in a rodent model of stroke. European journal of medicinal chemistry 2015, 101:604-615.
  187. Nishiyama S, Ohba H, Kanazawa M, Kakiuchi T, Tsukada H: Comparing α7 nicotinic acetylcholine receptor binding, amyloid‐β deposition, and mitochondria complex‐I function in living brain: A PET study in aged monkeys. Synapse 2015, 69(10):475-483.
  188. North AJ, Hayne DJ, Schieber C, Price K, White AR, Crouch PJ, Rigopoulos A, O’Keefe GJ, Tochon-Danguy H, Scott AM: Toward Hypoxia-Selective Rhenium and Technetium Tricarbonyl Complexes. Inorganic Chemistry 2015.
  189. Nugent S, Castellano C, Bocti C, Dionne I, Fulop T, Cunnane S: Relationship of metabolic and endocrine parameters to brain glucose metabolism in older adults: do cognitively-normal older adults have a particular metabolic phenotype? Biogerontology 2015:1-15.
  190. Nummenmaa L, Manninen S, Tuominen L, Hirvonen J, Kalliokoski KK, Nuutila P, Jääskeläinen IP, Hari R, Dunbar RIM, Sams M: Adult attachment style is associated with cerebral μ-opioid receptor availability in humans. Human brain mapping 2015, 36(9):3621-3628.
  191. Oborski M, Laymon C, Lieberman F, Drappatz J, Mountz J: A DCE-MRI based approach to FLT PET ROI definition for early therapy response assessment in GBM. Journal of Nuclear Medicine 2015, 56(supplement 3):1788-1788.
  192. Ofori E, Pasternak O, Planetta PJ, Burciu R, Snyder A, Febo M, Golde TE, Okun MS, Vaillancourt DE: Increased free water in the substantia nigra of Parkinson’s disease: a single-site and multi-site study. Neurobiology of aging 2015, 36(2):1097-1104.
  193. Oi N, Tokunaga M, Suzuki M, Nagai Y, Nakatani Y, Yamamoto N, Maeda J, Minamimoto T, Zhang M-R, Suhara T: Development of Novel PET Probes for Central 2-Amino-3-(3-hydroxy-5-methyl-4-isoxazolyl) propionic Acid Receptors. Journal of medicinal chemistry 2015, 58(21):8444-8462.
  194. Okita K, Ghahremani DG, Payer DE, Robertson CL, Mandelkern MA, London ED: Relationship of Alexithymia Ratings to Dopamine D2-type Receptors in Anterior Cingulate and Insula of Healthy Control Subjects but not Methamphetamine-Dependent Individuals. International Journal of Neuropsychopharmacology 2015:pyv129.
  195. Oliveira FP, Castelo-Branco M: Computer-aided diagnosis of Parkinson’s disease based on [123I] FP-CIT SPECT binding potential images, using the voxels-as-features approach and support vector machines. Journal of neural engineering 2015, 12(2):026008.
  196. Ory D, Planas A, Dresselaers T, Gsell W, Postnov A, Celen S, Casteels C, Himmelreich U, Debyser Z, Van Laere K: PET imaging of TSPO in a rat model of local neuroinflammation induced by intracerebral injection of lipopolysaccharide. Nuclear medicine and biology 2015, 42(10):753-761.
  197. Ory D, Postnov A, Koole M, Celen S, de Laat B, Verbruggen A, Van Laere K, Bormans G, Casteels C: Quantification of TSPO overexpression in a rat model of local neuroinflammation induced by intracerebral injection of LPS by the use of [18F] DPA-714 PET. European journal of nuclear medicine and molecular imaging 2015:1-10.
  198. Ota M, Ogawa S, Kato K, Masuda C, Kunugi H: Striatal and extrastriatal dopamine release in the common marmoset brain measured by positron emission tomography and [18 F] fallypride. Neuroscience research 2015.
  199. Ota M, Ogawa S, Kato K, Wakabayashi C, Kunugi H: Methamphetamine-sensitized rats show augmented dopamine release to methylphenidate stimulation: A positron emission tomography using [18 F] fallypride. Psychiatry Research: Neuroimaging 2015, 232(1):92-97.
  200. Pagani M, De Carli F, Morbelli S, Öberg J, Chincarini A, Frisoni GB, Galluzzi S, Perneczky R, Drzezga A, van Berckel BNM et al: Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer’s disease from healthy controls. A European Alzheimer’s Disease Consortium (EADC) study. NeuroImage: Clinical 2015, 7(0):34-42.
  201. Park HS, Kim E, Moon BS, Lim NH, Lee BC, Kim SE: In Vivo Tissue Pharmacokinetics of Carbon-11-Labeled Clozapine in Healthy Volunteers: A Positron Emission Tomography Study. CPT: Pharmacometrics & Systems Pharmacology 2015, 4(5):305-311.
  202. Park JH, Lee YK, Kim DH, Kim SJ, Lee J-H, Jeon TJ, Ryu YH, Lee JD: Usefulness of 18F-fluorodeoxyglucose Positron Emission Tomography–Computed Tomography in Monitoring Adhesive Capsulitis After Breast Cancer Treatment. Journal of computer assisted tomography 2015, 39(3):349-355.
  203. Parthoens J, Servaes S, Verhaeghe J, Stroobants S, Staelens S: Prelimbic Cortical Injections of a GABA Agonist and Antagonist: In Vivo Quantification of the Effect in the Rat Brain Using [18F] FDG MicroPET. Molecular Imaging and Biology 2015:1-9.
  204. Payer DE, Guttman M, Kish SJ, Tong J, Strafella A, Zack M, Adams JR, Rusjan P, Houle S, Furukawa Y: [11C]‐(+)‐PHNO PET imaging of dopamine D2/3 receptors in Parkinson’s disease with impulse control disorders. Movement Disorders 2015, 30(2):160-166.
  205. Perrotin A, Desgranges B, Landeau B, Mézenge F, La Joie R, Egret S, Pélerin A, de la Sayette V, Eustache F, Chételat G: Anosognosia in Alzheimer disease: Disconnection between memory and self‐related brain networks. Annals of neurology 2015, 78(3):477-486.
  206. Peters M, Willems P, Weijers R, Wierts R, Jutten L, Urbach C, Arts C, van Rhijn L, Brans B: Pseudarthrosis after lumbar spinal fusion: the role of 18F-fluoride PET/CT. European journal of nuclear medicine and molecular imaging 2015, 42(12):1891-1898.
  207. Peters MJ, Wierts R, Jutten EM, Halders SG, Willems PC, Brans B: Evaluation of a short dynamic 18F-fluoride PET/CT scanning method to assess bone metabolic activity in spinal orthopedics. Annals of Nuclear Medicine 2015:1-11.
  208. Petrik M, Zhai C, Novy Z, Urbanek L, Haas H, Decristoforo C: In Vitro and In Vivo Comparison of Selected Ga-68 and Zr-89 Labelled Siderophores. Molecular Imaging and Biology 2015:1-9.
  209. Pierce II LA, Elston BF, Clunie DA, Nelson D, Kinahan PE: A Digital Reference Object to Analyze Calculation Accuracy of PET Standardized Uptake Value. Radiology 2015.
  210. Pifferi F, Dorieux O, Castellano C-A, Croteau E, Masson M, Guillermier M, Van Camp N, Guesnet P, Alessandri J-M, Cunnane S: Long-chain n-3 PUFAs from fish oil enhance resting state brain glucose utilization and reduce anxiety in an adult nonhuman primate, the grey mouse lemur. Journal of lipid research 2015, 56(8):1511-1518.
  211. Placzek MS, Van de Bittner GC, Wey H-Y, Lukas SE, Hooker JM: Immediate and Persistent Effects of Salvinorin A on the Kappa Opioid Receptor in Rodents, Monitored In Vivo with PET. Neuropsychopharmacology 2015.
  212. Ponto LLB, Brashers-Krug TM, Pierson RK, Menda Y, Acion L, Watkins GL, Sunderland JJ, Koeppel JA, Jorge RE: Preliminary Investigation of Cerebral Blood Flow and Amyloid Burden in Veterans With and Without Combat-Related Traumatic Brain Injury. The Journal of neuropsychiatry and clinical neurosciences 2015.
  213. Ponto LLB, Menda Y, Magnotta VA, Yamada TH, Denburg NL, Schultz SK: Frontal hypometabolism in elderly breast cancer survivors determined by [18F] fluorodeoxyglucose (FDG) positron emission tomography (PET): a pilot study. International journal of geriatric psychiatry 2015, 30(6):587-594.
  214. Poulin É, Lebel R, Croteau É, Blanchette M, Tremblay L, Lecomte R, Lepage M: Optimization of the reference region method for dual pharmacokinetic modeling using Gd‐DTPA/MRI and 18F‐FDG/PET. Magnetic Resonance in Medicine 2015, 73(2):740-748.
  215. Prasannan A, Debele TA, Tsai H-C, Chao C-C, Lin C-P, Hsiue G-H: Synthesis and evaluation of the targeted binding of RGD-containing PEGylated-PEI/DNA polyplex micelles as radiotracers for a tumor-targeting imaging probe. RSC Advances 2015, 5(130):107455-107465.
  216. Prieto E, Martí-Climent JM, Morán V, Sancho L, Barbés B, Arbizu J, Richter JA: Brain PET imaging optimization with time of flight and point spread function modelling. Physica Medica 2015.
  217. Qamhawi Z, Towey D, Shah B, Pagano G, Seibyl J, Marek K, Borghammer P, Brooks DJ, Pavese N: Clinical correlates of raphe serotonergic dysfunction in early Parkinson’s disease. Brain 2015:awv215.
  218. Rademacher L, Prinz S, Winz O, Henkel K, Dietrich CA, Schmaljohann J, Shali SM, Schabram I, Stoppe C, Cumming P: Effects of smoking cessation on presynaptic dopamine function of addicted male smokers. Biological Psychiatry 2015.
  219. Rockne RC, Trister AD, Jacobs J, Hawkins-Daarud AJ, Neal ML, Hendrickson K, Mrugala MM, Rockhill JK, Kinahan P, Krohn KA: A patient-specific computational model of hypoxia-modulated radiation resistance in glioblastoma using 18F-FMISO-PET. Journal of The Royal Society Interface 2015, 12(103):20141174.
  220. Rodriguez-Vieitez E, Ni R, Gulyás B, Tóth M, Häggkvist J, Halldin C, Voytenko L, Marutle A, Nordberg A: Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study. European journal of nuclear medicine and molecular imaging 2015:1-14.
  221. Roelcke U, Wyss MT, Nowosielski M, Ruda R, Roth P, Hofer S, Galldiks N, Crippa F, Weller M, Soffietti R: Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. Neuro-oncology 2015.
  222. Rong Y, Vernaleken I, Winz OH, Goedicke A, Mottaghy FM, Kops ER: Simulation-based partial volume correction for dopaminergic PET imaging: Impact of segmentation accuracy. Z Med Phys 2015, 25(3):230-242.
  223. Rook JM, Tantawy MN, Ansari MS, Felts AS, Stauffer SR, Emmitte KA, Kessler RM, Niswender CM, Daniels JS, Jones CK et al: Relationship between In Vivo Receptor Occupancy and Efficacy of Metabotropic Glutamate Receptor Subtype 5 Allosteric Modulators with Different In Vitro Binding Profiles. Neuropsychopharmacology 2015, 40(3):755-765.
  224. Rosenberger I, Strauss A, Dobiasch S, Weis C, Szanyi S, Gil-Iceta L, Alonso E, Esparza MG, Gómez-Vallejo V, Szczupak B: Targeted diagnostic magnetic nanoparticles for medical imaging of pancreatic cancer. Journal of Controlled Release 2015, 214:76-84.
  225. Rosestedt M, Andersson KG, Mitran B, Tolmachev V, Löfblom J, Orlova A, Ståhl S: Affibody-mediated PET imaging of HER3 expression in malignant tumours. Scientific reports 2015, 5.
  226. Rothe JH, Rudolph I, Rohwer N, Kupitz D, Gregor-Mamoudou B, Derlin T, Furth C, Amthauer H, Brenner W, Buchert R et al: Time Course of Contrast Enhancement by Micro-CT with Dedicated Contrast Agents in Normal Mice and Mice with Hepatocellular Carcinoma: Comparison of One Iodinated and Two Nanoparticle-Based Agents. Academic Radiology 2015, 22(2):169-178.
  227. Rullmann M, Dukart J, Hoffmann K-T, Luthardt J, Tiepolt S, Patt M, Gertz H-J, Schroeter ML, Seibyl J, Schulz-Schaeffer WJ: Partial volume effect correction improves quantitative florbetaben beta-amyloid PET scan analysis. Journal of Nuclear Medicine 2015:jnumed. 115.161893.
  228. Sabri O, Becker G-A, Meyer PM, Hesse S, Wilke S, Graef S, Patt M, Luthardt J, Wagenknecht G, Hoepping A: First-in-human PET quantification study of cerebral α4β2* nicotinic acetylcholine receptors using the novel specific radioligand (−)-[18 F] Flubatine. NeuroImage 2015, 118:199-208.
  229. Sah B-R, Burger IA, Schibli R, Friebe M, Dinkelborg L, Graham K, Borkowski S, Bacher-Stier C, Valencia R, Srinivasan A et al: Dosimetry and First Clinical Evaluation of the New 18F-Radiolabeled Bombesin Analogue BAY 864367 in Patients with Prostate Cancer. Journal of Nuclear Medicine 2015, 56(3):372-378.
  230. Sahlholm K, Sijbesma JW, Maas B, Kwizera C, Marcellino D, Ramakrishnan NK, Dierckx RA, Elsinga PH, van Waarde A: Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses. Psychopharmacology 2015, 232(18):3443-3453.
  231. Šarić A, Sobočanec S, Šafranko ŽM, Hadžija MP, Bagarić R, Farkaš V, Švarc A, Marotti T, Balog T: Diminished Resistance to Hyperoxia in Brains of Reproductively Senescent Female CBA/H Mice. Medical science monitor basic research 2015, 21:191-199.
  232. Sasser TA, Chapman SE, Sanders I, Liepert L, Leevy M: Cross-Platform MRI/PET or MRI/SPECT Imaging, and Co-Registration. Bruker Application Note 2015.
  233. Saur L, Bagatini PB, Greggio S, Venturin GT, Vaz SP, dos Reis Ferreira K, Junqueira JS, Lara DR, DaCosta JC, Jeckel CMM: Antidepressant Effects of Ketamine Are Not Related to 18F-FDG Metabolism or Tyrosine Hydroxylase Immunoreactivity in the Ventral Tegmental Area of Wistar Rats. Neurochemical research 2015:1-12.
  234. Savonenko AV, Melnikova T, Wang Y, Ravert H, Gao Y, Koppel J, Lee D, Pletnikova O, Cho E, Sayyida N: Cannabinoid CB2 Receptors in a Mouse Model of Aβ Amyloidosis: Immunohistochemical Analysis and Suitability as a PET Biomarker of Neuroinflammation. PloS one 2015, 10(6):e0129618.
  235. Sawatzke AB, Norris AW, Spyropoulos F, Walsh SA, Acevedo MR, Hu S, Yao J, Wang C, Sunderland JJ, Boles Ponto LL: PET/CT imaging reveals unrivaled placental avidity for glucose compared to other tissues. Placenta 2015, 36(2):115-120.
  236. Sayman HB, Kanmaz B, Uslu I, Adil A-N, Cuocolo A, Carril JM, Cinaral F, Sherif E-R, Senocak M: Utility of left lateral supine position for myocardial perfusion single-photon emission computed tomography compared with other methods of correcting inferior wall attenuation. Nuclear medicine communications 2015, 36(3):268-278.
  237. Schieferstein H, Piel M, Beyerlein F, Lüddens H, Bausbacher N, Buchholz H-G, Ross TL, Rösch F: Selective binding to monoamine oxidase A: In vitro and in vivo evaluation of 18 F-labeled β-carboline derivatives. Bioorganic & medicinal chemistry 2015, 23(3):612-623.
  238. Schou M, Varnäs K, Jureus A, Ahlgren C, Malmquist J, Häggkvist J, Tari L, Wesolowski SS, Throner SR, Brown DG: Discovery and Preclinical Validation of [11C] AZ13153556, a Novel Probe for the Histamine Type 3 Receptor. ACS chemical neuroscience 2015.
  239. Sciagrà R, Passeri A, Cipollini F, Castagnoli H, Olivotto I, Burger C, Cecchi F, Pupi A: Validation of pixel-wise parametric mapping of myocardial blood flow with 13NH3 PET in patients with hypertrophic cardiomyopathy. European Journal of Nuclear Medicine and Molecular Imaging 2015, 42(10):1581-1588.
  240. Sekine T, Buck A, Delso G, ter Voert E, Huellner M, Veit-Haibach P, Warnock G: Evaluation of atlas-based MR-attenuation correction for integrated PET-MR in human brain by using PET-CT and PET-MR patient data. Journal of Nuclear Medicine 2015, 56(supplement 3):1618-1618.
  241. Selivanova SV, Toscano A, Abate C, Berardi F, Müller A, Krämer SD, Schibli R, Ametamey SM: Synthesis and pharmacological evaluation of 11 C-labeled piperazine derivative as a PET probe for sigma-2 receptor imaging. Nuclear medicine and biology 2015, 42(4):399-405.
  242. Selvaraju RK, Bulenga TN, Espes D, Lubberink M, Sörensen J, Eriksson B, Estrada S, Velikyan I, Eriksson O: Dosimetry of [68Ga] Ga-DO3A-VS-Cys40-Exendin-4 in rodents, pigs, non-human primates and human-repeated scanning in human is possible. American journal of nuclear medicine and molecular imaging 2015, 5(3):259-269.
  243. Sérrière S, Doméné A, Vercouillie J, Mothes C, Bodard S, Rodrigues N, Guilloteau D, Routier S, Page G, Chalon S: Assessment of the protection of dopaminergic neurons by an α7 nicotinic receptor agonist, PHA 543613 using [18F] LBT-999 in a Parkinson’s disease rat model. Frontiers in medicine 2015, 2.
  244. Sérrière S, Tauber C, Vercouillie J, Mothes C, Pruckner C, Guilloteau D, Kassiou M, Doméné A, Garreau L, Page G et al: Amyloid load and translocator protein 18 kDa in APPswePS1-dE9 mice: a longitudinal study. Neurobiology of Aging 2015, 36(4):1639-1652.
  245. Servagi-Vernat S, Differding S, Sterpin E, Hanin F-X, Labar D, Bol A, Lee JA, Grégoire V: Hypoxia-guided adaptive radiation dose escalation in head and neck carcinoma: A planning study. Acta Oncologica 2015(0):1-9.
  246. Shah D, Deleye S, Verhoye M, Staelens S, Van der Linden A: Resting-state functional MRI and [18F]-FDG PET demonstrate differences in neuronal activity between commonly used mouse strains. Neuroimage 2015.
  247. Shaikh F, Savells D, Awan O, Inayat F, Chaudhry A, Jerath N, Graham MM: Quantitative Imaging Analysis of FDG PET/CT Imaging for Detection of Central Neurolymphomatosis in a Case of Recurrent Diffuse B-Cell Lymphoma. Cureus 2015, 7(11).
  248. Shidahara M, Watabe H, Tashiro M, Okamura N, Furumoto S, Watanuki S, Furukawa K, Arakawa Y, Funaki Y, Iwata R: Quantitative kinetic analysis of PET amyloid imaging agents [11 C] BF227 and [18 F] FACT in human brain. Nuclear Medicine and Biology 2015.
  249. Shiha AA, de Cristóbal J, Delgado M, Fernández de la Rosa R, Bascuñana P, Pozo MA, García-García L: Subacute administration of fluoxetine prevents short-term brain hypometabolism and reduces brain damage markers induced by the lithium-pilocarpine model of epilepsy in rats. Brain Research Bulletin 2015, 111(0):36-47.
  250. Shingaki T, Hume WE, Takashima T, Katayama Y, Okauchi T, Hayashinaka E, Wada Y, Cui Y, Kusuhara H, Sugiyama Y et al: Quantitative Evaluation of mMate1 Function Based on Minimally Invasive Measurement of Tissue Concentration Using PET with [11C]Metformin in Mouse. Pharmaceutical Research 2015:1-10.
  251. Shukuri M, Mawatari A, Ohno M, Suzuki M, Doi H, Watanabe Y, Onoe H: Detection of cyclooxygenase-1 in activated microglia during amyloid plaque progression: PET studies in Alzheimer’s disease model mice. Journal of Nuclear Medicine 2015:jnumed. 115.166116.
  252. Sigurdardottir HL, Kranz GS, Rami‐Mark C, James GM, Vanicek T, Gryglewski G, Kautzky A, Hienert M, Traub‐Weidinger T, Mitterhauser M: Effects of norepinephrine transporter gene variants on NET binding in ADHD and healthy controls investigated by PET. Human brain mapping 2015.
  253. Simoncic U, Zanotti-Fregonara P: Image-derived input function with factor analysis and a-priori information. Nuclear medicine communications 2015, 36(2):187-193.
  254. Slavik R, Grether U, Müller Herder A, Gobbi L, Fingerle J, Ullmer C, Krämer SD, Schibli R, Mu L, Ametamey SM: Discovery of a High Affinity and Selective Pyridine Analog as a Potential PET Imaging Agent for Cannabinoid Type 2 Receptor. Journal of medicinal chemistry 2015.
  255. Slavik R, Herde AM, Bieri D, Weber M, Schibli R, Krämer SD, Ametamey SM, Mu L: Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline derivatives as PET tracers for imaging cannabinoid type 2 receptor. European Journal of Medicinal Chemistry 2015, 92(0):554-564.
  256. Smailagic N, Vacante M, Hyde C, Martin S, Ukoumunne O, Sachpekidis C: 18F‐FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). The Cochrane Library 2015.
  257. Spehl TS, Frings L, Hellwig S, Weiller C, Hüll M, Meyer PT, Amtage F: Role of Semiquantitative Assessment of Regional Binding Potential in 123I-FP-CIT SPECT for the Differentiation of Frontotemporal Dementia, Dementia With Lewy Bodies, and Alzheimer’s Dementia. Clinical nuclear medicine 2015, 40(1):e27-e33.
  258. Spiegelberg D, Mortensen AC, Selvaraju RK, Eriksson O, Stenerlöw B, Nestor M: Molecular imaging of EGFR and CD44v6 for prediction and response monitoring of HSP90 inhibition in an in vivo squamous cell carcinoma model. European journal of nuclear medicine and molecular imaging 2015:1-9.
  259. Stegmayr C, Schöneck M, Oliveira D, Willuweit A, Filss C, Galldiks N, Shah NJ, Coenen HH, Langen K-J: Reproducibility of O-(2-18F-fluoroethyl)-L-tyrosine uptake kinetics in brain tumors and influence of corticoid therapy: an experimental study in rat gliomas. European journal of nuclear medicine and molecular imaging 2015:1-9.
  260. Suda M, Onoguchi M, Tomiyama T, Ishihara K, Takahashi N, Sakurai M, Matsumoto K, Kumita S-i: The reproducibility of time-of-flight PET and conventional PET for the quantification of myocardial blood flow and coronary flow reserve with 13N-ammonia. J Nucl Cardiol 2015:1-16.
  261. Suridjan I, Pollock B, Verhoeff N, Voineskos A, Chow T, Rusjan P, Lobaugh N, Houle S, Mulsant B, Mizrahi R: In-vivo imaging of grey and white matter neuroinflammation in Alzheimer’s disease: a positron emission tomography study with a novel radioligand, [ 18F]-FEPPA. Molecular psychiatry 2015.
  262. Szczupak B, Martín A: Positron Emission Tomography Imaging of Dopaminergic Receptors in Rats. In: Dopamine Receptor Technologies. Volume 96, edn. Edited by Tiberi M: Springer New York; 2015: 197-208.
  263. T O’Brien J, Herholz K: Amyloid imaging for dementia in clinical practice. BMC medicine 2015, 13(1):163.
  264. Tahmasian M, Pasquini L, Scherr M, Meng C, Förster S, Bratec SM, Shi K, Yakushev I, Schwaiger M, Grimmer T: The lower hippocampus global connectivity, the higher its local metabolism in Alzheimer disease. Neurology 2015, 84(19):1956-1963.
  265. Takahashi K, Mizuno K, Sasaki AT, Wada Y, Tanaka M, Ishii A, Tajima K, Tsuyuguchi N, Watanabe K, Zeki S: Imaging the passionate stage of romantic love by dopamine dynamics. Frontiers in human neuroscience 2015, 9.
  266. Takuwa H, Maeda J, Ikoma Y, Tokunaga M, Wakizaka H, Uchida S, Kanno I, Taniguchi J, Ito H, Higuchi M: [11C] Raclopride binding in the striatum of minimally restrained and free‐walking awake mice in a positron emission tomography study. Synapse 2015.
  267. Temma T, Nishigori K, Onoe S, Sampei S, Kimura I, Ono M, Saji H: Radiofluorinated probe for PET imaging of fatty acid binding protein 4 in cancer. Nuclear medicine and biology 2015, 42(2):184-191.
  268. Terada T, Kakimoto A, Yoshikawa E, Kono S, Bunai T, Hosoi Y, Sakao-Suzuki M, Konishi T, Miyajima H, Ouchi Y: The Possible Link between GABAergic Dysfunction and Cognitive Decline in a Patient with Idiopathic Hypoparathyroidism. Internal Medicine 2015, 54(17):2245-2250.
  269. Terbeck S, Akkus F, Chesterman LP, Hasler G: The role of metabotropic glutamate receptor 5 in the pathogenesis of mood disorders and addiction: combining preclinical evidence with human Positron Emission Tomography (PET) studies. Frontiers in neuroscience 2015, 9.
  270. Thackeray J, Bankstahl J, Wang Y, Wollert K, Bengel F: Clinically relevant strategies for lowering cardiomyocyte glucose uptake for 18F-FDG imaging of myocardial inflammation in mice. European Journal of Nuclear Medicine and Molecular Imaging 2015, 42(5):771-780.
  271. Thackeray JT, Bankstahl JP, Bengel FM: Impact of image-derived input function and fit time intervals on Patlak quantification of myocardial glucose uptake in mice. Journal of Nuclear Medicine 2015, 56(10):1615-1621.
  272. Thanos PK, Michaelides M, Subrize M, Miller ML, Bellezza R, Cooney RN, Leggio L, Wang G-J, Rogers AM, Volkow ND: Roux-en-Y gastric bypass alters brain activity in regions that underlie reward and taste perception. PloS one 2015, 10(6).
  273. Thomae D, Servaes S, Vazquez N, Dedeurwaerdere S, Van der Veken P, Joossens J, Augustyns K, Stroobants S, Staelens S: Synthesis and preclinical evaluation of an 18 F labeled PDE7 inhibitor for PET neuroimaging. Nuclear medicine and biology 2015.
  274. Tichauer KM, Wang Y, Pogue BW, Liu JT: Quantitative in vivo cell-surface receptor imaging in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imaging. Physics in medicine and biology 2015, 60(14):R239.
  275. Tiwari AK, Ji B, Yui J, Fujinaga M, Yamasaki T, Xie L, Luo R, Shimoda Y, Kumata K, Zhang Y: [18F] FEBMP: Positron Emission Tomography Imaging of TSPO in a Model of Neuroinflammation in Rats, and in vitro Autoradiograms of the Human Brain. Theranostics 2015, 5(9):961.
  276. Tomadesso C, Perrotin A, Mutlu J, Mézenge F, Landeau B, Egret S, de la Sayette V, Jonin P-Y, Eustache F, Desgranges B: Brain structural, functional, and cognitive correlates of recent versus remote autobiographical memories in amnestic Mild Cognitive Impairment. NeuroImage: Clinical 2015.
  277. Tominaga K, Tsumoto C, Ataka S, Mizuno K, Takahashi K, Yamagami H, Tanigawa T, Kawabe J, Watanabe T, Fujiwara Y: Regional brain disorders of serotonin neurotransmission are associated with functional dyspepsia. Life sciences 2015, 137:150-157.
  278. Tomiyama T, Kumita S-i, Ishihara K, Suda M, Sakurai M, Hakozaki K, Hashimoto H, Takahashi N, Takano H, Kobayashi Y: Patients with reduced heart rate response to adenosine infusion have low myocardial flow reserve in 13N-ammonia PET studies. The international journal of cardiovascular imaging 2015, 31(5):1089-1095.
  279. Tóth M, Little P, Arnberg F, Häggkvist J, Mulder J, Halldin C, Gulyás B, Holmin S: Acute neuroinflammation in a clinically relevant focal cortical ischemic stroke model in rat: longitudinal positron emission tomography and immunofluorescent tracking. Brain Structure and Function 2015:1-12.
  280. Tran LBA, Bol A, Labar D, Karroum O, Mignion L, Bol V, Jordan BF, Grégoire V, Gallez B: DW‐MRI and 18F‐FLT PET for early assessment of response to radiation therapy associated with hypoxia‐driven interventions. Preclinical studies using manipulation of oxygenation and/or dose escalation. Contrast media & molecular imaging 2015.
  281. Tran L-B-A, Bol A, Labar D, Cao-Pham T-T, Jordan B, Grégoire V, Gallez B: Predictive value of 18F-FAZA PET imaging for guiding the association of radiotherapy with nimorazole: A preclinical study. Radiotherapy and Oncology 2015, 114(2):189-194.
  282. Trnovská J, Silhavý J, Zídek V, Simáková M, Mlejnek P, Landa V, Eigner S, Henke KE, Skop V, Oliyarnyk O: Gender-related effects on substrate utilization and metabolic adaptation in hairless spontaneously hypertensive rat. Physiol Res 2015, 64:51-60.
  283. Tsartsalis S, Dumas N, Tournier B, Pham T, Moulin-Sallanon M, Gregoire M-C, Charnay Y, Millet P: SPECT imaging of glioma with radioiodinated CLINDE: evidence from a mouse GL26 glioma model. EJNMMI research 2015, 5(1):9.
  284. Tsartsalis S, Tournier BB, Huynh-Gatz T, Dumas N, Ginovart N, Moulin-Sallanon M, Millet P: 5-HT2A receptor SPECT imaging with [123 I] R91150 under P-gp inhibition with tariquidar: more is better? Nuclear Medicine and Biology 2015.
  285. Tuominen L, Tuulari J, Karlsson H, Hirvonen J, Helin S, Salminen P, Parkkola R, Hietala J, Nuutila P, Nummenmaa L: Aberrant mesolimbic dopamine–opiate interaction in obesity. NeuroImage 2015, 122:80-86.
  286. Ueda M, Yamagami D, Watanabe K, Mori A, Kimura H, Sano K, Saji H, Ishikawa K, Hori M, Sakakita H et al: Histological and Nuclear Medical Comparison of Inflammation After Hemostasis with Non-Thermal Plasma and Thermal Coagulation. Plasma Processes and Polymers 2015:n/a-n/a.
  287. Vállez Garcia D, de Vries EJ, Toyohara J, Ishiwata K, Hatano K, Dierckx RJO, Doorduin J: Evaluation of [11C]CB184 for imaging and quantification of TSPO overexpression in a rat model of herpes encephalitis. European Journal of Nuclear Medicine and Molecular Imaging 2015:1-13.
  288. van der Lans AA, Vosselman MJ, Hanssen MJ, Brans B, van Marken Lichtenbelt WD: Supraclavicular skin temperature and BAT activity in lean healthy adults. The Journal of Physiological Sciences 2015:1-7.
  289. Velikyan I, Bulenga TN, Selvaraju R, Lubberink M, Espes D, Rosenström U, Eriksson O: Dosimetry of [177Lu]-DO3A-VS-Cys40-Exendin-4–impact on the feasibility of insulinoma internal radiotherapy. American journal of nuclear medicine and molecular imaging 2015, 5(2):109.
  290. Vicidomini C, Panico M, Greco A, Gargiulo S, Coda ARD, Zannetti A, Gramanzini M, Roviello GN, Quarantelli M, Alfano B et al: In vivo imaging and characterization of [18F]DPA-714, a potential new TSPO ligand, in mouse brain and peripheral tissues using small-animal PET. Nuclear Medicine and Biology 2015, 42(3):309-316.
  291. Vouche M, Salem R, Miller FH, Lemort M, Vanderlinden B, De Becker D, Hendlisz A, Flamen P: Y90 radioembolization of colorectal cancer liver metastases: response assessment by contrast-enhanced computed tomography with or without PET-CT guidance. Clinical imaging 2015, 39(3):454-462.
  292. Waldron A-M, Verhaeghe J, wyffels L, Schmidt M, Langlois X, Van Der Linden A, Stroobants S, Staelens S: Preclinical Comparison of the Amyloid-β Radioligands [11C]Pittsburgh compound B and [18F]florbetaben in Aged APPPS1-21 and BRI1-42 Mouse Models of Cerebral Amyloidosis. Molecular Imaging and Biology 2015:1-9.
  293. Waldron A-M, Wintmolders C, Bottelbergs A, Kelley JB, Schmidt ME, Stroobants S, Langlois X, Staelens S: In vivo molecular neuroimaging of glucose utilization and its association with fibrillar amyloid-β load in aged APPPS1-21 mice. Alzheimer’s Research & Therapy 2015, 7(1):1-11.
  294. Waldron A-M, Wyffels L, Verhaeghe J, Bottelbergs A, Richardson J, Kelley J, Schmidt M, Stroobants S, Langlois X, Staelens S: Quantitative μPET Imaging of Cerebral Glucose Metabolism and Amyloidosis in the TASTPM Double Transgenic Mouse Model of Alzheimer’s Disease. Current Alzheimer Research 2015, 12(7):694-703.
  295. Wang C, Placzek MS, Van de Bittner GC, Schroeder FA, Hooker JM: A Novel Radiotracer for Imaging Monoacylglycerol Lipase in the Brain Using Positron Emission Tomography. ACS Chemical Neuroscience 2015.
  296. Wangerin KA, Muzi M, Peterson LM, Linden HM, Novakova A, O’Sullivan F, Kurland BF, Mankoff DA, Kinahan PE: Effect of 18F-FDG uptake time on lesion detectability in PET imaging of early-stage breast cancer. Age (y) 2015, 61:51.56-80.50.
  297. Wathen CA, Caldwell C, Chanda N, Upendran A, Zambre A, Afrasiabi Z, Chapaman SE, Foje N, Leevy WM, Kannan R: Selective X-ray contrast enhancement of the spleen of living mice mediated by gold nanorods. Contrast media & molecular imaging 2015, 10(3):188-193.
  298. Weinl C, Vega SC, Riehle H, Stritt C, Calaminus C, Wolburg H, Mauel S, Breithaupt A, Gruber AD, Wasylyk B: Endothelial depletion of murine SRF/MRTF provokes intracerebral hemorrhagic stroke. Proceedings of the National Academy of Sciences 2015, 112(32):9914-9919.
  299. Weng Y-H, Chen C-Y, Lin K-J, Chen Y-L, Yeh T-H, Hsiao T, Chen J, Lu C-S, Wang H-L: (R1441C) LRRK2 induces the degeneration of SN dopaminergic neurons and alters the expression of genes regulating neuronal survival in a transgenic mouse model. Experimental neurology 2015.
  300. Wey H-Y, Wang C, Schroeder FA, Logan J, Price JC, Hooker JM: Kinetic Analysis and Quantification of [11C] Martinostat for in vivo HDAC Imaging of the Brain. ACS chemical neuroscience 2015.
  301. Wimana Z, Gebhart G, Guiot T, Vanderlinden B, Morandini R, Doumont G, Sherer F, Van Simaeys G, Goldman S, Ghanem G et al: Mucolytic Agents Can Enhance HER2 Receptor Accessibility for [89Zr]Trastuzumab, Improving HER2 Imaging in a Mucin-Overexpressing Breast Cancer Xenograft Mouse Model. Molecular Imaging and Biology 2015:1-7.
  302. Wu Y-W, Tseng P-H, Yang W-S: Alterations in myocardial glucose utilization in obese diabetic male db/db mice: a small-animal PET investigation. Journal of Nuclear Medicine 2015, 56(supplement 3):1478-1478.
  303. Xiao N-A, Zhang J, Zhou M, Wei Z, Wu X-L, Dai X-M, Zhu Y-G, Chen X-C: Reduction of Glucose Metabolism in Olfactory Bulb is an Earlier Alzheimer’s Disease-related Biomarker in 5XFAD Mice. Chinese medical journal 2015, 128(16):2220.
  304. Yamasaki T, Fujinaga M, Yui J, Wakizaka H, Ohya T, Nengaki N, Ogawa M, Ikoma Y, Hatori A, Xie L: Improved Visualization and Specific Binding for Metabotropic Glutamate Receptor Subtype 1 (mGluR1) Using [11 C] ITMM with Ultra-High Specific Activity in Small-Animal PET. PloS one 2015, 10(6):e0130006.
  305. Yang S-T, Hsiao I-T, Hsieh C-J, Chiang Y-H, Yen T-C, Chiu W-T, Lin K-J, Hu C-J: Accumulation of amyloid in cognitive impairment after mild traumatic brain injury. Journal of the Neurological Sciences 2015, 349(1–2):99-104.
  306. Yang Y, Zheng Y, Tomaselli E, Fang W, Liu S: Impact of Boronate Capping Groups on Biological Characteristics of Novel 99mTc (III) Complexes [99mTcCl (CDO)(CDOH) 2B-R](CDOH2= Cyclohexanedione Dioxime). Bioconjugate chemistry 2015, 26(2):316-328.
  307. Yasuno F, Kazui H, Morita N, Kajimoto K, Ihara M, Taguchi A, Yamamoto A, Matsuoka K, Kosaka J, Kudo T et al: Low amyloid-β deposition correlates with high education in cognitively normal older adults: a pilot study. International Journal of Geriatric Psychiatry 2015, 30(9):919-926.
  308. Yeh Y-W, Ho P-S, Chen C-Y, Kuo S-C, Liang C-S, Yen C-H, Huang C-C, Shiue C-Y, Huang W-S, Ma K-H: Suicidal ideation modulates the reduction in serotonin transporter availability in male military conscripts with major depression: A 4-[18F]-ADAM PET study. The World Journal of Biological Psychiatry 2015:1-11.
  309. Yeh Y-W, Ho P-S, Kuo S-C, Chen C-Y, Liang C-S, Yen C-H, Huang C-C, Ma K-H, Shiue C-Y, Huang W-S: Disproportionate reduction of serotonin transporter may predict the response and adherence to antidepressants in patients with major depressive disorder: a positron emission tomography study with 4-[18F]-ADAM. International Journal of Neuropsychopharmacology 2015, 18(7):pyu120.
  310. Yoon H-J, Kim Y, Kim BS: Intratumoral metabolic heterogeneity predicts invasive components in breast ductal carcinoma in situ. European radiology 2015:1-11.
  311. Yousefi BH, von Reutern B, Scherübl D, Manook A, Schwaiger M, Grimmer T, Henriksen G, Förster S, Drzezga A, Wester H-J: FIBT versus florbetaben and PiB: a preclinical comparison study with amyloid-PET in transgenic mice. EJNMMI research 2015, 5(1):1-13.
  312. Zitella LM, Teplitzky BA, Yager P, Hudson HM, Brintz K, Duchin Y, Harel N, Vitek JL, Baker KB, Johnson MD: Subject-specific computational modeling of DBS in the PPTg area. Frontiers in computational neuroscience 2015, 9.
2014
  1. Alf MF, Duarte JM, Lei H, Kramer SD, Mlynarik V, Schibli R, Gruetter R: MRS glucose mapping and PET joining forces: re-evaluation of the lumped constant in the rat brain under isoflurane anaesthesia. J Neurochem 2014, 129(4):672-682.
  2. Ardipradja K, Yeoh SD, Alt K, O’Keefe G, Rigopoulos A, Howells DW, Scott AM, Peter K, Ackerman U, Hagemeyer CE: Detection of activated platelets in a mouse model of carotid artery thrombosis with 18 F-labeled single-chain antibodies. Nucl Med Biol 2014, 41(3):229-237.
  3. Ashton JR, Befera N, Clark D, Qi Y, Mao L, Rockman HA, Johnson GA, Badea CT: Anatomical and functional imaging of myocardial infarction in mice using micro-CT and eXIA 160 contrast agent. Contrast media & molecular imaging 2014, 9(2):161-168.
  4. Baldinger P, Hahn A, Mitterhauser M, Kranz GS, Friedl M, Wadsak W, Kraus C, Ungersbock J, Hartmann A, Giegling I et al: Impact of COMT genotype on serotonin-1A receptor binding investigated with PET. Brain structure & function 2014, 219(6):2017-2028.
  5. Baldinger P, Kranz GS, Haeusler D, Savli M, Spies M, Philippe C, Hahn A, Hoflich A, Wadsak W, Mitterhauser M et al: Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET. Neuroimage 2014, 88(0):252-262.
  6. Barret O, Hannestad J, Alagille D, Vala C, Tavares A, Papin C, Morley T, Fowles K, Lee H, Seibyl J et al: Adenosine 2A Receptor Occupancy by Tozadenant and Preladenant in Rhesus Monkeys. Journal of Nuclear Medicine 2014, 55(10):1712-1718.
  7. Barret O, Thomae D, Tavares A, Alagille D, Papin C, Waterhouse R, McCarthy T, Jennings D, Marek K, Russell D et al: In Vivo Assessment and Dosimetry of 2 Novel PDE10A PET Radiotracers in Humans: 18F-MNI-659 and 18F-MNI-654. Journal of Nuclear Medicine 2014, 55(8):1297-1304.
  8. Blasi F, Oliveira BL, Rietz TA, Rotile NJ, Day H, Looby RJ, Ay I, Caravan P: Effect of Chelate Type and Radioisotope on the Imaging Efficacy of 4 Fibrin-Specific PET Probes. Journal of Nuclear Medicine 2014, 55(7):1157-1163.
  9. Bolcaen J, Descamps B, Deblaere K, Boterberg T, Hallaert G, Van den Broecke C, Decrock E, Vral A, Leybaert L, Vanhove C et al: MRI-guided 3D conformal arc micro-irradiation of a F98 glioblastoma rat model using the Small Animal Radiation Research Platform (SARRP). J Neurooncol 2014, 120(2):257-266.
  10. Branderhorst W, Blezer ELA, Houtkamp M, Ramakers RM, van den Brakel JH, Witteveen H, van der Have F, Gratama van Andel HA, Vastenhouw B, Wu C et al: Three-Dimensional Histologic Validation of High-Resolution SPECT of Antibody Distributions Within Xenografts. Journal of Nuclear Medicine 2014, 55(5):830-837.
  11. Brendel M, Delker A, Rotzer C, Boning G, Carlsen J, Cyran C, Mille E, Gildehaus FJ, Cumming P, Baumann K et al: Impact of partial volume effect correction on cerebral beta-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET. Neuroimage 2014, 84(0):843-853.
  12. Brendel M, Hogenauer M, Delker A, Sauerbeck J, Bartenstein P, Seibyl J, Rominger A, for the Alzheimer’s Disease Neuroimaging I: Improved longitudinal [F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction. Neuroimage 2014.
  13. Caravaggio F, Nakajima S, Borlido C, Remington G, Gerretsen P, Wilson A, Houle S, Menon M, Mamo D, Graff-Guerrero A: Estimating endogenous dopamine levels at D2 and D3 receptors in humans using the agonist radiotracer [(11)C]-(+)-PHNO. Neuropsychopharmacology 2014, 39(12):2769-2776.
  14. Chang WH, Lee IH, Chen KC, Chi MH, Chiu N-T, Yao WJ, Lu R-B, Yang YK, Chen PS: Oxytocin receptor gene rs53576 polymorphism modulates oxytocin–dopamine interaction and neuroticism traits—A SPECT study. Psychoneuroendocrinology 2014, 47(0):212-220.
  15. Chou JS, Chen CY, Chen YL, Weng YH, Yeh TH, Lu CS, Chang YM, Wang HL: (G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse. Neurobiol Dis 2014, 68(0):190-199.
  16. Cohrs B, Zhao Y, Lützen U, Culman J, Clement B, Zuhayra M: In vivo SPECT imaging of [123I]-labeled pentamidine pro-drugs for the treatment of human African trypanosomiasis, pharmacokinetics, and bioavailability studies in rats. International Journal of Pharmaceutics 2014, 477(1–2):167-175.
  17. Colin P, De Smet L, Vervaet C, Remon JP, Ceelen W, Van Bocxlaer J, Boussery K, Vermeulen A: A model based analysis of IPEC dosing of paclitaxel in rats. Pharm Res 2014, 31(10):2876-2886.
  18. Coughlin JM, Wang Y, Ma S, Yue C, Kim PK, Adams AV, Roosa HV, Gage KL, Stathis M, Rais R et al: Regional brain distribution of translocator protein using [(11)C]DPA-713 PET in individuals infected with HIV. Journal of neurovirology 2014, 20(3):219-232.
  19. Deleye S, Verhaeghe J, wyffels L, Dedeurwaerdere S, Stroobants S, Staelens S: Towards a reproducible protocol for repetitive and semi-quantitative rat brain imaging with 18 F-FDG: Exemplified in a memantine pharmacological challenge. NeuroImage 2014, 96(0):276-287.
  20. Deo AK, Borson S, Link JM, Domino K, Eary JF, Ke B, Richards TL, Mankoff DA, Minoshima S, O’Sullivan F et al: Activity of P-Glycoprotein, a β-Amyloid Transporter at the Blood–Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease. Journal of Nuclear Medicine 2014, 55(7):1106-1111.
  21. Dickens AM, Vainio S, Marjamaki P, Johansson J, Lehtiniemi P, Rokka J, Rinne J, Solin O, Haaparanta-Solin M, Jones PA et al: Detection of microglial activation in an acute model of neuroinflammation using PET and radiotracers 11C-(R)-PK11195 and 18F-GE-180. J Nucl Med 2014, 55(3):466-472.
  22. Dyke JP, Synan M, Ezell P, Ballon D, Racine J, Aaron RK: Characterization of bone perfusion by dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography in the Dunkin–Hartley guinea pig model of advanced osteoarthritis. Journal of Orthopaedic Research 2014:n/a-n/a.
  23. Eriksson J, Castegnetti G, Conroy S, Ericsson G, Giacomelli L, Hellesen C, Contributors J-E: Deuterium density profile determination at JET using a neutron camera and a neutron spectrometer. The Review of scientific instruments 2014, 85(11):11E106.
  24. Eriksson O, Selvaraju RK, Johansson L, Eriksson JW, Sundin A, Antoni G, Sörensen J, Eriksson B, Korsgren O: Quantitative Imaging of Serotonergic Biosynthesis and Degradation in the Endocrine Pancreas. Journal of Nuclear Medicine 2014, 55(3):460-465.
  25. Ettrup A, da Cunha-Bang S, McMahon B, Lehel S, Dyssegaard A, Skibsted AW, Jorgensen LM, Hansen M, Baandrup AO, Bache S et al: Serotonin 2A receptor agonist binding in the human brain with [(11)C]Cimbi-36. J Cereb Blood Flow Metab 2014, 34(7):1188-1196.
  26. Ewers M, Brendel M, Rizk-Jackson A, Rominger A, Bartenstein P, Schuff N, Weiner MW: Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects. NeuroImage: Clinical 2014, 4(0):45-52.
  27. Feng L, Svarer C, Thomsen G, de Nijs R, Larsen VA, Jensen P, Adamsen D, Dyssegaard A, Fischer W, Meden P et al: In Vivo Quantification of Cerebral Translocator Protein Binding in Humans Using 6-Chloro-2-(4′-123I-Iodophenyl)-3-(N,N-Diethyl)-Imidazo[1,2-a]Pyridine-3-Acetamide SPECT. Journal of Nuclear Medicine 2014, 55(12):1966-1972.
  28. Finnema SJ, Stepanov V, Ettrup A, Nakao R, Amini N, Svedberg M, Lehmann C, Hansen M, Knudsen GM, Halldin C: Characterization of [(11)C]Cimbi-36 as an agonist PET radioligand for the 5-HT(2A) and 5-HT(2C) receptors in the nonhuman primate brain. Neuroimage 2014, 84(0):342-353.
  29. Finnema SJ, Stepanov V, Nakao R, Sromek AW, Zhang T, Neumeyer JL, George SR, Seeman P, Stabin MG, Jonsson C et al: 18F-MCL-524, an 18F-Labeled Dopamine D2 and D3 Receptor Agonist Sensitive to Dopamine: A Preliminary PET Study. Journal of Nuclear Medicine 2014, 55(7):1164-1170.
  30. Forgacs PB, Conte MM, Fridman EA, Voss HU, Victor JD, Schiff ND: Preservation of electroencephalographic organization in patients with impaired consciousness and imaging-based evidence of command-following. Annals of Neurology 2014, 76(6):869-879.
  31. Freesmeyer M, Wiegand S, Schierz JH, Winkens T, Licht K: Multimodal evaluation of 2D and 3D ultrasound, computed tomography and magnetic resonance imaging in measurements of the thyroid volume using universally applicable cross-sectional imaging software: a phantom study. Ultrasound Med Biol 2014, 40(7):1453-1462.
  32. Giovannetti G, Pingitore A, Positano V, De Marchi D, Valvano G, Gibiino F, Aquaro GD, Lombardi M, Landini L, Santarelli MF: Improving sodium Magnetic Resonance in humans by design of a dedicated 23Na surface coil. Measurement 2014, 50(0):285-292.
  33. Gomez-Vallejo V, Vazquez N, Gona KB, Puigivila M, Gonzalez M, Sebastian ES, Martin A, Llop J: Synthesis and in vivo evaluation of (11) C-labeled (1,7-dicarba-closo-dodecaboran-1-yl)-N-{[(2S)-1-ethylpyrrolidin-2-yl]methyl}amide. Journal of labelled compounds & radiopharmaceuticals 2014, 57(4):209-214.
  34. Hahn A, Haeusler D, Kraus C, Hoflich AS, Kranz GS, Baldinger P, Savli M, Mitterhauser M, Wadsak W, Karanikas G et al: Attenuated serotonin transporter association between dorsal raphe and ventral striatum in major depression. Human brain mapping 2014:n/a-n/a.
  35. Hatashita S, Yamasaki H, Suzuki Y, Tanaka K, Wakebe D, Hayakawa H: [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2014, 41(2):290-300.
  36. Hazari PP, Schulz J, Vimont D, Chadha N, Allard M, Szlosek-Pinaud M, Fouquet E, Mishra AK: A new SiF-Dipropargyl glycerol scaffold as a versatile prosthetic group to design dimeric radioligands: synthesis of the [(18) F]BMPPSiF tracer to image serotonin receptors. ChemMedChem 2014, 9(2):337-349.
  37. Hazari PP, Schulz J, Vimont D, Chadha N, Allard M, Szlosek-Pinaud M, Fouquet E, Mishra AK: A New SiF–Dipropargyl Glycerol Scaffold as a Versatile Prosthetic Group to Design Dimeric Radioligands: Synthesis of the [18F]BMPPSiF Tracer to Image Serotonin Receptors. ChemMedChem 2014, 9(2):337-349.
  38. Hickey RD, Mao SA, Amiot B, Suksanpaisan L, Miller A, Nace R, Glorioso J, O’Connor MK, Peng KW, Ikeda Y et al: Noninvasive 3D imaging of liver regeneration in a mouse model of hereditary tyrosinemia type 1 using the sodium iodide symporter gene. Liver Transplantation 2014:n/a-n/a.
  39. Holub J, Meckel M, Kubíček V, Rösch F, Hermann P: Gallium(III) complexes of NOTA-bis (phosphonate) conjugates as PET radiotracers for bone imaging. Contrast media & molecular imaging 2014:n/a-n/a.
  40. Hsiao IT, Weng YH, Lin WY, Hsieh CJ, Wey SP, Yen TC, Kung MP, Lu CS, Lin KJ: Comparison of 99mTc-TRODAT-1 SPECT and 18 F-AV-133 PET imaging in healthy controls and Parkinson’s disease patients. Nucl Med Biol 2014, 41(4):322-329.
  41. Hsieh PC, Chen KC, Yeh TL, Lee IH, Chen PS, Yao WJ, Chiu NT, Chen CC, Liao MH, Yang YK: Lower availability of midbrain serotonin transporter between healthy subjects with and without a family history of major depressive disorder – a preliminary two-ligand SPECT study. European psychiatry : the journal of the Association of European Psychiatrists 2014(0).
  42. Huang SY, Bolch WE, Lee C, Van Brocklin HF, Pampaloni MH, Hawkins RA, Sznewajs A, DuBois SG, Matthay KK, Seo Y: Patient-Specific Dosimetry Using Pretherapy [I]m-iodobenzylguanidine ([ I]mIBG) Dynamic PET/CT Imaging Before [ I]mIBG Targeted Radionuclide Therapy for Neuroblastoma. Mol Imaging Biol 2014.
  43. Huang W, Li X, Chen Y, Li X, Chang M-C, Oborski MJ, Malyarenko DI, Muzi M, Jajamovich GH, Fedorov A et al: Variations of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Evaluation of Breast Cancer Therapy Response: A Multicenter Data Analysis Challenge. Translational Oncology 2014, 7(1):153-166.
  44. Huang YR, Pai CW, Cheng KH, Kuo WI, Chen MW, Chang KW: Dopamine D2/D3 receptor binding of [123I]epidepride in risperidone-treatment chronic MK-801-induced rat schizophrenia model using nanoSPECT/CT neuroimaging. Nuclear Medicine and Biology 2014, 41(8):681-687.
  45. Hyun O J, Lodge MA, Jagannath S, Buscaglia JM, Olagbemiro Y, Wahl RL: An Exocrine Pancreatic Stress Test with 11C-Acetate PET and Secretin Stimulation. Journal of Nuclear Medicine 2014, 55(7):1128-1131.
  46. Ides J, Thomae D, Wyffels L, Vangestel C, Messagie J, Joossens J, Lardon F, Van der Veken P, Augustyns K, Stroobants S et al: Synthesis and in vivo preclinical evaluation of an (18)F labeled uPA inhibitor as a potential PET imaging agent. Nucl Med Biol 2014, 41(6):477-487.
  47. Ito H, Shimada H, Shinotoh H, Takano H, Sasaki T, Nogami T, Suzuki M, Nagashima T, Takahata K, Seki C et al: Quantitative Analysis of Amyloid Deposition in Alzheimer Disease Using PET and the Radiotracer 11C-AZD2184. Journal of Nuclear Medicine 2014, 55(6):932-938.
  48. Jaruszewski KM, Curran GL, Swaminathan SK, Rosenberg JT, Grant SC, Ramakrishnan S, Lowe VJ, Poduslo JF, Kandimalla KK: Multimodal nanoprobes to target cerebrovascular amyloid in Alzheimer’s disease brain. Biomaterials 2014, 35(6):1967-1976.
  49. Kaur J, Khararjian A, Coleman RA, Constantinescu CC, Pan M-L, Mukherjee J: Spinal cord dopamine D2/D3 receptors: in vivo and ex vivo imaging in the rat using 18F/11C-fallypride. Nuclear Medicine and Biology 2014, 41(10):841-847.
  50. Kawamura K, Yamasaki T, Kumata K, Furutsuka K, Takei M, Wakizaka H, Fujinaga M, Kariya K, Yui J, Hatori A et al: Binding potential of (E)-[11C]ABP688 to metabotropic glutamate receptor subtype 5 is decreased by the inclusion of its (1)(1)C-labelled Z-isomer. Nucl Med Biol 2014, 41(1):17-23.
  51. Kimura Y, Ito H, Shiraishi T, Fujiwara H, Kodaka F, Takano H, Shimada H, Kanno I, Suhara T: Biodistribution and radiation dosimetry in humans of [11C]FLB 457, a positron emission tomography ligand for the extrastriatal dopamine D(2) receptor. Nucl Med Biol 2014, 41(1):102-105.
  52. Kitamura S, Yasuno F, Inoue M, Kosaka J, Kiuchi K, Matsuoka K, Kishimoto T, Suhara T: Increased binding of 5-HT1A receptors in a dissociative amnesic patient after the recovery process. Psychiatry Research: Neuroimaging 2014, 224(1):67-71.
  53. Knesaurek K, Warnock G, Sideras P, Burger C: Comparison of SUVr calculations in amyloid PET brain imaging. Journal of Nuclear Medicine 2014, 55(supplement 1):1873.
  54. Kranz GS, Rami-Mark C, Kaufmann U, Baldinger P, Hahn A, Hoflich A, Savli M, Stein P, Wadsak W, Mitterhauser M et al: Effects of hormone replacement therapy on cerebral serotonin-1A receptor binding in postmenopausal women examined with [carbonyl-(1)(1)C]WAY-100635. Psychoneuroendocrinology 2014, 45(0):1-10.
  55. Kubota Y, Miyagawa S, Fukushima S, Saito A, Watabe H, Daimon T, Sakai Y, Akita T, Sawa Y: Impact of cardiac support device combined with slow-release prostacyclin agonist in a canine ischemic cardiomyopathy model. J Thorac Cardiovasc Surg 2014, 147(3):1081-1087.
  56. Kuhn FP, Warnock GI, Burger C, Ledermann K, Martin-Soelch C, Buck A: Comparison of PET template-based and MRI-based image processing in the quantitative analysis of C11-raclopride PET. EJNMMI research 2014, 4(1):7.
  57. La Joie R, Landeau B, Perrotin A, Bejanin A, Egret S, Pelerin A, Mezenge F, Belliard S, de La Sayette V, Eustache F et al: Intrinsic connectivity identifies the hippocampus as a main crossroad between Alzheimer’s and semantic dementia-targeted networks. Neuron 2014, 81(6):1417-1428.
  58. Laffon E, Lamare F, de Clermont H, Burger IA, Marthan R: Variability of average SUV from several hottest voxels is lower than that of SUVmax and SUVpeak. European radiology 2014, 24(8):1964-1970.
  59. Lanz B, Poitry-Yamate C, Gruetter R: Image-Derived Input Function from the Vena Cava for 18F-FDG PET Studies in Rats and Mice. Journal of Nuclear Medicine 2014, 55(8):1380-1388.
  60. Lavisse S, Inoue K, Jan C, Peyronneau MA, Petit F, Goutal S, Dauguet J, Guillermier M, Dolle F, Rbah-Vidal L et al: [F]DPA-714 PET imaging of translocator protein TSPO (18 kDa) in the normal and excitotoxically-lesioned nonhuman primate brain. Eur J Nucl Med Mol Imaging 2014.
  61. Lee CH, Lin JJ, Lin KJ, Chang BL, Hsieh HY, Chen WH, Lin KL, Fung HC, Wu T: Caspr2 antibody limbic encephalitis is associated with Hashimoto thyroiditis and thymoma. J Neurol Sci 2014, 341(1-2):36-40.
  62. Liao YH, Chang YH, Sung LY, Li KC, Yeh CL, Yen TC, Hwang SM, Lin KJ, Hu YC: Osteogenic differentiation of adipose-derived stem cells and calvarial defect repair using baculovirus-mediated co-expression of BMP-2 and miR-148b. Biomaterials 2014, 35(18):4901-4910.
  63. Lin SC, Lin KJ, Hsiao IT, Hsieh CJ, Lin WY, Lu CS, Wey SP, Yen TC, Kung MP, Weng YH: In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET. J Nucl Med 2014, 55(1):73-79.
  64. Lin S-C, Lin K-J, Hsiao I-T, Hsieh C-J, Lin W-Y, Lu C-S, Wey S-P, Yen T-C, Kung M-P, Weng Y-H: In Vivo Detection of Monoaminergic Degeneration in Early Parkinson Disease by 18F-9-Fluoropropyl-(+)-Dihydrotetrabenzazine PET. Journal of Nuclear Medicine 2014, 55(1):73-79.
  65. Lohith TG, Zoghbi SS, Morse CL, Araneta MD, Barth VN, Goebl NA, Tauscher JT, Pike VW, Innis RB, Fujita M: Retest imaging of [11C]NOP-1A binding to nociceptin/orphanin FQ peptide (NOP) receptors in the brain of healthy humans. Neuroimage 2014, 87(0):89-95.
  66. Maier FC, Wehrl HF, Schmid AM, Mannheim JG, Wiehr S, Lerdkrai C, Calaminus C, Stahlschmidt A, Ye L, Burnet M et al: Longitudinal PET-MRI reveals beta-amyloid deposition and rCBF dynamics and connects vascular amyloidosis to quantitative loss of perfusion. Nature medicine 2014, 20(12):1485-1492.
  67. Marti-Climent JM, Dominguez-Prado I, Garcia-Velloso MJ, Boni V, Peñuelas I, Toledo I, Richter JA: [18F]fluorothymidine-positron emission tomography in patients with locally advanced breast cancer under bevacizumab treatment: Usefulness of different quantitative methods of tumor proliferation. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2014, 33(5):280-285.
  68. Martinez-Velez N, Xipell E, Jauregui P, Zalacain M, Marrodan L, Zandueta C, Vera B, Urquiza L, Sierrasesúmaga L, Julián MS et al: The Oncolytic Adenovirus Δ24-RGD in Combination With Cisplatin Exerts a Potent Anti-Osteosarcoma Activity. Journal of Bone and Mineral Research 2014, 29(10):2287-2296.
  69. Matsunari I, Miyazaki Y, Kobayashi M, Nishi K, Mizutani A, Kawai K, Hayashi A, Komatsu R, Yonezawa S, Kinuya S: Performance evaluation of the eXplore speCZT preclinical imaging system. Ann Nucl Med 2014, 28(5):484-497.
  70. Mattová J, Poučková P, Kučka J, Škodová M, Vetrík M, Štěpánek P, Urbánek P, Petřík M, Nový Z, Hrubý M: Chelating polymeric beads as potential therapeutics for Wilson’s disease. European Journal of Pharmaceutical Sciences 2014, 62(0):1-7.
  71. Mirbolooki MR, Upadhyay SK, Constantinescu CC, Pan M-L, Mukherjee J: Adrenergic pathway activation enhances brown adipose tissue metabolism: A [18F]FDG PET/CT study in mice. Nuclear Medicine and Biology 2014, 41(1):10-16.
  72. Morsbach F, Sah BR, Spring L, Puippe G, Gordic S, Seifert B, Schaefer N, Pfammatter T, Alkadhi H, Reiner CS: Perfusion CT best predicts outcome after radioembolization of liver metastases: a comparison of radionuclide and CT imaging techniques. European radiology 2014, 24(7):1455-1465.
  73. Mukai H, Ozaki D, Cui Y, Kuboyama T, Yamato-Nagata H, Onoe K, Takahashi M, Wada Y, Imanishi T, Kodama T et al: Quantitative evaluation of the improvement in the pharmacokinetics of a nucleic acid drug delivery system by dynamic PET imaging with (18)F-incorporated oligodeoxynucleotides. Journal of controlled release : official journal of the Controlled Release Society 2014, 180(0):92-99.
  74. Muller A, Mu L, Meletta R, Beck K, Rancic Z, Drandarov K, Kaufmann PA, Ametamey SM, Schibli R, Borel N et al: Towards non-invasive imaging of vulnerable atherosclerotic plaques by targeting co-stimulatory molecules. Int J Cardiol 2014, 174(3):503-515.
  75. Nakatomi Y, Mizuno K, Ishii A, Wada Y, Tanaka M, Tazawa S, Onoe K, Fukuda S, Kawabe J, Takahashi K et al: Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An 11C-(R)-PK11195 PET Study. Journal of Nuclear Medicine 2014, 55(6):945-950.
  76. Nesterov SV, Deshayes E, Sciagra R, Settimo L, Declerck JM, Pan XB, Yoshinaga K, Katoh C, Slomka PJ, Germano G et al: Quantification of Myocardial Blood Flow in Absolute Terms Using Rb PET Imaging: Results of RUBY-10 Study. JACC Cardiovascular imaging 2014.
  77. Nishiyama S, Ohba H, Kobashi T, Nakamasu Y, Nakao H, Ogata T, Kitashoji T, Tsukada H: Development of novel PET probe [11C](R,R)HAPT and its stereoisomer [11C](S,S)HAPT for vesicular acetylcholine transporter imaging: A PET study in conscious monkey. Synapse 2014, 68(7):283-292.
  78. Nugent S, Tremblay S, Chen KW, Ayutyanont N, Roontiva A, Castellano CA, Fortier M, Roy M, Courchesne-Loyer A, Bocti C et al: Brain glucose and acetoacetate metabolism: a comparison of young and older adults. Neurobiol Aging 2014, 35(6):1386-1395.
  79. Ogawa M, Umeda IO, Kosugi M, Kawai A, Hamaya Y, Takashima M, Yin H, Kudoh T, Seno M, Magata Y: Development of 111In-labeled liposomes for vulnerable atherosclerotic plaque imaging. J Nucl Med 2014, 55(1):115-120.
  80. Ohnishi A, Senda M, Yamane T, Sasaki M, Mikami T, Nishio T, Ikari Y, Nishida H, Shukuri M, Takashima T et al: Human whole-body biodistribution and dosimetry of a new PET tracer, [11C]ketoprofen methyl ester, for imagings of neuroinflammation. Nuclear Medicine and Biology 2014, 41(7):594-599.
  81. Ooms M, Celen S, Koole M, Langlois X, Schmidt M, De Angelis M, Andrés JI, Verbruggen A, Van Laere K, Bormans G: Synthesis and biological evaluation of carbon-11 and fluorine-18 labeled tracers for in vivo visualization of PDE10A. Nuclear Medicine and Biology 2014, 41(8):695-704.
  82. Orlova A, Malm M, Rosestedt M, Varasteh Z, Andersson K, Selvaraju RK, Altai M, Honarvar H, Strand J, Stahl S et al: Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule. Eur J Nucl Med Mol Imaging 2014, 41(7):1450-1459.
  83. Ouyang Y, Tinianow JN, Cherry SR, Marik J: Evaluation of 2-[18F]fluoroacetate kinetics in rodent models of cerebral hypoxia-ischemia. J Cereb Blood Flow Metab 2014, 34(5):836-844.
  84. Parthoens J, Verhaeghe J, Stroobants S, Staelens S: Deep Brain Stimulation of the Prelimbic Medial Prefrontal Cortex: Quantification of the Effect on Glucose Metabolism in the Rat Brain Using [ F]FDG MicroPET. Mol Imaging Biol 2014.
  85. Parthoens J, Verhaeghe J, Wyckhuys T, Stroobants S, Staelens S: Small-animal repetitive transcranial magnetic stimulation combined with [18F]-FDG microPET to quantify the neuromodulation effect in the rat brain. Neuroscience 2014, 275(0):436-443.
  86. Pellegrin M, Bouzourène K, Poitry-Yamate C, Mlynarik V, Feihl F, Aubert J-F, Gruetter R, Mazzolai L: Experimental peripheral arterial disease: new insights into muscle glucose uptake, macrophage, and T-cell polarization during early and late stages. Physiological Reports 2014, 2(2):n/a-n/a.
  87. Pérez-Campaña C, Sansaloni F, Gómez-Vallejo V, Baz Z, Martin A, Moya SE, Lagares JI, Ziolo RF, Llop J: Production of18F-Labeled Titanium Dioxide Nanoparticles by Proton Irradiation for Biodistribution and Biological Fate Studies in Rats. Particle & Particle Systems Characterization 2014, 31(1):134-142.
  88. Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM, Eary JF, Porter P, Shankar LK, Mankoff DA et al: A phase 2 study of 16alpha-[18F]-fluoro-17beta-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC). Mol Imaging Biol 2014, 16(3):431-440.
  89. Piel M, Schmitt U, Bausbacher N, Buchholz HG, Grunder G, Hiemke C, Rosch F: Evaluation of P-glycoprotein (abcb1a/b) modulation of [(18)F]fallypride in MicroPET imaging studies. Neuropharmacology 2014, 84(0):152-158.
  90. Ponto LLB, Menda Y, Magnotta VA, Yamada TH, Denburg NL, Schultz SK: Frontal hypometabolism in elderly breast cancer survivors determined by [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET): a pilot study. International Journal of Geriatric Psychiatry 2014:n/a-n/a.
  91. Poulin E, Lebel R, Croteau E, Blanchette M, Tremblay L, Lecomte R, Bentourkia M, Lepage M: Optimization of the reference region method for dual pharmacokinetic modeling using Gd-DTPA/MRI and F-FDG/PET. Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 2014:n/a-n/a.
  92. Prashanth R, Dutta Roy S, Mandal PK, Ghosh S: Automatic classification and prediction models for early Parkinson’s disease diagnosis from SPECT imaging. Expert Systems with Applications 2014, 41(7):3333-3342.
  93. Rahm V, Boxheimer L, Bruehlmeier M, Berberat J, Nitzsche EU, Remonda L, Roelcke U: Focal Changes in Diffusivity on Apparent Diffusion Coefficient MR Imaging and Amino Acid Uptake on PET Do Not Colocalize in Nonenhancing Low-Grade Gliomas. Journal of Nuclear Medicine 2014, 55(4):546-550.
  94. Rahmim A, Tahari AK, Schindler TH: Towards quantitative myocardial perfusion PET in the clinic. Journal of the American College of Radiology : JACR 2014, 11(4):429-432.
  95. Riverol M, Ordonez C, Collantes M, DiCaudo C, Penuelas I, Arbizu J, Marcilla I, Luquin MR: Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway. Neurobiol Dis 2014, 62(0):250-259.
  96. Rotering S, Deuther-Conrad W, Cumming P, Donat CK, Scheunemann M, Fischer S, Xiong G, Steinbach J, Peters D, Sabri O et al: Imaging of alpha7 nicotinic acetylcholine receptors in brain and cerebral vasculature of juvenile pigs with [(18)F]NS14490. EJNMMI research 2014, 4:43.
  97. Sah B-R, Schibli R, Waibel R, von Boehmer L, Bläuenstein P, Nexo E, Johayem A, Fischer E, Müller E, Soyka JD et al: Tumor Imaging in Patients with Advanced Tumors Using a New 99mTc-Radiolabeled Vitamin B12 Derivative. Journal of Nuclear Medicine 2014, 55(1):43-49.
  98. Schain M, Varnas K, Cselenyi Z, Halldin C, Farde L, Varrone A: Evaluation of two automated methods for PET region of interest analysis. Neuroinformatics 2014, 12(4):551-562.
  99. Schöll M, Damián A, Engler H: Fluorodeoxyglucose PET in Neurology and Psychiatry. PET Clinics 2014, 9(4):371-390.
  100. Schuster DM, Nanni C, Fanti S, Oka S, Okudaira H, Inoue Y, Sörensen J, Owenius R, Choyke P, Turkbey B et al: Anti-1-Amino-3-18F-Fluorocyclobutane-1-Carboxylic Acid: Physiologic Uptake Patterns, Incidental Findings, and Variants That May Simulate Disease. Journal of Nuclear Medicine 2014, 55(12):1986-1992.
  101. Schwenzer NF, Schmidt H, Gatidis S, Brendle C, Müller M, Königsrainer I, Claussen CD, Pfannenberg AC, Schraml C: Measurement of apparent diffusion coefficient with simultaneous MR/positron emission tomography in patients with peritoneal carcinomatosis: Comparison with 18F-FDG-PET. Journal of Magnetic Resonance Imaging 2014, 40(5):1121-1128.
  102. Selvaraju RK, Velikyan I, Asplund V, Johansson L, Wu Z, Todorov I, Shively J, Kandeel F, Eriksson B, Korsgren O et al: Pre-clinical evaluation of [(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 for imaging of insulinoma. Nucl Med Biol 2014, 41(6):471-476.
  103. Serriere S, Tauber C, Vercouillie J, Guilloteau D, Deloye JB, Garreau L, Galineau L, Chalon S: In vivo PET quantification of the dopamine transporter in rat brain with [18F]LBT-999. Nucl Med Biol 2014, 41(1):106-113.
  104. Shaikh S, Welch A, Ramalingam SL, Murray A, Wilson HM, McKiddie F, Brittenden J: Comparison of fluorodeoxyglucose uptake in symptomatic carotid artery and stable femoral artery plaques. The British journal of surgery 2014, 101(4):363-370.
  105. Shrestha SS, Liow JS, Lu S, Jenko K, Gladding RL, Svenningsson P, Morse CL, Zoghbi SS, Pike VW, Innis RB: 11C-CUMI-101, a PET radioligand, behaves as a serotonin 1A receptor antagonist and also binds to alpha(1) adrenoceptors in brain. J Nucl Med 2014, 55(1):141-146.
  106. Shrestha SS, Liow J-S, Lu S, Jenko K, Gladding RL, Svenningsson P, Morse CL, Zoghbi SS, Pike VW, Innis RB: 11C-CUMI-101, a PET Radioligand, Behaves as a Serotonin 1A Receptor Antagonist and Also Binds to α1 Adrenoceptors in Brain. Journal of Nuclear Medicine 2014, 55(1):141-146.
  107. Shrestha U, Verdin E, Yeghiazarians Y, Boyle A, Botvinick E, Seo Y, Gullberg G: Correspondence between regional myocardial blood flow measured with dynamic SPECT and coronary vasculature using angiography. Journal of Nuclear Medicine 2014, 55(supplement 1):1759.
  108. Siepel FJ, Brønnick KS, Booij J, Ravina BM, Lebedev AV, Pereira JB, Grüner R, Aarsland D: Cognitive executive impairment and dopaminergic deficits in de novo Parkinson’s disease. Movement Disorders 2014:n/a-n/a.
  109. Stein P, Baldinger P, Kaufmann U, Christina RM, Hahn A, Hoflich A, Kranz GS, Savli M, Wadsak W, Mitterhauser M et al: Relation of progesterone and DHEAS serum levels to 5-HT1A receptor binding potential in pre- and postmenopausal women. Psychoneuroendocrinology 2014, 46(0):52-63.
  110. Striepens N, Matusch A, Kendrick KM, Mihov Y, Elmenhorst D, Becker B, Lang M, Coenen HH, Maier W, Hurlemann R et al: Oxytocin enhances attractiveness of unfamiliar female faces independent of the dopamine reward system. Psychoneuroendocrinology 2014, 39(0):74-87.
  111. Su FY, Chuang EY, Lin PY, Chou YC, Chen CT, Mi FL, Wey SP, Yen TC, Lin KJ, Sung HW: Treatment of chemotherapy-induced neutropenia in a rat model by using multiple daily doses of oral administration of G-CSF-containing nanoparticles. Biomaterials 2014, 35(11):3641-3649.
  112. Suridjan I, Rusjan PM, Kenk M, Verhoeff NPLG, Voineskos AN, Rotenberg D, Wilson AA, Meyer JH, Houle S, Mizrahi R: Quantitative imaging of neuroinflammation in human white matter: A positron emission tomography study with translocator protein 18 kDa radioligand, [18F]-FEPPA. Synapse 2014, 68(11):536-547.
  113. Tahari AK, Bravo PE, Rahmim A, Bengel FM, Szabo Z: Initial human experience with Rubidium-82 renal PET/CT imaging. J Med Imaging Radiat Oncol 2014, 58(1):25-31.
  114. Takahashi K, Hosoya T, Onoe K, Doi H, Nagata H, Hiramatsu T, Li X-L, Watanabe Y, Wada Y, Takashima T et al: 11C-Cetrozole: An Improved C-11C-Methylated PET Probe for Aromatase Imaging in the Brain. Journal of Nuclear Medicine 2014, 55(5):852-857.
  115. Takemoto K, Hatano E, Nishii R, Kagawa S, Kishibe Y, Takahashi M, Yamauchi H, Matsumura K, Zaima M, Toriguchi K et al: Assessment of [(18)F]-fluoroacetate PET/CT as a tumor-imaging modality: preclinical study in healthy volunteers and clinical evaluation in patients with liver tumor. Ann Nucl Med 2014, 28(4):371-380.
  116. Tamimi F, Torres J, Al-Abedalla K, Lopez-Cabarcos E, Alkhraisat MH, Bassett DC, Gbureck U, Barralet JE: Osseointegration of dental implants in 3D-printed synthetic onlay grafts customized according to bone metabolic activity in recipient site. Biomaterials 2014, 35(21):5436-5445.
  117. Tavares AA, Caille F, Barret O, Papin C, Lee H, Morley TJ, Fowles K, Holden D, Seibyl JP, Alagille D et al: Whole-body biodistribution and dosimetry estimates of a novel radiotracer for imaging of serotonin 4 receptors in brain: [(1)(8)F]MNI-698. Nucl Med Biol 2014, 41(5):432-439.
  118. Tavares AAS, Caillé F, Barret O, Papin C, Lee H, Morley TJ, Fowles K, Holden D, Seibyl JP, Alagille D et al: In Vivo Evaluation of 18F-MNI698: An 18F-Labeled Radiotracer for Imaging of Serotonin 4 Receptors in Brain. Journal of Nuclear Medicine 2014, 55(5):858-864.
  119. Thackeray JT, Bankstahl JP, Wang Y, Wollert KC, Bengel FM: Clinically relevant strategies for lowering cardiomyocyte glucose uptake for F-FDG imaging of myocardial inflammation in mice. Eur J Nucl Med Mol Imaging 2014.
  120. Tiwari AK, Yui J, Fujinaga M, Kumata K, Shimoda Y, Yamasaki T, Xie L, Hatori A, Maeda J, Nengaki N et al: Characterization of a novel acetamidobenzoxazolone-based PET ligand for translocator protein (18 kDa) imaging of neuroinflammation in the brain. J Neurochem 2014, 129(4):712-720.
  121. Tolmachev V, Varasteh Z, Honarvar H, Hosseinimehr SJ, Eriksson O, Jonasson P, Frejd FY, Abrahmsen L, Orlova A: Imaging of Platelet-Derived Growth Factor Receptor β Expression in Glioblastoma Xenografts Using Affibody Molecule 111In-DOTA-Z09591. Journal of Nuclear Medicine 2014, 55(2):294-300.
  122. Tomiyama T, Ishihara K, Suda M, Kanaya K, Sakurai M, Takahashi N, Takano H, Nitta K, Hakozaki K, Kumita SI: Impact of time-of-flight on qualitative and quantitative analyses of myocardial perfusion PET studies using N-ammonia. J Nucl Cardiol 2014.
  123. Tran L-B-A, Bol A, Labar D, Karroum O, Bol V, Jordan B, Grégoire V, Gallez B: Potential role of hypoxia imaging using 18F-FAZA PET to guide hypoxia-driven interventions (carbogen breathing or dose escalation) in radiation therapy. Radiotherapy and Oncology 2014, 113(2):204-209.
  124. Tsartsalis S, Moulin-Sallanon M, Dumas N, Tournier BB, Ghezzi C, Charnay Y, Ginovart N, Millet P: Quantification of GABAA receptors in the rat brain with [(123)I]Iomazenil SPECT from factor analysis-denoised images. Nucl Med Biol 2014, 41(2):186-195.
  125. Tsartsalis S, Moulin-Sallanon M, Dumas N, Tournier BB, Ginovart N, Millet P: A Modified Simplified Reference Tissue Model for the Quantification of Dopamine D2/3 Receptors with [18F]Fallypride Images. Molecular imaging 2014, 13:1-14.
  126. Tsujikawa T, Zoghbi SS, Hong J, Donohue SR, Jenko KJ, Gladding RL, Halldin C, Pike VW, Innis RB, Fujita M: In vitro and in vivo evaluation of 11C-SD5024, a novel PET radioligand for human brain imaging of cannabinoid CB1 receptors. NeuroImage 2014, 84(0):733-741.
  127. Tsukada H, Nishiyama S, Ohba H, Kanazawa M, Kakiuchi T, Harada N: Comparing amyloid-beta deposition, neuroinflammation, glucose metabolism, and mitochondrial complex I activity in brain: a PET study in aged monkeys. Eur J Nucl Med Mol Imaging 2014.
  128. Tsukada H, Ohba H, Kanazawa M, Kakiuchi T, Harada N: Evaluation of 18F-BCPP-EF for mitochondrial complex 1 imaging in the brain of conscious monkeys using PET. Eur J Nucl Med Mol Imaging 2014, 41(4):755-763.
  129. Tsukada H, Ohba H, Nishiyama S, Kanazawa M, Kakiuchi T, Harada N: PET imaging of ischemia-induced impairment of mitochondrial complex I function in monkey brain. J Cereb Blood Flow Metab 2014, 34(4):708-714.
  130. Uchida H, Suzuki T, Graff-Guerrero A, Mulsant BH, Pollock BG, Arenovich T, Rajji TK, Mamo DC: Therapeutic Window for Striatal Dopamine D2/3 Receptor Occupancy in Older Patients with Schizophrenia: A Pilot PET Study. The American Journal of Geriatric Psychiatry 2014, 22(10):1007-1016.
  131. Valtorta S, Nicolini G, Tripodi F, Meregalli C, Cavaletti G, Avezza F, Crippa L, Bertoli G, Sanvito F, Fusi P et al: A novel AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse xenograft model of colorectal cancer. Investigational new drugs 2014, 32(6):1123-1133.
  132. Vazquez-Villoldo N, Domercq M, Martin A, Llop J, Gomez-Vallejo V, Matute C: P2X4 receptors control the fate and survival of activated microglia. Glia 2014, 62(2):171-184.
  133. Versiani MA, De-Deus G, Vera J, Souza E, Steier L, Pecora JD, Sousa-Neto MD: 3D mapping of the irrigated areas of the root canal space using micro-computed tomography. Clinical oral investigations 2014.
  134. Vo A, Volpe BT, Tang CC, Schiffer WK, Kowal C, Huerta PT, Ulug AM, Dewey SL, Eidelberg D, Diamond B: Regional brain metabolism in a murine systemic lupus erythematosus model. J Cereb Blood Flow Metab 2014.
  135. Warnock GI, Aerts J, Bahri MA, Bretin F, Lemaire C, Giacomelli F, Mievis F, Mestdagh N, Buchanan T, Valade A et al: Evaluation of 18F-UCB-H as a Novel PET Tracer for Synaptic Vesicle Protein 2A in the Brain. Journal of Nuclear Medicine 2014, 55(8):1336-1341.
  136. Wathen CA, Caldwell C, Chanda N, Upendran A, Zambre A, Afrasiabi Z, Chapaman SE, Foje N, Leevy WM, Kannan R: Selective X-ray contrast enhancement of the spleen of living mice mediated by gold nanorods. Contrast media & molecular imaging 2014:n/a-n/a.
  137. Wey H-Y, Catana C, Hooker JM, Dougherty DD, Knudsen GM, Wang DJJ, Chonde DB, Rosen BR, Gollub RL, Kong J: Simultaneous fMRI–PET of the opioidergic pain system in human brain. NeuroImage 2014, 102, Part 2(0):275-282.
  138. Wilson GD, Thibodeau BJ, Fortier LE, Pruetz BL, Galoforo S, Baschnagel AM, Chunta J, Oliver Wong CY, Yan D, Marples B et al: Glucose Metabolism Gene Expression Patterns and Tumor Uptake of 18F-Fluorodeoxyglucose After Radiation Treatment. International Journal of Radiation Oncology*Biology*Physics 2014, 90(3):620-627.
  139. Wimberley CJ, Fischer K, Reilhac A, Pichler BJ, Gregoire MC: A data driven method for estimation of B and appK using a single injection protocol with [C]raclopride in the mouse. Neuroimage 2014, 99C(0):365-376.
  140. wyffels L, Thomae D, Waldron A-M, Fissers J, Dedeurwaerdere S, Van der Veken P, Joossens J, Stroobants S, Augustyns K, Staelens S: In vivo evaluation of 18F-labeled TCO for pre-targeted PET imaging in the brain. Nuclear Medicine and Biology 2014, 41(6):513-523.
  141. Yagi M, Arentsen L, Shanley RM, Hui SK: High-throughput multiple-mouse imaging with micro-PET/CT for whole-skeleton assessment. Physica Medica 2014, 30(7):849-853.
  142. Yagi M, Arentsen L, Shanley RM, Rosen CJ, Kidder LS, Sharkey LC, Yee D, Koizumi M, Ogawa K, Hui SK: A dual-radioisotope hybrid whole-body micro-positron emission tomography/computed tomography system reveals functional heterogeneity and early local and systemic changes following targeted radiation to the murine caudal skeleton. Calcified tissue international 2014, 94(5):544-552.
  143. Yamasaki T, Fujinaga M, Yui J, Ikoma Y, Hatori A, Xie L, Wakizaka H, Kumata K, Nengaki N, Kawamura K et al: Noninvasive quantification of metabotropic glutamate receptor type 1 with [11C]ITDM: a small-animal PET study. J Cereb Blood Flow Metab 2014, 34(4):606-612.
  144. Yang FY, Chang WY, Chen JC, Lee LC, Hung YS: Quantitative assessment of cerebral glucose metabolic rates after blood-brain barrier disruption induced by focused ultrasound using FDG-MicroPET. Neuroimage 2014, 90(0):93-98.
  145. Yang F-Y, Chang W-Y, Li J-J, Wang H-E, Chen J-C, Chang C-W: Pharmacokinetic Analysis and Uptake of 18F-FBPA-Fr After Ultrasound-Induced Blood–Brain Barrier Disruption for Potential Enhancement of Boron Delivery for Neutron Capture Therapy. Journal of Nuclear Medicine 2014, 55(4):616-621.
  146. Yasuno F, Kazui H, Morita N, Kajimoto K, Ihara M, Taguchi A, Yamamoto A, Matsuoka K, Kosaka J, Kudo T et al: Low amyloid-β deposition correlates with high education in cognitively normal older adults: a pilot study. International Journal of Geriatric Psychiatry 2014:n/a-n/a.
  147. Yong Choi J, Lee M, Jeon TJ, Choi S-H, Choi YJ, Lee YK, Kim J-J, Ryu YH: Determination of optimal acquisition time of [18F]FCWAY PET for imaging serotonin 1A receptors in the healthy male subjects. Applied Radiation and Isotopes 2014, 89(0):141-145.
  148. Yu J, Tang YY, Feng HB, Cheng XX: A behavioral and micro positron emission tomography imaging study in a rat model of hypothyroidism. Behav Brain Res 2014, 271C(0):228-233.
  149. Zheng Y, Ji S, Tomaselli E, Ernest C, Freiji T, Liu S: Effect of co-ligands on chemical and biological properties of (99m)Tc(III) complexes [(99m)Tc(L)(CDO)(CDOH)2BMe] (L=Cl, F, SCN and N3; CDOH2=cyclohexanedione dioxime). Nucl Med Biol 2014, 41(10):813-824.
  150. Zuo Y, Mukhin AG, Garg S, Nazih R, Behm FM, Garg PK, Rose JE: Sex-Specific Effects of Cigarette Mentholation on Brain Nicotine Accumulation and Smoking Behavior. Neuropsychopharmacology 2014.
2013
  1. Abate C, Selivanova SV, Müller A, Krämer SD, Schibli R, Marottoli R, Perrone R, Berardi F, Niso M, Ametamey SM: Development of 3,4-dihydroisoquinolin-1(2H)-one derivatives for the Positron Emission Tomography (PET) imaging of σ2 receptors. European Journal of Medicinal Chemistry 2013, 69(0):920-930.
  2. Alf MF, Marti-Kehl MI, Schibli R, Kramer SD: FDG kinetic modeling in small rodent brain PET: optimization of data acquisition and analysis. EJNMMI research 2013, 3(1):61.
  3. Alf MF, Wyss MT, Buck A, Weber B, Schibli R, Kramer SD: Quantification of brain glucose metabolism by 18F-FDG PET with real-time arterial and image-derived input function in mice. J Nucl Med 2013, 54(1):132-138.
  4. Arbizu J, Prieto E, Martinez-Lage P, Marti-Climent JM, Garcia-Granero M, Lamet I, Pastor P, Riverol M, Gomez-Isla MT, Penuelas I et al: Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer’s disease dementia. Eur J Nucl Med Mol Imaging 2013, 40(9):1394-1405.
  5. Arenaza-Urquijo EM, Landeau B, La Joie R, Mevel K, Mézenge F, Perrotin A, Desgranges B, Bartrés-Faz D, Eustache F, Chételat G: Relationships between years of education and gray matter volume, metabolism and functional connectivity in healthy elders. NeuroImage 2013, 83(0):450-457.
  6. Bae WK, Park MS, Lee JH, Hwang JE, Shim HJ, Cho SH, Kim D-E, Ko HM, Cho C-S, Park I-K et al: Docetaxel-loaded thermoresponsive conjugated linoleic acid-incorporated poloxamer hydrogel for the suppression of peritoneal metastasis of gastric cancer. Biomaterials 2013, 34(4):1433-1441.
  7. Baldinger P, Hahn A, Mitterhauser M, Kranz GS, Friedl M, Wadsak W, Kraus C, Ungersbock J, Hartmann A, Giegling I et al: Impact of COMT genotype on serotonin-1A receptor binding investigated with PET. Brain structure & function 2013.
  8. Becker GA, Ichise M, Barthel H, Luthardt J, Patt M, Seese A, Schultze-Mosgau M, Rohde B, Gertz H-J, Reininger C et al: PET Quantification of 18F-Florbetaben Binding to β-Amyloid Deposits in Human Brains. Journal of Nuclear Medicine 2013, 54(5):723-731.
  9. Befera NT, Badea CT, Johnson GA: Comparison of 4D-MicroSPECT and MicroCT for Murine Cardiac Function. Mol Imaging Biol 2013.
  10. Berglund D, Karlsson M, Palanisamy S, Carlsson B, Korsgren O, Eriksson O: Imaging the in vivo fate of human T cells following transplantation in immunoincompetent mice — Implications for clinical cell therapy trials. Transplant Immunology 2013, 29(1–4):105-108.
  11. Boileau I, Payer D, Chugani B, Lobo D, Behzadi A, Rusjan PM, Houle S, Wilson AA, Warsh J, Kish SJ et al: The D2/3 dopamine receptor in pathological gambling: a positron emission tomography study with [11C]-(+)-propyl-hexahydro-naphtho-oxazin and [11C]raclopride. Addiction 2013:n/a-n/a.
  12. Bosch OG, Wagner M, Jessen F, Kuhn KU, Joe A, Seifritz E, Maier W, Biersack HJ, Quednow BB: Verbal memory deficits are correlated with prefrontal hypometabolism in (18)FDG PET of recreational MDMA users. PLoS One 2013, 8(4):e61234.
  13. Bretin F, Mauxion T, Warnock G, Bahri MA, Libert L, Lemaire C, Luxen A, Bardies M, Seret A, Plenevaux A: Hybrid MicroPET Imaging for Dosimetric Applications in Mice: Improvement of Activity Quantification in Dynamic MicroPET Imaging for Accelerated Dosimetry Applied to 6-[ F]Fluoro-L-DOPA and 2-[ F]Fluoro-L-Tyrosine. Mol Imaging Biol 2013.
  14. Bretin F, Warnock G, Bahri MA, Aerts J, Mestdagh N, Buchanan T, Valade A, Mievis F, Giacomelli F, Lemaire C et al: Preclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H. EJNMMI research 2013, 3(1):35.
  15. Busk M, Mortensen LS, Nordsmark M, Overgaard J, Jakobsen S, Hansen KV, Theil J, Kallehauge JF, D’Andrea FP, Steiniche T et al: PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice. Eur J Nucl Med Mol Imaging 2013, 40(2):186-197.
  16. Butler T, Ichise M, Teich AF, Gerard E, Osborne J, French J, Devinsky O, Kuzniecky R, Gilliam F, Pervez F et al: Imaging Inflammation in a Patient with Epilepsy Due to Focal Cortical Dysplasia. Journal of Neuroimaging 2013, 23(1):129-131.
  17. Ceccarini J, De Hert M, Van Winkel R, Peuskens J, Bormans G, Kranaster L, Enning F, Koethe D, Leweke FM, Van Laere K: Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. NeuroImage 2013, 79(0):304-312.
  18. Ceccarini J, Kuepper R, Kemels D, van Os J, Henquet C, Van Laere K: [ F]MK-9470 PET measurement of cannabinoid CB receptor availability in chronic cannabis users. Addict Biol 2013:n/a-n/a.
  19. Celen S, Koole M, Ooms M, De Angelis M, Sannen I, Cornelis J, Alcazar J, Schmidt M, Verbruggen A, Langlois X et al: Preclinical evaluation of [18F]JNJ42259152 as a PET tracer for PDE10A. NeuroImage 2013, 82(0):13-22.
  20. Chan S-C, Hsu C-L, Yen T-C, Ng S-H, Liao C-T, Wang H-M: The role of 18F-FDG PET/CT metabolic tumour volume in predicting survival in patients with metastatic nasopharyngeal carcinoma. Oral Oncology 2013, 49(1):71-78.
  21. Chang K-L, Hu Y-C, Hsieh B-S, Cheng H-L, Hsu H-W, Huang L-W, Su S-J: Combined effect of soy isoflavones and vitamin D3 on bone loss in ovariectomized rats. Nutrition 2013, 29(1):250-257.
  22. Chen D-Y, Wei H-J, Lin K-J, Huang C-C, Wang C-C, Wu C-T, Chao K-T, Chen K-J, Chang Y, Sung H-W: Three-dimensional cell aggregates composed of HUVECs and cbMSCs for therapeutic neovascularization in a mouse model of hindlimb ischemia. Biomaterials 2013, 34(8):1995-2004.
  23. Chen D-Y, Wei H-J, Lin W-W, Lin K-J, Huang C-C, Wu C-T, Hwang S-M, Chang Y, Sung H-W: Intramuscular delivery of 3D aggregates of HUVECs and cbMSCs for cellular cardiomyoplasty in rats with myocardial infarction. Journal of Controlled Release 2013, 172(2):419-425.
  24. Chen H-C, Chang H-T, Huang P-H, Chang MD-T, Liu R-S, Lin Y-J, Hsieh C-H: Molecular Imaging of Heparan Sulfate Expression with Radiolabeled Recombinant Eosinophil Cationic Protein Predicts Allergic Lung Inflammation in a Mouse Model for Asthma. Journal of Nuclear Medicine 2013, 54(5):793-800.
  25. Chen M-H, Lin K-J, Yang W-LR, Kao Y-W, Chen T-W, Chao S-C, Chang PM-H, Liu C-Y, Tzeng C-H, Chao Y et al: Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma. Cancer 2013, 119(2):293-303.
  26. Cheng C, Alt V, Dimitrakopoulou-Strauss A, Pan L, Thormann U, Schnettler R, Weber K, Strauss LG: Evaluation of new bone formation in normal and osteoporotic rats with a 3-mm femur defect: functional assessment with dynamic PET-CT (dPET-CT) using 2-deoxy-2-[(18)F]fluoro-D-glucose ( (18)F-FDG) and (18)F-fluoride. Mol Imaging Biol 2013, 15(3):336-344.
  27. Cheng N-M, Dean Fang Y-H, Tung-Chieh Chang J, Huang C-G, Tsan D-L, Ng S-H, Wang H-M, Lin C-Y, Liao C-T, Yen T-C: Textural Features of Pretreatment 18F-FDG PET/CT Images: Prognostic Significance in Patients with Advanced T-Stage Oropharyngeal Squamous Cell Carcinoma. Journal of Nuclear Medicine 2013, 54(10):1703-1709.
  28. Chételat G, Landeau B, Salmon E, Yakushev I, Bahri MA, Mézenge F, Perrotin A, Bastin C, Manrique A, Scheurich A et al: Relationships between brain metabolism decrease in normal aging and changes in structural and functional connectivity. NeuroImage 2013, 76(0):167-177.
  29. Chiuccariello L, Boileau I, Guranda M, Rusjan PM, Wilson AA, Zawertailo L, Houle S, Busto U, Le Foll B: Presentation of smoking-associated cues does not elicit dopamine release after one-hour smoking abstinence: A [11C]-(+)-PHNO PET study. PLoS One 2013, 8(3):e60382.
  30. Cho S-G, Kim JH, Cho JY, Kim HS, Bom H-S: Myocardial Blood Flow and Flow Reserve in Proximal and Mid-to-Distal Lesions of Left Anterior Descending Artery Measured By N-13 Ammonia PET/CT. Nuclear Medicine and Molecular Imaging 2013.
  31. Chuang E-Y, Lin K-J, Su F-Y, Mi F-L, Maiti B, Chen C-T, Wey S-P, Yen T-C, Juang J-H, Sung H-W: Noninvasive imaging oral absorption of insulin delivered by nanoparticles and its stimulated glucose utilization in controlling postprandial hyperglycemia during OGTT in diabetic rats. Journal of Controlled Release 2013, 172(2):513-522.
  32. Chuang E-Y, Nguyen GTH, Su F-Y, Lin K-J, Chen C-T, Mi F-L, Yen T-C, Juang J-H, Sung H-W: Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT. Biomaterials 2013, 34(32):7994-8001.
  33. Constantinescu CC, Garcia A, Mirbolooki MR, Pan M-L, Mukherjee J: Evaluation of [18F]Nifene biodistribution and dosimetry based on whole-body PET imaging of mice. Nuclear Medicine and Biology 2013, 40(2):289-294.
  34. Cumming P, Xiong G, Fougère CLA, Rominger A, Bartenstein P, Buchholz H-G, Piel M, Rösch F, Gründer G, Vernaleken I: Surrogate markers for cerebral blood flow correlate with [18F]-fallypride binding potential at dopamine D2/3 receptors in human striatum. Synapse 2013:n/a-n/a.
  35. Czoty PW, Gage HD, Garg PK, Garg S, Nader MA: Effects of repeated treatment with the dopamine D2/D3 receptor partial agonist aripiprazole on striatal D2/D3 receptor availability in monkeys. Psychopharmacology (Berl) 2013.
  36. Dhilly M, Guillouet S, Patin D, Fillesoye F, Abbas A, Gourand F, Tirel O, Galateau F, Mackenzie ET, Dumontet C et al: 2-[F]Fludarabine, a Novel Positron Emission Tomography (PET) Tracer for Imaging Lymphoma: a Micro-PET Study in Murine Models. Mol Imaging Biol 2013.
  37. Dos Santos Tavares AA, Barret O, Batis J, Alagille D, Koren A, Papin C, Kudej G, Nice K, Kordower JH, Cosgrove KP et al: Kinetic modeling and occupancy measures of the norepinephrine transporters in baboons using single photon emission computed tomography with 123I-INER. Synapse 2013, 67(1):30-41.
  38. Durymanov MO, Slastnikova TA, Kuzmich AI, Khramtsov YV, Ulasov AV, Rosenkranz AA, Egorov SY, Sverdlov ED, Sobolev AS: Microdistribution of MC1R-targeted polyplexes in murine melanoma tumor tissue. Biomaterials 2013, 34(38):10209-10216.
  39. Eriksson O, Selvaraju R, Borg B, Asplund V, Estrada S, Antoni G: 5-Fluoro-[β-11C]-L-tryptophan is a functional analogue of 5-hydroxy-[β-11C]-L-tryptophan in vitro but not in vivo. Nuclear Medicine and Biology 2013, 40(4):567-575.
  40. Ewers M, Brendel M, Rizk-Jackson A, Rominger A, Bartenstein P, Schuff N, Weiner MW, Alzheimer’s Disease Neuroimaging I: Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects. NeuroImage Clinical 2013, 4(0):45-52.
  41. Farwell MD, Chong DJ, Iida Y, Bae SA, Easwaramoorthy B, Ichise M: Imaging P-glycoprotein function in rats using [C]-N-desmethyl-loperamide. Ann Nucl Med 2013.
  42. Fischer DR: Musculoskeletal Imaging Using Fluoride PET. Seminars in Nuclear Medicine 2013, 43(6):427-433.
  43. Frings L, Spehl TS, Weber WA, Hüll M, Meyer PT: Amyloid-β Load Predicts Medial Temporal Lobe Dysfunction in Alzheimer Dementia. Journal of Nuclear Medicine 2013, 54(11):1909-1914.
  44. Frokjaer VG, Erritzoe D, Holst KK, Jensen PS, Rasmussen PM, Fisher PM, Baaré W, Madsen KS, Madsen J, Svarer C et al: Prefrontal serotonin transporter availability is positively associated with the cortisol awakening response. European Neuropsychopharmacology 2013, 23(4):285-294.
  45. Furumoto S, Okamura N, Furukawa K, Tashiro M, Ishikawa Y, Sugi K, Tomita N, Waragai M, Harada R, Tago T et al: A (18)F-Labeled BF-227 Derivative as a Potential Radioligand for Imaging Dense Amyloid Plaques by Positron Emission Tomography. Mol Imaging Biol 2013.
  46. Galluzzi S, Geroldi C, Amicucci G, Bocchio-Chiavetto L, Bonetti M, Bonvicini C, Cotelli M, Ghidoni R, Paghera B, Zanetti O et al: Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. Journal of neurology 2013, 260(2):640-650.
  47. Ghosh A, Wyss MT, Weber B: Somatotopic astrocytic activity in the somatosensory cortex. Glia 2013:n/a-n/a.
  48. Giovannetti G, Frijia F, Attanasio S, Menichetti L, Hartwig V, Vanello N, Ardenkjaer-Larsen JH, De Marchi D, Positano V, Schulte R et al: Magnetic resonance butterfly coils: Design and application for hyperpolarized 13C studies. Measurement 2013, 46(9):3282-3290.
  49. Giovannetti G, Frijia F, Hartwig V, Attanasio S, Menichetti L, Vanello N, Positano V, Ardenkjaer-Larsen JH, Lionetti V, Aquaro GD et al: Design of a quadrature surface coil for hyperpolarized 13C MRS cardiac metabolism studies in pigs. Concepts in Magnetic Resonance Part B: Magnetic Resonance Engineering 2013, 43(2):69-77.
  50. Giovannetti G, Frijia F, Hartwig V, Menichetti L, Positano V, Ardenkjaer-Larsen JH, Lionetti V, Aquaro GD, Marchi D, Schulte RF et al: Transmit-Only/Receive-Only Radiofrequency System for Hyperpolarized 13C MRS Cardiac Metabolism Studies in Pigs. Applied Magnetic Resonance 2013.
  51. González-Navarro H, Vinué Á, Sanz MJ, Delgado M, Pozo MA, Serrano M, Burks DJ, Andrés V: Increased dosage of Ink4/Arf protects against glucose intolerance and insulin resistance associated with aging. Aging Cell 2013, 12(1):102-111.
  52. Gould RW, Garg PK, Garg S, Nader MA: Effects of nicotinic acetylcholine receptor agonists on cognition in rhesus monkeys with a chronic cocaine self-administration history. Neuropharmacology 2013, 64(0):479-488.
  53. Hansen HD, Ettrup A, Herth MM, Dyssegaard A, Ratner C, Gillings N, Knudsen GM: Direct comparison of [18F]MH.MZ and [18F]altanserin for 5-HT2A receptor imaging with PET. Synapse 2013, 67(6):328-337.
  54. Harris PE, Farwell MD, Ichise M: PET quantification of pancreatic VMAT 2 binding using (+) and (-) enantiomers of [18F]FP-DTBZ in baboons. Nucl Med Biol 2013, 40(1):60-64.
  55. Hatashita S, Yamasaki H: Diagnosed Mild Cognitive Impairment Due to Alzheimer’s Disease with PET Biomarkers of Beta Amyloid and Neuronal Dysfunction. PLoS One 2013, 8(6):e66877.
  56. Hatashita S, Yamasaki H, Suzuki Y, Tanaka K, Wakebe D, Hayakawa H: [F]Flutemetamol amyloid-beta PET imaging compared with [C]PIB across the spectrum of Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2013.
  57. Hefti K, Holst SC, Sovago J, Bachmann V, Buck A, Ametamey SM, Scheidegger M, Berthold T, Gomez-Mancilla B, Seifritz E et al: Increased Metabotropic Glutamate Receptor Subtype 5 Availability in Human Brain After One Night Without Sleep. Biological Psychiatry 2013, 73(2):161-168.
  58. Hines CS, Fujita M, Zoghbi SS, Kim JS, Quezado Z, Herscovitch P, Miao N, Ferraris Araneta MD, Morse C, Pike VW et al: Propofol Decreases In Vivo Binding of 11C-PBR28 to Translocator Protein (18 kDa) in the Human Brain. J Nucl Med 2013, 54(1):64-69.
  59. Ho P-S, Ho KK-J, Huang W-S, Yen C-H, Shih M-C, Shen L-H, Ma K-H, Huang S-Y: Association study of serotonin transporter availability and SLC6A4 gene polymorphisms in patients with major depression. Psychiatry Research: Neuroimaging 2013, 212(3):216-222.
  60. Hsiao IT, Huang CC, Hsieh CJ, Wey SP, Kung MP, Yen TC, Lin KJ: Perfusion-like template and standardized normalization-based brain image analysis using (18)F-florbetapir (AV-45/Amyvid) PET. Eur J Nucl Med Mol Imaging 2013.
  61. Hsiao M-C, Lin K-J, Liu C-Y, Beck Schatz D: The interaction between dopamine transporter function, gender differences, and possible laterality in depression. Psychiatry Research: Neuroimaging 2013, 211(1):72-77.
  62. Huang C-C, Chen D-Y, Wei H-J, Lin K-J, Wu C-T, Lee T-Y, Hu H-Y, Hwang S-M, Chang Y, Sung H-W: Hypoxia-induced therapeutic neovascularization in a mouse model of an ischemic limb using cell aggregates composed of HUVECs and cbMSCs. Biomaterials 2013, 34(37):9441-9450.
  63. Huang C-C, Lin K-J, Cheng Y-W, Hsu C-A, Yang S-S, Shyur L-F: Hepatoprotective effect and mechanistic insights of deoxyelephantopin, a phyto-sesquiterpene lactone, against fulminant hepatitis. The Journal of Nutritional Biochemistry 2013, 24(3):516-530.
  64. Huang H-L, Yeh C-N, Lee W-Y, Huang Y-C, Chang K-W, Lin K-J, Tien S-F, Su W-C, Yang C-H, Chen J-T et al: [123I]Iodooctyl fenbufen amide as a SPECT tracer for imaging tumors that over-express COX enzymes. Biomaterials 2013, 34(13):3355-3365.
  65. Huang KL, Lin KJ, Hsiao IT, Kuo HC, Hsu WC, Chuang WL, Kung MP, Wey SP, Hsieh CJ, Wai YY et al: Regional amyloid deposition in amnestic mild cognitive impairment and Alzheimer’s disease evaluated by [18F]AV-45 positron emission tomography in Chinese population. PLoS One 2013, 8(3):e58974.
  66. Ikoma Y, Takano A, Varrone A, Halldin C: Graphic plot analysis for estimating binding potential of translocator protein (TSPO) in positron emission tomography studies with [18F]FEDAA1106. NeuroImage 2013, 69(0):78-86.
  67. Imabayashi E, Matsuda H, Tabira T, Arima K, Araki N, Ishii K, Yamashita F, Iwatsubo T, Japanese Alzheimer’s Disease Neuroimaging I: Comparison between brain CT and MRI for voxel-based morphometry of Alzheimer’s disease. Brain and Behavior 2013, 3(4):487-493.
  68. Jarcho JM, Feier NA, Bert A, Labus JA, Lee M, Stains J, Ebrat B, Groman SM, Tillisch K, Brody AL et al: Diminished neurokinin-1 receptor availability in patients with two forms of chronic visceral pain. PAIN 2013, 154(0):987-996.
  69. Kang S-R, Song H-C, Byun BH, Oh J-R, Kim H-S, Hong S-P, Kwon SY, Chong A, Kim J, Cho S-G et al: Intratumoral Metabolic Heterogeneity for Prediction of Disease Progression After Concurrent Chemoradiotherapy in Patients with Inoperable Stage III Non-Small-Cell Lung Cancer. Nuclear Medicine and Molecular Imaging 2013.
  70. Karmani L, Labar D, Valembois V, Bouchat V, Nagaswaran PG, Bol A, Gillart J, Levêque P, Bouzin C, Bonifazi D et al: Antibody-functionalized nanoparticles for imaging cancer: influence of conjugation to gold nanoparticles on the biodistribution of 89Zr-labeled cetuximab in mice. Contrast media & molecular imaging 2013, 8(5):402-408.
  71. Karroum O, Mignion L, Kengen J, Karmani L, Levêque P, Danhier P, Magat J, Bol A, Labar D, Grégoire V et al: Multimodal imaging of tumor response to sorafenib combined with radiation therapy: comparison between diffusion-weighted MRI, choline spectroscopy and 18F-FLT PET imaging. Contrast media & molecular imaging 2013, 8(3):274-280.
  72. Kasenda B, Haug V, Schorb E, Fritsch K, Finke J, Mix M, Hader C, Weber WA, Illerhaus G, Meyer PT: 18F-FDG PET is an independent outcome predictor in primary central nervous system lymphoma. J Nucl Med 2013, 54(2):184-191.
  73. Kawamura K, Hashimoto H, Ogawa M, Yui J, Wakizaka H, Yamasaki T, Hatori A, Xie L, Kumata K, Fujinaga M et al: Synthesis, metabolite analysis, and in vivo evaluation of [11C]irinotecan as a novel positron emission tomography (PET) probe. Nuclear Medicine and Biology 2013, 40(0):651-657.
  74. Ke AB, Eyal S, Chung FS, Link JM, Mankoff DA, Muzi M, Unadkat JD: Modeling Cyclosporine A Inhibition of the Distribution of a P-Glycoprotein PET Ligand, 11C-Verapamil, into the Maternal Brain and Fetal Liver of the Pregnant Nonhuman Primate: Impact of Tissue Blood Flow and Site of Inhibition. J Nucl Med 2013, 54(3):437-446.
  75. Kil K-E, Zhang Z, Jokivarsi K, Gong C, Choi J-K, Kura S, Brownell A-L: Radiosynthesis of N-(4-chloro-3-[11C]methoxyphenyl)-2-picolinamide ([11C]ML128) as a PET radiotracer for metabotropic glutamate receptor subtype 4 (mGlu4). Bioorganic & Medicinal Chemistry 2013, 21(19):5955-5962.
  76. Kim SW, Hooker JM, Otto N, Win K, Muench L, Shea C, Carter P, King P, Reid AE, Volkow ND et al: Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by PET. Nuclear Medicine and Biology 2013, 40(7):912-918.
  77. Kim YI, Ha S, So Y, Lee WW, Byun SS, Kim SE: Improved measurement of the glomerular filtration rate from Tc-99m DTPA scintigraphy in patients following nephrectomy. European radiology 2013.
  78. Kirch RD, Meyer PT, Geisler S, Braun F, Gehrig S, Langen K-J, von Hörsten S, Nikkhah G, Cassel J-C, Döbrössy M: Early deficits in declarative and procedural memory dependent behavioral function in a transgenic rat model of Huntington’s disease. Behavioural Brain Research 2013, 239(0):15-26.
  79. Kobayashi M, Cui Y, Sako T, Sasabe T, Mizoguchi N, Yamamoto K, Wada Y, Kataoka Y, Koshikawa N: Functional neuroimaging of aversive taste-related areas in the alert rat revealed by positron emission tomography. Journal of Neuroscience Research 2013:n/a-n/a.
  80. Kodaka F, Ito H, Kimura Y, Fujie S, Takano H, Fujiwara H, Sasaki T, Nakayama K, Halldin C, Farde L et al: Test-retest reproducibility of dopamine D2/3 receptor binding in human brain measured by PET with [11C]MNPA and [11C]raclopride. Eur J Nucl Med Mol Imaging 2013, 40(4):574-579.
  81. Lange C, Apostolova I, Lukas M, Huang KP, Hofheinz F, Gregor-Mamoudou B, Brenner W, Buchert R: Performance Evaluation of Stationary and Semi-Stationary Acquisition with a Non-Stationary Small Animal Multi-Pinhole SPECT System. Mol Imaging Biol 2013.
  82. Lauzurica N, Garcia-Garcia L, Fuentes JA, Delgado M: Hypophagia and induction of serotonin transporter gene expression in raphe nuclei of male and female rats after short-term fluoxetine treatment. Journal of physiology and biochemistry 2013, 69(1):69-74.
  83. Lim HS, Kim SJ, Noh YH, Lee BC, Jin SJ, Park HS, Kim S, Jang IJ, Kim SE: Exploration of optimal dosing regimens of haloperidol, a D2 Antagonist, via modeling and simulation analysis in a D2 receptor occupancy study. Pharm Res 2013, 30(3):683-693.
  84. Lin C-Y, Chang Y-H, Li K-C, Lu C-H, Sung L-Y, Yeh C-L, Lin K-J, Huang S-F, Yen T-C, Hu Y-C: The use of ASCs engineered to express BMP2 or TGF-β3 within scaffold constructs to promote calvarial bone repair. Biomaterials 2013, 34(37):9401-9412.
  85. Llaguno-Munive M, Medina LA, Jurado R, Romero-Pina M, Garcia-Lopez P: Mifepristone improves chemo-radiation response in glioblastoma xenografts. Cancer cell international 2013, 13(1):29.
  86. Martin A, Szczupak B, Gomez-Vallejo V, Plaza S, Padro D, Cano A, Llop J: PET imaging of serotoninergic neurotransmission with [C]DASB and [F]altanserin after focal cerebral ischemia in rats. J Cereb Blood Flow Metab 2013.
  87. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, Zhang M-R, Trojanowski John Q, Lee Virginia MY, Ono M et al: Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls. Neuron 2013, 79(6):1094-1108.
  88. Mateos-Pérez JM, Desco M, Dae MW, García-Villalba C, Cussó L, Vaquero JJ: Automatic TAC extraction from dynamic cardiac PET imaging using iterative correlation from a population template. Computer Methods and Programs in Biomedicine 2013, 111(2):308-314.
  89. Mazere J, Meissner WG, Sibon I, Lamare F, Tison F, Allard M, Mayo W: [123I]-IBVM SPECT imaging of cholinergic systems in multiple system atrophy: A specific alteration of the ponto-thalamic cholinergic pathways (Ch5–Ch6). NeuroImage: Clinical 2013, 3(0):212-217.
  90. McKinley ET, Ayers GD, Smith RA, Saleh SA, Zhao P, Washington MK, Coffey RJ, Manning HC: Limits of [18F]-FLT PET as a biomarker of proliferation in oncology. PLoS One 2013, 8(3):e58938.
  91. Mertens J, De Bruyne S, Van Damme N, Smeets P, Ceelen W, Troisi R, Laurent S, Geboes K, Peeters M, Goethals I et al: Standardized added metabolic activity (SAM) IN (18)F-FDG PET assessment of treatment response in colorectal liver metastases. Eur J Nucl Med Mol Imaging 2013, 40(8):1214-1222.
  92. Michaelides M, Miller ML, Subrize M, Kim R, Robison L, Hurd YL, Wang G-J, Volkow ND, Thanos PK: Limbic activation to novel versus familiar food cues predicts food preference and alcohol intake. Brain Research 2013, 1512(0):37-44.
  93. Mirbolooki MR, Constantinescu CC, Pan M-L, Mukherjee J: Targeting presynaptic norepinephrine transporter in brown adipose tissue: A novel imaging approach and potential treatment for diabetes and obesity. Synapse 2013, 67(2):79-93.
  94. Mu L, Bieri D, Slavik R, Drandarov K, Müller A, Čermak S, Weber M, Schibli R, Krämer SD, Ametamey SM: Radiolabeling and in vitro /in vivo evaluation of N-(1-adamantyl)-8-methoxy-4-oxo-1-phenyl-1,4-dihydroquinoline-3-carboxamide as a PET probe for imaging cannabinoid type 2 receptor. Journal of Neurochemistry 2013:n/a-n/a.
  95. Nakamura I, Hasegawa K, Wada Y, Hirase T, Node K, Watanabe Y: Detection of early stage atherosclerotic plaques using PET and CT fusion imaging targeting P-selectin in low density lipoprotein receptor-deficient mice. Biochemical and Biophysical Research Communications 2013, 433(1):47-51.
  96. Park H-J, Kim CH, Park ES, Park B, Oh SR, Oh M-K, Park CI, Lee JD: Increased GABA-A Receptor Binding and Reduced Connectivity at the Motor Cortex in Children with Hemiplegic Cerebral Palsy: A Multimodal Investigation Using 18F-Fluoroflumazenil PET, Immunohistochemistry, and MR Imaging. Journal of Nuclear Medicine 2013, 54(8):1263-1269.
  97. Peng Y-J, Lu Y-T, Liu K-S, Liu S-J, Fan L, Huang W-C: Biodegradable balloon-expandable self-locking polycaprolactone stents as buckling explants for the treatment of retinal detachment: An in vitro and in vivo study. Journal of Biomedical Materials Research Part A 2013, 101A(1):167-175.
  98. Perez-Campana C, Gomez-Vallejo V, Puigivila M, Martin A, Calvo-Fernandez T, Moya SE, Larsen ST, Gispert JD, Llop J: Assessing Lung Inflammation After Nanoparticle Inhalation Using 2-deoxy-2-[F]fluoro-D-glucose Positron Emission Tomography Imaging. Mol Imaging Biol 2013.
  99. Pérez-Campaña C, Sansaloni F, Gómez-Vallejo V, Baz Z, Martin A, Moya SE, Lagares JI, Ziolo RF, Llop J: Production of 18F-Labeled Titanium Dioxide Nanoparticles by Proton Irradiation for Biodistribution and Biological Fate Studies in Rats. Particle & Particle Systems Characterization 2013:n/a-n/a.
  100. Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM, Eary JF, Porter P, Shankar LK, Mankoff DA et al: A Phase 2 Study of 16alpha-[F]-fluoro-17beta-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC). Mol Imaging Biol 2013.
  101. Prestia A, Caroli A, Herholz K, Reiman E, Chen K, Jagust WJ, Frisoni GB: Diagnostic accuracy of markers for prodromal Alzheimer’s disease in independent clinical series. Alzheimer’s & Dementia 2013, 9(0):677-686.
  102. Prestia A, Muscio C, Caroli A, Frisoni GB: Computer-aided diagnostic reporting of FDG PET for the diagnosis of Alzheimer’s disease. Clinical and Translational Imaging 2013, 1(4):279-288.
  103. Ravert HT, Dorff P, Foss CA, Mease RC, Fan H, Holmquist CR, Phillips E, McCarthy DJ, Heys JR, Holt DP et al: Radiochemical synthesis and in vivo evaluation of [18F]AZ11637326: An agonist probe for the α7 nicotinic acetylcholine receptor. Nuclear Medicine and Biology 2013, 40(6):731-739.
  104. Rominger A, Brendel M, Burgold S, Keppler K, Baumann K, Xiong G, Mille E, Gildehaus F-J, Carlsen J, Schlichtiger J et al: Longitudinal Assessment of Cerebral β-Amyloid Deposition in Mice Overexpressing Swedish Mutant β-Amyloid Precursor Protein Using 18F-Florbetaben PET. Journal of Nuclear Medicine 2013, 54(7):1127-1134.
  105. Saigal N, Bajwa AK, Faheem SS, Coleman RA, Pandey SK, Constantinescu CC, Fong V, Mukherjee J: Evaluation of serotonin 5-HT1A receptors in rodent models using [18F]mefway PET. Synapse 2013, 67(9):596-608.
  106. Schain M, Benjaminsson S, Varnas K, Forsberg A, Halldin C, Lansner A, Farde L, Varrone A: Arterial input function derived from pairwise correlations between PET-image voxels. J Cereb Blood Flow Metab 2013.
  107. Schmid A, Schmitz J, Mannheim JG, Maier FC, Fuchs K, Wehrl HF, Pichler BJ: Feasibility of sequential PET/MRI using a state-of-the-art small animal PET and a 1 T benchtop MRI. Mol Imaging Biol 2013, 15(2):155-165.
  108. Schwenzer NF, Schmidt H, Gatidis S, Brendle C, Müller M, Königsrainer I, Claussen CD, Pfannenberg AC, Schraml C: Measurement of apparent diffusion coefficient with simultaneous MR/positron emission tomography in patients with peritoneal carcinomatosis: Comparison with 18F-FDG-PET. Journal of Magnetic Resonance Imaging 2013:n/a-n/a.
  109. Selvaraju RK, Velikyan I, Johansson L, Wu Z, Todorov I, Shively J, Kandeel F, Korsgren O, Eriksson O: In Vivo Imaging of the Glucagonlike Peptide 1 Receptor in the Pancreas with 68Ga-Labeled DO3A-Exendin-4. Journal of Nuclear Medicine 2013, 54(8):1458-1463.
  110. Shidahara M, Tashiro M, Okamura N, Furumoto S, Furukawa K, Watanuki S, Hiraoka K, Miyake M, Iwata R, Tamura H et al: Evaluation of the biodistribution and radiation dosimetry of the 18F-labelled amyloid imaging probe [18F]FACT in humans. EJNMMI research 2013, 3(1):32.
  111. Simonyan K, Herscovitch P, Horwitz B: Speech-induced striatal dopamine release is left lateralized and coupled to functional striatal circuits in healthy humans: A combined PET, fMRI and DTI study. NeuroImage 2013, 70(0):21-32.
  112. Sorensen J, Owenius R, Lax M, Johansson S: Regional distribution and kinetics of [18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer. Eur J Nucl Med Mol Imaging 2013, 40(3):394-402.
  113. Suzuki T, Graff-Guerrero A, Uchida H, Remington G, Caravaggio F, Borlido C, Pollock B, Mulsant B, Deluca V, Ismail Z et al: Dopamine D(2/3) occupancy of ziprasidone across a day: a within-subject PET study. Psychopharmacology (Berl) 2013.
  114. Tahari AK, Bravo PE, Rahmim A, Bengel FM, Szabo Z: Initial human experience with Rubidium-82 renal PET/CT imaging. Journal of Medical Imaging and Radiation Oncology 2013:n/a-n/a.
  115. Takashima T, Wu C, Takashima-Hirano M, Katayama Y, Wada Y, Suzuki M, Kusuhara H, Sugiyama Y, Watanabe Y: Evaluation of breast cancer resistance protein function in hepatobiliary and renal excretion using PET with 11C-SC-62807. J Nucl Med 2013, 54(2):267-276.
  116. Taniguchi J, Seki C, Takuwa H, Kawaguchi H, Ikoma Y, Fujinaga M, Kanno I, Zhang MR, Kuwabara S, Ito H: Evaluation of Rho-Kinase Activity in Mice Brain Using N-[C]Methyl-hydroxyfasudil with Positron Emission Tomography. Mol Imaging Biol 2013.
  117. Taratula O, Kuzmov A, Shah M, Garbuzenko OB, Minko T: Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. Journal of Controlled Release 2013, 171(3):349-357.
  118. Tavares AAdS, Batis J, Barret O, Alagille D, Vala C, Kudej G, Koren A, Cosgrove KP, Nice K, Kordower JH et al: In vivo evaluation of [123I]MNI-420: A novel single photon emission computed tomography radiotracer for imaging of adenosine 2A receptors in brain. Nuclear Medicine and Biology 2013, 40(3):403-409.
  119. Tavares AAS, Batis JC, Papin C, Jennings D, Alagille D, Russell DS, Vala C, Lee H, Baldwin RM, Zubal IG et al: Kinetic Modeling, Test–Retest, and Dosimetry of 123I-MNI-420 in Humans. Journal of Nuclear Medicine 2013, 54(10):1760-1767.
  120. Tomberli B, Cecchi F, Sciagra R, Berti V, Lisi F, Torricelli F, Morrone A, Castelli G, Yacoub MH, Olivotto I: Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease. Eur J Heart Fail 2013, 15(12):1363-1373.
  121. Tomberli B, Cecchi F, Sciagrà R, Berti V, Lisi F, Torricelli F, Morrone A, Castelli G, Yacoub MH, Olivotto I: Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson–Fabry disease. European Journal of Heart Failure 2013, 15(12):1363-1373.
  122. Tóth M, Varrone A, Steiger C, Laszlovszky I, Horváth A, Kiss B, Gyertyán I, Adham N, Halldin C, Gulyás B: Brain uptake and distribution of the dopamine D3/D2 receptor partial agonist [11C]cariprazine: An in vivo positron emission tomography study in nonhuman primates. Synapse 2013, 67(5):258-264.
  123. Toyohara J, Sakata M, Oda K, Ishii K, Ishiwata K: Longitudinal observation of [11C]4DST uptake in turpentine-induced inflammatory tissue. Nuclear Medicine and Biology 2013, 40(2):240-244.
  124. Tsai HC, Lin S-H, Lee IH, Chen PS, Chen KC, Yeh TL, Yao WJ, Chiu N-T, Lu R-B, Yang YK: Probing the association between dexamethasone-induced cortisol suppression and serotonin transporter availability among drug-free patients with major depressive disorder—A small-sample SPECT study with [123I]ADAM. Psychoneuroendocrinology 2013, 38(11):2805-2809.
  125. Tsukada H, Ohba H, Kanazawa M, Kakiuchi T, Harada N: Evaluation of F-BCPP-EF for mitochondrial complex 1 imaging in the brain of conscious monkeys using PET. Eur J Nucl Med Mol Imaging 2013.
  126. Valtorta S, Belloli S, Sanvito F, Masiello V, Di Grigoli G, Monterisi C, Fazio F, Picchio M, Moresco RM: Comparison of 18F-Fluoroazomycin-Arabinofuranoside and 64Cu-Diacetyl-Bis(N4-Methylthiosemicarbazone) in Preclinical Models of Cancer. Journal of Nuclear Medicine 2013, 54(7):1106-1112.
  127. Vázquez-Villoldo N, Domercq M, Martín A, Llop J, Gómez-Vallejo V, Matute C: P2X4 receptors control the fate and survival of activated microglia. Glia 2013:n/a-n/a.
  128. Vivash L, Gregoire M-C, Lau EW, Ware RE, Binns D, Roselt P, Bouilleret V, Myers DE, Cook MJ, Hicks RJ et al: 18F-Flumazenil: A γ-Aminobutyric Acid A–Specific PET Radiotracer for the Localization of Drug-Resistant Temporal Lobe Epilepsy. Journal of Nuclear Medicine 2013, 54(8):1270-1277.
  129. Walter B, Eiselt M, Cumming P, Xiong G, Hinz R, Uthe S, Brust P, Bauer R: Resistance of brain glucose metabolism to thiopental-induced CNS depression in newborn piglets. International Journal of Developmental Neuroscience 2013, 31(3):157-164.
  130. Wang C, Wilson CM, Moseley CK, Carlin SM, Hsu S, Arabasz G, Schroeder FA, Sander CY, Hooker JM: Evaluation of potential PET imaging probes for the orexin 2 receptors. Nuclear Medicine and Biology 2013, 40(8):1000-1005.
  131. Warnock G, Turtoi A, Blomme A, Bretin F, Bahri MA, Lemaire C, Libert LC, Seret AEJJ, Luxen A, Castronovo V et al: In Vivo PET/CT in a Human Glioblastoma Chicken Chorioallantoic Membrane Model: A New Tool for Oncology and Radiotracer Development. Journal of Nuclear Medicine 2013, 54(10):1782-1788.
  132. Welch A, Mingarelli M, Riedel G, Platt B: Mapping Changes in Mouse Brain Metabolism with PET/CT. Journal of Nuclear Medicine 2013, 54(11):1946-1953.
  133. Wolfs E, Struys T, Notelaers T, Roberts SJ, Sohni A, Bormans G, Van Laere K, Luyten FP, Gheysens O, Lambrichts I et al: 18F-FDG Labeling of Mesenchymal Stem Cells and Multipotent Adult Progenitor Cells for PET Imaging: Effects on Ultrastructure and Differentiation Capacity. J Nucl Med 2013, 54(3):447-454.
  134. Wu KY, Hsiao IT, Chen CS, Chen CH, Hsieh CJ, Wai YY, Chang CJ, Tseng HJ, Yen TC, Liu CY et al: Increased brain amyloid deposition in patients with a lifetime history of major depression: evidenced on F-florbetapir (AV-45/Amyvid) positron emission tomography. Eur J Nucl Med Mol Imaging 2013.
  135. Wyckhuys T, De Geeter N, Crevecoeur G, Stroobants S, Staelens S: Quantifying the Effect of Repetitive Transcranial Magnetic Stimulation in the Rat Brain by μSPECT CBF Scans. Brain Stimulation 2013, 6(4):554-562.
  136. Wyckhuys T, Verhaeghe J, Wyffels L, Langlois X, Schmidt M, Stroobants S, Staelens S: N-Acetylcysteine– and MK-801–Induced Changes in Glutamate Levels Do Not Affect In Vivo Binding of Metabotropic Glutamate 5 Receptor Radioligand 11C-ABP688 in Rat Brain. Journal of Nuclear Medicine 2013, 54(11):1954-1961.
  137. Yamasaki T, Kumata K, Yui J, Fujinaga M, Furutsuka K, Hatori A, Xie L, Ogawa M, Nengaki N, Kawamura K et al: Synthesis and evaluation of [11C]MMPIP as a potential radioligand for imaging of metabotropic glutamate 7 receptor in the brain. EJNMMI research 2013, 3(1):54.
  138. Yeh H-H, Tian M, Hinz R, Young D, Shavrin A, Mukhapadhyay U, Flores LG, Balatoni J, Soghomonyan S, Jeong HJ et al: Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with 18F-FAHA. NeuroImage 2013, 64(0):630-639.
  139. Zanotti-Fregonara P, Barth VN, Zoghbi SS, Liow JS, Nisenbaum E, Siuda E, Gladding RL, Rallis-Frutos D, Morse C, Tauscher J et al: 11C-LY2428703, a positron emission tomographic radioligand for the metabotropic glutamate receptor 1, is unsuitable for imaging in monkey and human brains. EJNMMI research 2013, 3(1):47.
  140. Zanotti-Fregonara P, Hirvonen J, Lyoo CH, Zoghbi SS, Rallis-Frutos D, Huestis MA, Morse C, Pike VW, Innis RB: Population-based input function modeling for [(18)F]FMPEP-d 2, an inverse agonist radioligand for cannabinoid CB1 receptors: validation in clinical studies. PLoS One 2013, 8(4):e60231.
2012
  1. Adachi K, Kobayashi M, Kawasaki T, Yokoyama C, Waddington JL, Sakagami H, Onoe H, Koshikawa N: Disruption of programmed masticatory movements in unilateral MPTP-treated monkeys as a model of jaw movement abnormality in Parkinson’s disease. Journal of neural transmission 2012, 119(8):933-941.
  2. Alexanderson E, Jacome R, Jimenez-Santos M, Ochoa JM, Romero E, Cabral MA, Ricalde A, Inarra F, Meave A, Alexanderson G: Evaluation of the endothelial function in hypertensive patients with 13N-ammonia PET. J Nucl Cardiol 2012, 19(5):979-986.
  3. Ando K, Obayashi S, Nagai Y, Oh-Nishi A, Minamimoto T, Higuchi M, Inoue T, Itoh T, Suhara T: PET analysis of dopaminergic neurodegeneration in relation to immobility in the MPTP-treated common marmoset, a model for Parkinson’s disease. PLoS One 2012, 7(10):e46371.
  4. Apostolova I, Wunder A, Dirnagl U, Michel R, Stemmer N, Lukas M, Derlin T, Gregor-Mamoudou B, Goldschmidt Jr, Brenner W et al: Brain perfusion SPECT in the mouse: Normal pattern according to gender and age. Neuroimage 2012, 63(4):1807-1817.
  5. Batis J, Barret O, Alagille D, Koren AO, Stehouwer JS, Cosgrove K, Goodman M, Seibyl J, Tamagnan G: In vivo evaluation of [123I]mZIENT as a SPECT radioligand for the serotonin transporter. Nuclear Medicine and Biology 2012, 39(8):1137-1141.
  6. Biesalski B, Yilmaz B, Buchholz H-G, Bausbacher N, Schreckenberger M, Thews O: An allogenic site-specific rat model of bone metastases for nuclear medicine and experimental oncology. Nuclear Medicine and Biology 2012, 39(4):502-508.
  7. Bieszczad KM, Kant R, Constantinescu CC, Pandey SK, Kawai HD, Metherate R, Weinberger NM, Mukherjee J: Nicotinic acetylcholine receptors in rat forebrain that bind (1)(8)F-nifene: relating PET imaging, autoradiography, and behavior. Synapse 2012, 66(5):418-434.
  8. Burger IA, Huser DM, Burger C, von Schulthess GK, Buck A: Repeatability of FDG quantification in tumor imaging: averaged SUVs are superior to SUVmax. Nuclear Medicine and Biology 2012, 39(5):666-670.
  9. Busk M, Mortensen LS, Nordsmark M, Overgaard J, Jakobsen S, Hansen KV, Theil J, Kallehauge JF, D’Andrea FP, Steiniche T et al: PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice. Eur J Nucl Med Mol Imaging 2012.
  10. Camus V, Payoux P, Barre L, Desgranges B, Voisin T, Tauber C, La Joie R, Tafani M, Hommet C, Chetelat G et al: Using PET with (18)F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging 2012, 39(4):621-631.
  11. Caroli A, Prestia A, Chen K, Ayutyanont N, Landau SM, Madison CM, Haense C, Herholz K, Nobili F, Reiman EM et al: Summary Metrics to Assess Alzheimer Disease-Related Hypometabolic Pattern with 18F-FDG PET: Head-to-Head Comparison. J Nucl Med 2012.
  12. Casteels C, Koole M, Celen S, Bormans G, Van Laere K: Preclinical evaluation and quantification of [(1)(8)F]MK-9470 as a radioligand for PET imaging of the type 1 cannabinoid receptor in rat brain. Eur J Nucl Med Mol Imaging 2012, 39(9):1467-1477.
  13. Chao K-T, Tsao H-H, Weng Y-H, Hsiao I-T, Hsieh C-J, Wey S-P, Yen T-C, Kung M-P, Lin K-J: Quantitative analysis of binding sites for 9-fluoropropyl-(+)-dihydrotetrabenazine ([18F]AV-133) in a MPTP-lesioned PD mouse model. Synapse 2012, 66(9):823-831.
  14. Chapman SE, Diener JM, Sasser TA, Correcher C, Gonzalez AJ, Avermaete TV, Leevy WM: Dual tracer imaging of SPECT and PET probes in living mice using a sequential protocol. American journal of nuclear medicine and molecular imaging 2012, 2(4):405-414.
  15. Chauvie S, Obertino M, Papaleo A, Ruspa M, Solano A, Gozzoli L, Gagliano A, Biggi A: A method for the visual analysis of early-stage Parkinson’s disease based on virtual MRI-derived SPECT images. International Journal of Imaging Systems and Technology 2012, 22(3):172-176.
  16. Chen Y-A, Huang W-S, Lin Y-S, Cheng C-Y, Liu R-S, Wang S-J, Li IH, Huang S-Y, Shiue C-Y, Chen C-Y et al: Characterization of 4-[18F]-ADAM as an imaging agent for SERT in non-human primate brain using PET: a dynamic study. Nuclear Medicine and Biology 2012, 39(2):279-285.
  17. Cheng C, Alt V, Dimitrakopoulou-Strauss A, Pan L, Thormann U, Schnettler R, Weber K, Strauss LG: Evaluation of New Bone Formation in Normal and Osteoporotic Rats with a 3-mm Femur Defect: Functional Assessment with Dynamic PET-CT (dPET-CT) Using 2-Deoxy-2-[(18)F]Fluoro-D-glucose ( (18)F-FDG) and (18)F-Fluoride. Mol Imaging Biol 2012.
  18. Constantinescu CC, Sevrioukov E, Garcia A, Pan ML, Mukherjee J: Evaluation of [(18)F]Mefway Biodistribution and Dosimetry Based on Whole-Body PET Imaging of Mice. Mol Imaging Biol 2012.
  19. Crunelle CL, de Wit TC, de Bruin K, Ramakers RM, van der Have F, Beekman FJ, van den Brink W, Booij J: Varenicline increases in vivo striatal dopamine D2/3 receptor binding: an ultra-high-resolution pinhole [123I]IBZM SPECT study in rats. Nuclear Medicine and Biology 2012, 39(5):640-644.
  20. de Lange C, Malinen E, Qu H, Johnsrud K, Skretting A, Saugstad OD, Munkeby BH: Dynamic FDG PET for assessing early effects of cerebral hypoxia and resuscitation in new-born pigs. Eur J Nucl Med Mol Imaging 2012.
  21. Döbrössy MD, Braun F, Klein S, Garcia J, Langen K-J, Weber WA, Nikkhah G, Meyer PT: [18F]desmethoxyfallypride as a novel PET radiotracer for quantitative in vivo dopamine D2/D3 receptor imaging in rat models of neurodegenerative diseases. Nuclear Medicine and Biology 2012, 39(7):1077-1080.
  22. Eigner S, Vera DR, Fellner M, Loktionova NS, Piel M, Lebeda O, Rosch F, Ross TL, Henke KE: Imaging of Protein Synthesis: In Vitro and In Vivo Evaluation of (44)Sc-DOTA-Puromycin. Mol Imaging Biol 2012.
  23. Eriksson O, Carlsson F, Blom E, Sundin A, Langström B, Korsgren O, Velikyan I: Preclinical evaluation of a 68Ga-labeled biotin analogue for applications in islet transplantation. Nuclear Medicine and Biology 2012, 39(3):415-421.
  24. Fellner M, Biesalski B, Bausbacher N, Kubicek V, Hermann P, Rosch F, Thews O: (68)Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitter. Nucl Med Biol 2012, 39(7):993-999.
  25. Fiechter M, Ghadri JR, Sidler M, Martin U, Landmesser U, Kaufmann PA, Lüscher TF, Templin C: Cardiac quadruple-fusion imaging: A brief report on a novel integrated multimodality approach for in vivo visualization of transplanted stem cells. International Journal of Cardiology 2012, 161(1):62-63.
  26. Fischer K, Sossi V, von Ameln-Mayerhofer A, Reischl G, Pichler BJ: In vivo quantification of dopamine transporters in mice with unilateral 6-OHDA lesions using [11C]methylphenidate and PET. Neuroimage 2012, 59(3):2413-2422.
  27. Forster S, Yousefi BH, Wester HJ, Klupp E, Rominger A, Forstl H, Kurz A, Grimmer T, Drzezga A: Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2012, 39(12):1927-1936.
  28. Fujita M, Hines CS, Zoghbi SS, Mallinger AG, Dickstein LP, Liow J-S, Zhang Y, Pike VW, Drevets WC, Innis RB et al: Downregulation of Brain Phosphodiesterase Type IV Measured with 11C-(R)-Rolipram Positron Emission Tomography in Major Depressive Disorder. Biological Psychiatry 2012, 72(7):548-554.
  29. Fujiwara H, Ito H, Kodaka F, Kimura Y, Takano H, Suhara T: Association between striatal subregions and extrastriatal regions in dopamine D(1) receptor expression: a positron emission tomography study. PLoS One 2012, 7(11):e49775.
  30. Galluzzi S, Geroldi C, Amicucci G, Bocchio-Chiavetto L, Bonetti M, Bonvicini C, Cotelli M, Ghidoni R, Paghera B, Zanetti O et al: Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. Journal of neurology 2012.
  31. Gruner JM, Paamand R, Kosteljanetz M, Broholm H, Hojgaard L, Law I: Brain perfusion CT compared with (1)(5)O-H(2)O PET in patients with primary brain tumours. Eur J Nucl Med Mol Imaging 2012, 39(11):1691-1701.
  32. Hahn A, Nics L, Baldinger P, Ungersbock J, Dolliner P, Frey R, Birkfellner W, Mitterhauser M, Wadsak W, Karanikas G et al: Combining image-derived and venous input functions enables quantification of serotonin-1A receptors with [carbonyl-(11)C]WAY-100635 independent of arterial sampling. Neuroimage 2012, 62(1):199-206.
  33. Hansen AE, Kristensen AT, Jorgensen JT, McEvoy FJ, Busk M, van der Kogel AJ, Bussink J, Engelholm SA, Kjaer A: (64)Cu-ATSM and (18)FDG PET uptake and (64)Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry. Radiation oncology 2012, 7:89.
  34. Hansen AE, Kristensen AT, Law I, McEvoy FJ, Kjaer A, Engelholm SA: Multimodality functional imaging of spontaneous canine tumors using 64Cu-ATSM and 18FDG PET/CT and dynamic contrast enhanced perfusion CT. Radiotherapy and Oncology 2012, 102(3):424-428.
  35. Herth MM, Hansen HD, Ettrup A, Dyssegaard A, Lehel S, Kristensen J, Knudsen GM: Synthesis and evaluation of [11C]Cimbi-806 as a potential PET ligand for 5-HT7 receptor imaging. Bioorganic & Medicinal Chemistry 2012, 20(14):4574-4581.
  36. Hesse S, Brust P, Mading P, Becker GA, Patt M, Seese A, Sorger D, Zessin J, Meyer PM, Lobsien D et al: Imaging of the brain serotonin transporters (SERT) with 18F-labelled fluoromethyl-McN5652 and PET in humans. Eur J Nucl Med Mol Imaging 2012, 39(6):1001-1011.
  37. Hirvonen J, Kreisl WC, Fujita M, Dustin I, Khan O, Appel S, Zhang Y, Morse C, Pike VW, Innis RB et al: Increased in vivo expression of an inflammatory marker in temporal lobe epilepsy. J Nucl Med 2012, 53(2):234-240.
  38. Hsiao IT, Huang CC, Hsieh CJ, Hsu WC, Wey SP, Yen TC, Kung MP, Lin KJ: Correlation of early-phase (18)F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies. Eur J Nucl Med Mol Imaging 2012, 39(4):613-620.
  39. Hu Y-C, Cheng H-L, Hsieh B-S, Huang L-W, Huang T-C, Chang K-L: Arsenic trioxide affects bone remodeling by effects on osteoblast differentiation and function. Bone 2012, 50(6):1406-1415.
  40. Huang J, Chunta JL, Amin M, Lee DY, Grills IS, Wong C-YO, Yan D, Marples B, Martinez AA, Wilson GD: Detailed Characterization of the Early Response of Head-Neck Cancer Xenografts to Irradiation Using 18F-FDG-PET Imaging. International Journal of Radiation Oncology*Biology*Physics 2012, 84(2):485-491.
  41. Huang K-L, Lin K-J, Ho M-Y, Chang Y-J, Chang C-H, Wey S-P, Hsieh C-J, Yen T-C, Hsiao I-T, Lee T-H: Amyloid deposition after cerebral hypoperfusion: Evidenced on [18F]AV-45 positron emission tomography. Journal of the Neurological Sciences 2012, 319(12):124-129.
  42. Ijuin R, Takashima T, Watanabe Y, Sugiyama Y, Suzuki M: Synthesis of [11C]dehydropravastatin, a PET probe potentially useful for studying OATP1B1 and MRP2 transporters in the liver. Bioorganic & Medicinal Chemistry 2012, 20(12):3703-3709.
  43. Jonsson CB, Camp JV, Wu A, Zheng H, Kraenzle JL, Biller AE, Vanover CD, Chu YK, Ng CK, Proctor M et al: Molecular imaging reveals a progressive pulmonary inflammation in lower airways in ferrets infected with 2009 H1N1 pandemic influenza virus. PLoS One 2012, 7(7):e40094.
  44. Kataoka M, Takashima T, Shingaki T, Hashidzume Y, Katayama Y, Wada Y, Oh H, Masaoka Y, Sakuma S, Sugiyama Y et al: Dynamic analysis of GI absorption and hepatic distribution processes of telmisartan in rats using positron emission tomography. Pharm Res 2012, 29(9):2419-2431.
  45. Kawasaki T, Marumo T, Shirakami K, Mori T, Doi H, Suzuki M, Watanabe Y, Chaki S, Nakazato A, Ago Y et al: Increase of 20-HETE synthase after brain ischemia in rats revealed by PET study with (11)C-labeled 20-HETE synthase-specific inhibitor. J Cereb Blood Flow Metab 2012.
  46. Kawashima S, Ueki Y, Kato T, Matsukawa N, Mima T, Hallett M, Ito K, Ojika K: Changes in striatal dopamine release associated with human motor-skill acquisition. PLoS One 2012, 7(2):e31728.
  47. Kimura Y, Simeon FG, Zoghbi SS, Zhang Y, Hatazawa J, Pike VW, Innis RB, Fujita M: Quantification of metabotropic glutamate subtype 5 receptors in the brain by an equilibrium method using 18F-SP203. Neuroimage 2012, 59(3):2124-2130.
  48. Kofler J, Lopresti B, Janssen C, Trichel AM, Masliah E, Finn OJ, Salter RD, Murdoch GH, Mathis CA, Wiley CA: Preventive immunization of aged and juvenile non-human primates to beta-amyloid. Journal of neuroinflammation 2012, 9:84.
  49. Kramer SD, Mu L, Muller A, Keller C, Kuznetsova OF, Schweinsberg C, Franck D, Muller C, Ross TL, Schibli R et al: 5-(2-18F-Fluoroethoxy)-L-Tryptophan as a Substrate of System L Transport for Tumor Imaging by PET. J Nucl Med 2012, 53(3):434-442.
  50. Kramer-Marek G, Bernardo M, Kiesewetter DO, Bagci U, Kuban M, Omer A, Zielinski R, Seidel J, Choyke P, Capala J: PET of HER2-positive pulmonary metastases with 18F-ZHER2:342 affibody in a murine model of breast cancer: comparison with 18F-FDG. J Nucl Med 2012, 53(6):939-946.
  51. Kranz GS, Hahn A, Baldinger P, Haeusler D, Philippe C, Kaufmann U, Wadsak W, Savli M, Hoeflich A, Kraus C et al: Cerebral serotonin transporter asymmetry in females, males and male-to-female transsexuals measured by PET in vivo. Brain structure & function 2012.
  52. Kraus C, Hahn A, Savli M, Kranz GS, Baldinger P, Höflich A, Spindelegger C, Ungersboeck J, Haeusler D, Mitterhauser M et al: Serotonin-1A receptor binding is positively associated with gray matter volume: A multimodal neuroimaging study combining PET and structural MRI. Neuroimage 2012, 63(3):1091-1098.
  53. Lanzenberger R, Baldinger P, Hahn A, Ungersboeck J, Mitterhauser M, Winkler D, Micskei Z, Stein P, Karanikas G, Wadsak W et al: Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET. Mol Psychiatry 2012.
  54. Lanzenberger R, Kranz GS, Haeusler D, Akimova E, Savli M, Hahn A, Mitterhauser M, Spindelegger C, Philippe C, Fink M et al: Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas. Neuroimage 2012, 63(2):874-881.
  55. Lauzurica N, Garcia-Garcia L, Fuentes JA, Delgado M: Hypophagia and induction of serotonin transporter gene expression in raphe nuclei of male and female rats after short-term fluoxetine treatment. Journal of physiology and biochemistry 2012.
  56. Lee W-Y, Wei H-J, Wang J-J, Lin K-J, Lin W-W, Chen D-Y, Huang C-C, Lee T-Y, Ma H-Y, Hwang S-M et al: Vascularization and restoration of heart function in rat myocardial infarction using transplantation of human cbMSC/HUVEC core-shell bodies. Biomaterials 2012, 33(7):2127-2136.
  57. Lehnert W, Gregoire M-C, Reilhac A, Meikle SR: Characterisation of partial volume effect and region-based correction in small animal positron emission tomography (PET) of the rat brain. Neuroimage 2012, 60(4):2144-2157.
  58. Leroy C, Karila L, Martinot J-L, Lukasiewicz M, Duchesnay E, Comtat C, Dollé F, Benyamina A, Artiges E, Ribeiro M-J et al: Striatal and extrastriatal dopamine transporter in cannabis and tobacco addiction: a high-resolution PET study. Addiction Biology 2012, 17(6):981-990.
  59. Lettfuss NY, Fischer K, Sossi V, Pichler BJ, von Ameln-Mayerhofer A: Imaging DA release in a rat model of L-DOPA-induced dyskinesias: A longitudinal in vivo PET investigation of the antidyskinetic effect of MDMA. Neuroimage 2012, 63(1):423-433.
  60. Li C-T, Hsieh J-C, Wang S-J, Yang B-H, Bai Y-M, Lin W-C, Lan C-C, Su T-P: Differential relations between fronto-limbic metabolism and executive function in patients with remitted bipolar I and bipolar II disorder. Bipolar Disorders 2012, 14(8):831-842.
  61. Lim HS, Kim SJ, Noh YH, Lee BC, Jin SJ, Park HS, Kim S, Jang IJ, Kim SE: Exploration of Optimal Dosing Regimens of Haloperidol, a D(2) Antagonist, via Modeling and Simulation Analysis in a D (2) Receptor Occupancy Study. Pharm Res 2012.
  62. Lin C-Y, Lin K-J, Li K-C, Sung L-Y, Hsueh S, Lu C-H, Chen G-Y, Chen C-L, Huang S-F, Yen T-C et al: Immune responses during healing of massive segmental femoral bone defects mediated by hybrid baculovirus-engineered ASCs. Biomaterials 2012, 33(30):7422-7434.
  63. Liu C-H, Wang H-M, Lin K-J, Kuo H-C, Weng Y-H, Shih T-S, Huang C-C: Long-term neurotoxic effects of dimethylamine borane intoxication. Journal of the Neurological Sciences 2012, 319(12):147-151.
  64. Lodge MA, Chaudhry MA, Wahl RL: Noise Considerations for PET Quantification Using Maximum and Peak Standardized Uptake Value. J Nucl Med 2012, 53(7):1041-1047.
  65. Lohith TG, Zoghbi SS, Morse CL, Araneta MF, Barth VN, Goebl NA, Tauscher JT, Pike VW, Innis RB, Fujita M: Brain and Whole-Body Imaging of Nociceptin/Orphanin FQ Peptide Receptor in Humans Using the PET Ligand 11C-NOP-1A. J Nucl Med 2012, 53(3):385-392.
  66. Lotfipour S, Mandelkern M, Alvarez-Estrada M, A LB: A Single Administration of Low-Dose Varenicline Saturates alpha4beta2(*) Nicotinic Acetylcholine Receptors in the Human Brain. Neuropsychopharmacology 2012.
  67. Manook A, Yousefi BH, Willuweit A, Platzer S, Reder S, Voss A, Huisman M, Settles M, Neff F, Velden J et al: Small-animal PET imaging of amyloid-beta plaques with [11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer’s disease. PLoS One 2012, 7(3):e31310.
  68. Martic-Kehl MI, Ametamey SM, Alf MF, Schubiger PA, Honer M: Impact of inherent variability and experimental parameters on the reliability of small animal PET data. EJNMMI research 2012, 2(1):26.
  69. Martin A, Gomez-Vallejo V, San Sebastian E, Padro D, Markuerkiaga I, Llarena I, Llop J: In vivo imaging of dopaminergic neurotransmission after transient focal ischemia in rats. J Cereb Blood Flow Metab 2012.
  70. Martin A, San Sebastian E, Gomez-Vallejo V, Llop J: Positron emission tomograghy with [13N]ammonia evidences long-term cerebral hyperperfusion after 2h-transient focal ischemia. Neuroscience 2012, 213(0):47-53.
  71. Martin-Moreno AM, Brera B, Spuch C, Carro E, Garcia-Garcia L, Delgado M, Pozo MA, Innamorato NG, Cuadrado A, de Ceballos ML: Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice. Journal of neuroinflammation 2012, 9:8.
  72. Mees G, Dierckx R, Mertens K, Vermeire S, Van Steenkiste M, Reutelingsperger C, D’Asseler Y, Peremans K, Van Damme N, Van de Wiele C: 99mTc-Labeled Tricarbonyl His-CNA35 as an Imaging Agent for the Detection of Tumor Vasculature. J Nucl Med 2012, 53(3):464-471.
  73. Menichetti L, Frijia F, Flori A, Wiesinger F, Lionetti V, Giovannetti G, Aquaro GD, Recchia FA, Ardenkjaer-Larsen JH, Santarelli MF et al: Assessment of real-time myocardial uptake and enzymatic conversion of hyperpolarized [1-(1)(3)C]pyruvate in pigs using slice selective magnetic resonance spectroscopy. Contrast media & molecular imaging 2012, 7(1):85-94.
  74. Mertens J, Dobbeleir A, Ham H, D’Asseler Y, Goethals I, Van de Wiele C: Standardized added metabolic activity (SAM): a partial volume independent marker of total lesion glycolysis in liver metastases. Eur J Nucl Med Mol Imaging 2012, 39(9):1441-1448.
  75. Michaelides M, Thanos PK, Kim R, Cho J, Ananth M, Wang G-J, Volkow ND: PET imaging predicts future body weight and cocaine preference. Neuroimage 2012, 59(2):1508-1513.
  76. Millet P, Moulin-Sallanon M, Tournier BB, Dumas N, Charnay Y, Ibanez V, Ginovart N: Quantification of dopamine D2/3 receptors in rat brain using factor analysis corrected [18F]Fallypride images. Neuroimage 2012, 62(3):1455-1468.
  77. Mishina M, Kimura Y, Naganawa M, Ishii K, Oda K, Sakata M, Toyohara J, Kobayashi S, Katayama Y, Ishiwata K: Differential effects of age on human striatal adenosine A1 and A2A receptors. Synapse 2012, 66(9):832-839.
  78. Müller U, Martic M, Kraljevic TG, Kristafor S, Ross TL, Ranadheera C, Müller A, Born M, Krämer SD, Raic-Malic S et al: Synthesis and evaluation of a C-6 alkylated pyrimidine derivative for the in vivo imaging of HSV1-TK gene expression. Nuclear Medicine and Biology 2012, 39(2):235-246.
  79. Nozaki T, Sugiyama K, Yagi S, Yoshikawa E, Kanno T, Asakawa T, Ito T, Terada T, Namba H, Ouchi Y: Effect of subthalamic nucleus stimulation during exercise on the mesolimbocortical dopaminergic region in Parkinson’s disease: a positron emission tomography study. J Cereb Blood Flow Metab 2012.
  80. Oboshi Y, Ouchi Y, Yagi S, Kono S, Nakai N, Yoshikawa E, Futatsubashi M, Terada T, Kim K, Harada K: In vivo mesolimbic D2/3 receptor binding predicts posttherapeutic clinical responses in restless legs syndrome: a positron emission tomography study. J Cereb Blood Flow Metab 2012.
  81. Odano I, Varrone A, Savic I, Ciumas C, Karlsson P, Jucaite A, Halldin C, Farde L: Quantitative PET analyses of regional [11C]PE2I binding to the dopamine transporter – Application to juvenile myoclonic epilepsy. Neuroimage 2012, 59(4):3582-3593.
  82. Ohba H, Harada N, Nishiyama S, Kakiuchi T, Kimura Y, Tsukada H: Feedback-controlled bolus plus infusion (FC-B/I) method for quantitative drug assessment in living brain with PET. J Cereb Blood Flow Metab 2012.
  83. Penheiter AR, Dingli D, Bender CE, Russell SJ, Carlson SK: Monitoring the initial delivery of an oncolytic measles virus encoding the human sodium iodide symporter to solid tumors using contrast-enhanced computed tomography. The Journal of Gene Medicine 2012, 14(9-10):590-597.
  84. Prior JO, Allenbach G, Valenta I, Kosinski M, Burger C, Verdun FR, Bischof Delaloye A, Kaufmann PA: Quantification of myocardial blood flow with 82Rb positron emission tomography: clinical validation with 15O-water. Eur J Nucl Med Mol Imaging 2012, 39(6):1037-1047.
  85. Quednow BB, Treyer V, Hasler F, Dörig N, Wyss MT, Burger C, Rentsch KM, Westera G, Schubiger PA, Buck A et al: Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography. Neuroimage 2012, 59(4):3922-3932.
  86. Reiner CS, Goetti R, Burger IA, Fischer MA, Frauenfelder T, Knuth A, Pfammatter T, Schaefer N, Alkadhi H: Liver Perfusion Imaging in Patients with Primary and Metastatic Liver Malignancy: Prospective Comparison between 99mTc-MAA SPECT and Dynamic CT Perfusion. Academic Radiology 2012, 19(5):613-621.
  87. Roy M, Nugent S, Tremblay-Mercier J, Tremblay Sb, Courchesne-Loyer A, Beaudoin J-Fo, Tremblay L, Descoteaux M, Lecomte R, Cunnane SC: The ketogenic diet increases brain glucose and ketone uptake in aged rats: A dual tracer PET and volumetric MRI study. Brain Research 2012, 1488(0):14-23.
  88. Samarin A, Burger C, Wollenweber SD, Crook DW, Burger IA, Schmid DT, von Schulthess GK, Kuhn FP: PET/MR imaging of bone lesions – implications for PET quantification from imperfect attenuation correction. Eur J Nucl Med Mol Imaging 2012, 39(7):1154-1160.
  89. Sasaki T, Ito H, Kimura Y, Arakawa R, Takano H, Seki C, Kodaka F, Fujie S, Takahata K, Nogami T et al: Quantification of Dopamine Transporter in Human Brain Using PET with 18F-FE-PE2I. J Nucl Med 2012, 53(7):1065-1073.
  90. Sasser TA, Chapman SE, Li S, Hudson C, Orton SP, Diener JM, Gammon ST, Correcher C, Leevy WM: Segmentation and measurement of fat volumes in murine obesity models using X-ray computed tomography. J Vis Exp 2012(62):e3680.
  91. Saulin A, Savli M, Lanzenberger R: Serotonin and molecular neuroimaging in humans using PET. Amino acids 2012, 42(6):2039-2057.
  92. Savli M, Bauer A, Mitterhauser M, Ding Y-S, Hahn A, Kroll T, Neumeister A, Haeusler D, Ungersboeck J, Henry S et al: Normative database of the serotonergic system in healthy subjects using multi-tracer PET. Neuroimage 2012, 63(1):447-459.
  93. Schain M, Toth M, Cselnyi Z, Stenkrona P, Halldin C, Farde L, Varrone A: Quantification of serotonin transporter availability with [11C]MADAM: A comparison between the ECAT HRRT and HR systems. Neuroimage 2012, 60(1):800-807.
  94. Schmid A, Schmitz J, Mannheim JG, Maier FC, Fuchs K, Wehrl HF, Pichler BJ: Feasibility of Sequential PET/MRI Using a State-of-the-Art Small Animal PET and a 1 T Benchtop MRI. Mol Imaging Biol 2012.
  95. Shimazawa M, Ito Y, Inokuchi Y, Yamanaka H, Nakanishi T, Hayashi T, Ji B, Higuchi M, Suhara T, Imamura K et al: An alteration in the lateral geniculate nucleus of experimental glaucoma monkeys: in vivo positron emission tomography imaging of glial activation. PLoS One 2012, 7(1):e30526.
  96. Shimizu K, Takashima T, Yamane T, Sasaki M, Kageyama H, Hashizume Y, Maeda K, Sugiyama Y, Watanabe Y, Senda M: Whole-body distribution and radiation dosimetry of [11C]telmisartan as a biomarker for hepatic organic anion transporting polypeptide (OATP) 1B3. Nuclear Medicine and Biology 2012, 39(6):847-853.
  97. Shingaki T, Takashima T, Wada Y, Tanaka M, Kataoka M, Ishii A, Shigihara Y, Sugiyama Y, Yamashita S, Watanabe Y: Imaging of gastrointestinal absorption and biodistribution of an orally administered probe using positron emission tomography in humans. Clin Pharmacol Ther 2012, 91(4):653-659.
  98. Simeon FG, Liow JS, Zhang Y, Hong J, Gladding RL, Zoghbi SS, Innis RB, Pike VW: Synthesis and characterization in monkey of [(11)C]SP203 as a radioligand for imaging brain metabotropic glutamate 5 receptors. Eur J Nucl Med Mol Imaging 2012, 39(12):1949-1958.
  99. Slomka PJ, Alexanderson E, Jacome R, Jimenez M, Romero E, Meave A, Le Meunier L, Dalhbom M, Berman DS, Germano G et al: Comparison of clinical tools for measurements of regional stress and rest myocardial blood flow assessed with 13N-ammonia PET/CT. J Nucl Med 2012, 53(2):171-181.
  100. Sorensen J, Owenius R, Lax M, Johansson S: Regional distribution and kinetics of [(18)F]fluciclovine (anti-[ (18)F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer. Eur J Nucl Med Mol Imaging 2012.
  101. Strauss LG, Koczan D, Seiz M, Tuettenberg J, Schmieder K, Pan L, Cheng C, Dimitrakopoulou-Strauss A: Correlation of the Ga-68-bombesin analog Ga-68-BZH3 with receptors expression in gliomas as measured by quantitative dynamic positron emission tomography (dPET) and gene arrays. Mol Imaging Biol 2012, 14(3):376-383.
  102. Sun A, Johansson S, Turesson I, Dayu A, Sörensen J: Imaging Tumor Perfusion and Oxidative Metabolism in Patients With Head-and-Neck Cancer Using 1- [11C]-Acetate PET During Radiotherapy: Preliminary Results. International Journal of Radiation Oncology*Biology*Physics 2012, 82(2):554-560.
  103. Suridjan I, Boileau I, Bagby M, Rusjan PM, Wilson AA, Houle S, Mizrahi R: Dopamine response to psychosocial stress in humans and its relationship to individual differences in personality traits. Journal of Psychiatric Research 2012, 46(7):890-897.
  104. Takahashi H, Fujie S, Camerer C, Arakawa R, Takano H, Kodaka F, Matsui H, Ideno T, Okubo S, Takemura K et al: Norepinephrine in the brain is associated with aversion to financial loss. Mol Psychiatry 2012.
  105. Takahata K, Ito H, Takano H, Arakawa R, Fujiwara H, Kimura Y, Kodaka F, Sasaki T, Nogami T, Suzuki M et al: Striatal and extrastriatal dopamine D(2) receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [(1)(1)C]raclopride and [(1)(1)C]FLB457. Psychopharmacology (Berl) 2012, 222(1):165-172.
  106. Takashima T, Kitamura S, Wada Y, Tanaka M, Shigihara Y, Ishii H, Ijuin R, Shiomi S, Nakae T, Watanabe Y et al: PET imaging-based evaluation of hepatobiliary transport in humans with (15R)-11C-TIC-Me. J Nucl Med 2012, 53(5):741-748.
  107. Tavares AAS, Jobson NK, Dewar D, Sutherland A, Pimlott SL, Batis J, Barret O, Seibyl J, Tamagnan G: Iodine-123 labeled reboxetine analogues for imaging of noradrenaline transporter in brain using single photon emission computed tomography. Synapse 2012, 66(11):923-930.
  108. Tian J, Smith MF, Ahmad G, Dilsizian V, Jimenez A, Dickfeld T: Integration of 3-dimensional scar models from SPECT to guide ventricular tachycardia ablation. J Nucl Med 2012, 53(6):894-901.
  109. Uchida H, Suzuki T, Graff-Guerrero A, Mulsant BH, Pollock BG, Arenovich T, Rajji TK, Mamo DC: Therapeutic Window for Striatal Dopamine D2/3 Receptor Occupancy in Older Patients With Schizophrenia: A Pilot PET Study. The American Journal of Geriatric Psychiatry 2012(0).
  110. van der Veen DR, Shao J, Chapman S, Leevy WM, Duffield GE: A diurnal rhythm in glucose uptake in brown adipose tissue revealed by in vivo PET-FDG imaging. Obesity (Silver Spring) 2012, 20(7):1527-1529.
  111. van der Veen DR, Shao J, Chapman S, Leevy WM, Duffield GE: A 24-hour temporal profile of in vivo brain and heart pet imaging reveals a nocturnal peak in brain 18F-fluorodeoxyglucose uptake. PLoS One 2012, 7(2):e31792.
  112. Vaquero JJ, Gao DW, Garcia-Villaba C, Bacharach S, Vanbrocklin H, Fang Q, Desco M, Lee R, Dae M: Approach to assessing myocardial perfusion in rats using static [13N]-ammonia images and a small-animal PET. Mol Imaging Biol 2012, 14(5):541-545.
  113. Varrone A, Gulyas B, Takano A, Stabin MG, Jonsson C, Halldin C: Simplified quantification and whole-body distribution of [18F]FE-PE2I in nonhuman primates: prediction for human studies. Nuclear Medicine and Biology 2012, 39(2):295-303.
  114. Vats D, Wang H, Esterhazy D, Dikaiou K, Danzer C, Honer M, Stuker F, Matile H, Migliorini C, Fischer E et al: Multimodal imaging of pancreatic beta cells in vivo by targeting transmembrane protein 27 (TMEM27). Diabetologia 2012, 55(9):2407-2416.
  115. Vincenti GM, Ambrosio G, Hyacinthe JN, Quercioli A, Seimbille Y, Mach F, Ratib O, Vallee JP, Schindler TH: Matching between regional coronary vasodilator capacity and corresponding circumferential strain in individuals with normal and increasing body weight. J Nucl Cardiol 2012, 19(4):693-703.
  116. Winkeler A, Boisgard R, Awde AR, Dubois A, Theze B, Zheng J, Ciobanu L, Dolle F, Viel T, Jacobs AH et al: The translocator protein ligand [(18)F]DPA-714 images glioma and activated microglia in vivo. Eur J Nucl Med Mol Imaging 2012.
  117. Yamasaki T, Fujinaga M, Maeda J, Kawamura K, Yui J, Hatori A, Yoshida Y, Nagai Y, Tokunaga M, Higuchi M et al: Imaging for metabotropic glutamate receptor subtype 1 in rat and monkey brains using PET with [(18)F]FITM. Eur J Nucl Med Mol Imaging 2012, 39(4):632-641.
  118. Yashio K, Katayama Y, Takashima T, Ishiguro N, Doi H, Suzuki M, Wada Y, Tamai I, Watanabe Y: Synthesis of [11C]uric acid, using [11C]phosgene, as a possible biomarker in PET imaging for diagnosis of gout. Bioorganic & Medicinal Chemistry Letters 2012, 22(1):115-119.
  119. Yeh C-B, Chou Y-H, Cheng C-Y, Lee M-S, Wang J-J, Lee C-H, Shiue C-Y, Su T-P, Huang W-S: Reproducibility of brain dopamine transporter binding with Tc-99m TRODAT-1 SPECT in healthy young men. Psychiatry Research: Neuroimaging 2012, 201(3):222-225.
  120. Zanotti-Fregonara P, Maroy R, Peyronneau MA, Trebossen R, Bottlaender M: Minimally invasive input function for 2-(18)F-fluoro-A-85380 brain PET studies. Eur J Nucl Med Mol Imaging 2012, 39(4):651-659.
  121. Zhang Y, Fox GB: PET imaging for receptor occupancy: meditations on calculation and simplification. Journal of Biomedical Research 2012, 26(2):69-76.
2011
  1. Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, Hiemeyer F, Wittemer-Rump SM, Seibyl J, Reininger C et al: Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet neurology 2011, 10(5):424-435.
  2. Barthel H, Luthardt J, Becker G, Patt M, Hammerstein E, Hartwig K, Eggers B, Sattler B, Schildan A, Hesse S et al: Individualized quantification of brain beta-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls. Eur J Nucl Med Mol Imaging 2011, 38(9):1702-1714.
  3. Bouquet W, Deleye S, Staelens S, De Smet L, Van Damme N, Debergh I, Ceelen WP, De Vos F, Remon JP, Vervaet C: Antitumour efficacy of two paclitaxel formulations for hyperthermic intraperitoneal chemotherapy (HIPEC) in an in vivo rat model. Pharm Res 2011, 28(7):1653-1660.
  4. Chauveau F, Boutin H, Van Camp N, Thominiaux C, Hantraye P, Rivron L, Marguet F, Castel MN, Rooney T, Benavides J et al: In vivo imaging of neuroinflammation in the rodent brain with [11C]SSR180575, a novel indoleacetamide radioligand of the translocator protein (18 kDa). Eur J Nucl Med Mol Imaging 2011, 38(3):509-514.
  5. Chen PS, Yeh TL, Lee IH, Lin CB, Tsai HC, Chen KC, Chiu N-T, Yao WJ, Yang YK, Chou Y-H: Effects of C825T polymorphism of the GNB3 gene on availability of dopamine transporter in healthy volunteers — A SPECT study. Neuroimage 2011, In Press, Corrected Proof.
  6. Constantinescu CC, Coleman RA, Pan ML, Mukherjee J: Striatal and extrastriatal microPET imaging of D2/D3 dopamine receptors in rat brain with [(1)(8)F]fallypride and [(1)(8)F]desmethoxyfallypride. Synapse 2011, 65(8):778-787.
  7. Deuther-Conrad W, Fischer S, Hiller A, Becker G, Cumming P, Xiong G, Funke U, Sabri O, Peters D, Brust P: Assessment of alpha7 nicotinic acetylcholine receptor availability in juvenile pig brain with [(1)F]NS10743. Eur J Nucl Med Mol Imaging 2011, 38(8):1541-1549.
  8. Dickstein LP, Zoghbi SS, Fujimura Y, Imaizumi M, Zhang Y, Pike VW, Innis RB, Fujita M: Comparison of 18F- and 11C-labeled aryloxyanilide analogs to measure translocator protein in human brain using positron emission tomography. Eur J Nucl Med Mol Imaging 2011, 38(2):352-357.
  9. Ettrup A, Hansen M, Santini MA, Paine J, Gillings N, Palner M, Lehel S, Herth MM, Madsen J, Kristensen J et al: Radiosynthesis and in vivo evaluation of a series of substituted (11)C-phenethylamines as 5-HT (2A) agonist PET tracers. Eur J Nucl Med Mol Imaging 2011, 38(4):681-693.
  10. Ettrup A, Mikkelsen JD, Lehel S, Madsen J, Nielsen EO, Palner M, Timmermann DB, Peters D, Knudsen GM: 11C-NS14492 as a novel PET radioligand for imaging cerebral alpha7 nicotinic acetylcholine receptors: in vivo evaluation and drug occupancy measurements. J Nucl Med 2011, 52(9):1449-1456.
  11. Finnema SJ, Varrone A, Hwang TJ, Halldin C, Farde L: Confirmation of fenfluramine effect on 5-HT(1B) receptor binding of [(11)C]AZ10419369 using an equilibrium approach. J Cereb Blood Flow Metab 2011.
  12. Fischer K, Sossi V, Schmid A, Thunemann M, Maier FC, Judenhofer MS, Mannheim JG, Reischl G, Pichler BJ: Noninvasive nuclear imaging enables the in vivo quantification of striatal dopamine receptor expression and raclopride affinity in mice. J Nucl Med 2011, 52(7):1133-1141.
  13. Garcia A, Mirbolooki MR, Constantinescu C, Pan M-L, Sevrioukov E, Milne N, Wang PH, Lakey J, Chandy KG, Mukherjee J: 18F-Fallypride PET of Pancreatic Islets: In Vitro and In Vivo Rodent Studies. Journal of Nuclear Medicine 2011, 52(7):1125-1132.
  14. Gould RW, Gage HD, Banks ML, Blaylock BL, Czoty PW, Nader MA: Differential effects of cocaine and MDMA self-administration on cortical serotonin transporter availability in monkeys. Neuropharmacology 2011, 61(1-2):245-251.
  15. Guenther T, Schönknecht P, Becker G, Olbrich S, Sander C, Hesse S, Meyer PM, Luthardt J, Hegerl U, Sabri O: Impact of EEG-vigilance on brain glucose uptake measured with [18F]FDG and PET in patients with depressive episode or mild cognitive impairment. Neuroimage 2011, 56(1):93-101.
  16. Haerle SK, Fischer DR, Schmid DT, Ahmad N, Huber GF, Buck A: 18F-FET PET/CT in advanced head and neck squamous cell carcinoma: an intra-individual comparison with 18F-FDG PET/CT. Mol Imaging Biol 2011, 13(5):1036-1042.
  17. Hanin FX, Pauwels S, Bol A, Melis M, Breeman W, de Jong M, Jamar F: Effect of interferon-alpha treatment on [68Ga-DOTA,Tyr3,Thre8]octreotide uptake in CA20948 tumors: a small-animal PET study. J Nucl Med 2011, 52(4):580-585.
  18. Herholz K, Westwood S, Haense C, Dunn G: Evaluation of a Calibrated 18F-FDG PET Score as a Biomarker for Progression in Alzheimer Disease and Mild Cognitive Impairment. Journal of Nuclear Medicine 2011, 52(8):1218-1226.
  19. Hines CS, Liow JS, Zanotti-Fregonara P, Hirvonen J, Morse C, Pike VW, Innis RB: Human biodistribution and dosimetry of (1)(1)C-CUMI-101, an agonist radioligand for serotonin-1a receptors in brain. PLoS One 2011, 6(9):e25309.
  20. Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C, Pike VW, Volkow ND, Huestis MA, Innis RB: Reversible and regionally selective downregulation of brain cannabinoid CB(1) receptors in chronic daily cannabis smokers. Mol Psychiatry 2011.
  21. Hoekzema E, Rojas S, Herance R, Pareto D, Abad S, Jimenez X, Figueiras FP, Popota F, Ruiz A, Flotats N et al: [(11)C]-DASB microPET imaging in the aged rat: frontal and meso-thalamic increases in serotonin transporter binding. Exp Gerontol 2011, 46(12):1020-1025.
  22. Huang CL, Wu YW, Wang SS, Tseng CD, Chiang FT, Hsu KL, Lee CM, Tzen KY: Continuous intravenous infusion of prostaglandin E1 improves myocardial perfusion reserve in patients with ischemic heart disease assessed by positron emission tomography: a pilot study. Ann Nucl Med 2011, 25(7):462-468.
  23. Kambe T, Motoi Y, Inoue R, Kojima N, Tada N, Kimura T, Sahara N, Yamashita S, Mizoroki T, Takashima A et al: Differential regional distribution of phosphorylated tau and synapse loss in the nucleus accumbens in tauopathy model mice. Neurobiology of Disease 2011, 42(3):404-414.
  24. Kemerink GJ, Visser MG, Franssen R, Beijer E, Zamburlini M, Halders SG, Brans B, Mottaghy FM, Teule GJ: Effect of the positron range of 18F, 68Ga and 124I on PET/CT in lung-equivalent materials. Eur J Nucl Med Mol Imaging 2011, 38(5):940-948.
  25. Kendziorra K, Wolf H, Meyer PM, Barthel H, Hesse S, Becker GA, Luthardt J, Schildan A, Patt M, Sorger D et al: Decreased cerebral alpha4beta2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer’s disease assessed with positron emission tomography. Eur J Nucl Med Mol Imaging 2011, 38(3):515-525.
  26. Kimura Y, Fujita M, Hong J, Lohith TG, Gladding RL, Zoghbi SS, Tauscher JA, Goebl N, Rash KS, Chen Z et al: Brain and Whole-Body Imaging in Rhesus Monkeys of 11C-NOP-1A, a Promising PET Radioligand for Nociceptin/Orphanin FQ Peptide Receptors. Journal of Nuclear Medicine 2011, 52(10):1638-1645.
  27. Kupers R, Frokjaer VG, Erritzoe D, Naert A, Budtz-Joergensen E, Nielsen FA, Kehlet H, Knudsen GM: Serotonin transporter binding in the hypothalamus correlates negatively with tonic heat pain ratings in healthy subjects: A [11C]DASB PET study. Neuroimage 2011, 54(2):1336-1343.
  28. Kurland BF, Peterson LM, Lee JH, Linden HM, Schubert EK, Dunnwald LK, Link JM, Krohn KA, Mankoff DA: Between-Patient and Within-Patient (Site-to-Site) Variability in Estrogen Receptor Binding, Measured In Vivo by 18F-Fluoroestradiol PET. Journal of Nuclear Medicine 2011, 52(10):1541-1549.
  29. la Fougère C, Grant S, Kostikov A, Schirrmacher R, Gravel P, Schipper HM, Reader A, Evans A, Thiel A: Where in-vivo imaging meets cytoarchitectonics: The relationship between cortical thickness and neuronal density measured with high-resolution [18F]flumazenil-PET. Neuroimage 2011, 56(3):951-960.
  30. Lambert B, Sturm E, Mertens J, Oltenfreiter R, Smeets P, Troisi R, Van Vlierberghe H, Defreyne L: Intra-arterial treatment with (90)Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital. Eur J Nucl Med Mol Imaging 2011, 38(12):2117-2124.
  31. Lin K-J, Lin W-Y, Hsieh C-J, Weng Y-H, Wey S-P, Lu C-S, Skovronsky D, Yen T-C, Chang C-J, Kung M-P et al: Optimal scanning time window for 18F-FP-(+)-DTBZ (18F-AV-133) summed uptake measurements. Nuclear Medicine and Biology 2011, 38(8):1149-1155.
  32. Lu P-L, Chen Y-C, Ou T-W, Chen H-H, Tsai H-C, Wen C-J, Lo C-L, Wey S-P, Lin K-J, Yen T-C et al: Multifunctional hollow nanoparticles based on graft-diblock copolymers for doxorubicin delivery. Biomaterials 2011, 32(8):2213-2221.
  33. Luquin MR, Manrique M, Guillan J, Arbizu J, Ordonez C, Marcilla I: Enhanced GDNF expression in dopaminergic cells of monkeys grafted with carotid body cell aggregates. Brain Research 2011, 1375(0):120-127.
  34. Madsen K, Erritzoe D, Mortensen EL, Gade A, Madsen J, Baare W, Knudsen GM, Hasselbalch SG: Cognitive function is related to fronto-striatal serotonin transporter levels–a brain PET study in young healthy subjects. Psychopharmacology (Berl) 2011, 213(2-3):573-581.
  35. Madsen K, Haahr MT, Marner L, Keller SH, Baare WF, Svarer C, Hasselbalch SG, Knudsen GM: Age and sex effects on 5-HT(4) receptors in the human brain: a [(11)C]SB207145 PET study. J Cereb Blood Flow Metab 2011.
  36. Madsen K, Marner L, Haahr M, Gillings N, Knudsen GM: Mass dose effects and in vivo affinity in brain PET receptor studies: a study of cerebral 5-HT4 receptor binding with [11C]SB207145. Nuclear Medicine and Biology 2011, 38(8):1085-1091.
  37. Madsen K, Neumann WJ, Holst K, Marner L, Haahr MT, Lehel S, Knudsen GM, Hasselbalch SG: Cerebral serotonin 4 receptors and amyloid-beta in early Alzheimer’s disease. J Alzheimers Dis 2011, 26(3):457-466.
  38. Maftei C-A, Shi K, Bayer C, Astner ST, Vaupel P: Comparison of (immuno-)fluorescence data with serial [18F]Fmiso PET/CT imaging for assessment of chronic and acute hypoxia in head and neck cancers. Radiotherapy and Oncology 2011, 99(3):412-417.
  39. Mancuso M, Orsucci D, Volterrani D, Siciliano G: Cognitive impairment and McArdle disease: Is there a link? Neuromuscular Disorders 2011, 21(5):356-358.
  40. Marner L, Knudsen GM, Madsen K, Holm S, Baare W, Hasselbalch SG: The reduction of baseline serotonin 2A receptors in mild cognitive impairment is stable at two-year follow-up. J Alzheimers Dis 2011, 23(3):453-459.
  41. Meyer PT, Hellwig S, Amtage F, Rottenburger C, Sahm U, Reuland P, Weber WA, Hüll M: Dual-Biomarker Imaging of Regional Cerebral Amyloid Load and Neuronal Activity in Dementia with PET and 11C-Labeled Pittsburgh Compound B. Journal of Nuclear Medicine 2011, 52(3):393-400.
  42. Mirbolooki MR, Constantinescu CC, Pan ML, Mukherjee J: Quantitative assessment of brown adipose tissue metabolic activity and volume using 18F-FDG PET/CT and β3-adrenergic receptor activation. EJNMMI research 2011, 1(1):30.
  43. Murphy FA, Poland CA, Duffin R, Al-Jamal KT, Ali-Boucetta H, Nunes A, Byrne F, Prina-Mello A, Volkov Y, Li S et al: Length-Dependent Retention of Carbon Nanotubes in the Pleural Space of Mice Initiates Sustained Inflammation and Progressive Fibrosis on the Parietal Pleura. The American Journal of Pathology 2011, 178(6):2587-2600.
  44. Nguyen H-N, Wey S-P, Juang J-H, Sonaje K, Ho Y-C, Chuang E-Y, Hsu C-W, Yen T-C, Lin K-J, Sung H-W: The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo. Biomaterials 2011, 32(10):2673-2682.
  45. Nkoulou R, Pazhenkottil AP, Kuest SM, Ghadri JR, Wolfrum M, Husmann L, Fiechter M, Buechel RR, Herzog BA, Koepfli P et al: Semiconductor Detectors Allow Low-Dose-Low-Dose 1-Day SPECT Myocardial Perfusion Imaging. Journal of Nuclear Medicine 2011, 52(8):1204-1209.
  46. Oh U, Fujita M, Ikonomidou VN, Evangelou IE, Matsuura E, Harberts E, Fujimura Y, Richert ND, Ohayon J, Pike VW et al: Translocator protein PET imaging for glial activation in multiple sclerosis. J Neuroimmune Pharmacol 2011, 6(3):354-361.
  47. Olivotto I, Girolami F, Sciagra R, Ackerman MJ, Sotgia B, Bos JM, Nistri S, Sgalambro A, Grifoni C, Torricelli F et al: Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. J Am Coll Cardiol 2011, 58(8):839-848.
  48. Penheiter AR, Griesmann GE, Federspiel MJ, Dingli D, Russell SJ, Carlson SK: Pinhole micro-SPECT/CT for noninvasive monitoring and quantitation of oncolytic virus dispersion and percent infection in solid tumors. Gene Ther 2011.
  49. Platt B, Drever B, Koss D, Stoppelkamp S, Jyoti A, Plano A, Utan A, Merrick G, Ryan D, Melis V et al: Abnormal cognition, sleep, EEG and brain metabolism in a novel knock-in Alzheimer mouse, PLB1. PLoS One 2011, 6(11):e27068.
  50. Rojas S, Martin A, Pareto D, Herance JR, Abad S, Ruiz A, Flotats N, Gispert JD, Llop J, Gomez-Vallejo V et al: Positron emission tomography with 11C-flumazenil in the rat shows preservation of binding sites during the acute phase after 2h-transient focal ischemia. Neuroscience 2011, 182(0):208-216.
  51. Rusjan PM, Wilson AA, Bloomfield PM, Vitcu I, Meyer JH, Houle S, Mizrahi R: Quantitation of translocator protein binding in human brain with the novel radioligand [18F]-FEPPA and positron emission tomography. J Cereb Blood Flow Metab 2011, 31(8):1807-1816.
  52. Shukuri M, Takashima-Hirano M, Tokuda K, Takashima T, Matsumura K, Inoue O, Doi H, Suzuki M, Watanabe Y, Onoe H: In Vivo Expression of Cyclooxygenase-1 in Activated Microglia and Macrophages During Neuroinflammation Visualized by PET with 11C-Ketoprofen Methyl Ester. Journal of Nuclear Medicine 2011, 52(7):1094-1101.
  53. Sobrado M, Delgado M, Fernandez-Valle E, Garcia-Garcia L, Torres M, Sanchez-Prieto J, Vivancos J, Manzanares R, Moro MA, Pozo MA et al: Longitudinal studies of ischemic penumbra by using 18F-FDG PET and MRI techniques in permanent and transient focal cerebral ischemia in rats. Neuroimage 2011, 57(1):45-54.
  54. Sonaje K, Lin K-J, Tseng MT, Wey S-P, Su F-Y, Chuang E-Y, Hsu C-W, Chen C-T, Sung H-W: Effects of chitosan-nanoparticle-mediated tight junction opening on the oral absorption of endotoxins. Biomaterials 2011, 32(33):8712-8721.
  55. Spreckelmeyer KN, Paulzen M, Raptis M, Baltus T, Schaffrath S, Van Waesberghe J, Zalewski MM, Rösch F, Vernaleken I, Schäfer WM et al: Opiate-Induced Dopamine Release Is Modulated by Severity of Alcohol Dependence: An [18F]Fallypride Positron Emission Tomography Study. Biological Psychiatry 2011, 70(8):770-776.
  56. Stahl AR, Heusner TA, Hartung V, Nagarajah J, Bockisch A, Hahn S, Antoch G, Jentzen W: Time Course of Tumor SUV in 18F-FDG PET of Breast Cancer: Presentation of a Simple Model Using a Single Reference Point for Time Corrections of Tumor SUVs. Journal of Nuclear Medicine 2011, 52(1):18-23.
  57. Strauss LG, Pan L, Cheng C, Haberkorn U, Dimitrakopoulou-Strauss A: Shortened acquisition protocols for the quantitative assessment of the 2-tissue-compartment model using dynamic PET/CT 18F-FDG studies. J Nucl Med 2011, 52(3):379-385.
  58. Stuart CA, Ross IR, Howell MEA, McCurry MP, Wood TG, Ceci JD, Kennel SJ, Wall J: Brain glucose transporter (Glut3) haploinsufficiency does not impair mouse brain glucose uptake. Brain Research 2011, 1384:15-22.
  59. Takahashi K, Yamagishi G, Hiramatsu T, Hosoya A, Onoe K, Doi H, Nagata H, Wada Y, Onoe H, Watanabe Y et al: Practical synthesis of precursor of [N-methyl-11C]vorozole, an efficient PET tracer targeting aromatase in the brain. Bioorganic & Medicinal Chemistry 2011, 19(4):1464-1470.
  60. Takashima T, Yokoyama C, Mizuma H, Yamanaka H, Wada Y, Onoe K, Nagata H, Tazawa S, Doi H, Takahashi K et al: Developmental Changes in P-Glycoprotein Function in the Blood-Brain Barrier of Nonhuman Primates: PET Study with R-11C-Verapamil and 11C-Oseltamivir. Journal of Nuclear Medicine 2011, 52(6):950-957.
  61. Takashima-Hirano M, Takashima T, Katayama Y, Wada Y, Sugiyama Y, Watanabe Y, Doi H, Suzuki M: Efficient sequential synthesis of PET Probes of the COX-2 inhibitor [11C]celecoxib and its major metabolite [11C]SC-62807 and in vivo PET evaluation. Bioorganic & Medicinal Chemistry 2011, 19(9):2997-3004.
  62. Tseng J-H, Ouyang C-H, Lin K-J, Yeh T-S: Significance of Insulin Signaling in Liver Regeneration Triggered by Portal Vein Ligation. Journal of Surgical Research 2011, 166(1):77-86.
  63. Tsukada H, Ohba H, Nishiyama S, Kakiuchi T: Differential effects of stress on [(1)(1)C]raclopride and [(1)(1)C]MNPA binding to striatal D/D dopamine receptors: a PET study in conscious monkeys. Synapse 2011, 65(1):84-89.
  64. van Rij CM, Sharkey RM, Goldenberg DM, Frielink C, Molkenboer JDM, Franssen GM, van Weerden WM, Oyen WJG, Boerman OC: Imaging of Prostate Cancer with Immuno-PET and Immuno-SPECT Using a Radiolabeled Anti-EGP-1 Monoclonal Antibody. Journal of Nuclear Medicine 2011, 52(10):1601-1607.
  65. Vandeputte C, Evens N, Toelen J, Deroose CM, Bosier B, Ibrahimi A, Van der Perren A, Gijsbers R, Janssen P, Lambert DM et al: A PET Brain Reporter Gene System Based on Type 2 Cannabinoid Receptors. Journal of Nuclear Medicine 2011, 52(7):1102-1109.
  66. Vangestel C, Van de Wiele C, Van Damme N, Staelens S, Pauwels P, Reutelingsperger CPM, Peeters M: 99mTc-(CO)3 His-Annexin A5 Micro-SPECT Demonstrates Increased Cell Death by Irinotecan During the Vascular Normalization Window Caused by Bevacizumab. Journal of Nuclear Medicine 2011, 52(11):1786-1794.
  67. Varnas K, Nyberg S, Halldin C, Varrone A, Takano A, Karlsson P, Andersson J, McCarthy D, Smith M, Pierson ME et al: Quantitative analysis of [(11)C]AZ10419369 binding to 5-HT(1B) receptors in human brain. J Cereb Blood Flow Metab 2011, 31(1):113-123.
  68. Varrone A, Stepanov V, Nakao R, Toth M, Gulyas B, Emond P, Deloye JB, Vercouillie J, Stabin MG, Jonsson C et al: Imaging of the striatal and extrastriatal dopamine transporter with (18)F-LBT-999: quantification, biodistribution, and radiation dosimetry in nonhuman primates. J Nucl Med 2011, 52(8):1313-1321.
  69. Varrone A, Toth M, Steiger C, Takano A, Guilloteau D, Ichise M, Gulyas B, Halldin C: Kinetic Analysis and Quantification of the Dopamine Transporter in the Nonhuman Primate Brain with 11C-PE2I and 18F-FE-PE2I. Journal of Nuclear Medicine 2011, 52(1):132-139.
  70. Viertl D, Bischof Delaloye A, Lanz B, Poitry-Yamate C, Gruetter R, Mlynarik V, Ametamey SM, Ross TL, Lehr HA, Andre PA et al: Increase of [(18)F]FLT Tumor Uptake In Vivo Mediated by FdUrd: Toward Improving Cell Proliferation Positron Emission Tomography. Mol Imaging Biol 2011, 13(2):321-331.
  71. Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, O’Keefe G, Ackerman U, Tochon-Danguy H, Chan JG et al: Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 2011, 52(8):1210-1217.
  72. von Forstner C, Zuhayra M, Ammerpohl O, Zhao Y, Tiwari S, Jansen O, Kalthoff H, Henze E, Egberts J-H: Expression of L amino acid transport system 1 and analysis of iodine-123-methyltyrosine tumor uptake in a pancreatic xenotransplantation model using fused high-resolution-micro-SPECT-MRI. Hepatobiliary; Pancreatic Diseases International 2011, 10(1):30-37.
  73. Wang TC, Hsiao IT, Cheng YK, Wey SP, Yen TC, Lin KJ: Noninvasive monitoring of tumor growth in a rat glioma model: comparison between neurological assessment and animal imaging. J Neurooncol 2011, 104(3):669-678.
  74. Waterval JJ, Van Dongen TM, Stokroos RJ, Teule JG, Kemerink GJ, Brans B, Nieman FH, Manni JJ: Bone metabolic activity in hyperostosis cranialis interna measured with 18F-fluoride PET. Eur J Nucl Med Mol Imaging 2011, 38(5):884-893.
  75. Yamashita S, Takashima T, Kataoka M, Oh H, Sakuma S, Takahashi M, Suzuki N, Hayashinaka E, Wada Y, Cui Y et al: PET imaging of the gastrointestinal absorption of orally administered drugs in conscious and anesthetized rats. J Nucl Med 2011, 52(2):249-256.
  76. Yokokura M, Mori N, Yagi S, Yoshikawa E, Kikuchi M, Yoshihara Y, Wakuda T, Sugihara G, Takebayashi K, Suda S et al: In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2011, 38(2):343-351.
  77. Yui J, Hatori A, Kawamura K, Yanamoto K, Yamasaki T, Ogawa M, Yoshida Y, Kumata K, Fujinaga M, Nengaki N et al: Visualization of early infarction in rat brain after ischemia using a translocator protein (18 kDa) PET ligand [11C]DAC with ultra-high specific activity. Neuroimage 2011, 54(1):123-130.
  78. Zanotti-Fregonara P, Liow JS, Fujita M, Dusch E, Zoghbi SS, Luong E, Boellaard R, Pike VW, Comtat C, Innis RB: Image-derived input function for human brain using high resolution PET imaging with [C](R)-rolipram and [C]PBR28. PLoS One 2011, 6(2):e17056.
  79. Zanotti-Fregonara P, Zoghbi SS, Liow J-S, Luong E, Boellaard R, Gladding RL, Pike VW, Innis RB, Fujita M: Kinetic analysis in human brain of [11C](R)-rolipram, a positron emission tomographic radioligand to image phosphodiesterase 4: A retest study and use of an image-derived input function. Neuroimage 2011, 54(3):1903-1909.
2010
  1. Alexanderson E, Ochoa JM, Calleja R, Juarez-Rojas JG, Prior JO, Jacome R, Romero E, Meave A, Posadas-Romero C: Endothelial Dysfunction in Systemic Lupus Erythematosus: Evaluation with 13N-Ammonia PET. J Nucl Med 2010, 51(12):1927-1931.
  2. Andersson JD, Varnas K, Cselenyi Z, Gulyas B, Wensbo D, Finnema SJ, Swahn BM, Svensson S, Nyberg S, Farde L et al: Radiosynthesis of the candidate beta-amyloid radioligand [(11)C]AZD2184: Positron emission tomography examination and metabolite analysis in cynomolgus monkeys. Synapse 2010, 64(10):733-741.
  3. Assem-Hilger E, Lanzenberger R, Savli M, Wadsak W, Mitterhauser M, Mien L-K, Stögmann E, Baumgartner C, Kletter K, Asenbaum S: Central serotonin 1A receptor binding in temporal lobe epilepsy: A [carbonyl-11C]WAY-100635 PET study. Epilepsy & Behavior 2010, 19(3):467-473.
  4. Baumann CA, Mu L, Wertli N, Kramer SD, Honer M, Schubiger PA, Ametamey SM: Syntheses and pharmacological characterization of novel thiazole derivatives as potential mGluR5 PET ligands. Bioorg Med Chem 2010.
  5. Biegon A, Kim SW, Logan J, Hooker JM, Muench L, Fowler JS: Nicotine blocks brain estrogen synthase (aromatase): in vivo positron emission tomography studies in female baboons. Biol Psychiatry 2010, 67(8):774-777.
  6. Blesa J, Juri C, Collantes M, Penuelas I, Prieto E, Iglesias E, Marti-Climent J, Arbizu J, Zubieta JL, Rodriguez-Oroz MC et al: Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An (18)F-DOPA and (11)C-DTBZ PET study. Neurobiol Dis 2010, 38(3):456-463.
  7. Burger C, Deschwanden A, Ametamey S, Johayem A, Mancosu B, Wyss M, Hasler G, Buck A: Evaluation of a bolus/infusion protocol for 11C-ABP688, a PET tracer for mGluR5. Nuclear Medicine and Biology 2010, 37(7):845-851.
  8. Burkhard N, Herzog BA, Husmann L, Pazhenkottil AP, Burger IA, Buechel RR, Valenta I, Wyss CA, Kaufmann PA: Coronary calcium score scans for attenuation correction of quantitative PET/CT (13)N-ammonia myocardial perfusion imaging. Eur J Nucl Med Mol Imaging 2010, 37(3):517-521.
  9. Casteels C, Bormans G, Van Laere K: The effect of anaesthesia on [(18)F]MK-9470 binding to the type 1 cannabinoid receptor in the rat brain. Eur J Nucl Med Mol Imaging 2010, 37(6):1164-1173.
  10. Casteels C, Martinez E, Bormans G, Camon L, de Vera N, Baekelandt V, Planas AM, Van Laere K: Type 1 cannabinoid receptor mapping with [18F]MK-9470 PET in the rat brain after quinolinic acid lesion: a comparison to dopamine receptors and glucose metabolism. Eur J Nucl Med Mol Imaging 2010, 37(12):2354-2363.
  11. Celen S, Koole M, De Angelis M, Sannen I, Chitneni SK, Alcazar J, Dedeurwaerdere S, Moechars D, Schmidt M, Verbruggen A et al: Preclinical evaluation of 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain. J Nucl Med 2010, 51(10):1584-1591.
  12. Christian N, Deheneffe S, Bol A, De Bast M, Labar D, Lee JA, Grégoire V: Is 18F-FDG a surrogate tracer to measure tumor hypoxia? Comparison with the hypoxic tracer 14C-EF3 in animal tumor models. Radiotherapy and Oncology 2010, 97(2):183-188.
  13. De Bruyne S, La Regina G, Staelens S, Wyffels L, Deleye S, Silvestri R, De Vos F: Radiosynthesis and in vivo evaluation of [11C]-labelled pyrrole-2-carboxamide derivates as novel radioligands for PET imaging of monoamine oxidase A. Nucl Med Biol 2010, 37(4):459-467.
  14. Dimitrakopoulou-Strauss A, Strauss LG, Egerer G, Vasamiliette J, Schmitt T, Haberkorn U, Kasper B: Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis. Eur J Nucl Med Mol Imaging 2010, 37(8):1481-1489.
  15. Doot RK, Muzi M, Peterson LM, Schubert EK, Gralow JR, Specht JM, Mankoff DA: Kinetic Analysis of 18F-Fluoride PET Images of Breast Cancer Bone Metastases. J Nucl Med 2010.
  16. Dukart J, Mueller K, Horstmann A, Vogt B, Frisch S, Barthel H, Becker G, Moller HE, Villringer A, Sabri O et al: Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies. Neuroimage 2010, 49(2):1490-1495.
  17. Elmenhorst D, Minuzzi L, Aliaga A, Rowley J, Massarweh G, Diksic M, Bauer A, Rosa-Neto P: In vivo and in vitro validation of reference tissue models for the mGluR(5) ligand [(11)C]ABP688. J Cereb Blood Flow Metab 2010, 30(8):1538-1549.
  18. Erritzoe D, Frokjaer VG, Haahr MT, Kalbitzer J, Svarer C, Holst KK, Hansen DL, Jernigan TL, Lehel S, Knudsen GM: Cerebral serotonin transporter binding is inversely related to body mass index. Neuroimage 2010.
  19. Ettrup A, Palner M, Gillings N, Santini MA, Hansen M, Kornum BR, Rasmussen LK, Nagren K, Madsen J, Begtrup M et al: Radiosynthesis and evaluation of 11C-CIMBI-5 as a 5-HT2A receptor agonist radioligand for PET. J Nucl Med 2010, 51(11):1763-1770.
  20. Eyal S, Ke B, Muzi M, Link JM, Mankoff DA, Collier AC, Unadkat JD: Regional P-glycoprotein activity and inhibition at the human blood-brain barrier as imaged by positron emission tomography. Clin Pharmacol Ther 2010, 87(5):579-585.
  21. Fujimura Y, Kimura Y, Simeon FG, Dickstein LP, Pike VW, Innis RB, Fujita M: Biodistribution and radiation dosimetry in humans of a new PET ligand, (18)F-PBR06, to image translocator protein (18 kDa). J Nucl Med 2010, 51(1):145-149.
  22. Goffin K, Van Paesschen W, Dupont P, Baete K, Palmini A, Nuyts J, Van Laere K: Anatomy-based reconstruction of FDG-PET images with implicit partial volume correction improves detection of hypometabolic regions in patients with epilepsy due to focal cortical dysplasia diagnosed on MRI. Eur J Nucl Med Mol Imaging 2010, 37(6):1148-1155.
  23. Goldbecker A, Buchert R, Berding G, Bokemeyer M, Lichtinghagen R, Wilke F, Ahl B, Weissenborn K: Blood-brain barrier permeability for ammonia in patients with different grades of liver fibrosis is not different from healthy controls. J Cereb Blood Flow Metab 2010, 30(7):1384-1393.
  24. Hanin FX, Pauwels S, Bol A, Breeman W, de Jong M, Jamar F: Tumor uptake of (68)Ga-DOTA-Tyr(3)-octreotate: animal PET studies of tumor flow and acute somatostatin receptor modulation in the CA20948 rat model. Nucl Med Biol 2010, 37(2):157-165.
  25. Heusner TA, Kuemmel S, Koeninger A, Hamami ME, Hahn S, Quinsten A, Bockisch A, Forsting M, Lauenstein T, Antoch G et al: Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging 2010, 37(6):1077-1086.
  26. Hoekzema E, Herance R, Rojas S, Pareto D, Abad S, Jiménez X, Figueiras FP, Popota F, Ruiz A, Torrent È et al: The effects of aging on dopaminergic neurotransmission: a microPET study of [11C]-raclopride binding in the aged rodent brain. Neuroscience 2010, 171(4):1283-1286.
  27. Hooker JM, Kim SW, Reibel AT, Alexoff D, Xu Y, Shea C: Evaluation of [11C]metergoline as a PET radiotracer for 5HTR in nonhuman primates. Bioorganic & Medicinal Chemistry 2010, 18(22):7739-7745.
  28. Hsiao IT, Lin KJ, Chang SI, Yen TC, Chen TC, Yeh TS: Impaired liver regeneration of steatotic rats after portal vein ligation: a particular emphasis on (99m)Tc-DISIDA scintigraphy and adiponectin signaling. J Hepatol 2010, 52(4):540-549.
  29. Huang YY, Ma KH, Tseng TW, Chou TK, Ng H, Mirsalis JC, Fu YK, Chu TC, Huang WS, Shiue CY: Biodistribution, toxicity and radiation dosimetry studies of the serotonin transporter radioligand 4-[(18)F]-ADAM in rats and monkeys. Eur J Nucl Med Mol Imaging 2010, 37(3):545-555.
  30. Ichise M, Harris PE: Imaging of beta-cell mass and function. J Nucl Med 2010, 51(7):1001-1004.
  31. Inabnet WB, Milone L, Harris P, Durak E, Freeby MJ, Ahmed L, Sebastian M, Lifante JC, Bessler M, Korner J: The utility of [(11)C] dihydrotetrabenazine positron emission tomography scanning in assessing beta-cell performance after sleeve gastrectomy and duodenal-jejunal bypass. Surgery 2010, 147(2):303-309.
  32. Janssen MH, Ollers MC, van Stiphout RG, Buijsen J, van den Bogaard J, de Ruysscher D, Lambin P, Lammering G: Evaluation of early metabolic responses in rectal cancer during combined radiochemotherapy or radiotherapy alone: sequential FDG-PET-CT findings. Radiother Oncol 2010, 94(2):151-155.
  33. Janssen MH, Ollers MC, van Stiphout RG, Riedl RG, van den Bogaard J, Buijsen J, Lambin P, Lammering G: Blood glucose level normalization and accurate timing improves the accuracy of PET-based treatment response predictions in rectal cancer. Radiother Oncol 2010, 95(2):203-208.
  34. Kalbitzer J, Erritzoe D, Holst KK, Nielsen FA, Marner L, Lehel S, Arentzen T, Jernigan TL, Knudsen GM: Seasonal changes in brain serotonin transporter binding in short serotonin transporter linked polymorphic region-allele carriers but not in long-allele homozygotes. Biol Psychiatry 2010, 67(11):1033-1039.
  35. Kasper B, Dimitrakopoulou-Strauss A, Strauss LG, Hohenberger P: Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib. Eur J Nucl Med Mol Imaging 2010, 37(10):1876-1882.
  36. Kawamura K, Naganawa M, Konno F, Yui J, Wakizaka H, Yamasaki T, Yanamoto K, Hatori A, Takei M, Yoshida Y et al: Imaging of I2-imidazoline receptors by small-animal PET using 2-(3-fluoro-[4-11C]tolyl)-4,5-dihydro-1H-imidazole ([11C]FTIMD). Nucl Med Biol 2010, 37(5):625-635.
  37. Kimura Y, Simeon FG, Hatazawa J, Mozley PD, Pike VW, Innis RB, Fujita M: Biodistribution and radiation dosimetry of a positron emission tomographic ligand, 18F-SP203, to image metabotropic glutamate subtype 5 receptors in humans. Eur J Nucl Med Mol Imaging 2010, 37(10):1943-1949.
  38. Kreisl WC, Fujita M, Fujimura Y, Kimura N, Jenko KJ, Kannan P, Hong J, Morse CL, Zoghbi SS, Gladding RL et al: Comparison of [(11)C]-(R)-PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker. Neuroimage 2010, 49(4):2924-2932.
  39. Kreisl WC, Liow JS, Kimura N, Seneca N, Zoghbi SS, Morse CL, Herscovitch P, Pike VW, Innis RB: P-Glycoprotein Function at the Blood-Brain Barrier in Humans Can Be Quantified with the Substrate Radiotracer 11C-N-Desmethyl-Loperamide. J Nucl Med 2010.
  40. Kuntner C, Bankstahl JP, Bankstahl M, Stanek J, Wanek T, Stundner G, Karch R, Brauner R, Meier M, Ding X et al: Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. Eur J Nucl Med Mol Imaging 2010, 37(5):942-953.
  41. la Fougere C, Boning G, Bartmann H, Wangler B, Nowak S, Just T, Wagner E, Winter P, Rominger A, Forster S et al: Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: effects of the novel P-glycoprotein inhibitor tariquidar. Neuroimage 2010, 49(2):1406-1415.
  42. Lambert B, Mertens J, Sturm EJ, Stienaers S, Defreyne L, D’Asseler Y: 99mTc-labelled macroaggregated albumin (MAA) scintigraphy for planning treatment with 90Y microspheres. Eur J Nucl Med Mol Imaging 2010, 37(12):2328-2333.
  43. Lauzurica N, Garcia-Garcia L, Pinto S, Fuentes JA, Delgado M: Changes in NPY and POMC, but not serotonin transporter, following a restricted feeding/repletion protocol in rats. Brain Res 2010, 1313:103-112.
  44. Lee PW, Hsu SH, Wang JJ, Tsai JS, Lin KJ, Wey SP, Chen FR, Lai CH, Yen TC, Sung HW: The characteristics, biodistribution, magnetic resonance imaging and biodegradability of superparamagnetic core-shell nanoparticles. Biomaterials 2010, 31(6):1316-1324.
  45. Lin CY, Chang YH, Lin KJ, Yen TC, Tai CL, Chen CY, Lo WH, Hsiao IT, Hu YC: The healing of critical-sized femoral segmental bone defects in rabbits using baculovirus-engineered mesenchymal stem cells. Biomaterials 2010.
  46. Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, Skovronsky D, Wai YY, Chang HP, Lo CW, Yao CH et al: Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent–a pilot study. Nucl Med Biol 2010, 37(4):497-508.
  47. Marner L, Frokjaer VG, Kalbitzer J, Lehel S, Madsen K, Baare WF, Knudsen GM, Hasselbalch SG: Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer’s disease: a combined [(11)C]DASB and [(18)F]altanserin-PET study. Neurobiol Aging 2010.
  48. Marner L, Gillings N, Madsen K, Erritzoe D, Baare WF, Svarer C, Hasselbalch SG, Knudsen GM: Brain imaging of serotonin 4 receptors in humans with [11C]SB207145-PET. Neuroimage 2010, 50(3):855-861.
  49. Mathe D, Balogh L, Polyak A, Kiraly R, Marian T, Pawlak D, Zaknun JJ, Pillai MR, Janoki GA: Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of (177)Lu-EDTMP, a potential bone pain palliation agent. Nucl Med Biol 2010, 37(2):215-226.
  50. Matsumoto R, Ichise M, Ito H, Ando T, Takahashi H, Ikoma Y, Kosaka J, Arakawa R, Fujimura Y, Ota M et al: Reduced serotonin transporter binding in the insular cortex in patients with obsessive-compulsive disorder: a [11C]DASB PET study. Neuroimage 2010, 49(1):121-126.
  51. Merron A, Baril P, Martin-Duque P, de la Vieja A, Tran L, Briat A, Harrington KJ, McNeish IA, Vassaux G: Assessment of the Na/I symporter as a reporter gene to visualize oncolytic adenovirus propagation in peritoneal tumours. Eur J Nucl Med Mol Imaging 2010, 37(7):1377-1385.
  52. Meyer PT, Bhagwagar Z, Cowen PJ, Cunningham VJ, Grasby PM, Hinz R: Simplified quantification of 5-HT2A receptors in the human brain with [11C]MDL 100,907 PET and non-invasive kinetic analyses. Neuroimage 2010, 50(3):984-993.
  53. Miyoshi M, Shinotoh H, Wszolek ZK, Strongosky AJ, Shimada H, Arakawa R, Higuchi M, Ikoma Y, Yasuno F, Fukushi K et al: In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers: A PET and MRI study. Parkinsonism Relat Disord 2010, 16(6):404-408.
  54. Mizuma H, Shukuri M, Hayashi T, Watanabe Y, Onoe H: Establishment of in vivo brain imaging method in conscious mice. J Nucl Med 2010, 51(7):1068-1075.
  55. Okamura N, Villemagne VL, Drago J, Pejoska S, Dhamija RK, Mulligan RS, Ellis JR, Ackermann U, O’Keefe G, Jones G et al: In vivo measurement of vesicular monoamine transporter type 2 density in parkinson disease with (18)F-AV-133. J Nucl Med 2010, 51(2):223-228.
  56. Prinsen K, Li J, Vanbilloen H, Vermaelen P, Devos E, Mortelmans L, Bormans G, Ni Y, Verbruggen A: Development and evaluation of a 68Ga labeled pamoic acid derivative for in vivo visualization of necrosis using positron emission tomography. Bioorg Med Chem 2010, 18(14):5274-5281.
  57. Rominger A, Mille E, Zhang S, Boning G, Forster S, Nowak S, Gildehaus FJ, Wangler B, Bartenstein P, Cumming P: Validation of the octamouse for simultaneous 18F-fallypride small-animal PET recordings from 8 mice. J Nucl Med 2010, 51(10):1576-1583.
  58. Rommel D, Abarca-Quinones J, Bol A, Peeters F, Lhommel R, Lonneux M, Labar D, Gregoire V, Duprez T: Early monitoring of external radiation therapy by [18F]-fluoromethylcholine positron emission tomography and 3-T proton magnetic resonance spectroscopy: an experimental study in a rodent rhabdomyosarcoma model. Nucl Med Biol 2010, 37(5):645-653.
  59. Saba W, Valette H, Peyronneau MA, Bramoulle Y, Coulon C, Curet O, George P, Dolle F, Bottlaender M: [(11)C]SL25.1188, a new reversible radioligand to study the monoamine oxidase type B with PET: preclinical characterisation in nonhuman primate. Synapse 2010, 64(1):61-69.
  60. Shi K, Souvatzoglou M, Astner ST, Vaupel P, Nusslin F, Wilkens JJ, Ziegler SI: Quantitative assessment of hypoxia kinetic models by a cross-study of dynamic 18F-FAZA and 15O-H2O in patients with head and neck tumors. J Nucl Med 2010, 51(9):1386-1394.
  61. Skinbjerg M, Liow JS, Seneca N, Hong J, Lu S, Thorsell A, Heilig M, Pike VW, Halldin C, Sibley DR et al: D2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: a PET study in a receptor internalization-deficient mouse model. Neuroimage 2010, 50(4):1402-1407.
  62. Sonaje K, Lin KJ, Wey SP, Lin CK, Yeh TH, Nguyen HN, Hsu CW, Yen TC, Juang JH, Sung HW: Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: Oral delivery using pH-Responsive nanoparticles vs. subcutaneous injection. Biomaterials 2010, 31(26):6849-6858.
  63. Sonaje K, Lin K-J, Wey S-P, Lin C-K, Yeh T-H, Nguyen H-N, Hsu C-W, Yen T-C, Juang J-H, Sung H-W: Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: Oral delivery using pH-Responsive nanoparticles vs. subcutaneous injection. Biomaterials 2010, 31(26):6849-6858.
  64. Spinelli S, Chefer S, Carson RE, Jagoda E, Lang L, Heilig M, Barr CS, Suomi SJ, Higley JD, Stein EA: Effects of Early-Life Stress on Serotonin(1A) Receptors in Juvenile Rhesus Monkeys Measured by Positron Emission Tomography. Biol Psychiatry 2010.
  65. Teragawa H, Morita K, Shishido H, Otsuka N, Hirokawa Y, Chayama K, Tamaki N, Kihara Y: Impaired myocardial blood flow reserve in subjects with metabolic syndrome analyzed using positron emission tomography and N-13 labeled ammonia. Eur J Nucl Med Mol Imaging 2010, 37(2):368-376.
  66. Terry GE, Hirvonen J, Liow JS, Seneca N, Tauscher JT, Schaus JM, Phebus L, Felder CC, Morse CL, Pike VW et al: Biodistribution and dosimetry in humans of two inverse agonists to image cannabinoid CB1 receptors using positron emission tomography. Eur J Nucl Med Mol Imaging 2010, 37(8):1499-1506.
  67. Valenta I, Quercioli A, Vincenti G, Nkoulou R, Dewarrat S, Rager O, Zaidi H, Seimbille Y, Mach F, Ratib O et al: Structural epicardial disease and microvascular function are determinants of an abnormal longitudinal myocardial blood flow difference in cardiovascular risk individuals as determined with PET/CT. J Nucl Cardiol 2010, 17(6):1023-1033.
  68. Van Camp N, Boisgard R, Kuhnast B, Theze B, Viel T, Gregoire MC, Chauveau F, Boutin H, Katsifis A, Dolle F et al: In vivo imaging of neuroinflammation: a comparative study between [(18)F]PBR111, [ (11)C]CLINME and [ (11)C]PK11195 in an acute rodent model. Eur J Nucl Med Mol Imaging 2010, 37(5):962-972.
  69. Van Laere K, Clerinx K, D’Hondt E, de Groot T, Vandenberghe W: Combined Striatal Binding and Cerebral Influx Analysis of Dynamic 11C-Raclopride PET Improves Early Differentiation Between Multiple-System Atrophy and Parkinson Disease. J Nucl Med 2010.
  70. Verjans J, Wolters S, Laufer W, Schellings M, Lax M, Lovhaug D, Boersma H, Kemerink G, Schalla S, Gordon P et al: Early molecular imaging of interstitial changes in patients after myocardial infarction: comparison with delayed contrast-enhanced magnetic resonance imaging. J Nucl Cardiol 2010, 17(6):1065-1072.
  71. Wenzel F, Young S, Wilke F, Apostolova I, Arlt S, Jahn H, Thiele F, Buchert R: B-spline-based stereotactical normalization of brain FDG PET scans in suspected neurodegenerative disease: impact on voxel-based statistical single-subject analysis. Neuroimage 2010, 50(3):994-1003.
  72. Wu YW, Chen YH, Wang SS, Jui HY, Yen RF, Tzen KY, Chen MF, Lee CM: PET assessment of myocardial perfusion reserve inversely correlates with intravascular ultrasound findings in angiographically normal cardiac transplant recipients. J Nucl Med 2010, 51(6):906-912.
  73. Yao J, Wang C, Walsh SA, Hu S, Sawatzke AB, Dang D, Segar JL, Ponto LL, Sunderland JJ, Norris AW: Localized fetomaternal hyperglycemia: spatial and kinetic definition by positron emission tomography. PLoS One 2010, 5(8):e12027.
  74. Yui J, Maeda J, Kumata K, Kawamura K, Yanamoto K, Hatori A, Yamasaki T, Nengaki N, Higuchi M, Zhang MR: 18F-FEAC and 18F-FEDAC: PET of the Monkey Brain and Imaging of Translocator Protein (18 kDa) in the Infarcted Rat Brain. J Nucl Med 2010, 51(8):1301-1309.
  75. Ziebell M, Holm-Hansen S, Thomsen G, Wagner A, Jensen P, Pinborg LH, Knudsen GM: Serotonin Transporters in Dopamine Transporter Imaging: A Head-to-Head Comparison of Dopamine Transporter SPECT Radioligands 123I-FP-CIT and 123I-PE2I. J Nucl Med 2010, 51(12):1885-1891.
2009
  1. Arakawa R, Ichimiya T, Ito H, Takano A, Okumura M, Takahashi H, Takano H, Yasuno F, Kato M, Okubo Y et al: Increase in thalamic binding of [(11)C]PE2I in patients with schizophrenia: a positron emission tomography study of dopamine transporter. J Psychiatr Res 2009, 43(15):1219-1223.
  2. Backes H, Ullrich R, Neumaier B, Kracht L, Wienhard K, Jacobs AH: Noninvasive quantification of (18)F-FLT human brain PET for the assessment of tumour proliferation in patients with high-grade glioma. Eur J Nucl Med Mol Imaging 2009.
  3. Bauer M, Karch R, Neumann F, Wagner CC, Kletter K, Muller M, Loscher W, Zeitlinger M, Langer O: Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier. J Cereb Blood Flow Metab 2009.
  4. Ceccarini G, Flavell RR, Butelman ER, Synan M, Willnow TE, Bar-Dagan M, Goldsmith SJ, Kreek MJ, Kothari P, Vallabhajosula S et al: PET imaging of leptin biodistribution and metabolism in rodents and primates. Cell Metab 2009, 10(2):148-159.
  5. Chauveau F, Van Camp N, Dolle F, Kuhnast B, Hinnen F, Damont A, Boutin H, James M, Kassiou M, Tavitian B: Comparative Evaluation of the Translocator Protein Radioligands 11C-DPA-713, 18F-DPA-714, and 11C-PK11195 in a Rat Model of Acute Neuroinflammation. J Nucl Med 2009, 50(3):468-476.
  6. Cho SS, Strafella AP: rTMS of the left dorsolateral prefrontal cortex modulates dopamine release in the ipsilateral anterior cingulate cortex and orbitofrontal cortex. PLoS One 2009, 4(8):e6725.
  7. Choi SJ, Kim SY, Kim SJ, Lee JS, Lee SJ, Park SA, Yun SC, Im KC, Oh SJ, Kim SW et al: Reproducibility of the kinetic analysis of 3′-deoxy-3′-[(18)F]fluorothymidine positron emission tomography in mouse tumor models. Nucl Med Biol 2009, 36(7):711-719.
  8. Christian N, Lee JA, Bol A, De Bast M, Jordan B, Gregoire V: The limitation of PET imaging for biological adaptive-IMRT assessed in animal models. Radiother Oncol 2009, 91(1):101-106.
  9. Collantes M, Prieto E, Penuelas I, Blesa J, Juri C, Marti-Climent JM, Quincoces G, Arbizu J, Riverol M, Zubieta JL et al: New MRI, 18F-DOPA and 11C-(+)-alpha-dihydrotetrabenazine templates for Macaca fascicularis neuroimaging: advantages to improve PET quantification. Neuroimage 2009, 47(2):533-539.
  10. Cui Y, Takashima T, Takashima-Hirano M, Wada Y, Shukuri M, Tamura Y, Doi H, Onoe H, Kataoka Y, Watanabe Y: 11C-PK11195 PET for the in vivo evaluation of neuroinflammation in the rat brain after cortical spreading depression. J Nucl Med 2009, 50(11):1904-1911.
  11. Eyal S, Chung FS, Muzi M, Link JM, Mankoff DA, Kaddoumi A, O’Sullivan F, Hebert MF, Unadkat JD: Simultaneous PET Imaging of P-Glycoprotein Inhibition in Multiple Tissues in the Pregnant Nonhuman Primate. J Nucl Med 2009, 50(5):798-806.
  12. Fink M, Wadsak W, Savli M, Stein P, Moser U, Hahn A, Mien LK, Kletter K, Mitterhauser M, Kasper S et al: Lateralization of the serotonin-1A receptor distribution in language areas revealed by PET. Neuroimage 2009, 45(2):598-605.
  13. Frokjaer VG, Vinberg M, Erritzoe D, Svarer C, Baare W, Budtz-Joergensen E, Madsen K, Madsen J, Kessing LV, Knudsen GM: High familial risk for mood disorder is associated with low dorsolateral prefrontal cortex serotonin transporter binding. NeuroImage 2009, 46(2):360-366.
  14. Fujimura Y, Zoghbi SS, Simeon FG, Taku A, Pike VW, Innis RB, Fujita M: Quantification of Translocator Protein (18 kDa) in the Human Brain with PET and a Novel Radioligand, 18F-PBR06. J Nucl Med 2009.
  15. Goffin K, Paesschen WV, Dupont P, Laere KV: Longitudinal microPET imaging of brain glucose metabolism in rat lithium-pilocarpine model of epilepsy. Exp Neurol 2009, 217(1):205-209.
  16. Goland R, Freeby M, Parsey R, Saisho Y, Kumar D, Simpson N, Hirsch J, Prince M, Maffei A, Mann JJ et al: 11C-Dihydrotetrabenazine PET of the Pancreas in Subjects with Long-Standing Type 1 Diabetes and in Healthy Controls. J Nucl Med 2009, 50(3):382-389.
  17. Goldstein DS, Holmes C, Sewell L, Kopin IJ: Hypertension Increases Cerebral 6-18F-Fluorodopa-Derived Radioactivity. J Nucl Med 2009, 50(9):1479-1482.
  18. Goldstein DS, Sewell L: Olfactory dysfunction in pure autonomic failure: Implications for the pathogenesis of Lewy body diseases. Parkinsonism Relat Disord 2009, 15(7):516-520.
  19. Grimmer T, Riemenschneider M, Forstl H, Henriksen G, Klunk WE, Mathis CA, Shiga T, Wester HJ, Kurz A, Drzezga A: Beta amyloid in Alzheimer’s disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 2009, 65(11):927-934.
  20. Haense C, Herholz K, Jagust WJ, Heiss WD: Performance of FDG PET for detection of Alzheimer’s disease in two independent multicentre samples (NEST-DD and ADNI). Dement Geriatr Cogn Disord 2009, 28(3):259-266.
  21. Hautzel H, Mottaghy FM, Specht K, Muller HW, Krause BJ: Evidence of a modality-dependent role of the cerebellum in working memory? An fMRI study comparing verbal and abstract n-back tasks. NeuroImage 2009, 47(4):2073-2082.
  22. Henriques de Figueiredo B, Barret O, Demeaux H, Lagarde P, De-Mones-Del-Pujol E, Kantor G, de Clermont-Gallerande H, Richaud P, Fernandez P: Comparison between CT- and FDG-PET-defined target volumes for radiotherapy planning in head-and-neck cancers. Radiother Oncol 2009, 93(3):479-482.
  23. Herzog BA, Husmann L, Valenta I, Gaemperli O, Siegrist PT, Tay FM, Burkhard N, Wyss CA, Kaufmann PA: Long-term prognostic value of 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. J Am Coll Cardiol 2009, 54(2):150-156.
  24. Hiraoka K, Okamura N, Funaki Y, Watanuki S, Tashiro M, Kato M, Hayashi A, Hosokai Y, Yamasaki H, Fujii T et al: Quantitative analysis of donepezil binding to acetylcholinesterase using positron emission tomography and [5-(11)C-methoxy]donepezil. NeuroImage 2009, 46(3):616-623.
  25. Horigome M, Kumazaki S, Hattori N, Kasai H, Aizawa K, Izawa A, Tomita T, Tsutsui H, Koyama J, Sakurai S et al: Noninvasive evaluation of coronary endothelial function following sirolimus-eluting stent implantation by using positron emission tomography. Cardiology 2009, 114(3):157-163.
  26. Itoh T, Abe K, Zoghbi SS, Inoue O, Hong J, Imaizumi M, Pike VW, Innis RB, Fujita M: PET Measurement of the In Vivo Affinity of 11C-(R)-Rolipram and the Density of Its Target, Phosphodiesterase-4, in the Brains of Conscious and Anesthetized Rats. J Nucl Med 2009, 50(5):749-756.
  27. Kalbitzer J, Frokjaer VG, Erritzoe D, Svarer C, Cumming P, Nielsen FA, Hashemi SH, Baare WF, Madsen J, Hasselbalch SG et al: The personality trait openness is related to cerebral 5-HTT levels. Neuroimage 2009, 45(2):280-285.
  28. Kempen DH, Yaszemski MJ, Heijink A, Hefferan TE, Creemers LB, Britson J, Maran A, Classic KL, Dhert WJ, Lu L: Non-invasive monitoring of BMP-2 retention and bone formation in composites for bone tissue engineering using SPECT/CT and scintillation probes. Journal of controlled release : official journal of the Controlled Release Society 2009, 134(3):169-176.
  29. Kim SW, Biegon A, Katsamanis ZE, Ehrlich CW, Hooker JM, Shea C, Muench L, Xu Y, King P, Carter P et al: Reinvestigation of the synthesis and evaluation of [N-methyl-(11)C]vorozole, a radiotracer targeting cytochrome P450 aromatase. Nucl Med Biol 2009, 36(3):323-334.
  30. Knesaurek K, Machac J, Zhang Z: Repeatability of regional myocardial blood flow calculation in 82Rb PET imaging. BMC Med Phys 2009, 9:2.
  31. Koole M, Lewis DM, Buckley C, Nelissen N, Vandenbulcke M, Brooks DJ, Vandenberghe R, Van Laere K: Whole-Body Biodistribution and Radiation Dosimetry of 18F-GE067: A Radioligand for In Vivo Brain Amyloid Imaging. J Nucl Med 2009, 50(5):818-822.
  32. la Fougere C, Boning G, Bartmann H, Wangler B, Nowak S, Just T, Wagner E, Winter P, Rominger A, Forster S et al: Uptake and binding of the serotonin 5-HT(1A) antagonist [(18)F]-MPPF in brain of rats: Effects of the novel P-glycoprotein inhibitor tariquidar. Neuroimage 2009.
  33. Le Foll B, Chefer SI, Kimes AS, Shumway D, Stein EA, Mukhin AG, Goldberg SR: Baseline expression of alpha4beta2* nicotinic acetylcholine receptors predicts motivation to self-administer nicotine. Biol Psychiatry 2009, 65(8):714-716.
  34. Lin KJ, Liao CH, Hsiao IT, Yen TC, Chen TC, Jan YY, Chen MF, Yeh TS: Improved hepatocyte function of future liver remnant of cirrhotic rats after portal vein ligation: a bonus other than volume shifting. Surgery 2009, 145(2):202-211.
  35. Lin KJ, Liu HL, Hsu PH, Chung YH, Huang WC, Chen JC, Wey SP, Yen TC, Hsiao IT: Quantitative micro-SPECT/CT for detecting focused ultrasound-induced blood-brain barrier opening in the rat. Nucl Med Biol 2009, 36(7):853-861.
  36. Liow JS, Kreisl W, Zoghbi SS, Lazarova N, Seneca N, Gladding RL, Taku A, Herscovitch P, Pike VW, Innis RB: P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys. J Nucl Med 2009, 50(1):108-115.
  37. Liu N, Li M, Li X, Meng X, Yang G, Zhao S, Yang Y, Ma L, Fu Z, Yu J: PET-Based Biodistribution and Radiation Dosimetry of Epidermal Growth Factor Receptor-Selective Tracer 11C-PD153035 in Humans. J Nucl Med 2009, 50(2):303-308.
  38. Lucatelli C, Honer M, Salazar JF, Ross TL, Schubiger PA, Ametamey SM: Synthesis, radiolabeling, in vitro and in vivo evaluation of [18F]-FPECMO as a positron emission tomography radioligand for imaging the metabotropic glutamate receptor subtype 5. Nucl Med Biol 2009, 36(6):613-622.
  39. Martin A, Boisgard R, Theze B, Van Camp N, Kuhnast B, Damont A, Kassiou M, Dolle F, Tavitian B: Evaluation of the PBR/TSPO radioligand [(18)F]DPA-714 in a rat model of focal cerebral ischemia. J Cereb Blood Flow Metab 2009.
  40. Menda Y, Boles Ponto LL, Dornfeld KJ, Tewson TJ, Watkins GL, Schultz MK, Sunderland JJ, Graham MM, Buatti JM: Kinetic Analysis of 3′-Deoxy-3′-18F-Fluorothymidine (18F-FLT) in Head and Neck Cancer Patients Before and Early After Initiation of Chemoradiation Therapy. J Nucl Med 2009.
  41. Miyoshi M, Ito H, Arakawa R, Takahashi H, Takano H, Higuchi M, Okumura M, Otsuka T, Kodaka F, Sekine M et al: Quantitative Analysis of Peripheral Benzodiazepine Receptor in the Human Brain Using PET with 11C-AC-5216. J Nucl Med 2009.
  42. Muzi M, Mankoff DA, Link JM, Shoner S, Collier AC, Sasongko L, Unadkat JD: Imaging of Cyclosporine Inhibition of P-Glycoprotein Activity Using 11C-Verapamil in the Brain: Studies of Healthy Humans. J Nucl Med 2009, 50(8):1267-1275.
  43. Namdar M, Schepis T, Koepfli P, Gaemperli O, Siegrist PT, Grathwohl R, Valenta I, Delaloye R, Klainguti M, Wyss CA et al: Caffeine impairs myocardial blood flow response to physical exercise in patients with coronary artery disease as well as in age-matched controls. PLoS One 2009, 4(5):e5665.
  44. Odano I, Halldin C, Karlsson P, Varrone A, Airaksinen AJ, Krasikova RN, Farde L: [18F]flumazenil binding to central benzodiazepine receptor studies by PET–quantitative analysis and comparisons with [11C]flumazenil. NeuroImage 2009, 45(3):891-902.
  45. Otsuka T, Ito H, Halldin C, Takahashi H, Takano H, Arakawa R, Okumura M, Kodaka F, Miyoshi M, Sekine M et al: Quantitative PET Analysis of the Dopamine D2 Receptor Agonist Radioligand 11C-(R)-2-CH3O-N-n-Propylnorapomorphine in the Human Brain. J Nucl Med 2009, 50(5):703-710.
  46. Price SJ, Fryer TD, Cleij MC, Dean AF, Joseph J, Salvador R, Wang DD, Hutchinson PJ, Clark JC, Burnet NG et al: Imaging regional variation of cellular proliferation in gliomas using 3′-deoxy-3′-[18F]fluorothymidine positron-emission tomography: an image-guided biopsy study. Clin Radiol 2009, 64(1):52-63.
  47. Ribeiro MJ, Thobois S, Lohmann E, du Montcel ST, Lesage S, Pelissolo A, Dubois B, Mallet L, Pollak P, Agid Y et al: A Multitracer Dopaminergic PET Study of Young-Onset Parkinsonian Patients With and Without Parkin Gene Mutations. J Nucl Med 2009, 50(8):1244-1250.
  48. Sciagra R, Sotgia B, Olivotto I, Cecchi F, Nistri S, Camici PG, Pupi A: Relationship between atrial fibrillation and blunted hyperemic myocardial blood flow in patients with hypertrophic cardiomyopathy. J Nucl Cardiol 2009, 16(1):92-96.
  49. Seneca N, Zoghbi SS, Liow JS, Kreisl W, Herscovitch P, Jenko K, Gladding RL, Taku A, Pike VW, Innis RB: Human Brain Imaging and Radiation Dosimetry of 11C-N-Desmethyl-Loperamide, a PET Radiotracer to Measure the Function of P-Glycoprotein. J Nucl Med 2009, 50(5):807-813.
  50. Sosabowski JK, Matzow T, Foster JM, Finucane C, Ellison D, Watson SA, Mather SJ: Targeting of CCK-2 receptor-expressing tumors using a radiolabeled divalent gastrin peptide. J Nucl Med 2009, 50(12):2082-2089.
  51. Takano A, Gulyas B, Varrone A, Halldin C: Comparative evaluations of norepinephrine transporter radioligands with reference tissue models in rhesus monkeys: (S,S)-[18F]FMeNER-D2 and (S,S)-[11C]MeNER. Eur J Nucl Med Mol Imaging 2009, 36(11):1892-1895.
  52. Takano A, Gulyas B, Varrone A, Maguire RP, Halldin C: Saturated norepinephrine transporter occupancy by atomoxetine relevant to clinical doses: a rhesus monkey study with (S,S)-[(18)F]FMeNER-D (2). Eur J Nucl Med Mol Imaging 2009, 36(8):1308-1314.
  53. Tantawy MN, Jones CK, Baldwin RM, Ansari MS, Conn PJ, Kessler RM, Peterson TE: [(18)F]Fallypride dopamine D2 receptor studies using delayed microPET scans and a modified Logan plot. Nucl Med Biol 2009, 36(8):931-940.
  54. Terry GE, Hirvonen J, Liow JS, Zoghbi SS, Gladding R, Tauscher JT, Schaus JM, Phebus L, Felder CC, Morse CL et al: Imaging and Quantitation of Cannabinoid CB1 Receptors in Human and Monkey Brains Using 18F-Labeled Inverse Agonist Radioligands. J Nucl Med 2009.
  55. Terry GE, Liow JS, Zoghbi SS, Hirvonen J, Farris AG, Lerner A, Tauscher JT, Schaus JM, Phebus L, Felder CC et al: Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand. Neuroimage 2009, 48(2):362-370.
  56. Valette H, Xiao Y, Peyronneau MA, Damont A, Kozikowski AP, Wei ZL, Kassiou M, Kellar KJ, Dolle F, Bottlaender M: 18F-ZW-104: A New Radioligand for Imaging Neuronal Nicotinic Acetylcholine Receptors–In Vitro Binding Properties and PET Studies in Baboons. J Nucl Med 2009, 50(8):1349-1355.
  57. Varrone A, Sjoholm N, Eriksson L, Gulyas B, Halldin C, Farde L: Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging 2009, 36(10):1639-1650.
  58. Visigalli I, Moresco RM, Belloli S, Politi LS, Gritti A, Ungaro D, Matarrese M, Turolla E, Falini A, Scotti G et al: Monitoring disease evolution and treatment response in lysosomal disorders by the peripheral benzodiazepine receptor ligand PK11195. Neurobiol Dis 2009, 34(1):51-62.
  59. Wyss MT, Obrist NM, Haiss F, Eckert R, Stanley R, Burger C, Buck A, Weber B: A beta-scintillator for surface measurements of radiotracer kinetics in the intact rodent cortex. NeuroImage 2009, 48(2):339-347.
  60. Yamato M, Kataoka Y, Mizuma H, Wada Y, Watanabe Y: PET and Macro- and Microautoradiographic Studies Combined with Immunohistochemistry for Monitoring Rat Intestinal Ulceration and Healing Processes. J Nucl Med 2009, 50(2):266-273.
2008
  1. Arakawa R, Okumura M, Ito H, Seki C, Takahashi H, Takano H, Nakao R, Suzuki K, Okubo Y, Halldin C et al: Quantitative Analysis of Norepinephrine Transporter in the Human Brain Using PET with (S,S)-18F-FMeNER-D2. J Nucl Med 2008, 49(8):1270-1276.
  2. Barret O, Mazere J, Seibyl J, Allard M: Comparison of noninvasive quantification methods of in vivo vesicular acetylcholine transporter using [123I]-IBVM SPECT imaging. J Cereb Blood Flow Metab 2008, 28(9):1624-1634.
  3. Boecker H, Henriksen G, Sprenger T, Miederer I, Willoch F, Valet M, Berthele A, Tolle TR: Positron emission tomography ligand activation studies in the sports sciences: measuring neurochemistry in vivo. Methods 2008, 45(4):307-318.
  4. Boy C, Meyer PT, Kircheis G, Holschbach MH, Herzog H, Elmenhorst D, Kaiser HJ, Coenen HH, Haussinger D, Zilles K et al: Cerebral A(1) adenosine receptors (A(1)AR) in liver cirrhosis. Eur J Nucl Med Mol Imaging 2008, 35(3):589-597.
  5. Brown AK, Kimura Y, Zoghbi SS, Simeon FG, Liow JS, Kreisl WC, Taku A, Fujita M, Pike VW, Innis RB: Metabotropic Glutamate Subtype 5 Receptors Are Quantified in the Human Brain with a Novel Radioligand for PET. J Nucl Med 2008, 49(12):2042-2048.
  6. Chowdhury I, Sengupta A, Maitra SK: Melatonin: fifty years of scientific journey from the discovery in bovine pineal gland to delineation of functions in human. Indian J Biochem Biophys 2008, 45(5):289-304.
  7. Christian N, Lee JA, Bol A, De Bast M, Gallez B, Gregoire V: Immobilization device for in vivo and in vitro multimodality image registration of rodent tumors. Radiother Oncol 2008, 87(1):147-151.
  8. Cropley VL, Fujita M, Bara-Jimenez W, Brown AK, Zhang XY, Sangare J, Herscovitch P, Pike VW, Hallett M, Nathan PJ et al: Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA. Psychiatry Res 2008, 163(2):171-182.
  9. Drzezga A, Grimmer T, Henriksen G, Stangier I, Perneczky R, Diehl-Schmid J, Mathis CA, Klunk WE, Price J, Dekosky S et al: Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer’s disease. Neuroimage 2008, 39(2):619-633.
  10. Feola M, Chauvie S, Rosso GL, Biggi A, Ribichini F, Bobbio M: Reversible impairment of coronary flow reserve in takotsubo cardiomyopathy: a myocardial PET study. J Nucl Cardiol 2008, 15(6):811-817.
  11. Frokjaer VG, Pinborg LH, Madsen J, de Nijs R, Svarer C, Wagner A, Knudsen GM: Evaluation of the Serotonin Transporter Ligand 123I-ADAM for SPECT Studies on Humans. J Nucl Med 2008, 49(2):247-254.
  12. Fujita M, Imaizumi M, Zoghbi SS, Fujimura Y, Farris AG, Suhara T, Hong J, Pike VW, Innis RB: Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation. Neuroimage 2008, 40(1):43-52.
  13. Gerstl F, Windischberger C, Mitterhauser M, Wadsak W, Holik A, Kletter K, Moser E, Kasper S, Lanzenberger R: Multimodal imaging of human early visual cortex by combining functional and molecular measurements with fMRI and PET. Neuroimage 2008, 41(2):204-211.
  14. Goffin K, Bormans G, Casteels C, Bosier B, Lambert DM, Grachev ID, Van Paesschen W, Van Laere K: An in vivo [(18)F]MK-9470 microPET study of type 1 cannabinoid receptor binding in Wistar rats after chronic administration of valproate and levetiracetam. Neuropharmacology 2008, 54(7):1103-1106.
  15. Goldstein DS, Holmes C, Bentho O, Sato T, Moak J, Sharabi Y, Imrich R, Conant S, Eldadah BA: Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord 2008, 14(8):600-607.
  16. Herzog H, Elmenhorst D, Winz O, Bauer A: Biodistribution and radiation dosimetry of the A(1) adenosine receptor ligand (18)F-CPFPX determined from human whole-body PET. Eur J Nucl Med Mol Imaging 2008, 35(8):1499-1506.
  17. Hjornevik T, Jacobsen LM, Qu H, Bjaalie JG, Gjerstad J, Willoch F: Metabolic plasticity in the supraspinal pain modulating circuitry after noxious stimulus-induced spinal cord LTP. Pain 2008, 140(3):456-464.
  18. Hooker JM, Xu Y, Schiffer W, Shea C, Carter P, Fowler JS: Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans. Neuroimage 2008, 41(3):1044-1050.
  19. Ichise M, Cohen RM, Carson RE: Noninvasive estimation of normalized distribution volume: application to the muscarinic-2 ligand [(18)F]FP-TZTP. J Cereb Blood Flow Metab 2008, 28(2):420-430.
  20. Imaizumi M, Briard E, Zoghbi SS, Gourley JP, Hong J, Fujimura Y, Pike VW, Innis RB, Fujita M: Brain and whole-body imaging in nonhuman primates of [11C]PBR28, a promising PET radioligand for peripheral benzodiazepine receptors. Neuroimage 2008, 39(3):1289-1298.
  21. Jentzen W, Weise R, Kupferschlager J, Freudenberg L, Brandau W, Bares R, Burchert W, Bockisch A: Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging 2008, 35(3):611-623.
  22. Kim SJ, Lee JS, Im KC, Kim SY, Park SA, Lee SJ, Oh SJ, Lee DS, Moon DH: Kinetic Modeling of 3′-Deoxy-3′-18F-Fluorothymidine for Quantitative Cell Proliferation Imaging in Subcutaneous Tumor Models in Mice. J Nucl Med 2008, 49(12):2057-2066.
  23. Kimes AS, Chefer SI, Matochik JA, Contoreggi CS, Vaupel DB, Stein EA, Mukhin AG: Quantification of nicotinic acetylcholine receptors in the human brain with PET: Bolus plus infusion administration of 2-[(18)F]F-A85380. Neuroimage 2008, 39(2):717-727.
  24. Lodge MA, Jacene HA, Pili R, Wahl RL: Reproducibility of Tumor Blood Flow Quantification with 15O-Water PET. J Nucl Med 2008, 49(10):1620-1627.
  25. Mazere J, Prunier C, Barret O, Guyot M, Hommet C, Guilloteau D, Dartigues JF, Auriacombe S, Fabrigoule C, Allard M: In vivo SPECT imaging of vesicular acetylcholine transporter using [(123)I]-IBVM in early Alzheimer’s disease. Neuroimage 2008, 40(1):280-288.
  26. McGoron AJ, Capille M, Georgiou MF, Sanchez P, Solano J, Gonzalez-Brito M, Kuluz JW: Post traumatic brain perfusion SPECT analysis using reconstructed ROI maps of radioactive microsphere derived cerebral blood flow and statistical parametric mapping. BMC Med Imaging 2008, 8:4.
  27. Meyer PT, Sattler B, Winz OH, Fundke R, Oehlwein C, Kendziorra K, Hesse S, Schaefer WM, Sabri O: Kinetic analyses of [(123)I]IBZM SPECT for quantification of striatal dopamine D2 receptor binding: A critical evaluation of the single-scan approach. Neuroimage 2008, 42(2):548-558.
  28. Millet P, Moulin M, Bartoli A, Del Guerra A, Ginovart N, Lemoucheux L, Buono S, Fagret D, Charnay Y, Ibanez V: In vivo quantification of 5-HT(1A)-[(18)F]MPPF interactions in rats using the YAP-(S)PET scanner and a beta-microprobe. Neuroimage 2008, 41(3):823-834.
  29. Mukhin AG, Kimes AS, Chefer SI, Matochik JA, Contoreggi CS, Horti AG, Vaupel DB, Pavlova O, Stein EA: Greater Nicotinic Acetylcholine Receptor Density in Smokers Than in Nonsmokers: A PET Study with 2-18F-FA-85380. J Nucl Med 2008, 49(10):1628-1635.
  30. Okumura M, Arakawa R, Ito H, Seki C, Takahashi H, Takano H, Haneda E, Nakao R, Suzuki H, Suzuki K et al: Quantitative analysis of NK1 receptor in the human brain using PET with 18F-FE-SPA-RQ. J Nucl Med 2008, 49(11):1749-1755.
  31. Patel VD, Lee DE, Alexoff DL, Dewey SL, Schiffer WK: Imaging dopamine release with Positron Emission Tomography (PET) and (11)C-raclopride in freely moving animals. Neuroimage 2008, 41(3):1051-1066.
  32. Pierson ME, Andersson J, Nyberg S, McCarthy DJ, Finnema SJ, Varnas K, Takano A, Karlsson P, Gulyas B, Medd AM et al: [(11)C]AZ10419369: A selective 5-HT(1B) receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain. Neuroimage 2008, 41(3):1075-1085.
  33. Rommel D, Abarca-Quinones J, Christian N, Peeters F, Lonneux M, Labar D, Bol A, Gregoire V, Duprez T: Alginate moulding: an empirical method for magnetic resonance imaging/positron emission tomography co-registration in a tumor rat model. Nucl Med Biol 2008, 35(5):571-577.
  34. Shidahara M, Ikoma Y, Seki C, Fujimura Y, Naganawa M, Ito H, Suhara T, Kanno I, Kimura Y: Wavelet denoising for voxel-based compartmental analysis of peripheral benzodiazepine receptors with (18)F-FEDAA1106. Eur J Nucl Med Mol Imaging 2008, 35(2):416-423.
  35. Shih YY, Chiang YC, Chen JC, Huang CH, Chen YY, Liu RS, Chang C, Jaw FS: Brain nociceptive imaging in rats using (18)f-fluorodeoxyglucose small-animal positron emission tomography. Neuroscience 2008, 155(4):1221-1226.
  36. Siegrist PT, Comte N, Holzmeister J, Sutsch G, Koepfli P, Namdar M, Duru F, Brunckhorst C, Scharf C, Kaufmann PA: Effects of AV delay programming on ventricular resynchronisation: role of radionuclide ventriculography. Eur J Nucl Med Mol Imaging 2008, 35(8):1516-1522.
  37. Siegrist PT, Husmann L, Knabenhans M, Gaemperli O, Valenta I, Hoefflinghaus T, Scheffel H, Stolzmann P, Alkadhi H, Kaufmann PA: (13)N-ammonia myocardial perfusion imaging with a PET/CT scanner: impact on clinical decision making and cost-effectiveness. Eur J Nucl Med Mol Imaging 2008, 35(5):889-895.
  38. Sotgia B, Sciagra R, Olivotto I, Casolo G, Rega L, Betti I, Pupi A, Camici PG, Cecchi F: Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy. J Nucl Med 2008, 49(7):1090-1096.
  39. Sprague DR, Fujita M, Ryu YH, Liow JS, Pike VW, Innis RB: Whole-body biodistribution and radiation dosimetry in monkeys and humans of the phosphodiesterase 4 radioligand [(11)C](R)-rolipram: comparison of two-dimensional planar, bisected and quadrisected image analyses. Nucl Med Biol 2008, 35(4):493-500.
  40. Strauss LG, Koczan D, Klippel S, Pan L, Cheng C, Willis S, Haberkorn U, Dimitrakopoulou-Strauss A: Impact of Angiogenesis-Related Gene Expression on the Tracer Kinetics of 18F-FDG in Colorectal Tumors. J Nucl Med 2008, 49(8):1238-1244.
  41. Terry G, Liow JS, Chernet E, Zoghbi SS, Phebus L, Felder CC, Tauscher J, Schaus JM, Pike VW, Halldin C et al: Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents. Neuroimage 2008, 41(3):690-698.
  42. Thanos PK, Michaelides M, Benveniste H, Wang GJ, Volkow ND: The effects of cocaine on regional brain glucose metabolism is attenuated in dopamine transporter knockout mice. Synapse 2008, 62(5):319-324.
  43. Thanos PK, Michaelides M, Piyis YK, Wang GJ, Volkow ND: Food restriction markedly increases dopamine D2 receptor (D2R) in a rat model of obesity as assessed with in-vivo muPET imaging ([11C] raclopride) and in-vitro ([3H] spiperone) autoradiography. Synapse 2008, 62(1):50-61.
  44. Treyer V, Streffer J, Ametamey SM, Bettio A, Blauenstein P, Schmidt M, Gasparini F, Fischer U, Hock C, Buck A: Radiation dosimetry and biodistribution of 11C-ABP688 measured in healthy volunteers. Eur J Nucl Med Mol Imaging 2008, 35(4):766-770.
  45. Van Laere K, Bormans G, Sanabria-Bohorquez SM, de Groot T, Dupont P, De Lepeleire I, de Hoon J, Mortelmans L, Hargreaves RJ, Atack JR et al: In vivo characterization and dynamic receptor occupancy imaging of TPA023B, an alpha 2/alpha 3/alpha 5 subtype selective gamma-aminobutyric acid-a partial agonist. Biol Psychiatry 2008, 64(2):153-161.
  46. Van Laere K, Goffin K, Casteels C, Dupont P, Mortelmans L, de Hoon J, Bormans G: Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18)F]MK-9470 PET. Neuroimage 2008, 39(4):1533-1541.
  47. Van Laere K, Koole M, Sanabria Bohorquez SM, Goffin K, Guenther I, Belanger MJ, Cote J, Rothenberg P, De Lepeleire I, Grachev ID et al: Whole-body biodistribution and radiation dosimetry of the human cannabinoid type-1 receptor ligand 18F-MK-9470 in healthy subjects. J Nucl Med 2008, 49(3):439-445.
  48. von Forstner C, Egberts JH, Ammerpohl O, Niedzielska D, Buchert R, Mikecz P, Schumacher U, Peldschus K, Adam G, Pilarsky C et al: Gene Expression Patterns and Tumor Uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an Orthotopic Mouse Xenotransplantation Model of Pancreatic Cancer. J Nucl Med 2008, 49(8):1362-1370.
  49. Wullner U, Gundisch D, Herzog H, Minnerop M, Joe A, Warnecke M, Jessen F, Schutz C, Reinhardt M, Eschner W et al: Smoking upregulates alpha4beta2* nicotinic acetylcholine receptors in the human brain. Neurosci Lett 2008, 430(1):34-37.
  50. Yasuno F, Ota M, Kosaka J, Ito H, Higuchi M, Doronbekov TK, Nozaki S, Fujimura Y, Koeda M, Asada T et al: Increased binding of peripheral benzodiazepine receptor in Alzheimer’s disease measured by positron emission tomography with [11C]DAA1106. Biol Psychiatry 2008, 64(10):835-841.
  51. Zoghbi SS, Liow JS, Yasuno F, Hong J, Tuan E, Lazarova N, Gladding RL, Pike VW, Innis RB: 11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. J Nucl Med 2008, 49(4):649-656.
2007
  1. Adachi I, Gaemperli O, Valenta I, Schepis T, Siegrist PT, Treyer V, Burger C, Morita K, Kaufmann PA: Assessment of myocardial perfusion by dynamic O-15-labeled water PET imaging: validation of a new fast factor analysis. J Nucl Cardiol 2007, 14(5):698-705.
  2. Ametamey SM, Treyer V, Streffer J, Wyss MT, Schmidt M, Blagoev M, Hintermann S, Auberson Y, Gasparini F, Fischer UC et al: Human PET Studies of Metabotropic Glutamate Receptor Subtype 5 with 11C-ABP688. J Nucl Med 2007, 48(2):247-252.
  3. Boutin H, Chauveau F, Thominiaux C, Gregoire MC, James ML, Trebossen R, Hantraye P, Dolle F, Tavitian B, Kassiou M: 11C-DPA-713: A Novel Peripheral Benzodiazepine Receptor PET Ligand for In Vivo Imaging of Neuroinflammation. J Nucl Med 2007, 48(4):573-581.
  4. Brown AK, Fujita M, Fujimura Y, Liow JS, Stabin M, Ryu YH, Imaizumi M, Hong J, Pike VW, Innis RB: Radiation Dosimetry and Biodistribution in Monkey and Man of 11C-PBR28: A PET Radioligand to Image Inflammation. J Nucl Med 2007, 48(12):2072-2079.
  5. Cha W, Meyerhoff ME: Catalytic generation of nitric oxide from S-nitrosothiols using immobilized organoselenium species. Biomaterials 2007, 28(1):19-27.
  6. Chow TW, Takeshita S, Honjo K, Pataky CE, St Jacques PL, Kusano ML, Caldwell CB, Ramirez J, Black S, Verhoeff NP: Comparison of manual and semi-automated delineation of regions of interest for radioligand PET imaging analysis. BMC nuclear medicine 2007, 7:2.
  7. Dimitrakopoulou-Strauss A, Hohenberger P, Haberkorn U, Macke HR, Eisenhut M, Strauss LG: 68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG. J Nucl Med 2007, 48(8):1245-1250.
  8. Doyle B, Kemp BJ, Chareonthaitawee P, Reed C, Schmeckpeper J, Sorajja P, Russell S, Araoz P, Riederer SJ, Caplice NM: Dynamic tracking during intracoronary injection of 18F-FDG-labeled progenitor cell therapy for acute myocardial infarction. J Nucl Med 2007, 48(10):1708-1714.
  9. Elmenhorst D, Meyer PT, Matusch A, Winz OH, Zilles K, Bauer A: Test-retest stability of cerebral A1 adenosine receptor quantification using [18F]CPFPX and PET. Eur J Nucl Med Mol Imaging 2007, 34(7):1061-1070.
  10. Frumberg DB, Fernando MS, Lee DE, Biegon A, Schiffer WK: Metabolic and behavioral deficits following a routine surgical procedure in rats. Brain Res 2007, 1144:209-218.
  11. Ginovart N, Willeit M, Rusjan P, Graff A, Bloomfield PM, Houle S, Kapur S, Wilson AA: Positron emission tomography quantification of [(11)C]-(+)-PHNO binding in the human brain. J Cereb Blood Flow Metab 2007, 27(4):857-871.
  12. Honer M, Stoffel A, Kessler LJ, Schubiger PA, Ametamey SM: Radiolabeling and in vitro and in vivo evaluation of [(18)F]-FE-DABP688 as a PET radioligand for the metabotropic glutamate receptor subtype 5. Nucl Med Biol 2007, 34(8):973-980.
  13. Imaizumi M, Kim HJ, Zoghbi SS, Briard E, Hong J, Musachio JL, Ruetzler C, Chuang DM, Pike VW, Innis RB et al: PET imaging with [(11)C]PBR28 can localize and quantify upregulated peripheral benzodiazepine receptors associated with cerebral ischemia in rat. Neurosci Lett 2007, 411(3):200-205.
  14. Jentzen W, Freudenberg L, Eising EG, Heinze M, Brandau W, Bockisch A: Segmentation of PET Volumes by Iterative Image Thresholding. J Nucl Med 2007, 48(1):108-114.
  15. Kim SW, Ding YS, Alexoff D, Patel V, Logan J, Lin KS, Shea C, Muench L, Xu Y, Carter P et al: Synthesis and positron emission tomography studies of C-11-labeled isotopomers and metabolites of GTS-21, a partial alpha7 nicotinic cholinergic agonist drug. Nucl Med Biol 2007, 34(5):541-551.
  16. Lanzenberger RR, Mitterhauser M, Spindelegger C, Wadsak W, Klein N, Mien LK, Holik A, Attarbaschi T, Mossaheb N, Sacher J et al: Reduced serotonin-1A receptor binding in social anxiety disorder. Biol Psychiatry 2007, 61(9):1081-1089.
  17. Lauwers E, Beque D, Van Laere K, Nuyts J, Bormans G, Mortelmans L, Casteels C, Vercammen L, Bockstael O, Nuttin B et al: Non-invasive imaging of neuropathology in a rat model of alpha-synuclein overexpression. Neurobiol Aging 2007, 28(2):248-257.
  18. Le Foll B, Chefer SI, Kimes AS, Shumway D, Goldberg SR, Stein EA, Mukhin AG: Validation of an extracerebral reference region approach for the quantification of brain nicotinic acetylcholine receptors in squirrel monkeys with PET and 2-18F-fluoro-A-85380. J Nucl Med 2007, 48(9):1492-1500.
  19. Leroy C, Comtat C, Trebossen R, Syrota A, Martinot JL, Ribeiro MJ: Assessment of 11C-PE2I Binding to the Neuronal Dopamine Transporter in Humans with the High-Spatial-Resolution PET Scanner HRRT. J Nucl Med 2007, 48(4):538-546.
  20. Love Z, Wang F, Dennis J, Awadallah A, Salem N, Lin Y, Weisenberger A, Majewski S, Gerson S, Lee Z: Imaging of mesenchymal stem cell transplant by bioluminescence and PET. J Nucl Med 2007, 48(12):2011-2020.
  21. Maeda J, Higuchi M, Inaji M, Ji B, Haneda E, Okauchi T, Zhang MR, Suzuki K, Suhara T: Phase-dependent roles of reactive microglia and astrocytes in nervous system injury as delineated by imaging of peripheral benzodiazepine receptor. Brain Res 2007, 1157:100-111.
  22. Mather SJ, McKenzie AJ, Sosabowski JK, Morris TM, Ellison D, Watson SA: Selection of radiolabeled gastrin analogs for Peptide receptor-targeted radionuclide therapy. J Nucl Med 2007, 48(4):615-622.
  23. Matusch A, Hurlemann R, Rota Kops E, Winz OH, Elmenhorst D, Herzog H, Zilles K, Bauer A: Acute S-ketamine application does not alter cerebral [18F]altanserin binding: a pilot PET study in humans. Journal of neural transmission 2007, 114(11):1433-1442.
  24. Meyer PT, Elmenhorst D, Boy C, Winz O, Matusch A, Zilles K, Bauer A: Effect of aging on cerebral A1 adenosine receptors: A [18F]CPFPX PET study in humans. Neurobiol Aging 2007, 28(12):1914-1924.
  25. Mirrione MM, Schiffer WK, Fowler JS, Alexoff DL, Dewey SL, Tsirka SE: A novel approach for imaging brain-behavior relationships in mice reveals unexpected metabolic patterns during seizures in the absence of tissue plasminogen activator. Neuroimage 2007, 38(1):34-42.
  26. Mitterhauser M, Toegel S, Wadsak W, Lanzenberger RR, Mien LK, Kuntner C, Wanek T, Eidherr H, Ettlinger DE, Viernstein H et al: Pre vivo, ex vivo and in vivo evaluations of [(68)Ga]-EDTMP. Nucl Med Biol 2007, 34(4):391-397.
  27. Miyata J, Hirao K, Namiki C, Fukuyama H, Okada T, Miki Y, Hayashi T, Murai T: Interfrontal commissural abnormality in schizophrenia: tractography-assisted callosal parcellation. Schizophr Res 2007, 97(1-3):236-241.
  28. Oishi N, Hashikawa K, Yoshida H, Ishizu K, Ueda M, Kawashima H, Saji H, Fukuyama H: Quantification of nicotinic acetylcholine receptors in Parkinson’s disease with (123)I-5IA SPECT. J Neurol Sci 2007, 256(1-2):52-60.
  29. Penuelas I, Aranguren XL, Abizanda G, Marti-Climent JM, Uriz M, Ecay M, Collantes M, Quincoces G, Richter JA, Prosper F: (13)N-ammonia PET as a measurement of hindlimb perfusion in a mouse model of peripheral artery occlusive disease. J Nucl Med 2007, 48(7):1216-1223.
  30. Praschak-Rieder N, Kennedy J, Wilson AA, Hussey D, Boovariwala A, Willeit M, Ginovart N, Tharmalingam S, Masellis M, Houle S et al: Novel 5-HTTLPR allele associates with higher serotonin transporter binding in putamen: a [(11)C] DASB positron emission tomography study. Biol Psychiatry 2007, 62(4):327-331.
  31. Rodriguez-Gomez JA, Lu JQ, Velasco I, Rivera S, Zoghbi SS, Liow JS, Musachio JL, Chin FT, Toyama H, Seidel J et al: Persistent dopamine functions of neurons derived from embryonic stem cells in a rodent model of Parkinson disease. Stem Cells 2007, 25(4):918-928.
  32. Ryu YH, Liow JS, Zoghbi S, Fujita M, Collins J, Tipre D, Sangare J, Hong J, Pike VW, Innis RB: Disulfiram inhibits defluorination of (18)F-FCWAY, reduces bone radioactivity, and enhances visualization of radioligand binding to serotonin 5-HT1A receptors in human brain. J Nucl Med 2007, 48(7):1154-1161.
  33. Schepis T, Gaemperli O, Treyer V, Valenta I, Burger C, Koepfli P, Namdar M, Adachi I, Alkadhi H, Kaufmann PA: Absolute quantification of myocardial blood flow with 13N-ammonia and 3-dimensional PET. J Nucl Med 2007, 48(11):1783-1789.
  34. Schiffer WK, Mirrione MM, Dewey SL: Optimizing Experimental Protocols for Quantitative Behavioral Imaging with 18F-FDG in Rodents. J Nucl Med 2007, 48(2):277-287.
  35. Seneca N, Cai L, Liow JS, Zoghbi SS, Gladding RL, Hong J, Pike VW, Innis RB: Brain and whole-body imaging in nonhuman primates with [11C]MeS-IMPY, a candidate radioligand for beta-amyloid plaques. Nucl Med Biol 2007, 34(6):681-689.
  36. Shetty HU, Zoghbi SS, Liow JS, Ichise M, Hong J, Musachio JL, Halldin C, Seidel J, Innis RB, Pike VW: Identification and regional distribution in rat brain of radiometabolites of the dopamine transporter PET radioligand [(11)C]PE2I. Eur J Nucl Med Mol Imaging 2007, 34(5):667-678.
  37. Sprague DR, Chin FT, Liow JS, Fujita M, Burns HD, Hargreaves R, Stubbs JB, Pike VW, Innis RB, Mozley PD: Human Biodistribution and Radiation Dosimetry of the Tachykinin NK1 Antagonist Radioligand [18F]SPA-RQ: Comparison of Thin-Slice, Bisected, and 2-Dimensional Planar Image Analysis. J Nucl Med 2007, 48(1):100-107.
  38. Strobel K, Burger C, Schneider P, Weber M, Hany TF: MIBG-SPECT/CT-angiography with 3-D reconstruction of an extra-adrenal phaeochromocytoma with dissection of an aortic aneurysm. Eur J Nucl Med Mol Imaging 2007, 34(1):150.
  39. Takano A, Arakawa R, Hayashi M, Takahashi H, Ito H, Suhara T: Relationship between neuroticism personality trait and serotonin transporter binding. Biol Psychiatry 2007, 62(6):588-592.
  40. Thanos PK, Michaelides M, Benveniste H, Wang GJ, Volkow ND: Effects of chronic oral methylphenidate on cocaine self-administration and striatal dopamine D2 receptors in rodents. Pharmacol Biochem Behav 2007, 87(4):426-433.
  41. Treyer V, Streffer J, Wyss MT, Bettio A, Ametamey SM, Fischer U, Schmidt M, Gasparini F, Hock C, Buck A: Evaluation of the metabotropic glutamate receptor subtype 5 using PET and 11C-ABP688: assessment of methods. J Nucl Med 2007, 48(7):1207-1215.
  42. Vaupel DB, Stein EA, Mukhin AG: Quantification of alpha4beta2* nicotinic receptors in the rat brain with microPET and 2-[18F]F-A-85380. Neuroimage 2007, 34(4):1352-1362.
  43. Wyss MT, Ametamey SM, Treyer V, Bettio A, Blagoev M, Kessler LJ, Burger C, Weber B, Schmidt M, Gasparini F et al: Quantitative evaluation of (11)C-ABP688 as PET ligand for the measurement of the metabotropic glutamate receptor subtype 5 using autoradiographic studies and a beta-scintillator. Neuroimage 2007, 35(3):1086-1092.
  44. Wyss MT, Spaeth N, Biollaz G, Pahnke J, Alessi P, Trachsel E, Treyer V, Weber B, Neri D, Buck A: Uptake of 18F-Fluorocholine, 18F-FET, and 18F-FDG in C6 Gliomas and Correlation with 131I-SIP(L19), a Marker of Angiogenesis. J Nucl Med 2007, 48(4):608-614.
  45. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM: Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53(3):337-351.
  46. Zappe AC, Reichold J, Burger C, Weber B, Buck A, Pfeuffer J, Logothetis NK: Quantification of cerebral blood flow in nonhuman primates using arterial spin labeling and a two-compartment model. Magn Reson Imaging 2007, 25(6):775-783.
  47. Zhang MR, Kumata K, Maeda J, Yanamoto K, Hatori A, Okada M, Higuchi M, Obayashi S, Suhara T, Suzuki K: 11C-AC-5216: a novel PET ligand for peripheral benzodiazepine receptors in the primate brain. J Nucl Med 2007, 48(11):1853-1861.
Before 2007
  1. Ametamey SM, Bruehlmeier M, Kneifel S, Kokic M, Honer M, Arigoni M, Buck A, Burger C, Samnick S, Quack G et al: PET studies of 18F-memantine in healthy volunteers. Nuclear Medicine and Biology 2002, 29(2):227-231.
  2. Ametamey SM, Kessler LJ, Honer M, Wyss MT, Buck A, Hintermann S, Auberson YP, Gasparini F, Schubiger PA: Radiosynthesis and Preclinical Evaluation of 11C-ABP688 as a Probe for Imaging the Metabotropic Glutamate Receptor Subtype 5. J Nucl Med 2006, 47(4):698-705.
  3. Araya R, Noguchi T, Yuhki M, Kitamura N, Higuchi M, Saido TC, Seki K, Itohara S, Kawano M, Tanemura K et al: Loss of M(5) muscarinic acetylcholine receptors leads to cerebrovascular and neuronal abnormalities and cognitive deficits in mice. Neurobiol Dis 2006, 24(2):334-344.
  4. Arigoni M, Kneifel S, Fandino J, Khan N, Burger C, Buck A: Simplified quantitative determination of cerebral perfusion reserve with H2(15)O PET and acetazolamide. Eur J Nucl Med 2000, 27(10):1557-1563.
  5. Bauer A, Holschbach MH, Meyer PT, Boy C, Herzog H, Olsson RA, Coenen HH, Zilles K: In vivo imaging of adenosine A1 receptors in the human brain with [18F]CPFPX and positron emission tomography. NeuroImage 2003, 19(4):1760-1769.
  6. Bauer M, Langer O, Dal-Bianco P, Karch R, Brunner M, Abrahim A, Lanzenberger R, Hofmann A, Joukhadar C, Carminati P et al: A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer’s disease. Clin Pharmacol Ther 2006, 80(3):216-227.
  7. Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, Weber WA, Schwaiger M: Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med 2005, 46(8):1333-1341.
  8. Benveniste H, Fowler JS, Rooney W, Ding Y-S, Baumann AL, Moller DH, Du C, Backus W, Logan J, Carter P et al: Maternal and Fetal 11C-Cocaine Uptake and Kinetics Measured In Vivo by Combined PET and MRI in Pregnant Nonhuman Primates. J Nucl Med 2005, 46(2):312-320.
  9. Berding G, Muller-Vahl K, Schneider U, Gielow P, Fitschen J, Stuhrmann M, Harke H, Buchert R, Donnerstag F, Hofmann M et al: [(123)I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB(1) receptors before and after Delta(9)-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in tourette patients. Biol Psychiatry 2004, 55(9):904-915.
  10. Berding G, Schneider U, Gielow P, Buchert R, Donnerstag F, Brandau W, Knapp WH, Emrich HM, Muller-Vahl K: Feasibility of central cannabinoid CB(1) receptor imaging with [(124)I]AM281 PET demonstrated in a schizophrenic patient. Psychiatry research 2006, 147(2-3):249-256.
  11. Bettio A, Honer M, Muller C, Bruhlmeier M, Muller U, Schibli R, Groehn V, Schubiger AP, Ametamey SM: Synthesis and Preclinical Evaluation of a Folic Acid Derivative Labeled with 18F for PET Imaging of Folate Receptor-Positive Tumors. J Nucl Med 2006, 47(7):1153-1160.
  12. Bicik I, Radanov BP, Schafer N, Dvorak J, Blum B, Weber B, Burger C, von Schulthess GK, Buck A: PET with 18fluorodeoxyglucose and hexamethylpropylene amine oxime SPECT in late whiplash syndrome. Neurology 1998, 51(2):345-350.
  13. Boecker H, Sprenger T, Henriksen G, Toelle TR, Spilker ME: Optimal Duration of PET Studies with 18F-Fluoroethyl-Diprenorphine. J Nucl Med 2005, 46(12):2092-2096.
  14. Boumezbeur F, Besret L, Valette J, Gregoire MC, Delzescaux T, Maroy R, Vaufrey F, Gervais P, Hantraye P, Bloch G et al: Glycolysis versus TCA cycle in the primate brain as measured by combining 18F-FDG PET and 13C-NMR. J Cereb Blood Flow Metab 2005, 25(11):1418-1423.
  15. Brenner W, Vernon C, Muzi M, Mankoff DA, Link JM, Conrad EU, Eary JF: Comparison of different quantitative approaches to 18F-fluoride PET scans. J Nucl Med 2004, 45(9):1493-1500.
  16. Bruehlmeier M, Roelcke U, Blauenstein P, Missimer J, Schubiger PA, Locher JT, Pellikka R, Ametamey SM: Measurement of the extracellular space in brain tumors using 76Br-bromide and PET. J Nucl Med 2003, 44(8):1210-1218.
  17. Bruehlmeier M, Roelcke U, Schubiger PA, Ametamey SM: Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. J Nucl Med 2004, 45(11):1851-1859.
  18. Buchert R, Thomasius R, Nebeling B, Petersen K, Obrocki J, Jenicke L, Wilke F, Wartberg L, Zapletalova P, Clausen M: Long-term effects of “ecstasy” use on serotonin transporters of the brain investigated by PET. J Nucl Med 2003, 44(3):375-384.
  19. Buchert R, Wilke F, van den Hoff J, Mester J: Improved statistical power of the multilinear reference tissue approach to the quantification of neuroreceptor ligand binding by regularization. J Cereb Blood Flow Metab 2003, 23(5):612-620.
  20. Buck A, Burger C: Effect of intravascular ligand binding on parameter estimates derived from tracer kinetic modelling. Eur J Nucl Med 1996, 23(4):422-430.
  21. Buck A, Nguyen N, Burger C, Ziegler S, Frey L, Weigand G, Erhardt W, Senekowitsch-Schmidtke R, Pellikka R, Blauenstein P et al: Quantitative evaluation of manganese-52m as a myocardial perfusion tracer in pigs using positron emission tomography. Eur J Nucl Med 1996, 23(12):1619-1627.
  22. Buck A, Westera G, vonSchulthess GK, Burger C: Modeling alternatives for cerebral carbon-11-iomazenil kinetics. J Nucl Med 1996, 37(4):699-705.
  23. Buck A, Schirlo C, Jasinksy V, Weber B, Burger C, von Schulthess GK, Koller EA, Pavlicek V: Changes of cerebral blood flow during short-term exposure to normobaric hypoxia. J Cereb Blood Flow Metab 1998, 18(8):906-910.
  24. Buck A, Gucker PM, Schonbachler RD, Arigoni M, Kneifel S, Vollenweider FX, Ametamey SM, Burger C: Evaluation of serotonergic transporters using PET and [11C](+)McN-5652: assessment of methods. J Cereb Blood Flow Metab 2000, 20(2):253-262.
  25. Burger C, Buck A: Tracer kinetic modelling of receptor data with mathematical metabolite correction. Eur J Nucl Med 1996, 23(5):539-545.
  26. Burger C, Buck A: Requirements and implementation of a flexible kinetic modeling tool. J Nucl Med 1997, 38(11):1818-1823.
  27. Burger C, Goerres G, Schoenes S, Buck A, Lonn AH, Von Schulthess GK: PET attenuation coefficients from CT images: experimental evaluation of the transformation of CT into PET 511-keV attenuation coefficients. Eur J Nucl Med Mol Imaging 2002, 29(7):922-927.
  28. Cannon DM, Ichise M, Fromm SJ, Nugent AC, Rollis D, Gandhi SK, Klaver JM, Charney DS, Manji HK, Drevets WC: Serotonin transporter binding in bipolar disorder assessed using [11C]DASB and positron emission tomography. Biol Psychiatry 2006, 60(3):207-217.
  29. Carroll TJ, Teneggi V, Jobin M, Squassante L, Treyer V, Hany TF, Burger C, Wang L, Bye A, Von Schulthess GK et al: Absolute quantification of cerebral blood flow with magnetic resonance, reproducibility of the method, and comparison with H2(15)O positron emission tomography. J Cereb Blood Flow Metab 2002, 22(9):1149-1156.
  30. Casteels C, Vermaelen P, Nuyts J, Van Der Linden A, Baekelandt V, Mortelmans L, Bormans G, Van Laere K: Construction and evaluation of multitracer small-animal PET probabilistic atlases for voxel-based functional mapping of the rat brain. J Nucl Med 2006, 47(11):1858-1866.
  31. Chareonthaitawee P, Christenson SD, Anderson JL, Kemp BJ, Hodge DO, Ritman EL, Gibbons RJ: Reproducibility of Measurements of Regional Myocardial Blood Flow in a Model of Coronary Artery Disease: Comparison of H215O and 13NH3 PET Techniques. J Nucl Med 2006, 47(7):1193-1201.
  32. Ciernik IF, Dizendorf E, Baumert BG, Reiner B, Burger C, Davis JB, Lutolf UM, Steinert HC, Von Schulthess GK: Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. International Journal of Radiation Oncology*Biology*Physics 2003, 57(3):853-863.
  33. Ciernik IF, Huser M, Burger C, Davis JB, Szekely G: Automated functional image-guided radiation treatment planning for rectal cancer. Int J Radiat Oncol Biol Phys 2005, 62(3):893-900.
  34. Cropley VL, Fujita M, Musachio JL, Hong J, Ghose S, Sangare J, Nathan PJ, Pike VW, Innis RB: Whole-Body Biodistribution and Estimation of Radiation-Absorbed Doses of the Dopamine D1 Receptor Radioligand 11C-NNC 112 in Humans. J Nucl Med 2006, 47(1):100-104.
  35. de Quervain DJ, Henke K, Aerni A, Treyer V, McGaugh JL, Berthold T, Nitsch RM, Buck A, Roozendaal B, Hock C: Glucocorticoid-induced impairment of declarative memory retrieval is associated with reduced blood flow in the medial temporal lobe. Eur J Neurosci 2003, 17(6):1296-1302.
  36. Dimitrakopoulou-Strauss A, Strauss LG, Burger C: Quantitative PET studies in pretreated melanoma patients: a comparison of 6-[18F]fluoro-L-dopa with 18F-FDG and (15)O-water using compartment and noncompartment analysis. J Nucl Med 2001, 42(2):248-256.
  37. Dimitrakopoulou-Strauss A, Strauss LG, Schwarzbach M, Burger C, Heichel T, Willeke F, Mechtersheimer G, Lehnert T: Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. J Nucl Med 2001, 42(5):713-720.
  38. Dimitrakopoulou-Strauss A, Strauss LG, Heichel T, Wu H, Burger C, Bernd L, Ewerbeck V: The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesions. J Nucl Med 2002, 43(4):510-518.
  39. Dimitrakopoulou-Strauss A, Strauss LG, Burger C, Ruhl A, Irngartinger G, Stremmel W, Rudi J: Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J Nucl Med 2004, 45(9):1480-1487.
  40. Dimitrakopoulou-Strauss A, Georgoulias V, Eisenhut M, Herth F, Koukouraki S, Macke HR, Haberkorn U, Strauss LG: Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using(68)Ga-DOTATOC PET and comparison with (18)F-FDG PET. Eur J Nucl Med Mol Imaging 2006, 33(7):823-830.
  41. Dizendorf E, Hany TF, Buck A, von Schulthess GK, Burger C: Cause and magnitude of the error induced by oral CT contrast agent in CT-based attenuation correction of PET emission studies. J Nucl Med 2003, 44(5):732-738.
  42. Finnema SJ, Seneca N, Farde L, Shchukin E, Sovago J, Gulyas B, Wikstrom HV, Innis RB, Neumeyer JL, Halldin C: A preliminary PET evaluation of the new dopamine D2 receptor agonist [11C]MNPA in cynomolgus monkey. Nucl Med Biol 2005, 32(4):353-360.
  43. Fujimura Y, Ikoma Y, Yasuno F, Suhara T, Ota M, Matsumoto R, Nozaki S, Takano A, Kosaka J, Zhang MR et al: Quantitative Analyses of 18F-FEDAA1106 Binding to Peripheral Benzodiazepine Receptors in Living Human Brain. J Nucl Med 2006, 47(1):43-50.
  44. Fujita M, Seibyl JP, Verhoeff NP, Ichise M, Baldwin RM, Zoghbi SS, Burger C, Staley JK, Rajeevan N, Charney DS et al: Kinetic and equilibrium analyses of [(123)I]epidepride binding to striatal and extrastriatal dopamine D(2) receptors. Synapse 1999, 34(4):290-304.
  45. Fujita M, Tamagnan G, Zoghbi SS, Al-Tikriti MS, Baldwin RM, Seibyl JP, Innis RB: Measurement of alpha4beta2 nicotinic acetylcholine receptors with [123I]5-I-A-85380 SPECT. J Nucl Med 2000, 41(9):1552-1560.
  46. Fujita M, Al-Tikriti MS, Tamagnan G, Zoghbi SS, Bozkurt A, Baldwin RM, Innis RB: Influence of acetylcholine levels on the binding of a SPECT nicotinic acetylcholine receptor ligand [123I]5-I-A-85380. Synapse 2003, 48(3):116-122.
  47. Fujita M, Ichise M, van Dyck CH, Zoghbi SS, Tamagnan G, Mukhin AG, Bozkurt A, Seneca N, Tipre D, DeNucci CC et al: Quantification of nicotinic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPET. Eur J Nucl Med Mol Imaging 2003, 30(12):1620-1629.
  48. Fujita M, Varrone A, Kim KM, Watabe H, Zoghbi SS, Seneca N, Tipre D, Seibyl JP, Innis RB, Iida H: Effect of scatter correction on the compartmental measurement of striatal and extrastriatal dopamine D2 receptors using [123I]epidepride SPET. Eur J Nucl Med Mol Imaging 2004, 31(5):644-654.
  49. Fujita M, Zoghbi SS, Crescenzo MS, Hong J, Musachio JL, Lu J-Q, Liow J-S, Seneca N, Tipre DN, Cropley VL: Quantification of brain phosphodiesterase 4 in rat with (R)-[11C]Rolipram-PET. NeuroImage 2005, 26(4):1201-1210.
  50. Fujita M, Ichise M, Zoghbi SS, Liow JS, Ghose S, Vines DC, Sangare J, Lu JQ, Cropley VL, Iida H et al: Widespread decrease of nicotinic acetylcholine receptors in Parkinson’s disease. Ann Neurol 2006, 59(1):174-177.
  51. Gallezot J-D, Bottlaender M, Gregoire M-C, Roumenov D, Deverre J-R, Coulon C, Ottaviani M, Dolle F, Syrota A, Valette H: In Vivo Imaging of Human Cerebral Nicotinic Acetylcholine Receptors with 2-18F-Fluoro-A-85380 and PET. J Nucl Med 2005, 46(2):240-247.
  52. Ginovart N, Wilson AA, Meyer JH, Hussey D, Houle S: Positron emission tomography quantification of [(11)C]-DASB binding to the human serotonin transporter: modeling strategies. J Cereb Blood Flow Metab 2001, 21(11):1342-1353.
  53. Ginovart N, Meyer JH, Boovariwala A, Hussey D, Rabiner EA, Houle S, Wilson AA: Positron emission tomography quantification of [(11)C]-harmine binding to monoamine oxidase-A in the human brain. J Cereb Blood Flow Metab 2005.
  54. Goerres GW, Kamel E, Heidelberg TN, Schwitter MR, Burger C, von Schulthess GK: PET-CT image co-registration in the thorax: influence of respiration. Eur J Nucl Med Mol Imaging 2002, 29(3):351-360.
  55. Goerres GW, Kamel E, Seifert B, Burger C, Buck A, Hany TF, Von Schulthess GK: Accuracy of image coregistration of pulmonary lesions in patients with non-small cell lung cancer using an integrated PET/CT system. J Nucl Med 2002, 43(11):1469-1475.
  56. Goerres GW, Burger C, Kamel E, Seifert B, Kaim AH, Buck A, Buehler TC, Von Schulthess GK: Respiration-induced attenuation artifact at PET/CT: technical considerations. Radiology 2003, 226(3):906-910.
  57. Goerres GW, Burger C, Schwitter MR, Heidelberg TN, Seifert B, von Schulthess GK: PET/CT of the abdomen: optimizing the patient breathing pattern. European radiology 2003, 13(4):734-739.
  58. Goerres GW, Ziegler SI, Burger C, Berthold T, Von Schulthess GK, Buck A: Artifacts at PET and PET/CT caused by metallic hip prosthetic material. Radiology 2003, 226(2):577-584.
  59. Henke K, Mondadori CRA, Treyer V, Nitsch RM, Buck A, Hock C: Nonconscious formation and reactivation of semantic associations by way of the medial temporal lobe. Neuropsychologia 2003, 41(8):863-876.
  60. Henke K, Treyer V, Weber B, Nitsch RM, Hock C, Wieser HG, Buck A: Functional neuroimaging predicts individual memory outcome after amygdalohippocampectomy. Neuroreport 2003, 14(9):1197-1202.
  61. Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, Macke HR, Eisenhut M, Debus J, Haberkorn U: Characterization of 68Ga-DOTA-D-Phe1-Tyr3-Octreotide Kinetics in Patients with Meningiomas. J Nucl Med 2005, 46(5):763-769.
  62. Herzog H, Tellmann L, Fulton R, Stangier I, Kops ER, Bente K, Boy C, Hurlemann R, Pietrzyk U: Motion Artifact Reduction on Parametric PET Images of Neuroreceptor Binding. J Nucl Med 2005, 46(6):1059-1065.
  63. Honer M, Bruhlmeier M, Missimer J, Schubiger AP, Ametamey SM: Dynamic imaging of striatal D2 receptors in mice using quad-HIDAC PET. J Nucl Med 2004, 45(3):464-470.
  64. Honer M, Hengerer B, Blagoev M, Hintermann S, Waldmeier P, Schubiger PA, Ametamey SM: Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice. Nucl Med Biol 2006, 33(5):607-614.
  65. Huber R, Treyer V, Borbely AA, Schuderer J, Gottselig JM, Landolt HP, Werth E, Berthold T, Kuster N, Buck A et al: Electromagnetic fields, such as those from mobile phones, alter regional cerebral blood flow and sleep and waking EEG. Journal of sleep research 2002, 11(4):289-295.
  66. Ichise M, Meyer JH, Yonekura Y: An introduction to PET and SPECT neuroreceptor quantification models. J Nucl Med 2001, 42(5):755-763.
  67. Ichise M, Toyama H, Innis RB, Carson RE: Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab 2002, 22(10):1271-1281.
  68. Ichise M, Liow JS, Lu JQ, Takano A, Model K, Toyama H, Suhara T, Suzuki K, Innis RB, Carson RE: Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 2003, 23(9):1096-1112.
  69. Ihara M, Tomimoto H, Ishizu K, Mukai T, Yoshida H, Sawamoto N, Inoue M, Doi T, Hashikawa K, Konishi J et al: Decrease in cortical benzodiazepine receptors in symptomatic patients with leukoaraiosis: a positron emission tomography study. Stroke 2004, 35(4):942-947.
  70. Ikoma Y, Takano A, Ito H, Kusuhara H, Sugiyama Y, Arakawa R, Fukumura T, Nakao R, Suzuki K, Suhara T: Quantitative analysis of 11C-verapamil transfer at the human blood-brain barrier for evaluation of P-glycoprotein function. J Nucl Med 2006, 47(9):1531-1537.
  71. Ikoma Y, Yasuno F, Ito H, Suhara T, Ota M, Toyama H, Fujimura Y, Takano A, Maeda J, Zhang MR et al: Quantitative analysis for estimating binding potential of the peripheral benzodiazepine receptor with [(11)C]DAA1106. J Cereb Blood Flow Metab 2006.
  72. Itier V, Schonbachler R, Tribollet E, Honer M, Prinz K, Marguerat A, Bertrand S, Bunnelle WH, Schubiger PA, Meyer MD et al: A-186253, a specific antagonist of the alpha 4 beta 2 nAChRs: its properties and potential to study brain nicotinic acetylcholine receptors. Neuropharmacology 2004, 47(4):538-557.
  73. Ito H, Ota M, Ikoma Y, Seki C, Yasuno F, Takano A, Maeda J, Nakao R, Suzuki K, Suhara T: Quantitative analysis of dopamine synthesis in human brain using positron emission tomography with L-[beta-11C]DOPA. Nuclear medicine communications 2006, 27(9):723-731.
  74. Jacobs AH, Thomas A, Kracht LW, Li H, Dittmar C, Garlip G, Galldiks N, Klein JC, Sobesky J, Hilker R et al: 18F-Fluoro-L-Thymidine and 11C-Methylmethionine as Markers of Increased Transport and Proliferation in Brain Tumors. J Nucl Med 2005, 46(12):1948-1958.
  75. Kaim AH, Burger C, Ganter CC, Goerres GW, Kamel E, Weishaupt D, Dizendorf E, Schaffner A, von Schulthess GK: PET-CT-guided percutaneous puncture of an infected cyst in autosomal dominant polycystic kidney disease: case report. Radiology 2001, 221(3):818-821.
  76. Kamel E, Hany TF, Burger C, Treyer V, Lonn AH, von Schulthess GK, Buck A: CT vs 68Ge attenuation correction in a combined PET/CT system: evaluation of the effect of lowering the CT tube current. Eur J Nucl Med Mol Imaging 2002, 29(3):346-350.
  77. Kamel EM, Goerres GW, Burger C, von Schulthess GK, Steinert HC: Recurrent laryngeal nerve palsy in patients with lung cancer: detection with PET-CT image fusion — report of six cases. Radiology 2002, 224(1):153-156.
  78. Kamel EM, Burger C, Buck A, von Schulthess GK, Goerres GW: Impact of metallic dental implants on CT-based attenuation correction in a combined PET/CT scanner. European radiology 2003, 13(4):724-728.
  79. Kaufmann PA, Schirlo C, Pavlicek V, Berthold T, Burger C, von Schulthess GK, Koller EA, Buck A: Increased myocardial blood flow during acute exposure to simulated altitudes. J Nucl Cardiol 2001, 8(2):158-164.
  80. Kaufmann PA, Namdar M, Matthew F, Roffi M, Aschkenasy SV, van der Loo B, Sutsch G, Luscher TF, Jenni R: Novel doppler assessment of intracoronary volumetric flow reserve: validation against PET in patients with or without flow-dependent vasodilation. J Nucl Med 2005, 46(8):1272-1277.
  81. Kim JS, Ichise M, Sangare J, Innis RB: PET Imaging of Serotonin Transporters with [11C]DASB: Test-Retest Reproducibility Using a Multilinear Reference Tissue Parametric Imaging Method. J Nucl Med 2006, 47(2):208-214.
  82. Knoch D, Treyer V, Regard M, Muri RM, Buck A, Weber B: Lateralized and frequency-dependent effects of prefrontal rTMS on regional cerebral blood flow. Neuroimage 2006, 31(2):641-648.
  83. Koepfli P, Hany TF, Wyss CA, Namdar M, Burger C, Konstantinidis AV, Berthold T, Von Schulthess GK, Kaufmann PA: CT attenuation correction for myocardial perfusion quantification using a PET/CT hybrid scanner. J Nucl Med 2004, 45(4):537-542.
  84. Koepfli P, Wyss CA, Namdar M, Fretz G, Seebauer M, Schirlo C, Kaufmann PA: Impact of altitude exposure on myocardial blood flow and flow reserve. International Congress Series 2004, 1264:111-116.
  85. Koepfli P, Wyss CA, Namdar M, Klainguti M, von Schulthess GK, Luscher TF, Kaufmann PA: {beta}-Adrenergic Blockade and Myocardial Perfusion in Coronary Artery Disease: Differential Effects in Stenotic Versus Remote Myocardial Segments. J Nucl Med 2004, 45(10):1626-1631.
  86. Koukouraki S, Strauss LG, Georgoulias V, Eisenhut M, Haberkorn U, Dimitrakopoulou-Strauss A: Comparison of the pharmacokinetics of (68)Ga-DOTATOC and [ (18)F]FDG in patients with metastatic neuroendocrine tumours scheduled for (90)Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006, 33(10):1115-1122.
  87. Kunz P, Hoffend J, Altmann A, Dimitrakopoulou-Strauss A, Koczan D, Eisenhut M, Bonaterra GA, Dengler TJ, Mier W, Haberkorn U et al: Angiopoietin-2 overexpression in morris hepatoma results in increased tumor perfusion and induction of critical angiogenesis-promoting genes. J Nucl Med 2006, 47(9):1515-1524.
  88. Lin KJ, Liu CY, Wey SP, Hsiao IT, Wu J, Fu YK, Yen TC: Brain SPECT imaging and whole-body biodistribution with [(123)I]ADAM – a serotonin transporter radiotracer in healthy human subjects. Nucl Med Biol 2006, 33(2):193-202.
  89. Liptrot M, Adams KH, Martiny L, Pinborg LH, Lonsdale MN, Olsen NV, Holm S, Svarer C, Knudsen GM: Cluster analysis in kinetic modelling of the brain: a noninvasive alternative to arterial sampling. NeuroImage 2004, 21(2):483-493.
  90. Matusch A, Meyer PT, Bier D, Holschbach MH, Woitalla D, Elmenhorst D, Winz OH, Zilles K, Bauer A: Metabolism of the A(1) adenosine receptor PET ligand [(18)F]CPFPX by CYP1A2: implications for bolus/infusion PET studies. Nucl Med Biol 2006, 33(7):891-898.
  91. Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, Houle S: Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psychiatry 2001, 158(11):1843-1849.
  92. Meyer PT, Bier D, Holschbach MH, Boy C, Olsson RA, Coenen HH, Zilles K, Bauer A: Quantification of cerebral A1 adenosine receptors in humans using [18F]CPFPX and PET. J Cereb Blood Flow Metab 2004, 24(3):323-333.
  93. Meyer PT, Elmenhorst D, Bier D, Holschbach MH, Matusch A, Coenen HH, Zilles K, Bauer A: Quantification of cerebral A(1) adenosine receptors in humans using [(18)F]CPFPX and PET: an equilibrium approach. Neuroimage 2005, 24(4):1192-1204.
  94. Meyer PT, Elmenhorst D, Zilles K, Bauer A: Simplified quantification of cerebral A(1) adenosine receptors using [(18)F]CPFPX and PET: Analyses based on venous blood sampling. Synapse 2005, 55(4):212-223.
  95. Meyer PT, Circiumaru V, Cardi CA, Thomas DH, Bal H, Acton PD: Simplified quantification of small animal [18F]FDG PET studies using a standard arterial input function. Eur J Nucl Med Mol Imaging 2006, 33(8):948-954.
  96. Meyer PT, Elmenhorst D, Matusch A, Winz O, Zilles K, Bauer A: 18F-CPFPX PET: On the Generation of Parametric Images and the Effect of Scan Duration. J Nucl Med 2006, 47(2):200-207.
  97. Meyer PT, Elmenhorst D, Matusch A, Winz O, Zilles K, Bauer A: A1 adenosine receptor PET using [18F]CPFPX: displacement studies in humans. Neuroimage 2006, 32(3):1100-1105.
  98. Mikolajczyk K, Szabatin M, Rudnicki P, Grodzki M, Burger C: A JAVA environment for medical image data analysis: initial application for brain PET quantitation. Med Inform (Lond) 1998, 23(3):207-214.
  99. Mirrione MM, Schiffer WK, Siddiq M, Dewey SL, Tsirka SE: PET imaging of glucose metabolism in a mouse model of temporal lobe epilepsy. Synapse 2006, 59(2):119-121.
  100. Muzi M, Mankoff DA, Grierson JR, Wells JM, Vesselle H, Krohn KA: Kinetic Modeling of 3′-Deoxy-3′-Fluorothymidine in Somatic Tumors: Mathematical Studies. J Nucl Med 2005, 46(2):371-380.
  101. Muzi M, Vesselle H, Grierson JR, Mankoff DA, Schmidt RA, Peterson L, Wells JM, Krohn KA: Kinetic Analysis of 3′-Deoxy-3′-Fluorothymidine PET Studies: Validation Studies in Patients with Lung Cancer. J Nucl Med 2005, 46(2):274-282.
  102. Muzi M, Spence AM, O’Sullivan F, Mankoff DA, Wells JM, Grierson JR, Link JM, Krohn KA: Kinetic analysis of 3′-deoxy-3′-18F-fluorothymidine in patients with gliomas. J Nucl Med 2006, 47(10):1612-1621.
  103. Namdar M, Koepfli P, Grathwohl R, Siegrist PT, Klainguti M, Schepis T, Delaloye R, Wyss CA, Fleischmann SP, Gaemperli O et al: Caffeine decreases exercise-induced myocardial flow reserve. J Am Coll Cardiol 2006, 47(2):405-410.
  104. Nowak B, Stellbrink C, Sinha AM, Kaiser H-J, Reinartz P, Koos R, Markus K, Hanrath P, Buell U, Schaefer WM: Effects of cardiac resynchronization therapy on myocardial blood flow measured by oxygen-15 water positron emission tomography in idiopathic-dilated cardiomyopathy and left bundle branch block. The American Journal of Cardiology 2004, 93(4):496-499.
  105. Patt JT, Spang JE, Buck A, Cristina H, Arras M, Schubiger PA, Westera G: Synthesis and in vivo studies of the stereoisomers of N-[11C]methyl-homoepibatidine. Nuclear Medicine and Biology 2001, 28(6):645-655.
  106. Praschak-Rieder N, Wilson AA, Hussey D, Carella A, Wei C, Ginovart N, Schwarz MJ, Zach J, Houle S, Meyer JH: Effects of tryptophan depletion on the serotonin transporter in healthy humans. Biol Psychiatry 2005, 58(10):825-830.
  107. Quick HH, Kuehl H, Kaiser G, Aker S, Bosk S, Debatin JF, Ladd ME: Interventional MR Angiography with a Floating Table. Radiology 2003, 229(2):598-602.
  108. Rice O, Saintvictor S, Michaelides M, Thanos P, Gatley SJ: MicroPET investigation of chronic long-term neurotoxicity from heavy ion irradiation. AAPS J 2006, 8(3):E508-514.
  109. Rusjan P, Mamo D, Ginovart N, Hussey D, Vitcu I, Yasuno F, Tetsuya S, Houle S, Kapur S: An automated method for the extraction of regional data from PET images. Psychiatry research 2006, 147(1):79-89.
  110. Ryzhikov NN, Seneca N, Krasikova RN, Gomzina NA, Shchukin E, Fedorova OS, Vassiliev DA, Gulyas B, Hall H, Savic I et al: Preparation of highly specific radioactivity [(18)F]flumazenil and its evaluation in cynomolgus monkey by positron emission tomography. Nucl Med Biol 2005, 32(2):109-116.
  111. Schiffer WK, Alexoff DL, Shea C, Logan J, Dewey SL: Development of a simultaneous PET/microdialysis method to identify the optimal dose of (11)C-raclopride for small animal imaging. J Neurosci Methods 2005, 144(1):25-34.
  112. Schiffer WK, Mirrione MM, Biegon A, Alexoff DL, Patel V, Dewey SL: Serial microPET measures of the metabolic reaction to a microdialysis probe implant. J Neurosci Methods 2006, 155(2):272-284.
  113. Schiffer WK, Volkow ND, Fowler JS, Alexoff DL, Logan J, Dewey SL: Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. Synapse 2006, 59(4):243-251.
  114. Schmid DT, John H, Zweifel R, Cservenyak T, Westera G, Goerres GW, von Schulthess GK, Hany TF: Fluorocholine PET/CT in Patients with Prostate Cancer: Initial Experience. Radiology 2005, 235(2):623-628.
  115. Schmidt K, Hoffend J, Altmann A, Kiessling F, Strauss L, Koczan D, Mier W, Eisenhut M, Kinscherf R, Haberkorn U: Troponin I overexpression inhibits tumor growth, perfusion, and vascularization of morris hepatoma. J Nucl Med 2006, 47(9):1506-1514.
  116. Schmidt K, Hoffend J, Altmann A, Strauss LG, Dimitrakopoulou-Strauss A, Engelhardt B, Koczan D, Peter J, Dengler TJ, Mier W et al: Angiostatin Overexpression in Morris Hepatoma Results in Decreased Tumor Growth but Increased Perfusion and Vascularization. J Nucl Med 2006, 47(3):543-551.
  117. Schnider A, Treyer V, Buck A: The human orbitofrontal cortex monitors outcomes even when no reward is at stake. Neuropsychologia 2005, 43(3):316-323.
  118. Schonbachler RD, Gucker PM, Arigoni M, Kneifel S, Vollenweider FX, Buck A, Burger C, Berthold T, Bruhlmeier M, Schubiger PA et al: PET imaging of dopamine transporters in the human brain using [11C]-[beta]-CPPIT, a cocaine derivative lacking the 2[beta]-ester function. Nuclear Medicine and Biology 2002, 29(1):19-27.
  119. Schwarzbach MH, Dimitrakopoulou-Strauss A, Willeke F, Hinz U, Strauss LG, Zhang YM, Mechtersheimer G, Attigah N, Lehnert T, Herfarth C: Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg 2000, 231(3):380-386.
  120. Seneca N, Andree B, Sjoholm N, Schou M, Pauli S, Mozley PD, Stubbs JB, Liow JS, Sovago J, Gulyas B et al: Whole-body biodistribution, radiation dosimetry estimates for the PET norepinephrine transporter probe (S,S)-[18F]FMeNER-D2 in non-human primates. Nuclear medicine communications 2005, 26(8):695-700.
  121. Siegrist PT, Gaemperli O, Koepfli P, Schepis T, Namdar M, Valenta I, Aiello F, Fleischmann S, Alkadhi H, Kaufmann PA: Repeatability of cold pressor test-induced flow increase assessed with H(2)(15)O and PET. J Nucl Med 2006, 47(9):1420-1426.
  122. Siessmeier T, Zhou Y, Buchholz HG, Landvogt C, Vernaleken I, Piel M, Schirrmacher R, Rosch F, Schreckenberger M, Wong DF et al: Parametric mapping of binding in human brain of d2 receptor ligands of different affinities. J Nucl Med 2005, 46(6):964-972.
  123. Spaeth N, Wyss MT, Pahnke J, Biollaz G, Lutz A, Goepfert K, Westera G, Treyer V, Weber B, Buck A: Uptake of (18)F-fluorocholine, (18)F-fluoro-ethyl-L: -tyrosine and (18)F-fluoro-2-deoxyglucose in F98 gliomas in the rat. Eur J Nucl Med Mol Imaging 2006, 33(6):673-682.
  124. Spilker ME, Sprenger T, Valet M, Henriksen G, Wagner K, Wester H-J, Toelle TR, Boecker H: Quantification of [18F]diprenorphine kinetics in the human brain with compartmental and non-compartmental modeling approaches. NeuroImage 2004, 22(4):1523-1533.
  125. Steinert HC, Dellea MM, Burger C, Stahel R: Therapy response evaluation in malignant pleural mesothelioma with integrated PET-CT imaging. Lung Cancer 2005, 49 Suppl 1:S33-35.
  126. Strauss LG, Dimitrakopoulou-Strauss A, Haberkorn U: Shortened PET data acquisition protocol for the quantification of 18F-FDG kinetics. J Nucl Med 2003, 44(12):1933-1939.
  127. Strauss LG, Dimitrakopoulou-Strauss A, Koczan D, Bernd L, Haberkorn U, Ewerbeck V, Thiesen HJ: 18F-FDG kinetics and gene expression in giant cell tumors. J Nucl Med 2004, 45(9):1528-1535.
  128. Tauscher J, Kapur S, Verhoeff NP, Hussey DF, Daskalakis ZJ, Tauscher-Wisniewski S, Wilson AA, Houle S, Kasper S, Zipursky RB: Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch Gen Psychiatry 2002, 59(6):514-520.
  129. Thireou T, Strauss LG, Dimitrakopoulou-Strauss A, Kontaxakis G, Pavlopoulos S, Santos A: Performance evaluation of principal component analysis in dynamic FDG-PET studies of recurrent colorectal cancer. Computerized Medical Imaging and Graphics 2003, 27(1):43-51.
  130. Tipre DN, Fujita M, Chin FT, Seneca N, Vines D, Liow JS, Pike VW, Innis RB: Whole-body biodistribution and radiation dosimetry estimates for the PET dopamine transporter probe 18F-FECNT in non-human primates. Nuclear medicine communications 2004, 25(7):737-742.
  131. Tipre DN, Lu JQ, Fujita M, Ichise M, Vines D, Innis RB: Radiation dosimetry estimates for the PET serotonin transporter probe 11C-DASB determined from whole-body imaging in non-human primates. Nuclear medicine communications 2004, 25(1):81-86.
  132. Tipre DN, Goldstein DS: Cardiac and extracardiac sympathetic denervation in Parkinson’s disease with orthostatic hypotension and in pure autonomic failure. J Nucl Med 2005, 46(11):1775-1781.
  133. Tipre DN, Zoghbi SS, Liow JS, Green MV, Seidel J, Ichise M, Innis RB, Pike VW: PET Imaging of Brain 5-HT1A Receptors in Rat In Vivo with 18F-FCWAY and Improvement by Successful Inhibition of Radioligand Defluorination with Miconazole. J Nucl Med 2006, 47(2):345-353.
  134. Treyer V, Jobin M, Burger C, Teneggi V, Buck A: Quantitative cerebral H2(15)O perfusion PET without arterial blood sampling, a method based on washout rate. Eur J Nucl Med Mol Imaging 2003, 30(4):572-580.
  135. Treyer V, Buck A, Schnider A: Effects of baseline task position on apparent activation in functional imaging of memory. Neuropsychologia 2006, 44(3):462-468.
  136. Van Laere K, Casteels C, De Ceuninck L, Vanbilloen B, Maes A, Mortelmans L, Vandenberghe W, Verbruggen A, Dom R: Dual-Tracer Dopamine Transporter and Perfusion SPECT in Differential Diagnosis of Parkinsonism Using Template-Based Discriminant Analysis. J Nucl Med 2006, 47(3):384-392.
  137. Van Laere K, Nuttin B, Gabriels L, Dupont P, Rasmussen S, Greenberg BD, Cosyns P: Metabolic Imaging of Anterior Capsular Stimulation in Refractory Obsessive-Compulsive Disorder: A Key Role for the Subgenual Anterior Cingulate and Ventral Striatum. J Nucl Med 2006, 47(5):740-747.
  138. Verhoeff NP, Hussey D, Lee M, Tauscher J, Papatheodorou G, Wilson AA, Houle S, Kapur S: Dopamine depletion results in increased neostriatal D(2), but not D(1), receptor binding in humans. Mol Psychiatry 2002, 7(3):233, 322-238.
  139. Vogel R, Indermuhle A, Reinhardt J, Meier P, Siegrist PT, Namdar M, Kaufmann PA, Seiler C: The quantification of absolute myocardial perfusion in humans by contrast echocardiography: algorithm and validation. J Am Coll Cardiol 2005, 45(5):754-762.
  140. von Borczyskowski D, Wilke F, Martin B, Brenner W, Clausen M, Mester J, Buchert R: Evaluation of a new expert system for fully automated detection of the Alzheimer’s dementia pattern in FDG PET. Nuclear medicine communications 2006, 27(9):739-743.
  141. Weber B, Burger C, Biro P, Buck A: A femoral arteriovenous shunt facilitates arterial whole blood sampling in animals. Eur J Nucl Med Mol Imaging 2002, 29(3):319-323.
  142. Weber B, Fouad K, Burger C, Buck A: White matter glucose metabolism during intracortical electrostimulation: a quantitative [(18)F]Fluorodeoxyglucose autoradiography study in the rat. Neuroimage 2002, 16(4):993-998.
  143. Weber B, Spath N, Wyss M, Wild D, Burger C, Stanley R, Buck A: Quantitative cerebral blood flow measurements in the rat using a beta-probe and H2 15O. J Cereb Blood Flow Metab 2003, 23(12):1455-1460.
  144. Weber B, Burger C, Wyss MT, von Schulthess GK, Scheffold F, Buck A: Optical imaging of the spatiotemporal dynamics of cerebral blood flow and oxidative metabolism in the rat barrel cortex. Eur J Neurosci 2004, 20(10):2664-2670.
  145. Weber B, Westera G, Treyer V, Burger C, Khan N, Buck A: Constant-infusion H(2)15O PET and acetazolamide challenge in the assessment of cerebral perfusion status. J Nucl Med 2004, 45(8):1344-1350.
  146. Westera G, Buck A, Burger C, Leenders KL, von Schulthess GK, Schubiger AP: Carbon-11 and iodine-123 labelled iomazenil: a direct PET-SPET comparison. Eur J Nucl Med 1996, 23(1):5-12.
  147. Willeit M, Ginovart N, Kapur S, Houle S, Hussey D, Seeman P, Wilson AA: High-Affinity States of Human Brain Dopamine D2/3 Receptors Imaged by the Agonist [(11)C]-(+)-PHNO. Biol Psychiatry 2006, 59(5):389-394.
  148. Wu H, Dimitrakopoulou-Strauss A, Heichel TO, Lehner B, Bernd L, Ewerbeck V, Burger C, Strauss LG: Quantitative evaluation of skeletal tumours with dynamic FDG PET: SUV in comparison to Patlak analysis. Eur J Nucl Med 2001, 28(6):704-710.
  149. Wyss CA, Koepfli P, Fretz G, Seebauer M, Schirlo C, Kaufmann PA: Influence of altitude exposure on coronary flow reserve. Circulation 2003, 108(10):1202-1207.
  150. Wyss CA, Koepfli P, Mikolajczyk K, Burger C, von Schulthess GK, Kaufmann PA: Bicycle exercise stress in PET for assessment of coronary flow reserve: repeatability and comparison with adenosine stress. J Nucl Med 2003, 44(2):146-154.
  151. Zimmermann K, Grunberg J, Honer M, Ametamey S, August Schubiger P, Novak-Hofer I: Targeting of renal carcinoma with 67/64Cu-labeled anti-L1-CAM antibody chCE7: selection of copper ligands and PET imaging. Nuclear Medicine and Biology 2003, 30(4):417-427.
  152. Zoghbi SS, Shetty HU, Ichise M, Fujita M, Imaizumi M, Liow JS, Shah J, Musachio JL, Pike VW, Innis RB: PET Imaging of the Dopamine Transporter with 18F-FECNT: A Polar Radiometabolite Confounds Brain Radioligand Measurements. J Nucl Med 2006, 47(3):520-527.